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ABSTRACT 
 
Thyroid cancer is the most common endocrine malignancy, and its 
incidence is increasing worldwide. In the attempt to better understand thyroid 
cancerogenesis at the molecular level, we searched for  transcriptional changes 
induced by oncogene-driven transformation in a model system of rat thyroid 
cells. By using global gene profiling through DNA microarrays, we identified a 
group of genes whose expression level increased as a consequence of ectopic 
expression of either RET/PTC, RAS or BRAF oncogene. These genes are 
typically involved in human papillary thyroid cancer (PTC). A subset of  genes 
identified through this screening are related to inflammation and immunity, and 
include chemokines, cytokines, and their receptors. In particular, we found that 
the chemokine receptor CXCR2 and its ligand CXCL1, CXCR3 and its ligand 
CXCL10, CD44 and its ligand OPN, are expressed by transformed, but not by 
parental untransformed thyroid cells; we also found that CXCR4, another 
chemokine receptor, is expressed only by transformed cells, while its ligand, 
SDF-1 is not. In this thesis project, we focused on the role of these receptor-
ligand couples, and on the role of the CXCR4 receptor by evaluating the 
biological activities of these molecules and by dissecting the molecular 
mechanisms underlying their biological action in human thyroid 
carcinogenesis. Here, we also evaluated the potential terapeutic targeting of 
CXCR4 in anaplastic thyroid carcinoma models. Finally, we investigate how 
molecules secreted by thyroid cancer cells can influence tumor 
microenvironment in these neoplasias. 
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INTRODUCTION 
 
Cancer is a severe and progressive disease caused by the uncontrolled 
proliferation of a cellular clone, defined as neoplastic. The eminent oncologist 
Richard Willis has probably provided one of the most clarifying definitions of 
neoplastic disease: “it is an abnormal tissue whose excessive growth is not 
synchronous with that of the normal surrounding tissue. Moreover, the cancer 
cells proliferate even after the stimuli that have induced their growth are 
terminated” (Willis, 1952). Remarkably, cancer cells compete with the normal 
ones for nutrition and energy, thus causing disease into the host.  
It is well known that the uncontrolled proliferation of neoplastic cells is 
caused by gene mutations, leading to activation of oncogenes (i.e., “gain-of-
function” mutations) and/or inactivation of tumor suppressors  (i.e., “loss-of-
function” mutations). Moreover, the mutation in only one gene is not sufficient 
to produce cancer: many other genetic as well as epigenetic alterations are 
necessary to neoplastically transform cells. 
Weinberg has proposed a model (known as the “six hallmarks of 
cancer) according to which a normal cell has to acquire six unphysiological 
hallmarks to become a transformed one (Weinberg et al., 2000). These 
hallmarks are: 
1. Self sufficient growth. Cancer cells synthesize the factors necessary 
for their growth or constitutively activate the receptors for these growth 
factors, thus sustaining their expansion in the absence of proliferation signals. 
2. Loss of the ability to respond to growth-inhibiting signals from the 
surrounding tissues. 
3. Resistance to terminal differentiation, senescence and apoptosis 
4. Unrestrained proliferation 
5. Self autonomous and unrestrained angiogenesis 
6. Ability to move through basal membranes and vessels and, in turn, to 
invade distal tissues, a process known as metastatization.  
Remarkably, however, some of the cancer cell characteristics are also 
influenced by signals coming from the surrounding microenvironment, 
including fibroblasts, endothelial cells and cells of the immune system. 
 
Thyroid cancer  
 
Thyroid cancer is the most frequent endocrine malignancy with an 
incidence of about 9-100000 cases/year; moreover, the incidence increases 
with the age, reaching a plateau at 50 years.  
Although a minor cause of cancer mortality, thyroid tumors represent a 
simple and powerful experimental model for studying the cell and molecular 
biology of tumorigenesis in human epithelial cells. 
The thyroid gland develops in the embryo as a tubular evagination of 
the pharyngeal endoderm at the bases of the tongue. It is located in the neck, 
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beside the trachea. The functional thyroid unit consists of the follicle, a hollow 
spheroid lined by a single layer of columnar epithelial (follicular) cells, filled 
with colloid containing thyreoglobulin secreted by these cells. A small 
minority of follicles include a second epithelial cell type, the C or 
parafollicular cell, which arises from a quite different embryological origin – 
the neuroectoderm of the neural crest. 
 
 
Figure 1: Features of thyroid tumors (Modified from Williams 2002). 
 
Classification 
Malignant thyroid tumors can derive from any of the gland cellular 
populations, being the cancers deriving from the epithelial cells the most 
frequent ones. The thyroid medullary carcinomas (MTC) derive from the 
calcitonin-secerning parafollicular C cells. From follicular cells derive: (1) the 
differentiated carcinomas, including the papillary carcinoma (PTC), the 
follicular-papillary carcinoma and the follicular carcinoma (FTC); (2) the 
recently identified poorly differentiated carcinomas, (PDC), hystologically in 
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between the un- and the differentiated tumors; (3) the undifferentiated or 
anaplastic carcinomas (ATC) (Rosai 2004).  
Etiopathogenesis, clinical features and molecular genetics of the 
thyroid tumors 
 
The etiopathogenesis of thyroid tumors is still largely unknown; 
however, some risk factors have been identified. A well-established cause of 
thyroid carcinogenesis in humans is the exposure to ionizing radiation, 
especially in the neck region, predisposing to chromosomal breaks and, in turn, 
to chromosomal rearrangments and activation of oncogenes or loss of tumor 
suppressor genes. In fact, about 2-4% of the patients irradiated to treat diseases 
such as acne or enlarged thymus, develop a differentiated thyroid carcinoma 
after about 20-30 years. Accordingly, the frequency of papillary thyroid 
carcinomas is dramatically increased in the children exposed to the massive 
release of radionuclides that followed the explosion of the nuclear reactor in 
Chernobyl in 1986. In contrast, however, the therapy with I131 does not 
increase the risk of developing a thyroid tumor. On the contrary, the role of the 
iodine deficiency in thyroid carcinogenesis is not well established, being the 
epidemiological data collected in goitrogenic areas quite contradictory. Among 
the habitants of these areas the frequency of the thyroid adenocarcinomas, in 
particular of the more aggressive follicular histotypes, seems to be elevated. 
Thus, it has been hypothesized that TSH chronic stimulation has a pathogenetic 
role; this hypothesis has also been supported by the evidence that both the 
thyroid tumors and the metastasis do express TSH receptors. Accordingly, it 
has been demonstrated that suppressing the TSH synthesis with high doses of 
L-thyroxin reduces the risk of tumor recurrence and metastasis (Williams 
2002).  
The majority of patients presents with a nodule in their thyroid, which 
typically does not cause symptoms. Occasionally, in the more aggressive cases, 
symptoms caused by compression or infiltration, such as dysphonia, dysphagia 
or dyspnea, do occur. Malignant thyroid nodules, differently from the cystic 
benign ones, are generally single and their consistency is harder than that of the 
surrounding parenchyma. They are usually mobile; however, later on, the 
tumor can progress infiltrating other neck tissues and becoming fixed. 
Sometimes the first sign of disease is a laterocervical lympdoadenopathy that 
can be caused by metastasis.  
 
Histotypes of thyroid cancer 
 
Papillary thyroid carcinomas 
 
Papillary thyroid carcinomas (PTC) account for 75 to 80% of all 
thyroid cancers, showing an incidence peak at 40–50 years; They usually 
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metastasize to the cervical lymphonodes; distant metastasis are uncommon, but 
lung and bone are the most frequent sites.  
Several studies on thyroid tumors have allowed the identification of 
many genetic alterations. In particular, in about 40-50% of papillary thyroid 
carcinomas the kinase domain of the tyrosine kinase receptor for the GDNF, c-
Ret (REarranged during Transfection), is fused with the N-terminal region of 
constitutively expressed, heterologous genes, such as H4 (in RET/PTC1) or 
RFG (in RET/PTC3). In RET/PTC rearrangements, fusion with protein 
partners, possessing protein-protein interaction domains, provides RET/PTC 
proteins with coiled-coil domains, thereby resulting in ligand-independent 
activation of c-Ret tyrosine kinase activity (Santoro et al. 1995). Similar 
rearrangements of the high affinity receptor for NGF (Nerve Growth Factor), 
TRKA, can be also found, at a low prevalence (in about 10% of the tumors), in 
human PTC. RET activates many intracellular signaling pathways. Upon 
binding to ligand, it dimerizes and autophosphorylates various cytoplasmic 
tyrosines. The phosphorylated tyrosines thus become binding sites for 
intracellular molecules containing phosphotyrosine-binding motifs, thereby 
initiating a diverse array of signaling pathways (Santoro et al. 2004). In 
RET/PTC rearrangements, fusion with protein partners possessing coiled-coil 
domains provides RET/PTC kinases with dimerizing interfaces, thereby 
resulting in ligand-independent autophosphorylation. The RET intracellular 
domain contains at least 12 autophosphorylation sites, 11 of which are 
maintained in RET/PTC proteins (Kawamoto et al. 2004). Tyr 905 is located in 
the activation loop and its phosphorylation stabilizes the enzyme in an active 
conformation. Moreover, when phosphorylated, Tyr 905 binds some SH2-
containing proteins, such as Grb7 and Grb10 (Pandey et al. 1996). 
Phosphorylated Tyr 1015 and Tyr 1096 are responsible for binding of PLCγ 
and GRB2, respectively (Jhiang S.M. 2000; Hansford et al. 2000; Airaksinen 
M.S. et al. 1999; van Weering et al. 1998). Several protein adaptors (Fig. 2), 
Shc, FRS2, IRS1/2, DOK1/4/5, RAI/NShc and Enigma recognize 
phosphorylated Tyr 1062 (Jhiang S.M. 2000; Hansford et al. 2000; Airaksinen 
M.S. et al. 1999; van Weering et al. 1998; Lorenzo et al. 1997, Pelicci et al. 
2002, Melillo et al 2001). The multi-docking site Tyr1062, upon 
phosphorylation, is responsible for the activation of the phosphatidylinositol 3-
kinase (PI3K)/AKT and the mitogen-activated protein kinase (MAPK) 
pathways, the latter involving the extracellular-regulated kinase (ERKs), c-Jun 
amino-terminal protein kinase (JNKs) and the p38 MAPK (Jhiang S.M. 2000; 
Hansford et al. 2000; van Weering et al. 1998). 
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Figure 2: Signaling pathways activated by RET (modified from Drosten 2006) 
 
Activating point mutations in RAS small GTPase are found roughly in 10% of 
PTC, mainly in those belonging to the follicular variant (PTC-FV) (Zhu et al. 
2003). Point mutations in BRAF are the most common genetic lesion found in 
PTC (up to 50% of the cases) (Kimura et al. 2003; Xu et al. 2003; Soares et al. 
2003). BRAF is a member of the RAF family of serine/threonine kinases and it 
is a component of the RAF-MEK-ERK signaling module. Activation of the 
RAF proteins is mediated through binding of RAS in its GTP-bound state. 
Once activated, RAF kinases phosphorylate MEK which in turn 
phosphorylates and activates ERK (Malumbres et al. 2003). A Glutamine for 
Valine substitution at residue 600 (V600E) in the activation segment accounts 
for more than 90% mutations of BRAF in PTC (Kimura et al. 2003; Cohen et 
al. 2003; Soares et al. 2003). This mutation enhances BRAF activity through 
disruption of the autoinhibited state of the kinase (Fig. 3).  
 
 
Figure 3: Structure of the BRAF gene. CR: conserved regions; triangles denote the common oncogenic mutations 
(modified form . 
 
In human PTCs the genetic alterations of RET/PTC, RAS and BRAF 
are mutually exclusive, suggesting the existence of a common signaling 
cascade; moreover, mutations at more than one of these sites are unlikely to 
provide an additional biological advantage (Kimura et al. 2003, Cohen et al. 
2003, Soares et al. 2003) 
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Follicular thyroid carcinomas 
Follicular carcinoma is also a well-differentiated cancer developing 
from thyroid cells. About 10 to 30% of thyroid cancers are follicular cancers. 
Follicular carcinoma is particularly linked to dietary iodine deficiency 
(Williams et al. 1977) and both iodine deficiency and genetic influences could 
account for its link with a history of nodular goiter (Ron E et al. 1987). 
In Follicular thyroid carcinoma (FTC) the presence of K-, H-, and N-
RAS mutations is quite common. More recently, it has been shown that a quite 
high proportion of FTC carry the PAX8/PPARγ rearrangement (Nikiforova 
MN et al. 2003). PAX8 encodes a thyroid-specific transcrition factor, while 
PPARγ is a nuclear receptor involved in lipid metabolism and tumorigenesis. 
The resulting fusion protein has dominant negative activity on wild type 
PPARγ (Kroll et al. 2000).  
 
Anaplastic thyroid carcinomas 
 
Anaplastic thyroid carcinoma (ATC) is the most aggressive type of 
thyroid cancer. ATC cancer cells are extremely undifferentiated and spread 
rapidly to other parts of the body. ATCs make up only about 1% of all thyroid 
cancers, but they are highly malignant tumours that histologically appear 
wholly or partially composed of undifferentiated cells that exhibit 
immunohistochemical or ultrastructural features indicative of epithelial 
differentiation. Undifferentiated carcinomas typically spread beyond the 
thyroid by direct local extension. Metastases to regional nodes are also 
common but their presence is often overshadowed by the presence of extensive 
soft tissue invasion. Distant metastases may be present in any site. No effective 
therapy is known for ATC and prognosis is quite negative with a mean survival 
of less than one year. 
Point mutations in the RAS oncogene and in the tumor suppressor p53 
have been described in anaplastic carcinomas (Garcia-Rostan et al. 2003, 
Donghi et al. 1993, Fagin 1993). It is well known that p53 safeguards the cell 
cycle, the DNA repair and the apoptotic processes; thus, mutations in its 
sequence can account for the progression from a more differentiated to an 
anaplastic carcinoma, according to a model already described for the colon 
carcinoma by Vogelstein (Vogelstein et al., 1988). Garcia-Rostan and 
colleagues found somatic mutations within the PI3K catalytic subunit in 23% 
of analysed ATC (Garcia-Rostan et al. 2005) Mutations of BRAF gene have 
been detected in anaplastic carcinoma with well-differentiated components, 
presumably arising from preexisting papillary tumours (Nikiforova MN et al. 
2003). 
These tumors, because undifferentiated, do not significatively 
incorporate radioiodide; however, it can be utilized in the treatment protocols if 
a residual ability to incorporate it can be ascertained. Only very few responses 
have been reported with combined antracyclines-paclitaxel regimens. If the 
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tumor is sensible, the radiation therapy of the neck can be exploited for a 
palliative cure. 
 
Medullary thyroid carcinomas 
The cells involved in medullary cancers are the neuroendocrine C cells of the 
thyroid that produce calcitonin. About 5 to 7% of all thyroid cancers are 
medullary cancers. Of the four types of thyroid cancer, only medullary cancer 
has a clear genetic predisposition that can be passed on in families.  
Germline point mutations in RET cause the dominantly inherited cancer 
syndromes: multiple endocrine neoplasia (MEN) 2A and 2B, familial 
medullary thyroid carcinoma (FMTC). MEN2 patients are invariably affected 
by Medullary Thyroid  Carcinoma (MTC), a malignant tumour arising from 
calcitonin-secreting C cells of the thyroid. Additional features can be present in 
MEN2A (pheochromocytoma and parathyroid adenoma) and MEN2B 
(pheochromocytoma, mucosal neuroma and ganglioneuroma of the intestine) 
(Brandi at al. 2001). Most MEN2B patients carry the M918T substitution in the 
P + 1 loop in the kinase domain. In MEN2A and most FMTC patients 
mutations affects one cysteine of the extracellular cysteine-rich domain of RET 
(609, 611, 618, 620, 630, 634) that can change to different residues. A good 
genotype-phenotype correlation is observed. In particular, about 90% of 
MEN2A patients have Cys634 mutation, and this mutation is highly predictive 
of the presence of pheochromocytoma and parathyroid hyperplasia. (Santoro et 
al. 1995; Carlomagno et al. 1997). RET activation by mutations targeting the 
intracellular domain is less understood (Santoro et al. 1995, Iwashita et al. 
1999) but it can be envisaged that a modification of the structure of the kinase 
may switch on its enzymatic function. 
 
Immune system and cancerogenesis 
The first reports describing the presence of immune system cells in the 
neoplastic tissues were published at the end of the XIX century. Paul Ehrlich 
hypothesized that the immune system had a relevant role in blocking cancer 
cells spreading (Ehrlich, 1909). Burnet e Thomas further developed this 
hypothesis. In details, Burnet proposed that new, tumor-specific antigens could 
provoke an efficient immunological response, thus eliminating cancer cells 
(Burnet 1957, 1964, 1971). Thomas reasoned that complex and long-surviving 
organisms had to have biological mechanisms able to protect them from cancer 
cells proliferation (Thomas, 1959). However, in 1982, Thomas bitterly 
admitted, “the greatest trouble with the idea of immunosurveillance is that it 
cannot be shown to exist in experimental animals” (Thomas, 1982). Only later, 
thanks to the development of useful animal models, it has been possible to 
show that an immunosurveillance mechanism does exist and that it is indeed 
able to recognize and eliminate cancer cells.  
Recently, Schreiber and colleagues have proposed a “seventh hallmark 
of cancer”, the ability to escape immunosurveillance (Dunn et al., 2004). The 
immunosurveillance mechanism has been proved in mice deficient for genes 
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(such as RAG, IFN-α, IFN- α R) necessary for the induction of an efficient 
immune response. These mice develop tumors either spontaneously or after 
treatment with carcinogenic agents. Moreover, the tumors are frequently very 
aggressive and develop even after treatment with very low doses of 
carcinogens (Dunn et al., 2004). 
These, as well as other reports, have lead to the conclusion that both the 
innate and the adaptive immune systems recognize and attack cancer cells. 
Immunosurveillance is part of a more vast process defined by Schreiber as 
“immunoediting”. This process consist of three phases (Fig. 4): 
1. An acute inflammatory response phase successfully induced and 
terminated by the immune system;  
2. A steady-state phase, while cancer and immune system fight against 
each other, causing a chronic inflammatory response; 
3. A third phase, when cancer prevail the immune system in two 
different ways: i) “immunoselection”, i.e., the selection of non-immunogenic 
clones; ii) “immunosubversion”. In this latter case, cancer cells actively escape 
the immune system, producing immunosuppressive cytokines or recruiting 
IDO+ dendritic cells, unable to present the antigen, or Treg CD4+CD25+, able 
to suppress immune response (Zitvogel et al. 2006). 
 
 
Figure 4: The Three Phases of the Cancer Immunoediting (modified from Dunn 2004) 
Thus, an efficient immune response can eliminate cancer cells; 
however, the chronic activation of inflammatory cells present within or, more 
frequently, surrounding the neoplasia can sustain cancer cell proliferation. 
 
Chronic inflammation and cancer 
A functional relationship between chronic inflammation and cancer has 
been envisaged long ago and has been later demonstrated by several clinical 
and epidemiological evidences. Among the more compelling ones there are the 
association between: a) intestinal chronic inflammatory diseases (Chron’s 
disease and ulcerative rettocolitis) and the adenocarcinoma of the colon; b) 
chronic HCV hepatitis and liver carcinoma; c) Helicobacter pylori-induced 
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chronic gastritis and gastric carcinoma; d) asbestosis and mesothelioma; e) 
BPCO and lung cancer; f) chronic esophagitis and carcinoma of the esophagus 
(Coussens et al., 2002). Moreover, a 40-50% reduction in the incidence of 
colorectal cancer is associated with the regular use of non-steroidal anti-
inflammatory drugs (NSAIDs), inhibiting the COX enzyme that catalyzes the 
synthesis of pro-inflammatory mediators, such as prostaglandins (Baron e 
Sadler, 2000; Williams et al., 1999). For most of the above-mentioned tumors, 
the etiopathogenic factors causing the chronic inflammatory response are well 
recognized, including a viral or a bacterial infection or a prolonged exposure to 
environmental chemicals. However, the molecular mechanisms causing the 
transition from a physiological response, such as inflammation, to neoplastic 
transformation are still largely unknown. 
Inflammation is a physiological, protective response organized by the 
organism in response to tissue damages. Several chemical signals initiate and 
sustain the inflammatory response whose aim is repairing the damage. Several 
cells migrate in the sites of tissue damage, thanks to the action of chemotactic 
and adhesion proteins, including the integrin and selectin family members 
(Coussens et al., 2002). The first migrating cells are neutrophiles, macrophages 
and mast cells, secreting ROS, vasoactive proteins, such as histamine and 
leukotrienes, and several other factors, such as cytokines, chemokines and 
proteases that remodel the extracellular matrix (de Visser et al., 2006). 
 
 
Figure 5: A model of innate and adaptive immune-cell function during inflammation-associated cancer development 
(modified from De Visser 2006). 
 
Inflammation is an auto-limiting process; however, the abnormal 
persistence of the stimuli that first induced the inflammatory response or the 
failure of the mechanisms determining its termination cause chronic 
inflammation (Coussens et al., 2002).  
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Cancer cells secrete several cytokines and chemokines, thus recruiting 
leukocytes into tumor site. Leukocytes physiologically secrete ROS and RNS, 
to eliminate the pathogens. However, these highly reactive metabolites induce 
the production of peroxynitrite and other mutagenic agents; therefore, they can 
induce “DNA damage”, i.e. mutations in proliferating cells (Coussens et al., 
2002). Thus, in the case of a persistent tissue damage the O2 and N highly 
reactive metabolites secreted by the inflammatory cells induce point mutations, 
rearrangements and double strand breaks in the DNA of proliferating cells 
DNA. This results in a higher probability of oncogenes activation or of tumor 
suppressors loss of function. For example, Pollard and colleagues have shown 
that transgenic mice prone to breast cancer develop less proliferating and 
invasive tumors when crossed with mice deficient for CSF-1, a macrophage 
chemotactic factor (Lin et al. 2001). 
 
Inflammation and tumoral neoangiogenesis 
In adults angiogenesis is a process induced by tissue remodeling 
(Folkman, 1997). Thus, neoangiogenesis physiologically occurs in the 
endometrial regeneration during the menstrual cycle, in the wound healing 
processes and during the mammary gland evolution and involution of the 
mammary gland (Coussens et al., 1999). On the contrary, it pathologically 
ensues in inflammation and during tumoral growth (Ferrara, 1995; Hanahan 
and Folkman, 1996; Klein, 1999). In both cases, it induces activation, 
proliferation and migration of endothelial cell precursors. Moreover, 
endothelial cell proliferation and migration is facilitates by the proteolytic 
digestion of the extracellular matrix. In the case of a physiological 
neoangiogenetic response, such as the one occurring in the wound healing 
processes, the lesions induce the secretion of proangiogenic factor by 
inflammatory cells.  
Neoplastic growth is influenced not only by proliferation but also by 
other phenomena, the most important one being the activation of angiogenic 
programs. In fact, the diameter of a tumor cannot overcome 1-2 mm, if it is not 
efficiently vascularized, because this is probably the maximal distance the 
oxygen and the nutritive factors can reach once left the vessels. Thus, if not 
vascolarized, the tumor cannot get growing because hypoxia induces apoptosis. 
Neoangiogenesis has two effects on tumoral growth: i) it supplies oxygen and 
nutrition factors; ii) the newly formed endothelial cells induce cancer cells 
proliferation, by producing several growth factors, such as IGF, PDGF, GM-
CSF ed IL-1. Angiogenesis and lymphangiogenesis are essential characteristics 
not only for tumor growth but also for metastasization. Thus, a clear 
correlation exists among angiogenesis, cancer progression and the ability of the 
malignant cells to metastasize.  
Both the cancer cells and the inflammatory cells infiltrating the tumor 
secrete several angiogenic factors, the most important being VEGF (Vascular 
Endothelial Growth Factor) and bFGF (Basic Fibroblast Growth Factor). These 
two growth factors are secreted by many different cancer cells, being their 
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blood levels higher in a significant percentage of neoplastic patients. 
Remarkably, however, cancer cells may also secrete anti-angiogenic proteins, 
such as angiostatin, endostatin and tumstatin (Ruegg, 2006). Thus, tumoral 
growth is the result of a fine balance between pro- and anti-angiogenic factors, 
this balance being extremely precarious during tumor progression. Thus, 
neoangiogenesis is a physiological phenomenon during, for example, wound 
healing: however, it becomes a pathological one when it sustains tumoral 
growth. In the first case the signals limiting angiogenesis do prevail; tumor 
progression is instead characterized by a shift in the balance between pro- and 
anti-angiogenic factors (Fig. 6).  
 
Figure 6: Leukocytes and bone marrow-derived inflammatory cells (BMDC) often infiltrate tumors, that “educate” 
these cells to produce tumor-promoting factors, which stimulate angiogenesis, lymphangiogenesis, and tumor cell 
invasion. (modified from Ruegg 2006) 
 
Mast cells 
Mast cells have been first identified in 1877 by a medical student, Paul 
Ehrlich (Beaven, 1976). They derive from bone marrow precursors and are 
present in all human tissues. Mast cells immunological activation results in the 
secretion of several pro-inflammatory factors, cytokines and chemokines. 
Moreover, mast cells have a relevant role in the pathogenesis of allergic 
diseases, being stimulated by the IgE-induced FcεRI receptor activation 
(Marone et al., 2005). Mast cells are hystologically discriminated because 
metachromatic, this characteristic being a consequence of the interaction 
between dyes, such as toluidin blu, and the acidic proteoglycans in their 
cytoplasm. Moreover, mast cells can be also identified by 
immunohystochemistry, using antibodies direct against tryptase or the 
membrane c-kit receptor. Finally, they can be distinguished by basophils in 
electronic microscopy because they are characterized by a villic plasma 
membrane, by a monolobulate nucleus, often eccentric, and by a cytoplasm 
rich of eterogeneous granules and lipidic bodies. 
In mammals and in the other vertebrates, there is a large number of 
mast cells in all the vascularized tissues, near vessels, nerves, muscle cells and 
mucosal glands. In details, mast cells are in all the tissues exposed to the 
external environment, such as the skin, the gastro-intestinal and the respiratory 
apparatus, being potential entry routes for pathogens and allergens. Thus, 
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together with dendritic cells, mast cells are among the first immune cell 
populations to interact with environmental antigens, allergens, bacteria, viruses 
and parasites (Galli et al., 2005). The c-kit receptor ligand, the Stem Cell 
Factor (SCF), is the most relevant factor for human mast cell maturation and 
differentiation (Galli et al., 2005). Several immunological and non-
immunological stimuli can activate mast cells and stimulate the secretion of 
different proteins. Mast cells can be, in fact, activated by the canonical IgE-
mediated response, by several immunological stimuli (such as C3a, C5a, the 
NGF-activated TRKA receptor, the IgG-activated Fc α RI, etc.), as well as by 
many non-immunological stimuli (such as P substance, VIP, somatostatin, 
morphin, etc.). Among the proteins secreted by activated mast cells there are 
preformed factors, lipidic mediators, cytokines and chemokines. The 
preformed factors are stored in secretory granules and are extracellularly 
released within few minutes. The secretory granules mainly contain: histamine, 
Tryptase, chimase, carbossipeptidase A e proteoglycanes (heparin e 
condroitinsolfate E). Histamine is one of the more important biogenic amine 
and exerts its biological effects by activating four different transmembrane 
receptors. Tryptase is a 110-130 kDa MW tetramer. This enzyme cleaves in 
vitro C3 to C3a; however, its function is still largely unknown (Hallgren and 
Pejler 2006).  
Among the lipidic mediators there are the cyclo-oxygenases (PGD2 e 
PGE2) and the lipo-oxygenases (LTC4, LTD4, LTE4) metabolites. The latter 
ones induce airways contractions and increase vascular permeability; on the 
other hand, PGD2 exert a potent chemotactic activity. Human mast cells secrete 
several cytokines. Mast cell-produced TNF- α regulates adhesion proteins 
expression in epithelial and endothelial cells and increase bronchial reactivity. 
Among the other secreted cytokines there are IL-13, regulating TH2 cell 
differentiation and IgE synthesis; IL-3, GM-CSF and IL-5, critical for 
eosinophiles maturation and survival; and IL-6 (Prussin and Metcalfe, 2006). 
Finally, human mast cells secrete several chemokines: IL-8, CCL3/MIP-1 α, 
CXCL1/GRO- α e CXCL10/IP-10. Relevantly, mast cells secretory responses 
can be influenced by both genetic and environmental factors.  
Mast cells are the primary cellular component in the immediated, Ig-E 
mediated, type I hypersensitive reactions. They also have a role in the innate 
immune responses as they can be activated via TLRs, phagocyting 
microorganisms. Mast cells, as macrophages, are long surviving cells; 
moreover, the mast cells number in a specific site can increase as more 
precursors cells are recruited and/or induced to mature. Mast cells number 
increases in case of immediate hypersensitive reactions (rhinitis, eczema, 
asthma), of infections caused by intestinal worms, of chronic inflammation 
and/or tissue remodeling (reumathoid arthritis, for example). During the last 
years it has been shown that mast cells also play an important role in case of 
neoplastic disease.  
In 1891, Westphal first described the presence of a mast cell infiltrate in 
cancer tissues.  This finding has been later on confirmed by studies describing 
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the presence of mast cells in tumors experimentally induced in mice as well as 
in several human cancers (Norrby e Wooley 1993; Meininger, 1995), including 
gastric adenocarcinomas, endometrial carcinomas (Ribatti et al., 2006), 
melanomas, squamo- and basocellular carcinomas of the skin (Coussens et al., 
1999; Smirnova et al., 2005), prostate adenocarcinomas (Deng et al., 2004), 
cutaneous hemangiomas (Qu et al., 1995),  lymphomas (Crocker, 1984), and 
myelomas (Ribatti et al., 1999; Vacca et al., 2001). Remarkably, the intense 
inflammatory reactions, induced in the host by three of the most aggressive 
human cancers, i.e. melanomas, breast carcinomas and colon carcinomas, 
involve several inflammatory cells populations, including mast cells, mainly 
localized at the tumor edge (Norrby e Wooley, 1993). However, mast cell 
function in tumor progression remains largely unknown.  
Several evidences have shown that mast cell infiltration is elevated in 
different tumors (Coussens et al., 1999; Smirnova et al., 2005; Ribatti et al., 
1999; Vacca et al., 2001; Qu et al., 1995; Crocker, 1984). Coussens and 
colleagues have developed an efficient transgenic mouse model of 
squamocellular carcinoma, induced by the HPV16 early region expression in 
the basal keratinocytes. In this tumor model, the authors have observed an 
intense inflammatory response, characterized by a rich mast cell infiltration 
and angiogenesis. Mast cells co-localized with subepithelial and subendothelial 
basal membranes that are active sites of extracellular matrix remodeling. 
Moreover, the authors identified two mast cells mediators, the Tryptase 
mMCP-6 and the chimase mMCP-4, stimulating fibroblast proliferation and 
progelatinase B (MMP-9) activation, respectively. Finally, these results have 
been further validated by the evidence that cancer progression in greatly 
impaired in mast cell deficient mice (Coussens et al., 1999). Thus, the authors 
have hypothesized that, during the first phases of tumors development 
(hyperplasia and dysplasia), the tumor infiltrating mast cells induce 
angiogenesis both directly and indirectly, activating proGelatinase B (MMP-9) 
and secreting proangiogenetic factors captured by the extracellular matrix. 
Later during tumor progression, the transcription of proangiogenetic factors is 
upregulated in cancer cells.  
Multiple myeloma is characterized by a rich mast cell infiltration and 
by neoangiogenesis (Vacca et al., 2001). Tosato and coworkers have 
demonstrated that mast cells, recruited in situ by the VEGF-A secreted by 
multiple myeloma cells, induce tumor growth by producing angiopoietin-1 
(Ang1) that, in turn, activates the endothelial specific tyrosine kinase receptor 
Tie2. Ang1-activated Tie2 induces endothelial cell proliferation and neo-
vessels sprouting. Moreover, it stimulates the migration of stem cells that can 
differentiate in endothelial cells. Mast cell-secreted Ang1 and plasma cell-
produced VEGF-A have, therefore, a synergistic effect (Tosato et al.2004). In 
conclusion, therefore, the above-described studies highlight how cancer cells 
take advantage of mast cells-secreted factors. In particular, mast cells have a 
relevant role in inducing tumoral neoangiogenesis by secreting several 
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proangiogenetic factors, such as different VEGF isoforms, angiopoietin-1, 
heparin, histamine, metallo- and serine-proteases.  
 
Thyroid cancer and inflammation 
An association between Hashimoto’s thyroiditis and thyroid cancer has 
been reported in about the 30% of the cases (Di Pasquale, 2001; Wirtschafter.et 
al., 1997; Mechler et al., 2001; Segal et al., 1985; Eisemberg et al., 1989; Ott et 
al., 1987; Sclafani et al., 1993; Pisanu et al., 2003), the increased incidence of 
carcinomas in patients with thyroiditis suggesting they might be a precancerous 
condition. The vast majority of thyroiditis-associated carcinomas are papillary; 
however, also follicular, anaplastic, medullary and squamous carcinomas have 
been reported. Hashimoto thyroiditis is an autoimmune disorder in which the 
immune system reacts against a variety of thyroid antigens. The overriding 
feature of Hashimoto thyroiditis is the progressive depletion of thyroid 
epithelial cells (thyrocytes), which are gradually replaced by mononuclear cell 
infiltration and fibrosis. Multiple immunologic mechanisms may contribute to 
the death of thyrocytes. Sensitization of autoreactive CD4+ T-helper cells to 
thyroid antigens appears to be the initiating event. Hashimoto’s thyroiditis is 
characterized by proliferating nodules as well as cytological alterations and 
nuclear modifications similar to those of the papillary carcinomas. The thyroid 
follicular cells may have chromosomal defects, such as the rare trisomy of 
chromosome 10 or the rearrangement RET/PTC1, the hallmark of many 
papillary thyroid carcinomas. Several other evidences suggest a role for 
RET/PTC in the association between thyroiditis and cancer. In fact, patients 
exposed to radiation from the Chernobyl nuclear power plant disaster often 
develop not only RET/PTC-induced papillary tumors but also an associated 
autoimmune thyroiditis (Williams et al 2002). Accordingly, transgenic mice 
engineered to express RET/PTC develop papillary carcinomas and chronic 
thyroiditis (Powell et al. 1998). Finally, Wirtschafter and colleagues have 
detected RET/PTC expression in about the 90% of the Hashimoto’s thyroiditis 
they have analyzed (Wirtschafter et al., 1997). These data are, however, 
partially in contrast with the report by Rhoden and colleagues. These authors 
have found only few follicular cells expressing very low levels of the 
rearranged protein in Hashimoto’s thyroiditis, thus suggesting that RET/PTC 
expression does not necessarily predict the development of a papillary 
carcinoma in patients with thyroiditis (Rhoden et al., 2006). 
Two models have been hypothesized to explain the association between 
Hashimoto’s thyroiditis and RET/PTC. The first one suggests that 
inflammation might facilitate the rearrangement. According to this hypothesis, 
free radicals production, cytokine secretion, cellular proliferation as well as 
other phenomena correlated with inflammation might predispose to the 
rearrangement in follicular cells. Another hypothesis suggests that it is the 
rearrangement that influences the thyroid inflammation. Accordingly, 
RET/PTC induces a severe inflammatory response in animal models (Powell et 
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al., 2003; Melillo et al., 2005; Puxeddu et al., 2003) and the synthesis of many 
inflammatory proteins in epithelial thyroid cells.  
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AIMS OF THE STUDY    
 
Since the biochemical cascade RET/PTC3-RAS-BRAF is frequently 
activated in PTCs, and the mutations in these three genes are mutually 
exclusive, we sought to analyze the transcriptional program induced by these 
oncogenes in rat thyroid epithelial cells. The gene expression signature 
common to the three oncogenes revealed the induction of genes related to 
inflammation and immunity. These genes have been functionally characterized 
and theis specific role in thyroid carcinogenesis has been investigated. 
The specific aims were as follows: 
• Development of an in vitro model of thyroid cells expressing 
RET/PTC3-HRAS-BRAF oncogenes    
• Identification of gene expression profiles of rat thyroid cells expressing 
RET/PTC3-HRAS-BRAF 
• Functional characterization of selected induced genes and of the 
biological effects exerted on thyroid cancer cells:  
o CXCL1/Gro α 
o CXCL10/IP10 
o Osteopontin (OPN) 
o CXCR4 
• Characterization of the role(s) of mast cells infiltrate and in the 
development of human thyroid cancer. 
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MATERIALS AND METHODS 
 
Plasmids 
All the molecular constructs used in this study were cloned in pCDNA3(Myc-
His) (Invitrogen, Groningen, The Netherlands). The RET/PTC constructs 
encode the short (RET-9) RET spliced form and are described elsewhere 
(Melillo et al 2001). For simplicity, we numbered the residues of RET/PTC 
proteins according to the corresponding residues in unrearranged RET. 
RET/PTC1 and RET/PTC3 constructs encode the H4-RET and RFG-RET 
chimeric oncogenes, respectively. RET/PTC3(K-) is a kinase-dead mutant, 
carrying the substitution of the catalytic lysine (residue 758 in full-length RET) 
with a methionine. RET/PTC3(Y1062F) and RET/PTC3(Y1015F) carry 
substitutions of the indicated tyrosines with phenylalanine residues. BRAF and 
the kinase dead BRAF (K-) were kindly donated by C.J. Marshall (Davies et al 
2002). BRAF(V600E) was obtained by site-directed mutagenesis using the 
QuickChange mutagenesis kit (Stratagene, La Jolla, CA). The mutation was 
confirmed by DNA sequencing. HRAS(V12) and HRAS(N17) plasmids are 
described elsewhere (Castellone et al 2003). 
 
Cell cultures and transfections 
PC Cl 3 (hereafter "PC") is a differentiated thyroid follicular cell line derived 
from 18-month-old Fischer rats. PC cells were cultured in Coon’s modified 
Ham F12 medium supplemented with 5% calf serum and a mixture of 6 
hormones (6H), including thyrotropin (TSH, 10 mU/ml), hydrocortisone (10 
nM), insulin (10 µg/ml), apo-transferrin (5 µg/ml), somatostatin (10 ng/ml) and 
glycyl-histidyl-lysine (10 ng/ml) (Sigma Chemical Co., St. Louis, MO) (Fusco 
et al 1987). For stable transfections, 5 x10
5
 PC cells were plated 48 h before 
transfection in 60-mm tissue culture dishes. The medium was changed to 
Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) containing 5% calf 
serum and 6H. Three hours later, calcium phosphate DNA precipitates were 
incubated with the cells for 1 h. DNA precipitates were removed, and cells 
were washed with serum-free DMEM and incubated with 15% glycerol in 
HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid)-buffered saline 
for 2 min. Finally, cells were washed with DMEM and incubated in Coon's 
modified F12 medium supplemented with 5% calf serum and 6H. Two days 
later, G418 (neomycin) was added at a concentration of 400 µg/ml. Mass 
populations (pool#3) of several hundred cell clones were pooled and expanded; 
two independent cell clones (Cl#1 and 2) for each transfection were also 
isolated. For the colony formation assay, two dishes of PC were transfected 
with each plasmid. Two days later, G418 was added to one dish, whereas the 
other dish was kept in medium containing 5% calf serum without 6H. After 15 
days, cells colonies were fixed in 11 % glutaraldehyde in PBS, rinsed in 
distilled water, stained with 0.1% crystal violet in 20% methanol for 15 min 
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and counted. The percentage of hormone-independent colonies with respect to 
the total number of G418-resistant colonies was calculated as the average of 
three independent determinations ± SD. HEK293 cells were from American 
Type Culture Collection (ATCC) and were grown in DMEM supplemented 
with 10% fetal calf serum. Transient transfections were carried out with 5  g 
of total DNA in the lipofectamine reagent according to the manufacturer's 
instructions (Invitrogen). TPC1, FB2, BCPAP, BHP2-7, and BHP5-16 human 
PTC cell lines were grown in DMEM supplemented with 10% fetal calf serum. 
The P5 primary culture of normal human thyroid follicular cells was kindly 
donated by F. Curcio and was grown as described (Curcio et al 1994). HMC-1 
(Human Mast Cell Line) were kindly donated by JH Butterfield and grown in 
Iscove’s (Life Technologies) supplemented with 10% fetal calf serum without 
α-thiglicerol (Butterfield et al. 1988). LAD-2 cells (kindly donated by AS 
Kirshenbaum) were grown in StemPro-34 (Life Technologies) supplemented 
with human recombinant Stem Cell Factor (100 ng/ml) (Peprotech, Rocky Hill, 
NY) (Kirstmbaum et al. 2003). 
 
RNA silencing 
Small inhibitor duplex RNAs targeting human BRAF have been previously 
described (Hingorani et al 2003). Duplex oligonucleotides targeting rat BRAF 
and CXCR4 were designed with a siRNA selection program available online at 
http://jura.wi.mit.edu/siRNAext/, and were chemically sinthesized by 
PROLIGO, Boulder, CO. Sense strands for siRNA targeting were the 
following: 
Rat BRAF: 5’-AAAGCCACAGCUGGCUAUUGUUA-3’ 
Human BRAF: 5’-AGAAUUGGAUCUGGAUCAUdTdT-3’ 
Human CXCR4: 5’-GAGGGGAUCAGCAGUAUAUAC -3’ 
Scrambled: 5’-rArCrCrgUrCrgrAUUUrCrArCrCrCrgrgTT-3’ 
For siRNA transfection, PC RET/PTC3, BHT101 and TPC1 cells were grown 
under standard conditions. The day before transfection, cells were plated in 6-
well dishes at 50-60% confluency. Transfection was performed using 5-15µg 
of duplex RNA and 6µl of Oligofectamine reagent (Invitrogen), as previously 
described (Hingorani et al 2003). Cells were harvested at different time points 
post-transfection and analyzed. For growth curves, PC RET/PTC3 cells were 
transfected; 12 h after transfection, 1x10
5
 cells were plated and counted at the 
indicated time points. 
 
Tissue samples 
Retrospectively-collected archival frozen thyroid tissue samples from 18 
patients affected by papillary thyroid carcinomas (PTC) were retrieved from 
the files of the Pathology Department of the University of Pisa upon informed 
consent. Special care was taken to select cases whose corresponding 
histological samples were available for matched analysis. Sections (4-µM 
 29 
thick) of paraffin-embedded samples were stained with hematoxylin and eosin 
for histological examination to ensure that the samples fulfilled the diagnostic 
criteria required for the identification of PTC (enlarged nuclei with fine dusty 
chromatin, nuclear grooves, single or multiple micro/macro nucleoli and 
intranuclear inclusions). Normal thyroid tissue samples were also retrieved 
from the files of the Pathology Department of the University of Pisa. 
 
RNA extraction and reverse transcription polymerase chain reaction 
Total RNA was isolated by the RNeasy Kit (Qiagen, Crawley, West Sussex, 
UK) and subjected to on-column DNase digestion with the RNase-free DNase 
set (Qiagen) according to the manufacturer’s instructions. Where indicated, 
cells were transfected with BRAF siRNA or treated with U0126 (20µM) and 
harvested 72h after treatment. The quality of RNA was verified by 
electrophoresis through 1% agarose gel and visualized with ethidium bromide. 
Random-primed first strand cDNA was synthesized in a 50 µl reaction volume 
starting from 2 µg RNA by using the GeneAmp RNA PCR Core Kit (Applied 
Biosystems, Warrington, UK). Primers were designed by using software 
available at http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi 
and synthesized by the MWG Biotech (Ebersberg, Germany). To exclude DNA 
contamination, each PCR reaction was also performed on untranscribed RNA. 
Quantitative (real-time) reverse transcription polymerase chain reactions (Q-
RT-PCR) were performed by using the SYBR Green PCR Master mix 
(Applied Biosystems) in the iCycler apparatus (Bio-Rad, Munich, Germany). 
Amplification reactions (25µl final reaction volume) contained 200 nM of each 
primer, 3 mM MgCl2, 300 µM dNTPs, 1x SYBR Green PCR buffer, 0.1U/µl 
AmpliTaq Gold DNA Polymerase, 0.01U/µl Amp Erase, RNase-free water, 
and 2 µl cDNA samples. Thermal cycling conditions were optimized for each 
primer pair and are available upon request. To verify the absence of non-
specific products, 80 cycles of melting curve (55°C for 10 sec) were 
performed. In all cases, the melting curve confirmed that a single product was 
generated. Amplification was monitored by measuring the increase in 
fluorescence caused by the SYBR-Green binding to double-stranded DNA. 
Fluorescent threshold values were measured in triplicate and fold changes were 
calculated by the formula: 2-(sample 1 ΔCt - sample 2 ΔCt), where ΔCt is the difference 
between the amplification fluorescent thresholds of the mRNA of interest and 
the ß actin mRNA.  
 
Oligonucleotide DNA microarray 
The detailed protocol for the microarray hybridizations, sample preparation, 
and the Rat Genome U34 Set is available from Affymetrix (Santa Clara, CA). 
Briefly, 10 µg purified total RNA was transcribed into a first cDNA using 
Superscript RT (Invitrogen), in the presence of T7-oligo(dT)24 primer, 
deoxyribonucleoside  triphosphates (dNTPs), and T7 RNA polymerase 
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promoter (Invitrogen). The double-stranded (ds)–cDNA was cleaned and an in 
vitro transcription reaction was then performed to generate biotinylated cRNA 
which, after fragmentation, was used in a hybridization assay on RG-U34A and 
RG-U34B GeneChip microarrays. The A array contains probes representing 
full-length or annotated genes as well as EST clusters. The B array contains 
only EST clusters. Before hybridization, the efficiency of cDNA synthesis was 
estimated on a test chip by calculating the ratios for 5' and middle intensities 
relative to 3' for the control genes actin and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Biotinylated RNA used as a target in the microarray 
hybridization was stained with a streptavidin-phycoerithrin conjugation 
including an amplification step with a secondary antibody and scanned in a 
confocal laser-scanning microscope (Hewlett Packard GeneArray Scanner 
G2500A). Normalization was performed by global scaling, with the arrays 
scaled to an average intensity of 150. Analysis of differential expression was 
performed by Microarray Suite software 5.0 (Affymetrix). The final results 
were imported into Microsoft Excel (Microsoft). 
 
Protein studies 
Protein extractions and immunoblotting experiments were performed according 
to standard procedures. Briefly, cells were harvested in lysis buffer (50 mM 
HEPES, pH7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 
1.5 mM MgCl2, 10 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO4, 
10 µg of aprotinin/ml, 10 µg of leupeptin/ml) and clarified by centrifugation at 
10,000 x g. Protein concentration was estimated with a modified Bradford 
assay (Bio-Rad, Munich, Germany). Immune complexes were detected with 
the enhanced chemiluminescence kit (ECL, Amersham). Signal intensity was 
analyzed at the Phosphorimager (Typhoon 8600, Amersham Pharmacia 
Biotech) interfaced with the ImageQuant software. Anti-RET is an affinity-
purified polyclonal antibody raised against the tyrosine kinase protein fragment 
of human RET. Anti-ERK (#9101) and anti-phospho-ERK (#9102) were from 
Cell Signaling (Beverley, MA). Anti-myc antibody and antibodies to D1 
cyclin, BRAF and c-RAF were from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). Anti-RAS and anti-phosphotyrosine antibodies were from Upstate 
Biotechnology Inc., (Lake Placid, NY, USA). Anti-AKT and anti-
phosphoAKT, specific for the active AKT phosphorylated at serine 473, were 
from Cell Signaling (Beverly, MA). Monoclonal anti-αtubulin was from Sigma 
Chemical Co. Anti-OPN goat polyclonal antibody (K20) and rabbit polyclonal 
anti-CD44 (H300) were obtained fromSanta Cruz Biotechnology, Inc. (Santa 
Cruz, CA). Anti-CXCR4 antibodies were from Abcam ltd. (Cambridge, UK). 
Histamine receptors antibody were from Chemicon International (U.S.A.) 
Secondary antibodies coupled to horseradish peroxidase were from Amersham 
Pharmacia Biotech. For the BRAF kinase assay, cells were cultured for 12h in 
serum-deprived medium and harvested. BRAF kinase was immunoprecipitated 
with the anti-myc epitope antibody and resuspended in a kinase buffer 
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containing 25mM sodium pyrophosphate, 10 µCi 
32
P ATP and 1µg of 
recombinant GST MEK (Upstate Biotechnology Inc.). After 30 min incubation 
at 4°C, reactions were stopped by adding 2X Laemmli buffer. Proteins were 
then subjected to 12% SDS gel electrophoresis. The radioactive signal was 
analyzed at the Phosphorimager. 
 
ELISA assay 
Thyroid cells plated in 6-well dishes were allowed to grow to 70% confluency 
and then serum-deprived for 24 h. Culture media were cleared by 
centrifugation at 2,000 RPM at 4°C to remove detached cells and debris. 
CXCL1, CXCL10 OPN and SDF-1  levels in culture supernatants were 
measured using a quantitative immunoassay ELISA kit (QuantiKine 
colorimetric Sandwich assay ELISA, R&D Systems, UK), following the 
manufacturer’s instructions. For chemokine detection in TPC1 BRAF-depleted 
cells, supernatants were harvested 96 h after siRNA transfection. Cells were 
serum starved for 4 h before harvesting. Triplicated samples were analyzed at 
490 nM with an ELISA reader (Model 550 microplate reader, Bio-Rad). 
 
Flow cytometric analysis 
Subconfluent TPC1 cells were detached from culture dishes with a solution of 
0.5 mM EDTA, and then washed three times in PBS buffer. After saturation 
with 1 g of human IgG/10
5
 cells, cells were incubated for 20 min on ice with 
fluorescein- or phycoerytrin-labeled antibodies specific for human CXCR2, 
CXCR3 CD44v6 and CXCR4 (R&D Systems (Minneapolis, MN) or isotype 
control antibody. After incubation, unreacted antibody was removed by 
washing cells twice in PBS buffer. Cells resuspended in PBS were analyzed on 
a FACSCalibur cytofluorimeter using the CellQuest software (Becton 
Dickinson, San Jose, CA). Analyses were performed in triplicate. In each 
analysis, a total of 10
4 events were calculated. 
 
Matrigel invasion 
In vitro invasiveness through Matrigel was assayed using transwell cell culture 
chambers according to described procedures. Briefly, confluent cell 
monolayers were harvested with trypsin/EDTA and centrifuged at 800Xg for 
10 min. The cell suspension (1X105 cells/well) was added to the upper 
chamber of a pre-hydrated polycarbonate membrane filter of 8 µM pore size 
(Costar, Cambridge, MA, USA) coated with 35 µg Matrigel (Collaborative 
Research Inc., Bedford, MA, USA). The lower chamber was filled with 
complete medium and, when required, recombinant SDF-1, CXCL1 or 10 
(Peprotech, Princeton Business Park, Rocky Hill, NJ), at the concentration of 
100 ng/ml, were added to the lower chamber. When required, the cells were 
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pretreated for 12h with U0126 (20 uM) or for 20 min with CXCL1, CXCL10, 
CXCR2 and CXCR3 blocking antibodies (1 µg/ml, R&D), pertussis toxin (0.1 
µg/ml, Calbiochem, San Diego, CA) or the blocking compounds SB225002 
(10 nM, Calbiochem) and TAK-779 (100 nM). The latter reagent was obtained 
through the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH (Rockville, MD). Where indicated, PC RET/PTC3 and 
TPC1 cells were transfected with BRAF siRNA, harvested, respectively, 48 
and 72h after transfection, and plated on Matrigel. Cells were then incubated at 
37°C in a humidified incubator in 5% CO2 and 95% air for 24 h. Non-
migrating cells on the upper side of the filter and Matrigel were wiped off and 
migrating cells on the reverse side of the filter were stained with 0.1% crystal 
violet in 20% methanol for 15 min, and photographed. The stained cells were 
lysed in 10% acetic acid. Triplicated samples were analyzed at 570 nM with an 
ELISA reader (Model 550 microplate reader, Bio-Rad). The results were 
expressed as percentage of migrating cells with respect to the PC RET/PTC3 or 
the chemokine-stimulated TPC1 cells. 
 
Chemotaxis 
In vitro chemotaxis through Fibronectin was assayed using transwell cell 
culture chambers according to described procedures. The cell suspension 
(1X105 cells/well) was added to the upper chamber of a pre-hydrated 
polycarbonate membrane filter of 8 µM pore size (Costar, Cambridge, MA, 
USA) coated with 50 µl of 10% fibronectin in PBS (Sigma Chemical Co., St. 
Louis, MO). The lower chamber was filled with PTCs cells conditioned culture 
medium and, when required, purified blocking antibodies against VEGF-A 
(Santa Cruz Biotechnology, CA USA) were added to the lower chamber. Cells 
were then incubated at 37°C in a humidified incubator in 5% CO2 and 95% air 
for 2 h. Non-migrating cells on the upper side of the filter and fibronectin were 
wiped off and migrating cells on the reverse side of the filter were stained with 
0.1% crystal violet in 20% methanol for 15 min, and photographed. The 
stained cells were lysed in 10% acetic acid. Triplicated samples were analyzed 
at 570 nM with an ELISA reader (Model 550 microplate reader, Bio-Rad). The 
results were expressed as percentage of migrating cells with respect to the PC 
RET/PTC3 or the chemokine-stimulated TPC1 cells. 
 
 
S-phase entry 
S-phase entry was evaluated by BrdU incorporation and indirect 
immunofluorescence. Cells were grown on coverslips, and serum deprived for 
30 h. When indicated, cells were treated with recombnant human CXCL1, 
CXCL10, SDF-1  (Peprotech, Princeton Business Park, Rocky Hill, NJ) or 
OPN (R&D Systems, UK), at the concentration of 100 ng/ml, for 30 h. When 
required, the cells were treated for 24 h with CXCL1, CXCL10, CXCR2, 
CXCR3, CXCR4, CD44v6 blocking antibodies (1µg/ml, R&D), pertussis toxin 
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(0.1 µg/ml, Calbiochem, San Diego, CA) or the blocking compounds 
SB225002 (10 nM, Calbiochem), TAK-779 (100 nM), AMD3100 (Sigma 
Chemical Co., St. Louis, MO). BrdU was added at a concentration of 10 µM 
for the last 2 h. Subsequently, cells were fixed in 3% paraformaldehyde and 
permeabilized with 0.2% Triton X-100. BrdU-positive cells were revealed with 
Texas-Red-conjugated secondary antibodies, respectively (Jackson Immuno 
Research Laboratories, Inc. Philadelphia, PA). Cell nuclei were identified by 
Hoechst staining. Fluorescence was visualized with a Zeiss 140 epifluorescent 
microscope. 
 
 
Xenografts in nude mice 
Mice were housed in barrier facilities and 12-hour light-dark cycles and 
received food and water ad libitum at the Dipartimento di Biologia e 
Patologia Cellulare e Molecolare (University of Naples “Federico II”, 
Naples, Italy). This study was conducted in accordance with Italian 
regulations for experimentation on animals.  All manipulations were 
performed while mice were under isoflurane gas anesthesia. No mouse 
showed signs of wasting or other signs of toxicity. BHT101, ARO, KAT4, 
Npa cells (5x106/mouse) or HMC-1 (1x106/mouse) were inoculated 
subcutaneously into the right dorsal portion of 4-week-old male BALB/c 
nu/nu mice (Jackson Laboratories, Bar Harbor, ME). For AMD3100 
treatments started when tumors measured 40 mm3; mice were randomized to 
receive AMD3100 (n=10, 1.25 mg/kg/twice a day) or vehicle alone (n=10, 
PBS) by intraperitoneal injection for 5 consecutive days/week for 3-4 
weeks. Tumor diameters were measured at regular intervals with calipers. 
Tumor volumes (V) were calculated with the formula: V= A x B2/2 
(A=axial diameter; B= rotational diameter). Tumors were excised and fixed 
overnight in neutral buffered formalin and processed by routine methods.  
 
Histamine release 
Mast cells (6 x 104 cells/tube) were resuspended in PCG, and 0.3 ml of the cell 
suspension was placed in 12 x 75-mm polyethylene tubes (Sarsted-Princeton, 
NJ) and warmed to 37°C; 0.1 ml of each prewarmed releasing stimulus was 
added, and incubation was continued at 37°C (de Paulis et al 1996). The 
reactions were stopped by centrifugation (1000 x g, 22°C, 2 min), and the cell-
free supernatants were assayed for histamine content with an automated 
fluorometric technique (Siranganian 1974). Total histamine content was 
assessed by lysis induced by incubating the cells with 2% HClO4 before 
centrifugation. To calculate histamine release as a percentage of total cellular 
histamine, the spontaneous release of histamine from basophils (2–12% of the 
total cellular histamine) was subtracted from both the numerator and 
denominator (de Paulis et al 2006). All values are based on the means of 
duplicate determinations. Replicates differed in histamine content by <10%. 
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Statistical analysis 
Significance was determined by the Mann-Whitney U Test (STATSOFT 6.0, 
Tulsa OK). A P value < 0.05 was considered statistically significant.  
 35 
RESULTS 
 
The RET/PTC-RAS-BRAF-induced cytokines sustains the mitogenic and 
invasive phenotype of thyroid cancer cells 
 
A biochemical cascade linking RET/PTC to the activation of RAS, 
BRAF and ERK 
We first wanted to investigate whether RET/PTC3, HRAS and BRAF 
belong to the same linear signaling pathway. To this aim we transiently co-
transfected HEK293 cells with myc-tagged BRAF and with the RET/PTC3, 
HRAS, RET/PTC3 (Y1062F) and RET/PTC3 (Y1015F) constructs depicted in 
figure 7. 
 
 
Figure 7: Schematic representation of the constructs used in this study. SP: RET signal peptide; EC: extracellular 
domain; Cys: cysteine-rich; TM: transmembrane; JX: juxtamembrane; TK: tyrosine kinase; CR: conserved BRAF 
regions; ED: RAS effector domain; H: heterogeneous region; C: CAAX tail 
 
We examined BRAF activity in an immunocomplex kinase assay, with 
the oncogenic BRAF(V600E) and the kinase-dead BRAF(K-) mutants as 
positive and negative controls, respectively. BRAF activation was induced by 
co-transfection of the RET/PTC3 and HRAS(V12) oncogenes. BRAF 
activation (figure 8) depends on RET/PTC3 kinase activity, on the integrity of 
tyrosine 1062, crucial for RET activation of ERK1/2 pathway, and requires 
RAS. In fact RET/PTC3-mediated BRAF activation, is blocked by the 
expression of the dominant-interfering HRAS(N17) mutant. 
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Figure 8: Protein lysates extracted from HEK293 cells transfected with the indicated plasmids underwent 
immunoprecipitation with anti-tag (myc) antibody. Kinase assay was performed with GST-MEK as a substrate. BRAF 
and RET/PTC3 were detected by western blot. 
 
 We tested the ERK1/2 stimulation downstream RET/PTC3(Y1062)-
RAS-BRAF cascade. The immunoblot with phosho-specific antibody, shown 
in Figure 9, shos that RET/PTC3- stimulated ERK in a Y1062-, RAS- and 
BRAF- dependent fashion, being obstructed by the expression of HRAS(N17) 
and BRAF(K-) dominant negative mutants. Taken together, these findings 
demonstrate that the phosphorylation of RET/PTC tyrosine 1062 triggers RAS-
dependent stimulation of BRAF signaling. 
 
Figure 9: HEK293 cells transfected with the indicated plasmids were harvested, and protein extracts were 
subjected to immunoblotting with antiphospho-p44/p42 MAP kinase antibodies. The blot was re-probed with anti-
p44/p42 antibodies for normalization. RET/PTC3 and RAS were detected by western blotting with specific antibodies. 
 
Generation of the cellular model system 
PC is a continuous line of follicular thyroid cells, derived from Fischer 
rats, that constitutes a model system to study differentiation and growth 
regulation in an epithelial thyroid cell setting. We generated marker-selected 
clones and mass-populations of PC cells stably transfected with RET/PTC3, 
HRAS(V12) or BRAF(V600E). The oncogene-transfected cell populations 
showed a similar, but not identical, transformed phenotype (figure 10). 
RET/PTC3, HRAS(V12) and BRAF(V600E) oncogenes abolished the 
dependency of PC cell proliferation from TSH, the major growth regulator for 
thyreocytes (not shown). Consistently, transformed cells maintained increased 
levels of G1 cyclin D1 under conditions of TSH-deprivation. Moreover, PC 
 37 
cells transformed by the three oncogenes exerted an in vitro invasive 
phenotype through Matrigel and loss the differentiated phenotype, as shown by 
TG, TTF-1 and PAX-8, thyroid differentiation markers expression (not 
shown). In the case of RET/PTC3, all the transformation features depended on 
tyrosine 1062. 
 
PC Cl3          PC RET/PTC3 (Y1062F)             PC RET/PTC3                    PC HAS(V12)                 PCBRAFV600E 
 
Figure 10: Mass populations of PC cells transfected with the indicated plasmids were photographed by using a phase-
contrast light microscope (magnification X150). RET/PTC3, RET/PTC3(Y1015F), BRAF(V600E) and HRAS(V12) 
expressing cells displayed a transformed morphology, whereas RET/PTC3(Y1062F) cells were virtually 
indistinguishable from parental cells. 
 
A gene expression signature of the RET/PTC3-RAS-BRAF axis in 
thyroid cells 
We then explored gene expression changes after PC thyroid cell 
transformation mediated by RET/PTC3, HRAS(V12) or BRAF(V600E). As a 
control, we used cells expressing the RET/PTC3(Y1062F) mutant. To obtain 
the expression profiles of these cells, we used rat oligonucleotide-based DNA 
microarrays (Affymetrix, GeneChip) containing >16,000 known genes and 
EST clusters. RNA was extracted from mass populations of cells, converted 
into fluorescently labeled cRNA, and hybridized to arrays. Each chip was 
analyzed with the Affymetrix Microarray Suite 5.0 Software to generate raw 
expression data. Fold change (signal log ratio: SLR) was calculated by pair 
wise comparison of probe pairs from the experiment (cells expressing the 
different oncogenes) versus baseline (untransfected parental cells). Genes with 
changes in mRNA abundance in response to the different oncogenes were 
sorted by defining a filter query that "passed" only data sets that were denoted 
“increased” or “decreased” by the software.  
By examining the expression profiles, we observed that some genes 
were regulated by only one or two oncoproteins. However, cross-comparison 
of the results revealed a group of sequences that were regulated in a similar 
fashion in RET/PTC3, HRAS(V12) and BRAF(V600E) cells. Whereas the 
former probably reflect the specific biological activity of each oncoprotein, the 
common targets represent a transcriptional signature of the expression of the 
three oncogenes in thyrocytes. As shown in figure 11, where genes with a fold 
change of 4 or more are depicted, many of the genes induced by RET/PTC3 
were also induced by HRAS(V12) (54%) and BRAF(V600E) (48%). Overall, 
60 (41%) of the oligonucleotide probe pairs induced in RET/PTC3 cells were 
induced in both HRAS(V12) and BRAF(V600E) cells, and as many as 87% 
were Y1062-dependent. Similarly, sorting of HRAS(V12)- and 
BRAF(V600E)-induced sequences showed that RET/PTC3 cells up-regulated a 
large set of them in a Y1062-dependent fashion. Of the 2,517 oligonucleotide 
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probes pairs whose expression was decreased in RET/PTC3 cells, 338 were 
down-regulated by 4-fold or more. Again, a large fraction of these sequences 
was also down-regulated in HRAS(V12) (44%) and in BRAF(V600E) (36%) 
cells. Overall, 104 (31%) genes were down-regulated by all the three 
oncogenes, with 66 of them (64%) being dependent on the integrity of Y1062.  
 
Figure 11: Graphic representation of the gene expression changes (fold-change ≥4) in RET/PTC3, 
BRAF(V600E) and HRAS(V12) cells versus baseline (PC): panel left: up-regulated genes and panel right: down-
regulated genes. The number of up-regulated and down-regulated genes is represented on the y-axis. Arrows indicate 
the Y1062-dependent genes or the RET/PTC3, BRAF(V600E) and HRAS(V12) common targets. The different groups 
of genes are highlighted. Average signal log ratio (ASLR) is reported. 
 
To assess the accuracy of the microarray results, we analyzed by 
reverse transcription polymerase chain reaction (RT-PCR) the expression of a 
subset of genes that had a fold change >4 in cells transformed by the three 
oncogenes. To exclude that gene expression changes may be due to a clonal 
effect during selection, we analyzed gene expression levels on the mass 
population (pool#3) and on two individual clones (Cl#1 and 2) for each cell 
line; thus, statistical analysis of expression changes induced by each oncogene 
was performed. To verify whether the activation of the RAS-BRAF-ERK 
pathway was required for gene expression regulation induced by RET/PTC3, 
the expression levels of the genes were measured by Q-RT-PCR in RET/PTC3 
cells in which the pathway was transiently obstructed, either by BRAF siRNA 
or by treatment with the MEK inhibitor U0126. Expression changes of 60% of 
the genes were affected by both BRAF silencing and U0126 treatment and 
there was a complete concordance between U0126 and siRNA treatment. 
Scrambled siRNA, used as a negative control, did not affect expression levels 
(not shown). 
Interestingly, a large set of genes associated with inflammation and 
immune response (cytokines, chemokines and their receptors) were up-
regulated more than 4 fold in cells expressing RET/PTC3, HRAS(V12) and 
BRAF(V600E). These genes included: the cytokine Osteopontin with its 
receptor CD44 and the chemokines CXCL1/GRO-α (Growth Regulated 
Oncogene-α), CXCL10/IP-10 (interferon-γ-inducible protein 10), CCL2 
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(monocyte chemotactic protein-1). Based on the microarray data, CXCR2, the 
receptor for CXCL1, and CXCR3, the CXCL10-receptor, were also up-
regulated.  
We examined genes coding for the chemokines CXCL1/GRO-α and 
CXCL10/IP-10. A large panel of primary and continuous human thyroid cell 
lines derived from normal tissue and major types of tumors has been collected 
in order to validate the array’s data in a human model. Most of these cell lines 
have been characterized for naturally-occurred RET/PTC, RAS or BRAF 
mutations. This resource has been employed to confirm chemokine and 
chemokine receptor overexpression (not shown), to correlate this feature to the 
underlying oncogenic lesion and to perform functional studies. 
 
Autocrine loops that sustain mitogenesis and motility of thyroid 
cancer cells 
Chemokines are small chemotactic cytokines that are subdivided into 
two main families (α or CXC and β or CC chemokines) on the basis of the 
relative position of cysteine residues (Dhawan et al.2002). Chemokines bind to 
7-transmembrane receptors present in the cell surface that are coupled to Gαi 
class G proteins and can therefore be inhibited by Bordetella pertussis toxin 
(PTX). Chemokine receptor activation leads to a cascade of cellular events: 
generation of diacylglycerol and inositol triphosphate, release of intracellular 
calcium, inhibition of adenylyl cyclase, and activation of several signaling 
proteins including Janus tyrosine kinase/signal transducers and activators of 
transcription (Jak/STAT), protein kinase C, phospholipase C, 
phosphatidylinositol 3-kinase (PI3K) and small GTPases of the Ras and Rho 
families. This cascades result in the activation of AKT and ERK and in cell 
polarization, adhesion and migration (Luster et al. 1998; Mellado et al. 2002).  
Having shown that mRNA for CXCL1 and CXCL10 are up-regulated 
in rat and human PTC cell lines, we evaluated whether these chemokines were 
released in cell supernatants. An ELISA assay demonstrated that CXCL1 and 
CXCL10 were more abundantly secreted by human PTC cell lines 
spontaneously carrying the RET/PTC1 rearrangement (TPC1, FB2, BHP2-7) 
or the BRAF(V600E) mutation (BCPAP, BHP5-16) with respect to P5, a 
primary culture of normal human thyroid follicular cells (Figure 12).  
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Figure 12: CXCL1 and CXCL10 secretion in human PTC cells was evaluated by ELISA: triplicate determinations (± 
S.D.). Normal thyroid cells (P5) were used as a negative control. 
 
Accordingly, the receptors for the chemokines CXCL1 and CXCL10 
(CXCR2 and CXCR3, respectively) were expressed on the cell surface of the 
PTC cell lines as assessed by flow cytometric analysis (not shown). The up-
regulation of two chemokines was also confirmed in a larger set of tumor 
samples (n. 18) with respect to normal thyroid tissue (Figure 13).  
 
 
Figure 13: Expression chemokines  in human PTC samples versus five normal thyroid tissues by Q-RT-PCR. The PTC 
samples were characterized for the presence of either a RET/PTC rearrangement or a BRAF(V600E) mutation. For 
each target (x-axis), the expression levels values of tumors (y-axis) were calculated relative to the average expression 
level in normal tissues (TN). All the experiments have been performed in triplicate P value was calculated by the 
Mann-Whitney Test 
 
To verify the activation of downstream signaling pathways by the 
two receptors, TPC1 cells, derived from a human PTC carrying the 
RET/PTC1 rearrangement, were selected. Cells were stimulated with 
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recombinant CXCL1 or CXCL10, harvested at different time points, and 
activation of ERK and AKT was analyzed by phospho-specific 
antibodies. Both chemokines stimulated a potent ERK and AKT 
phosphorylation starting after 1 min of treatment; ERK activation was 
faster than AKT activation (Figure 14).  
 
Figure 14: Stimulation with CXCL1 and CXCL10 (100 ng/ml) induced time-dependent ERK and AKT activation in 
TPC1 cells. Cell lysates were harvested at the indicated time points; western blots were probed with the indicated 
antibodies. 
 
Since CXCR2 and CXCR3 are expressed and functional in 
thyroid cells we evaluated their biological role in PTC cells. We 
measured S-phase entry, upon chemokines stimulation in TPC-1 cells 
by BrdU incorporation assay. Treatment with recombinant CXCL1 and 
CXCL10 stimulated DNA synthesis of TPC1 cells. Selective antagonists 
for CXCR2 (SB225002) and CXCR3 (TAK-779) (White 1998; Gao 
2003) and blocking antibodies to chemokines and receptors also 
inhibited basal proliferation, consistent with the autocrine production of 
chemokines by these cells (figure 15). 
 
Figure 15: BrdU-incorporation was measured to evaluate S-phase entry upon treatment with CXCL1 or 
CXCL10 or the indicated inhibitors. Average results of three independent experiments ± S.D. 
 
Finally, we asked whether chemokines can stimulate cell invasiveness 
through Matrigel. TPC1 cells displayed low levels of invasiveness in basal 
conditions; exogenous CXCL1 or CXCL10 induced a strong migratory 
response. Basal TPC1 migration through Matrigel was inhibited by treatment 
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with PTX, with selective antagonists (SB225002 and TAK-779) with CXCR2- 
or CXCR3-blocking antibodies and with CXCL1- or CXCL10-blocking 
antibodies, but not by non-specific IgG. Cell motility was also blocked by 
treatment of TPC1 cells with BRAF siRNA and U0126. This effect was not 
observed when a scrambled control siRNA was used (figure 16). 
 
Figure 16: TPC1 cells were seeded in the upper chamber of 8 µM pore transwells and allowed to migrate for 24 h 
towards serum-free medium or, a gradient of CXCL1 or CXCL10. Where indicated, cells were preincubated with 
blocking antibodies, control antibodies, chemical inhibitors, or PTX. The BRAF-ERK pathway was blocked either by 
using BRAF siRNA or by U0126 treatment.  
These data suggested the existence of autocrine loops sustained by 
CXCL1 and CXCL10 and their receptors that confer mitogenic and motogenic 
abilities to PTC cells  
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Role of Osteopontin in Human Papillary Thyroid Carcinomas 
The cytokine OPN and its receptor CD44 are major transcriptional 
targets of RET/PTC3-RAS-BRAF in thyroid cells identified through 
microarrays screening. In a previous work, we demonstrated that the OPN-
CD44 autocrine loop is present and functional in thyroid papillary carcinoma 
cells (Castellone et al. 2004). OPN is a non-collagenous, sialic acid-rich, and 
glycosylated phosphoprotein (Butler 1989; Denhardt and Guo 1993). OPN 
binds to several integrins and to CD44. This protein is involved in normal 
tissue remodeling processes such as bone resorption, angiogenesis, wound 
healing and tissue injury as well as certain diseases such as restenosis, 
atherosclerosis, tumorigenesis and autoimmune diseases (Liaw 1998; Rittling 
and Novick 1999). OPN expression is upregulated in several cancers and 
associated with tumor progression and metastasis (Senger et al. 1983; Craig 
1990). OPN induces cell adhesion and migration, ECM-invasion, and cell 
proliferation by interacting with its receptors αvβ3 and CD44. CD44 is a 
member of the immunoglobulin super family that is expressed in most 
epithelial and non-epithelial cells. Functionally, CD44 binds Hyaluronane in 
extracelluar matrix. CD44 is also an OPN cell surface receptor, and it is 
frequently overexpressed in neoplastic cells. CD44 pre-mRNA is encoded by 
20 exons, which are subjected to alternative splicing. The presence of the v6 
exon is required for efficient OPN binding. While CD44s expression does not 
necessarly convey metastatic potential, CD44 variant isoforms, especially 
CD44v6, have beeen identified as markers for metastatic behavior in 
hepatocellular, breast, colorectal and gastric cancers. Here we investigate 
whether OPN could be used as a marker of malignancy in papillary thyroid 
carcinomas. 
 
OPN expression in PTC 
We measured OPN expression by immunohistochemistry with an anti-
OPN-specific monoclonal antibody in 117 thyroid samples from patients who 
had undergone surgical resection of the thyroid gland for benign or malignant 
lesions (not shown).  
OPN was virtually undetectable (<10% of cells) in normal thyroid 
glands (n = 34), follicular adenomas (n = 7), and multinodular goiters (n = 5). 
In contrast, most of the PTC samples examined (60 of 71), were positive for 
OPN expression, and positivity was confined to tumor cells. The prevalence 
and intensity of OPN staining significantly correlated with the presence of 
lymph node metastases (P = 0.0091) and tumor size (P = 0.0001). Furthermore, 
85% (34 of 40) of the classic PTC tumors and 100% (8 of 8) of the tall cell 
variant PTCs displayed intense OPN immunoreactivity in more than 70% of 
the cells, whereas PTC-FV tumors were characterized by less intense or 
negative staining. Finally, in accordance with previous data, classic PTC (n = 
40) were invariably positive also to CD44v6-specific monoclonal antibodies.  
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Protein lysates were harvested from a pool of normal human thyroid 
tissues and from six classic PTC samples and analysed by immunoblotting. 
OPN levels were normalized to tubulin. As shown in figure 17 OPN protein 
was abundantly over-expressed in all carcinomas compared to normal tissues. 
To determine whether up-regulation occurred at the transcriptional level we 
examined a small sample set using q-RT-PCR. Levels of OPN transcripts were 
significantly higher in tumor samples than in normal thyroid tissue (not 
shown). 
 
 
Figure 17: OPN up-regulation in PTC samples. A, OPN protein levels were evaluated by immunoblot in 
PTC samples and in a pool of five normal thyroid samples (NT). Equal amounts of proteins (100 µg) were 
immunoblotted with anti-OPN polyclonal antibodies. Antitubulin monoclonal antibody was used as a control for equal 
loading. 
 
To establish a model system with which to study the role of OPN, we 
analysed OPN mRNA expression in cultured human thyroid cells. In these 
experiments we used P5, a primary culture, and a panel of PTC cells lines. As 
shown by RT-PCR experiment, all the PTC cell lines analyzed overexpressed 
OPN by more than 10-fold with respect to normal thyrocytes; BCPAP cells 
were the least positive (not shown). To verify that the up-regulated OPN was 
indeed secreted by PTC cells, we used an ELISA assay. PTC cells, but not 
normal P5 cells, secreted abundant OPN in the culture medium. Again, BCPAP 
cells were the least positive (figure 18) 
 
 
Figure 18: OPN up-regulation in cultured PTC cells. OPN protein secretion by PTC cells was evaluated by ELISA. 
Normal thyroid cells (P5) were used as the negative control. The results of three independent determinations performed 
in triplicate ± SD are reported. 
 
We then screened PTC cell lines for CD44 expression by RT-PCR 
using primers designed on exons 2 and v6. All cancer cells tested, but not 
normal cells, contained high levels of CD44v6 mRNA (not shown). We 
therefore used flow-cytometry to determine whether CD44v6 was expressed on 
the surface of PTC cells. As shown in Figure 19, the TPC1 and BCPAP PTC 
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cell lines featured homogeneous cell membrane CD44v6 expression, whereas 
the others displayed varying expression levels of CD44v6. 
 
 
Figure 19: Flow cytometric analysis of cell surface expression of CD44v6 receptor in the indicated PTC cell lines. The 
shadowed curve is the negative control antibody. 
 
OPN activates intracellular signaling and invasiveness of PTC cells 
OPN secretion and cell surface CD44v6 expression reflected the 
existence of an autocrine OPN-CD44 axis that affected PTC cells. To verify 
that this axis was functional in human PTC cell lines, we examined cell 
invasion of Matrigel under basal conditions and in the presence of exogenous 
recombinant OPN. As shown in Figure 20, OPN induces a strong invasive 
phenotype in PTC cells in comparison with normal cells. Interestingly, TPC 
and BCPAP cells, which expressed the highest levels of CD44v6, displayed the 
best migratory response to OPN.  
 
 
Figure 20: OPN-mediated signaling and Matrigel invasion. A, Matrigel invasion of TPC cells in response to normal 
culture medium or exogenous recombinant OPN. Cells were incubated for 24 h. Thereafter, filters were fixed and 
stained. The upper surface was wiped clean, and cells on the lower surface were stained with 0.1% crystal violet. The 
stained cells were lysed in 10% acetic acid. Invasive ability is expressed as the percentage of migrating cells with 
respect to the total cell number. Quantification was performed in triplicate samples with an ELISA reader. This figure 
is representative of three independent experiments. 
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To evaluate whether OPN was able to induce a biochemical response in 
PTC cells, we selected BCPAP cells, which express high levels of CD44v6 and 
relatively low levels of OPN. Cells were harvested at different time points. 
Cells were subjected to Western Blot analysis and probed respectively with 
phospho-antibodies against MAPK and Akt. MAPK and Akt were readily 
activated in stimulated cells (not shown). It has been previously reported that in 
immortalized liver carcinoma cells (HepG2), OPN up-regulates CD44v6 in a 
concentration- and time dependent fashion (Gao C et al. 2003). To determine 
whether this was also the case for thyroid cancer cells, we stimulated BCPAP 
with OPN and evaluated CD44 expression by Western Blot analysis. As shown 
in the Figure 21, OPN treatment significantly increased CD44 protein levels.  
 
Figure 21: BCPAP cells were stimulated with recombinant OPN for 12 h. Total cell lysates were then prepared and 
subjected to immunoblot with anti-CD44 antibodies. OPN stimulated CD44 up-regulation and sustained MAPK 
activation, as shown by staining of the same filter with anti-pMAPK antibodies. The filter was stripped and reprobed 
with anti-MAPK antibodies to show equal protein loading. 
 
We have shown that OPN stimulates Matrigel invasion and ERK/Akt 
activation. We sought to determine whether these effects were mediated by the 
CD44 receptor. To this aim, BCPAP were stimulated with OPN in the presence 
or the absence of blocking compounds, and downstream signaling and 
migration ability were evaluated. As shown in figure 22, CD44 functions as an 
OPN signaling receptor in PTC cells. In fact, pretreatment with CD44 blocking 
antibodies inhibited MAPK and Akt activation by OPN and also prevented 
migration through Matrigel. Matrigel invasion induced by OPN is also 
dependent on the MAPK and Akt pathways. 
 
 
Figure 22: CD44 is involved in OPN-mediated cellular effects. A, Where indicated, cells were preincubated 
(12 h) with U0126 (10 µM), wortmannin (100 nM), or CD44-blocking antibody. Total cell lysates were prepared 5 and 
30 min after stimulation with the cytokine, as indicated. MAPK and AKT activation was assessed by immunoblot. B, 
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Cells were preincubated (12 h) with CD44-blocking antibodies, U0126, or wortmannin. Matrigel invasion was 
analyzed. 
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Role of CXCR4 in Human Anaplastic Thyroid Carcinomas 
CXCR4 is a G protein-coupled receptor (GPCR) that transduces 
cellular signals for stromal cell derived factor 1 (SDF1), a member of the CXC 
branch of the chemokine family also designated CXCL12. SDF-1 is 
chemotactic for B- and T-lymphocyte subsets and is critical for the migration 
of progenitors during embryologic development of the central nervous, 
cardiovascular, and hematopoietic systems (Tachibana 1998; Zou 1998).  
CXCR4 has been shown to have a key role in germ cell migration during 
embryogenesis and blockade of this receptor in humans results in 
immobilization of hematopoietic stem cells (Lapidot and Petit 2002). The 
expression of CXCR4 by mammary carcinoma and other malignancies results 
in the hijacking of its ability to mediate directed migration resulting in the 
programming of metastatic spread to target organs that secrete SDF-1 (ie. 
lymph nodes, bone marrow, lung, and liver). Blockade of CXCR4 with a 
monoclonal antibody has been reported to inhibit the metastasis of mammary 
carcinoma cells in a xenografts model in immunodeficient mice (Muller 2001). 
In a previous report we demonstrated that CXCR4 expression depends on the 
integrity of the RET/PTC-RAS-BRAF pathway, and that oncogenic activation 
of each of these proteins can drive CXCR4 overexpression (Castellone et al. 
2004). We also found that CXCR4 is expressed and functional in human cell 
lines derived from papillary thyroid cancers but not in normal thyroid cells. 
The presence of this receptor has also been confirmed in a set of human PTCs 
by immunohistochemistry. Anaplastic thyroid carcinoma (ATC) is a rare 
thyroid cancer type with an extremely poor prognosis that, in some cases, 
seems to derive from preexisting well differentiated thyroid tumors (WDTC). 
Here we investigate whether CXCR4 expression is maintained in the 
progression from WDTC to ATC, and whether it is biologically relevant.  
 
CXCR4 expression in ATC.  
Firstly we evaluated CXCR4 mRNA and protein levels in a set of ATC 
samples versus different samples of normal thyroid tissue. CXCR4 was found 
to be up-regulated in most of the tumor samples by real time PCR (figure 23).  
 
Figure 23: Expression levels of CXCR4 in human ATC samples versus six normal thyroid tissues by real-time RT-
PCR. CXCR4 expression levels of tumors (y-axis) are calculated relative to the mean CXCR4 level of normal human 
thyroid tissues (NT). All experiments have been performed in triplicate, and the average value of the results was 
plotted on the diagram. P value was calculated with the two-tailed, non-parametric Mann-Whitney test.  
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To verify whether CXCR4 mRNA overexpression resulted in an 
increase in the protein levels, we used protein extracts from a different set of 
ATC samples and 3 normal thyroid tissues in an immunoblot experiment with 
CXCR4 specific antibodies. As shown in Figure 24, CXCR4 protein levels are 
higher in ATC samples than in normal thyroid. As a positive control for 
CXCR4 expression, the ATC cell line ARO was used.  
 
Figure 24: Protein lysates (100 µg) extracted from the indicated samples underwent western blotting with anti-
CXCR4 specific antibodies. Immunocomplexes were revealed by enhanced chemiluminescence. Equal protein 
loading was ascertained by anti-tubulin immunoblot. NT= normal thyroid tissue; ATC= Anaplastic thyroid 
carcinoma samples. 
 
Finally, CXCR4 antibodies were used in immunohistochemistry 
experiments. We evaluated CXCR4 expression in normal thyroid tissues and in 
a set of ATC samples (n=33). While no CXCR4 expression was detected in 
normal thyroid tissues, 13 (39%) of the ATC samples scored positive for 
CXCR4 (not shown). These data indicated that a significant fraction of human 
ATCs, similarly to other epithelial cancers, features high expression levels of 
the CXCR4 receptor. Furthermore, they suggested that the increase in CXCR4 
levels occurs at the transcriptional level. 
Several transgenic mice models of thyroid cancer have been developed 
by using various oncogenes under the transcriptional control of the thyroid-
specific thyroglobulin bovine promoter. Mice expressing either RET/PTC3 
(TGPTC3) or TRK/T1 (TGTRK) oncogene (Powell et al. 1998, Russell et al 
2000), develop PTC-like tumors; NRAS transgene expression results in 
follicular tumors that progress to poorly differentiated carcinomas (TGNRAS) 
(Vitagliano et al. 2006); finally, animals expressing the Simian virus 40 large T 
antigen (TGSV) present aggressive thyroid cancer with features similar to 
human ATC (Ledent et al. 1991). To evaluate the expression of CXCR4 in 
these animal models, we performed western blot analysis with CXCR4 
antibodies in different tumor samples of the transgenic mice. Histologic 
diagnosis of the thyroid lesion was verified before processing of the samples. 
CXCR4 levels were higher in ATC models than in normal mouse thyroid tissue 
(not shown). These data, together with previously published (Castellone et al, 
2004) data suggest that CXCR4 up-regulation is a frequent event in thyroid 
tumorigenesis and that it may correlates with the malignancy of the disease.  
 
CXCR4 is a functional receptor in human ATC cells 
We first identified a suitable cell model to study the role of CXCR4 in 
ATC. To this aim we tested various normal thyroid and ATC-derived primary 
and continuous cell lines for CXCR4 expression by western blot analysis. 
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Normal thyroid cultures displayed low or undetectable CXCR4 expression 
level, several ATC cell lines featured high levels of the CXCR4 receptor. The 
increased levels of CXCR4 proteins were associated to an increase in CXCR4 
mRNA levels, as assessed by quantitative PCR (Q-PCR) analysis (not shown). 
To verify the expression of the receptor on the cell surface we performed flow 
cytometry experiments using a PE-conjugated mouse monoclonal anti-CXCR4 
antibody. The percentage of CXCR4 positive cells was determined (figure 25). 
As shown in the figure both primary (S11T) and continuos ATC cell lines 
feature membrane expression of CXCR4. 
 
 
Figure 25: Flow cytometric analysis (FACS) of surface expressed CXCR4 in ATC cells. Subconfluent cells were 
detached from culture dishes and incubated with phycoerytrin-labeled (PE) antibodies specific for human CXCR4 
(R&D Systems, Minneapolis, MN). 
 
SDF-1, was not expressed by ATC cells as assessed by Q-PCR or by ELISA assay (data not shown). 
We selected two cell lines, S11T and BHT101 for further experiments. 
We tested the phosphorylation of two downstream effectors, ERK1/2 and 
AKT, using phospho-specific antibodies upon stimulation with human 
recombinant SDF-1α. SDF-1α induced rapid and sustained activation of 
ERK1/2 in both cell lines. AKT activation was also achieved in BHT101 cells 
upon SDF-1α treatment, while it was less evident in S11T cells (not shown). 
Together, these data indicate that CXCR4 is functional in ATC cells. 
 
Biological activity of CXCR4 in ATC cells 
To test whether SDF-1α was able to increase the proliferation rate in 
these cells, BHT101 and S11T cells were maintained in low serum (2.5%) 
growth conditions for 24h, and then either left untreated or stimulated with 
SDF-1α for 12h. as shown in figure that SDF-1α consistently enhanced DNA 
synthesis in both BHT101 and S11T cells. We then used a specific CXCR4 
inhibitor, AMD3100 and a small duplex RNA oligo specific for CXCR4, to 
block this effect. CXCR4 RNA interference was verified by western blot 
analysis in BHT101 cells (not shown). Normal thyroid cells were insensitive to 
SDF-1α stimulation, to CXCR4 silencing and to the effect of AMD3100. As 
shown in Figure 26, CXCR4 silencing and AMD3100 inhibited SDF-1α-
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mediated BrdU incorporation in ATC cells. When we used the control 
scrambled siRNA, this inhibitory effect was not observed. The positive effect 
of SDF-1α on cell proliferation, measured as S-phase entry, was also observed 
in other ATC cell lines. To evaluate whether SDF-1α could stimulate ATC cell 
growth, we also performed growth curves in low serum (2.5%) conditions. 
SDF-1α increased their proliferation rate, and AMD3100 reverted this effect 
(not shown).  
     A       B 
 
Figure 26: A) BrdU-incorporation was measured to evaluate S-phase entry upon treatment of BHT101 cells with 
SDF-1α in the presence or in the absence of the CXCR4 inhibitor AMD3100. B) CXCR4 RNA interference was 
used to transiently suppress CXCR4 expression in BHT101 cells. BHT101 cells were transfected with small 
interfering RNAs against CXCR4 (siRNA CXCR4) or control non specific small duplex RNA containing the 
same nucleotides, but in scrambed fashion (siRNA SCR), and harvested 48 and 72 h later.  
 
 
AMD3100 inhibits ATC tumor formation in nude mice 
It has been previously shown that the CXCR4/SDF-1α axis plays an 
important role in the growth and in the metastatic ability of several epithelial 
cancers. Since we had shown that CXCR4 inhibition blocked SDF1α -
mediated ATC cell growth in culture, and since it has been shown that this 
chemokine is secreted by stromal tumoral cells (Orimo et al. 2005), we 
reasoned that SDF-1α -CXCR4 axis blockade by AMD3100 might inhibit 
ATC tumor growth. To this aim, we selected BHT101, ARO and KAT4 cells 
for their ability to respond to SDF-1α and their ability to form tumors in vivo 
with high efficiency. Nude mice were injected subcutaneously with 5x10
6
 
cells. When tumors measured approximately 40 mm3, mice (n=20 for each cell 
line) were randomized to receive AMD3100 (1.25 mg/kg/twice a day 
intraperitoneously) or vehicle 5 days/week for 3-4 weeks. Tumor diameters 
were measured at regular intervals with caliper. After 21 days, the mean 
volume of BHT101 tumors in mice treated with AMD3100 was 48 mm3, while 
that of mice treated with vehicle was 620 mm3. Tumors induced by ARO and 
KAT4 reached the volume of 40 mm3 in only one week. Also in this case 
AMD3100 was able to inhibit tumor growth, although to a lesser extent. In 
fact, ARO-induced tumor mean volume at the end of treatment with AMD3100 
was 220 mm3, while that of mice treated with vehicle was 625 mm3. Similar 
results were also obtained when KAT4 cells were used. In this case, the 
difference between the mean volume of AMD3100-treated versus vehicle-
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treated tumors was not statistically significanct after three weeks. However, 
when treatment was extended for one additional week, AMD3100-treated 
tumor-mean volume was 180 mm3, while that of mice treated with vehicle was 
690 mm3, and the p value was 0.039. These data, taken together, demonstrate 
that treatment with AMD3100 strongly inhibits ATC tumor growth (figure 27).  
 
 
Figure 27: Anti-tumorigenic effects of AMD3100 in ATC cell xenograftss. BHT101, ARO and KAT4 cells. All p 
values were two-sided, and differences were statistically significant at P <.05.  
 
 53 
Role of mast cell infiltrate in PTC 
The expression profile of rat thyroid cancer cells transfected with 
RET/PTC3, HRAS(V12) and BRAF, shows that the three oncogenes 
induced the expression of a group of genes, including cytokines and 
chemokines, associated with inflammation and immune response. Among 
these, chemokines and VEGF have been shown to have a strong 
chemoattractant potential toward mast cells (Bishoff at al. 2007, Marone et 
al unpublished observation).  
 
Presence of mast cells in papillary thyroid tumors 
We first evaluated by immunohistochemistry the presence of mast cells 
in 10 normal thyroid tissues and in a set of 96 PTC tissues. The 
immunostaining of mast cells was performed with a specific mouse 
monoclonal human anti-tryptase antibody, which specifically stains mast cells.  
A representative immunostaining is shown in Figure 28 A: the PTC samples 
displayed the presence of a significant mast cell infiltrate, while the normal 
tissues did not. Mast cell infiltrate was quantified and the distribution of the 
mast cell infiltrate in the samples is shown in Figure 28 B. Normal thyroid 
tissue was characterized by absence or low levels of mast cell infiltrate, while 
all the PTC samples showed a remarkable mast cell infiltrate. Presence and 
intensity of mast cell infiltrate did not correlate with clinico-patological 
parameters, such as gender, age, etc. Instead, the presence of mast cell infiltrate 
at the invasion front positively correlated with capsule invasion (figure 28 C).  
 
 
Figure 28: A) Immunohistochemical detection of mast cells presence in normal thyroid tissues and in PTC tumor 
samples; B) graphic quantification of mast cell infiltration; C) correlation of mast cell invasion front and capsule 
inavsion. 
 
In our laboratory transgenic mice models of PTC have been generated, 
in which the TRK oncogene is under the transcriptional control of the 
thyreoglobulin promoter (Russel et al. 2000). These mice develop tumors 
similar to human PTCs. These tumors were analyzed for mast cell infiltrate 
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with toluidin bleu staining. Thyroid tumors from Tg-TRK transgenic mice 
showed a significant presence of mast cell infiltrate in comparison to normal 
control mice thyroid (not shown). 
It has been previously shown that the presence of mast cells plays an 
important role in the growth of several epithelial cancers. To verify whether 
this is also the case for thyroid cancer, we used xenografts of PTC cells in the 
presence or in the absence of mast cells in nude mice. To this aim, we have 
selected the Npa cells derived from a human PTC, for their ability to form 
tumors in vivo with high efficiency and HMC-1, a human continuous cell line 
derived from a mastocytosis expressing a constitutivly active cKit mutant 
(Butterfield et al., 1988). Mice were divided into three groups and the cells 
were injected subcutaneous.  The first group was injected with 5x106 Npa cells, 
the second with 1x106 HMC-1 cells, and the third was co-injected with 5x106 
Npa cells and 1x106 HMC-1 cells.  
As shown in figure 29A, HMC-1 cells alone did not induce tumor 
formation. In contrast, Npa cell xenografts induced tumor growth with high 
efficiency. These tumors appeared at 3 weeks after the injection. When Npa 
where co-injected with HMC-1 cells, tumors occurred earlier and the final 
volume after 3 weeks was consistently higher than those of the NPA tumors. 
End-stage tumors excised from the animals at 6 weeks postinoculation 
were immunostained for tryptase antigen and the proliferation antigen Ki67, a 
marker for cycling cells. The immunostaining for tryptase (figure 29B) on 
mixed xenografts showed that HMC-1 cells were present in these tumors; these 
data indicate that mast cells survive and proliferate in the presence of PTC 
cells. On the other hand the immunostaining for Ki67 (figure 29C) indicated an 
enhanced proliferative index when compared to tumors induced by the Npa 
cells alone. Thus the presence of mast cells enhanced the proliferation of Npa 
cells.  
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Figure 29: A) mast cell effects on Npa xenografts growth; B) immunostaining of xenografts for tryptase and 
Ki67 respectively; C) graphic of Ki67 immunostaining. 
Then, we asked whether the substantial increase in the tumor size could 
be attributable to an increase in angiogenesis. To address this question, tumor 
tissues were also evaluated by using the CD31 antibody and quantitatively 
assessed for vessel number and diameter. This analysis did not reveal a 
significant enhancement of vascularization in Npa/HMC-1 compared to Npa 
tumors. The staining with toluidin bleu, which stains murine mast cells, didn’t 
show the presence of endogenous mast cells in Npa tumors. Thus, mast cells 
enhanced tumor formation by increasing Npa proliferation. This proliferation 
does not seem to be a consequence of increased vessel density. 
 
PTC cells action on the mast cells 
The immunohistochemical observations suggested a protumorigenic 
role of mast cells in papillary thyroid carcinomas. To identify the mechanism 
of recruitment of mast cell in the tumoral site we performed an in vitro 
chemotaxis assay. To this aim, we selected two mast cells lines, HMC-1 and 
LAD-2. LAD-2 is a continous cells line that requires SCF for survival and 
therefore is more similar to primary human mast cells. We tested the ability of 
conditioned culture media from three PTC cell lines (TPC-1, FB2 and Npa) to 
induce migration of mast cells through a fibronectin matrix. As shown in figure 
30, conditioned culture media from each of the tree cell lines were able to 
induce migration of the HMC-1 and LAD-2 cells; non-conditioned culture 
medium was used as a negative control. 
It has been previously shown that PTC cells are able to produce VEGF-
A (Vascular Endothelial Growth Factor A) (Viglietto et al, 1995). Furthermore 
VEGF was one of the genes up-regulated in our gene expression profile 
experiments. The VEGF family members are secreted dimeric glycoproteins, 
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consisting of five members VEGF-A, B, C, D and PLGF (placenta growth 
factor). VEGF-A, a prototype member of a VEGF family, plays a key role in 
blood vessel growth, induction of vascular permeability, in cardiovascular, 
haematopoietic and lymphatic development and induction of a leukocyte 
chemotaxis (Ferrara 2003). Since VEGF-A is a strong chemoattractant for mast 
cells (Marone et al, unpublished observation) we asked wheter this factor was 
responsible for the chemotactic activity. We then blocked VEGF-A activity in 
PTCs conditioned media with three different blocking antibodies. Figure 30 
shows that mast cell chemotaxis is significantly impaired by blocking 
antibodies to VEGF-A.  
 
LAD-2                  HMC-1 
 
Figure 30: LAD-2 or HMC-1 cells were seeded in the upper chamber of 8 µM pore transwells and allowed to migrate 
through fibronectin for 2 h towards serum-free medium or conditioned culture medium from TPC-1 or Npa cell. Where 
indicated, cells were preincubated with VEGF A blocking antibodies. Thereafter, filters were fixed and stained. The 
upper surface was wiped clean, and cells on the lower surface were stained with 0.1% crystal violet. The stained cells 
were lysed in 10% acetic acid. Invasive ability is expressed as the percentage of migrating cells with respect to the total 
cell number. Quantification was performed in triplicate samples with an ELISA reader. This figure is representative of 
three independent experiments. 
 
Human mast cells exert their biological functions almost exclusively by 
humoral immune mechanisms. The array of mediators released by human mast 
cells is enormous and explains how mast cells can be involved in so many 
different physiological and pathophysiological functions. Mast cell activation 
can be achieved by different stimuli and includes: preformed granule release, 
cytokine and chemokines synthesis and lipid mediators generation.  
To evaluate whether PTC conditioned culture media could induce 
histamine release from mast cells, we used Npa and primary lung mast cells. 
Figure 31 shows that Npa conditioned culture medium induces histamine 
release from primary lung mast cells.  
 
Figure 31: quantification of Histamine release from HMLC stimulated with Npa conditioned culture 
medium, A23187 calcium ionophore as control. 
To verify whether PTC conditioned media could induce transcriptional 
response in mast cells, we analyzed by Quantitative Real Time Polymerase 
Chain Reaction (qRT-PCR) the mRNA levels of a set of genes encoding for 
cytokines and chemokines. Mast cells were incubated for 24 hours with PTC 
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conditioned culture media, total RNA were extracted and subjected to qPCR. 
Figure 32 shows that the treatment of mast cells with PTC conditioned culture 
media significantly up-regulated the mRNA of genes involved in the activation 
of mast cells: IL-6, GM-CSF, TNF-α, CXCL1/Gro α and CXCL10/IP10. 
Finally, an ELISA assay demonstrated that CXCL1 and CXCL10 (not shown) 
are abundantly secreted by HMC-1 and LAD-2 cell lines stimulated with PTC 
conditioned culture media. 
 
 
Figure 32: PTC conditioned culture media transcriptional activation of HMC-1;mRNA up-reglualtion of IL-6, GM-
CSF, TNF-α cytokines and CXCL1 and CXCL10. 
Mast cells action on PTC cell lines  
Then, we asked whether mast cells conditioned culture medium could 
increase the proliferation rate of PTC cells. To address this point, we measured 
BrdU incorporation as readout of DNA synthesis after 48h of treatment of PTC 
cells with HMC-1 and LAD-2 conditioned culture media. Figure 33 shows that 
treatment with the two conditioned culture media caused an increase in BrdU 
incorporation rate in PTC cells compared with the non-conditioned medium. 
The average results of three independent experiments is reported. 
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Figure 33: BrdU-incorporation was measured to evaluate S-phase entry upon treatment of FB2 and Npa 
cells with HMC-1 or LAD-2 conditioned culture media. 
 
Mast cells conditioned culture medium triggers chemotaxis and 
enhances the invasive behavior of PTC cells 
The presence of mast cells at the invasion front correlated with the 
invasion of the capsule in human PTC. We investigated if mast cells 
conditioned culture medium was able to enhance migration and extracellular 
matrix invasion of the PTC cells by using Matrigel chemoinvasion assay. PTC 
cells (TPC1, FB2, NIM and Npa) were seeded onto the top chamber of 
transwells, and their ability to invade a reconstituted extracellular matrix 
(matrigel) toward mast cells conditioned culture medium was evaluated. After 
24 h of incubation migrating cells were stained and counted. Figure 34 shows 
that mast cells conditioned culture media are able to induce a remarkable 
migration in matrigel of PTC cells, while non-conditioned media were not. 
 
 
Figure 34: PTC cells were seeded onto upper chamber of 8 µM pore transwells and allowed to migrate through 
Matrigel for 24 h towards serum-free medium or conditioned culture medium from HMC-1 cells. Thereafter, filters 
were fixed and stained. The upper surface was wiped clean, and cells on the lower surface were stained with 0.1% 
crystal violet. The stained cells were lysed in 10% acetic acid. Invasive ability is expressed as the percentage of 
migrating cells with respect to the total cell number. Quantification was performed in triplicate samples with an ELISA 
reader. This figure is representative of three independent experiments. 
 
Identification of mediators of mast cells biological activities  
Since Histamine (His) is an important mediator stored in the granules of 
the mast cells, we asked whether this molecule could mediate mast cell-
induced proliferation of PTC cells. To this aim we first verified the expression 
of the four principal histamine receptors, namely H1, H2, H3, H4, on PTC cells. 
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A large panel of PTC cell lines was analysed by RT-PCR the up-regulation of 
H1 and H2 receptors but not H3 and H4 in PTC cells was found, with respect 
to normal thyroid cells (not shown). We also confirmed the expression of the 
H1 and H2 receptors by western blot analysis Figure 35. Protein levels were 
normalized to tubulin (not shown).   
 
 
Figure 35: H1 and H2 protein up-regulation in PTC cells, evaluated by immunoblot.  
 
Then, we evaluated the ability of histamine to enhance the proliferation 
rate of PTC cells lines by performing growth curves. Histamine had a modest 
but reproducible effect in enhancing PTC cells growth (not shown). BrdU 
assay on Npa cell treated with Histamine confirmed the results of the growth 
curves: histamine induces a modest enhancement of S-phase entry Figure 36. 
 
       Npa 
 
Figure 36: BrdU-incorporation was measured to evaluate S-phase entry upon treatment of Npa cells with 
Histamine and where indicated Histamine inhibitors Ranitidine or Levocitirizine. 
 
Clearly histamine couldn’t account for the strong mitogenic activities of 
the mast cell conditioned culture medium. We then hypotesized that other 
mediators might be responsible for those effects. We previously observed that 
two chemokines, CXCL1/GRO-α and CXCL10/IP10, were important 
mediators of PTC proliferation and invasive ability and moreover, the PTC 
conditioned culture medium induces an up-regulation of their expression and 
secretion in HMC-1 and LAD-2 cells. For these reasons we hypotesized that 
the combination of histamine with this two chemokines could account for mast 
cell conditioned media-induced proliferation. 
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In Figure 37 we show that a combination of histamine and 
CXCL1/GROα and CXCL10/IP10 induced thyroid cancer cell proliferation 
with high efficiency. Indeed in the BrdU proliferation assay we observed that 
histamine induces 7% of BrdU positive cells, CXCL1/GROα and 
CXCL10/IP10 induced 30%; when all the three mediators were added, we 
obtained an additive effect, with 60% of BrdU positive cells.  
 
 
Figure 37: BrdU-incorporation was measured to evaluate S-phase entry upon treatment with Histamine, CXCL1, 
CXCL10 or in combination. Average results of three independent experiments ± S.D. 
 
To confirm these results we used blocking antibodies for the two 
chemokines in immunodepletion experiments. The removal of each chemokine 
from mast cells conditioned media strongly reduced the proliferation rate of 
PTC cells; proliferation was completely reverted to basal levels by ablation of 
the two chemokines. The addition of the recombinant chemokines to the 
immunodepleted conditioned culture medium carried back the proliferation 
rate to that of the complete conditioned culture medium (figure 38). 
Importantly, we also observed that the conditioned media from primary mast 
cells (HMLC) induce the same enhancement of proliferation in PTC cell (not 
shown). 
 
 
Figure 38: BrdU-incorporation was measured to evaluate S-phase entry upon treatment with HMC-1 or LAD-2 
conditioned culture media, were indicated conditioned culture media are immunodepleted for CXCL1, CXCL10 and in 
combination.  
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These results suggest that a bidirectional crosstalking between papillary 
thyroid cancer and mast cells exists. Mast cells recruited in tumor site by PTC 
cells promote a more severe phenotype by enhancing proliferation and invasive 
ability of the PTC cancer cells. 
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DISCUSSION 
 
RET/PTC rearrangements are prevalent in thyroid papillary carcinomas 
and experimental evidences indicate that they are able to initiate thyroid 
carcinogenesis, although, very little is known about the mechanisms by which 
RET/PTC oncogenes transform thyroid follicular cells. Model systems of 
thyroid follicular cells have been widely used to study growth regulation and 
neoplastic transformation (Kimura et al. 2003). By using a rat thyroid cell line 
(PC cells) expressing RET/PTC, HRAS and BRAF oncogenes, we show that 
these oncogenic proteins belong to the same signaling cascade and are involved 
in the initiation of PTC carcinogenesis. This pathway starts at the level of RET 
and, sequentially, triggers RAS, BRAF and ERK stimulation. Consistent with 
this finding, activating mutations in the three corresponding genes are mutually 
exclusive in PTC samples (Kimura et al. 2003; Cohen et al. 2003; Soares et al. 
2003). In PC thyroid cells, the three activated oncoproteins induce a 
transformed phenotype together with the stimulation of widely overlapping 
gene expression signatures. We observed that most of the common targets are 
under the control of RET/PTC Y1062, this is consistent with the key role of 
this tyrosine residue to activate the HRAS/ BRAF/ERK pathway. However, the 
analysis of transcriptional profiles indicates  that the three oncoproteins are not 
completely equivalent. Indeed, in addition to targets common to RET/PTC3, 
HRAS and BRAF, there were relatively large sets of genes specifically 
modulated by only one or two of the three oncogenes. Overall, the similarity 
between transcriptional profiles of HRAS(V12) and BRAF(V600E)  thyroid 
cells was greater than those between RET/PTC3 and HRAS or RET/PTC3 and 
BRAF cells. This was not  unexpected; although the three oncoproteins work 
together along a single cascade, they are biochemically different, and therefore 
able to trigger specific signals in  addition to the common ones. Molecular 
genetic evidences nicely support this concept. For instance, BRAF mutations 
are frequently associated with aggressive  thyroid carcinomas, such as poorly 
differentiated and anaplastic carcinomas, that rarely, if ever, harbor RET/PTC 
rearrangements (Nikiforova et al. 2003). On the  other hand, RAS point-
mutations are rare in classic PTC and, instead, characterize PTC of the 
follicular variant that are rarely affected by mutations in BRAF or RET  (Zhu 
et al. 2003). Consistent with this, PC RAS(V12) and PC BRAF(V600E) cells 
express genes that are potentially implicated in cancer progression.  
Our data show that the RET/PTC-RAS-BRAF signaling cascade 
stimulates the overexpression of several cytokines and chemokines, i.e., OPN, 
CCL2, CXCL1 and CXCL10. Interestingly we also found the expression of 
some receptors for these cytokines such as CD44, OPN receptor, and 
chemokines CXCR4, CXCR2 and CXCR3, the receptors for SDF1, CXCL1 
and CXCL10, respectively. Therefore, several autocrine/paracrine loops may 
mediate biological activities in PTC that are relevant for the establishment of 
the neoplastic phenotype, e.g., autonomous proliferation and motility. 
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Chemokines orchestrate immune reactions, but are also involved in the 
pathogenesis of several human diseases, such as chronic obstructive pulmonary 
diseases, asthma and allergic diseases, atherosclerosis and cancer. 
Interestingly, high levels of some chemokines, such as CXCL8, CXCL12, 
CXCL9 and CXCL10 have been detected at high levels in the thyroid and in 
the serum of patients affcted by autoimmune thyroid diseases, such as Grave’s 
disease (GD) and Hashimoto’s thyroiditis (HT). Since several years an 
association between autoimmune thyroid diseases and well differentiated 
thryoid carcinomas has been reported, in particular between HT and papillary 
thyroid carcinoma (PTC). These observation are sustained by the observation 
that some cells, in the context of HT, display a RET/PTC rearrangement, which 
is typical of PTC. Our data, by identifying chemokines and inflammatory 
mediators as part of the program of gene expression induced by the RET/PTC 
oncoprotein, support the hypothesis that oncogene activation precedes and 
causes inflammation. 
We show that OPN up-regulation is involved in the invasive phenotype 
of PTC. Overall, as many as 70% of human PTC are estimated to carry 
mutations at the level of the RET-RAS-BRAF-ERK signaling cascade (Fagin 
et al. 2004)). We previously reported high levels of OPN and CD44v6 in 
follicular cells derived from rat thyroid glands and transformed by the 
RET/PTC oncogene (Castellone et al. 2004). We here show that OPN and 
CD44v6 up-regulation is a common feature of PTC cells that express the 
RET/PTC or BRAF V600E oncogenes. This finding suggests that activation of 
the OPN-CD44v6 axis is one of the end points of the RET-RAS-BRAF-ERK 
oncogenic cascade. This model is consistent with the idea that in other cell 
types, OPN expression is induced by the RAS oncogene (Wu et al. 2000, 
Denhardt et al. 2003) and is dependent on the ERK cascade (Geissinger et al. 
2002), and that CD44v6 splicing is under control of the RAS-ERK pathway 
(Matter et al. 2005). Since OPN is able to induce CD44v6 overexpression (Gao 
et al. 2003), it is conceivable that in PTC cells, the RET-RAS-BRAF-ERK 
oncogenic cascade triggers OPN and CD44v6 up-regulation; this leads to 
OPN-CD44v6 binding, thereby further increasing CD44v6 up-regulation and 
enhancing ERK and AKT signaling. It is noteworthy that AKT activation is a 
common feature of aggressive thyroid cancers (Vasko et al. 2004). The 
foregoing functional autocrine loop may sustain the invasive capability of PTC 
cells consistently. In this study we show that OPN up-regulation correlates 
with aggressive clinicopathological features of PTC. Indeed, the presence of 
lymph node metastases and tumor size both positively correlated with OPN 
positivity. Thus, OPN might be a diagnostic and prognostic marker for these 
tumors. Indeed, OPN, which also occurs in blood, has already proven useful as 
a tumor marker for ovarian (Schorge et al. 2004) and lung (Schneider et al. 
2004) carcinomas. Given the low prevalence of OPN overexpression in PTC-
FV, our findings anticipate that OPN detection will have a rather low 
sensitivity in this particular PTC variant. However, our series of PTC-FV is too 
small to draw firm conclusions. Furthermore, it should be noted that the PTC-
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FV were all included in the T1-T2 stages, where the positivity for OPN is less 
prevalent. Our experiments with CD44-blocking antibodies and ERK kinase 
and PI3-K inhibitors provide proof of principle that the OPN-CD44v6 pathway 
may be a molecular target for therapeutic intervention in cases of aggressive 
PTC. 
We previously reported functional expression of CXCR4 in human 
papillary thyroid cancer (Castellone et al. 2004). Furthermore, Hwang and 
colleagues showed that an anaplastic cell line, ARO, expressed high levels of 
functional CXCR4 (Hwang et al. 2003). We screened a large panel of human 
ATC established and primary cell cultures for CXCR4 expression, both at the 
mRNA and at the protein level, this receptor is overexpressed in ATC with 
respect to normal thyroid samples. In contrast, SDF-1 was not detected. The 
molecular mechanisms underlying CXCR4 up-regulation in ATC are currently 
unknown. Since we had previously shown that CXCR4 expression was under 
the control of the RET/PTC-RAS-BRAF-ERK pathway in PTCs (Castellone et 
al. 2004), and since this pathway is also activated in ATC, we asked whether 
CXCR4 expression correlated with the BRAF status in ATC. The ATC cell 
lines that we used in this study had been previously characterized for BRAF 
mutations. Furthermore, human ATC samples were screened for the presence 
of BRAF mutations. We found that most of the samples expressed CXCR4, 
and this expression was present in both the BRAF positive and in the BRAF 
negative tumors and cell lines. These data suggest that CXCR4 upregulation in 
ATC is not necessarily linked to the BRAF pathway, and that it can be possibly 
achieved through different mechanisms. The mechanisms of CXCR4 up-
regulation in cancer so far described are various and complex. It has been 
shown that NF-kappaB positively regulates the expression of CXCR4 (Helbig 
et al. 2003) in breast cancer cells. Interestingly, NFKB is activated in human 
thyroid cancer cells (Visconti et al. 1997, Pacifico et al 2004). Transduction of 
human thyroid cancer cells with the mutant BRAF(V600E) allele induced an 
increase in NFKB DNA-binding activity (Palona et al. 2006). Thus, it is 
possible that CXCR4 expression in ATC is sustained by high NFKB activity, 
which can be the result either of BRAF activation or of the activation of other 
still undiscovered pathways.  
We also show that the CXCR4 expressed on the ATC cell surface is 
able to transduce biochemical signals into the cell. Indeed, stimulation of ATC 
cells with recombinant human SDF-1  activated ERK1/2 and, less 
consistently, AKT pathways in ATC cells. Moreover, we found that SDF-1  
stimulated cell growth of different ATC cell cultures, which was inhibited by 
the small CXCR4 inhibitor AMD3100. Given the high rate of mortality of this 
cancer and the lack of effective therapies, we focused our efforts in the 
identification of novel potential therapeutic targets in ATC. We found that the 
treatment with AMD3100 significantly suppressed the development of tumors 
in  different xenograft models of ATC cells in nude mice.  
The more dramatic biological effects of CXCR4 inhbition observed in the 
animals with respect with those observed in cell culture could be explained 
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by the fact that SDF-1 can act, in tumor microenvironment, at multiple 
levels. Indeed, tumoral stromal cells, such as fibroblasts and bone marrow 
derived cells, express high levels of SDF-1 (Orimo et al. 2005), which can 
directly enhance the growth of epithelial tumoral cells and can recruit 
endothelial progenitors, thus favoring angiogenesis. However, when we 
analyzed xenograft tumors for CD31-positive tumor capillaries, we found 
that there were no differences in vessel density of AMD3100-treated versus 
untreated tumors. Preliminary data suggest that AMD3100 activity in 
xenografts correlates better with a proapoptotic than with an antiproliferative 
activity (Guarino et al., unpublished observation). Our findings are in accord 
with previous reports regarding the use of CXCR4 inhibitors in brain tumor 
models (Rubin et al 2003, Yang et al. 2007).  Although treatment of ATC 
xenografts with AMD3100 did not induce a complete regression of tumors, 
we observed a strong reduction in growth rate, which was more dramatic in 
the case of BHT101 xenografts. It is conceivable that the combination of 
conventional anticancer therapies with CXCR4 targeting would display a 
stronger antineoplastic effect. Given the strong antitumor activity of 
AMD3100, newer generation compounds have been developed, such as 
AMD3465. This compound differs from the bicyclam AMD3100 in that it is 
a monocyclam endowed with greater solubility in water, higher affinity for 
CXCR4 and a potent anti-tumor activity (Yang et al. 2007). Although these 
compounds are effective in inhibiting various cancers, long-term sustained 
dosing of AMD3100 displayed certain toxicity (Hendrix et al. 2004). For this 
reason further studies, aimed at understanding the effects of long-term 
administration of CXCR4 inhibitors, must be pursued. Despite these 
considerations, our data, together with several other reports, strongly 
indicate that the inhibiton of this pathway should be actively evaluated as a 
novel anticancer therapy. 
PTC is associated with a striking chronic inflammatory reaction in 
about 30% of cases (Rosai 1992; Scarpino et al. 2000). Chemokines secreted 
by tumor cells can recruit leukocytes (macrophages, dendritic cells, T cells and 
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natural killer cells) to tumor sites. We have shown that RET/PTC/RAS/BRAF 
oncogenes in PTC induced an “inflammatory program” that, among other 
effects, can trigger rapid recruitment of inflammatory cells to the tumor site. 
Recents studies have demonstrated that mast cells, a component of innate 
immunity, are present in several tumors, (Ribatti et al. 1999, Vacca et al. 2001, 
tosato et al. 2004, Coussens et al. 1999, Soucek et al. 2007) We found that 
human PTCs display an intense mast cells infiltrate, which is not present in 
normal thyroid. Mast cell infiltrate positively correlated with invasive ability of 
PTCs, but not with vessel density. This result is in contrast with other 
observations showing that in several cancer types mast cell infiltrate correlates 
with increased angiogenesis (Coussens et al. 1999, Soucek et al.2007). Our 
data instead support a role of mast cells in PTC cell proliferation. Not only 
mast cell induced cell growth in vivo and in vitro, but also stimulated PTC cell 
invasion. Mast cell, once activated, can secrete a plethora of growth factors, 
angiogenic factor, pro-inflammatory molecules. The activation of mast cells 
can be activated through various stimuli. The nature of these stimuli in our 
model system is currently unknown, and will be the object of further 
investigation. The activity of mast cells on thyroid cancer cells has been 
investigated through mast cells conditioned media stimulation of PTC cell. 
These experiments showed that chemokines (CXCL1 and CXCL10) contained 
in mast cell conditioned media together with histamine, strongly induced PTC 
cell proliferation. These results indicate that mast cell infiltrate promote 
proliferation and invasive ability of PTC. These data also suggest that the 
inhibition of chemokines, by blocking both auotcrine loops and mast cell 
released factors, might be a potential therapy for these carcinomas. 
Furthermore, therapies that block mast cell degranulation or cytokine synthesis 
could also be of potential interst in these cancers. Our data, although indicating 
a role for mast cells in PTC formation, also raise new questions. When are 
mast cell recruited in PTC formation? In same model systems, such as those 
proposed by Coussens (Junakar et al. 2006), mast cell infiltrate is foud at very 
early stages. Whether this is the case also for PTC is currently under 
investigation. Are mast cells necessary for PTC cancer formation? Experiments 
in wich mast cells deficient mice (Kit-/-) will be crossed with PTC-prone mice 
clarify this issue. 
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CONCLUSIONS 
Our findings, taken together, indicate that oncogenes typically activated 
in human PTCs induce a common transcriptional signature characterized by the 
presence of genes encoding for inflammatory factors, such as cytokines and 
chemokines. Interestingly,  the  receptors for some of these ligands are also 
overexpressed, thus generating autocrine loops that sustain PTC growth and 
invasive ability; these data suggest that these soluble mediators and/or their 
receptors  can be targeted by novel therapeutic agents for the treatment of 
thyroid carcinomas. In support of this, we identify CXCR4 as potential target 
of ATC anticancer therapy and suggest that AMD3100, or other specific 
CXCR4 inhibitors, should be developed and tested for the therapy of human 
ATC. Finally, our data support the occurrence of a complex interplay between 
mast cells and PTC cells, whereby PTC cells support mast cell recruitment, 
survival and activation, and mast cells sustain PTC cell proliferation and 
invasive ability.  
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Abstract
Anaplastic thyroid carcinoma (ATC) is a rare thyroid cancer
type with an extremely poor prognosis. Despite appropriate
treatment, which includes surgery, radiotherapy, and chemo-
therapy, this cancer is invariably fatal. CXCR4 is the receptor
for the stromal cell-derived factor-1 (SDF-1)/CXCL12 chemo-
kine and it is expressed in a variety of solid tumors, including
papillary thyroid carcinoma. Here, we show that ATC cell lines
overexpress CXCR4, both at the level of mRNA and protein.
Furthermore, we found that CXCR4 was overexpressed in ATC
clinical samples, with respect to normal thyroid tissues by
real-time PCR and immunohistochemistry. Treatment of ATC
cells with SDF-1 induced proliferation and increase in
phosphorylation of extracellular signal-regulated kinases
and protein kinase B/AKT. These effects were blocked by the
specific CXCR4 antagonist AMD3100 and by CXCR4 RNA
interference. Moreover, AMD3100 effectively reduced tumor
growth in nude mice inoculated with different ATC cells. Thus,
we suggest that CXCR4 targeting is a novel potential strategy
in the treatment of human ATC. [Cancer Res 2007;67(24):1–9]
Introduction
Thyroid cancer accounts for the majority of endocrine neo-
plasms worldwide (1). Malignant tumors derived from the thyroid
gland include well-differentiated thyroid carcinomas (WDTC;
papillary and follicular) and undifferentiated or anaplastic thyroid
carcinomas (ATC). Another group of cancers falls between these
two types, the so-called poorly differentiated thyroid carcinomas
(PDC). WDTC represents >90% of all thyroid cancers, whereas
ATC accounts for approximately 2% to 5% of them (2–4). WDTC
management requires surgery and adjuvant radioactive iodine
(5, 6). Whereas most of the patients with WDTC have an excellent
prognosis, those that present with PDC or ATC have a poor
prognosis. PDC displays intermediate biological and clinical
features between WDTC and ATC. Indeed, these tumors display
high propensity to recur and metastasize. Furthermore, they tend
to a progressive dedifferentiation, which leads to the decrease in
the levels of the sodium iodide symporter. As a consequence of this,
these tumors are unable to concentrate iodine and become
resistant to radiometabolic therapy (4, 7). ATC is the most
malignant thyroid tumor and one of the more fatal human
malignancy with a median survival from the time of diagnosis of
only 4 to 12 months (8, 9). ATC is more frequent in iodine-deficient
areas and can be associated with other thyroid disorders. These
tumors arise at a mean age of 55 to 65 years, are more common in
women, and present usually as a rapidly growing mass, localized in
the anterior neck area, which rapidly metastasizes at lungs, bone,
and brain. Treatment of ATC with surgery, radiotherapy, and
chemotherapy, alone or in combination, shows little or no effect on
patient’s survival (10). For these reasons, novel treatment strategies
are urgently needed. Unlike the WDTC, the molecular mechanisms
underlying the development of human ATC are largely unknown.
Genetic rearrangements of the RET and TRKA tyrosine kinase
receptors, point mutations of the BRAF serine-threonine kinase or,
less frequently, RAS mutations, are typically found in papillary
thyroid carcinoma (PTC). Rearrangements of PPARg or RAS point
mutations are instead found in human FTC (11, 12). Among these
genetic alterations, RAS or BRAF point mutations are detected at
low frequency in ATC, suggesting that some ATC may arise from a
preexisting WDTC, whereas others arise de novo (12, 13).
Inactivating point mutations of the p53 tumor suppressor and
activating point mutations of the h-catenin or the PIK3CA are also
found in ATC (13, 14).
In the attempt to better characterize human ATC at the
molecular level, we aimed to study the involvement of chemokine
and chemokine receptors in these tumors. Chemokines are small
secretory proteins that were initially reported to control the
recruitment and the activation of immune cells in inflammation
(16). These molecules exert their action through binding to a group
of seven-transmembrane G protein–coupled receptors. All chemo-
kine receptors initiate signal transduction by activating a member
of the Gi family of G proteins which, on receptor activation,
dissociates into a and hg subunits. The Ga subunit inhibits
adenylyl cyclase, whereas the Ghg dimer activates the phospho-
lipase Ch and the phosphatidylinositol 3-kinase pathways, with the
activation of downstream signaling. It has becoming clear recently
that chemokines are also involved in cancer cell migration,
survival, and growth (17). Not only chemokines regulate some
important features of cancer cells but are also involved in the
regulation of tumor angiogenesis and leukocyte recruitment (17).
In particular, the chemokine receptor CXCR4 and its ligand stromal
cell-derived factor-1 (SDF-1)/CXCL12 have been implicated in the
metastatic spread of breast cancer cells (18). CXCR4 is one of the
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most important chemokine receptors for cancer cells. Indeed, it is
expressed in a great number of human solid and hematologic
cancers, including breast, prostate, brain, colon, and lung cancer
(19, 20). We and others previously reported the overexpression and
functional activity of CXCR4 in thyroid cancer (21, 22). In this
report, we show that human ATC cells express high levels of CXCR4
and that the CXCR4-SDF-1/CXCL12 axis sustains the growth of
ATC cells. Finally, we provide evidences that targeting CXCR4
might be exploited as a novel anticancer therapy for human ATC.
Materials and Methods
Cell lines. Human primary cultures of normal thyroid and ATC cells
were obtained from F. CurcioQ3 (P5, P5-2N, P5-3N, P5-4N, and HTU8) and H.
ZitzelsbergerQ4 (S11T, S77T, and S14T) and cultured as described previously
(23). Primary cultures of ATC were also a kind gift of H. Zitzelsberger. Of
these, only the S11T displays a BRAF(V600E) mutation in heterozygosis.4FN1
Human thyroid papillary cancer cell lines TPC1, FB2, and NIM have been
described previously (24–26). TPC1 and FB2 cells harbor a RET/PTC1
rearrangement. NPA87 cells derive from a PDC and harbor a BRAF(V600E)
mutation in homozygosis (23). The anaplastic cells ARO, KAT4, BHT101,
and FB1 cells harbor a BRAF(V600E) mutation in heterozygosis; 8505C and
FRO harbor a BRAF(V600E) mutation in homozygosis (23); and CAL62 cells
express wild-type BRAF but mutant NRAS allele. Continuous cell lines were
maintained in DMEM supplemented with 10% fetal bovine serum, 1%
penicillin-streptomycin, and 1% glutamine.
RNA extraction and reverse transcription PCR. Total RNA was
isolated by the RNeasy kit (Qiagen) and subjected to on-column DNase
digestion with the RNase-free DNase set (Qiagen) according to the
manufacturer’s instructions. The quality of RNA was verified by electro-
phoresis through 1% agarose gel and visualized with ethidium bromide.
RNA (1 Ag) from each sample was reverse transcribed with the QuantiTect
Reverse Transcription (Qiagen) using an optimized blend of oligo(dT) and
random primers according to the manufacturer’s instructions. To design
a quantitative reverse transcription-PCR (RT-PCR) assay, we used the
Human ProbeLibray system (Exiqon). Briefly, Exiqon provides 90 human
prevalidated Taqman probes (8–9 nucleotides long) that recognizef99% of
human transcripts in the RefSeq database at the National Center for
Biotechnology Information. The ProbeFinder assay design software
(available online)5FN2 was used to design primer pairs and probes. All
fluorogenic probes were dual labeled with FAM at 5¶-end and with a black
quencher at the 3¶-end. Primer pairs and PCR conditions are available on
request. Quantitative RT-PCR was performed in a Chromo 4 Detector (MJ
Research) in 96-well plates using a final volume of 20 AL. For each PCR, 8 AL
of 2.5 RealMasterMix Probe ROX (Eppendorf AG), 200 nmol/L of each
primer, 100 nmol/L probe, and cDNA generated from 50 ng of total RNA
were used. PCRs were performed in triplicate and fold changes were
calculated with the following formula: 2(sample 1 DC t  sample 2 DC t), where
DCt is the difference between the amplification fluorescent thresholds of
the mRNA of interest and the mRNA of RNA polymerase 2 used as an
internal reference.
Immunohistochemistry. Retrospectively collected archival thyroid
tissue samples from patients affected by ATCs were retrieved from the
files of the Pathology Department of the University of Pisa on informed
consent. Sections (4 Am thick) of paraffin-embedded samples were stained
with H&E for histologic examination to ensure that the samples fulfilled the
diagnostic criteria required for the identification of ATC. Normal thyroid
tissue samples were also retrieved from the files of the Pathology
Department of the University of Pisa.
For immunohistochemistry, paraffin sections (3–5 Am) were dewaxed in
xylene, dehydrated through graded alcohols, and blocked with 5%
nonimmune mouse serum in PBS with 0.05% sodium azide for 5 min.
Mouse monoclonal antibody against CXCR4 (clone 12G5; R&D Systems)
was added at 1:1,000 dilution for 15 min. After incubation with biotinylated
anti-mouse secondary antibody for 15 min followed by streptavidin-biotin
complex for 15 min (Catalyzed Signal Amplification System, DAKO),
sections were developed for 5 min with 0.05% 3,3¶-diaminobenzidine
tetrahydrochloride and 0.01% hydrogen peroxide in 0.05 mol/L Tris-HCl
buffer (pH 7.6), counterstained with hematoxylin, dehydrated, and
mounted.
Protein studies. Immunoblotting experiments were performed accord-
ing to standard procedures. Briefly, cells were harvested in lysis buffer
[50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 10% glycerol, 1% Triton
X-100, 1 mmol/L EGTA, 1.5 mmol/L MgCl2, 10 mmol/L NaF, 10 mmol/L
sodium pyrophosphate, 1 mmol/L Na3VO4, 10 Ag/mL aprotinin, 10 Ag/mL
leupeptin] and clarified by centrifugation at 10,000  g . For protein
extraction from human tissues, snap-frozen samples were immediately
homogenized in lysis buffer by using the Mixer Mill apparatus (Qiagen).
Protein concentration was estimated with a modified Bradford assay (Bio-
Rad). Antigens were revealed by an enhanced chemiluminescence detection
kit (Amersham). Anti-CXCR4 antibodies were from Abcam Ltd. For the
evaluation of mitogen-activated protein kinase (MAPK) and AKT activity on
SDF-1a triggering, BHT101 and S11T cells were serum deprived for 12 h and
then stimulated with human recombinant SDF-1a (R&D Systems) for the
indicated time. Anti-phosphorylated p44/42 MAPK, anti-p44/42 MAPK,
anti-phosphorylated AKT, and anti-AKT antibodies were from New England
Biolabs. Anti-tubulin monoclonal antibody was from Sigma Chemical.
Secondary anti-mouse and anti-rabbit antibodies coupled to horseradish
peroxidase were from Bio-Rad.
Flow cytometric analysis. Subconfluent cells were detached from
culture dishes with a solution of 0.5 mmol/L EDTA and then washed thrice
in PBS buffer. After saturation with 1 Ag of human IgG/105 cells, cells were
incubated for 20 min on ice with phycoerythrin (PE)-labeled antibodies
specific for human CXCR4 (R&D Systems) or isotype control antibody. After
incubation, unreacted antibody was removed by washing cells twice in PBS
buffer. Cells resuspended in PBS were analyzed on a FACSCalibur
cytofluorimeter using the CellQuest software (Becton Dickinson). Analyses
were performed in triplicate. In each analysis, a total of 104 events were
calculated.
Cell proliferation. S-phase entry was evaluated by bromodeoxyuridine
(BrdUrd) Q6incorporation and indirect immunofluorescence. Cells were grown
on coverslips, kept in 2.5% serum for 24 h, and then treated with
recombinant SDF-1a (100 ng/mL) for 48 h. BrdUrd was added at a
concentration of 10 Amol/L for the last 1 h. Subsequently, cells were fixed in
3% paraformaldehyde and permeabilized with 0.2% Triton X-100. BrdUrd-
positive cells were revealed with Texas red–conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories, Inc.). Cell nuclei were
identified by Hoechst staining. Fluorescence was visualized with a Zeiss 140
epifluorescent microscope.
For growth curves, cells were plated at a density of 0.5  105 in low-
serum conditions (2.5%) and counted at the indicated time points.
RNA interference. Small inhibitor duplex RNAs targeting human CXCR4
have been described previously (27) Q7and were chemically synthesized by
Proligo. Sense strand for human CXCR4 small interfering RNA (siRNA)
targeting was the following: 5¶-GAGGGGAUCAGCAGUAUAUAC-3¶.
Small duplex RNAs containing the same nucleotides, but in scrambled
fashion (siRNA SCR), were used as a negative control. For siRNA transfection,
ATC cells were grown under standard conditions. The day before
transfection, cells were plated in six-well dishes at 50% to 60% confluency.
Transfection was performed using 5 to 15 Ag of duplex RNA and 6 AL of
Oligofectamine reagent (Invitrogen). Cells were harvested at 48 and 72 h after
transfection and analyzed for protein expression and biological activity.
Xenografts in nude mice. Mice were housed in barrier facilities and
12-h light-dark cycles and received food and water ad libitum at the
Dipartimento di Biologia e Patologia Cellulare e Molecolare (University of
Naples ‘‘Federico II,’’ Naples, Italy). This study was conducted in accordance
with Italian regulations for experimentation on animals. All manipulations
were performed while mice were under isoflurane gas anesthesia. No mouse
4 G. Salvatore, unpublished observation.
5 http://www.probelybrary.comQ5
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showed signs of wasting or other signs of toxicity. BHT101, ARO, or KAT4
cells (5  106 per mouse) were inoculated s.c. into the right dorsal portion
of 4-week-old male BALB/c nu/nu mice (The Jackson Laboratory). When
tumors measured 40 mm3, mice were randomized to receive AMD3100
(n = 10; 1.25 mg/kg/twice daily) or vehicle alone (n = 10; PBS) by i.p.
injection for 5 consecutive days per week for 3 to 4 weeks. Tumor diameters
were measured at regular intervals with calipers. Tumor volumes (V ) were
calculated with the following formula: V = A  B2 / 2 (A = axial diameter;
B = rotational diameter). Tumors were excised and fixed overnight in
neutral buffered formalin and processed by routine methods.
Statistical analysis. To compare CXCR4 mRNA levels in normal thyroid
tissues versus ATC samples, we used the Mann-Whitney nonparametric test
and the GraphPad Instat software, v.3.0b. To compare ATC xenograft
growth in AMD3100-treated versus untreated animals, we used the
unpaired Student’s t test (normal distributions and equal variances) and
the GraphPad Instat software, v.3.0b. All P values were two sided, and
differences were considered statistically significant at P < 0.05.
Results
CXCR4 is overexpressed in surgical samples of human ATC.
We compared CXCR4 mRNA levels in a set of ATC samples (n = 15)
versus different samples of normal thyroid tissue (n = 5). As shown
in Fig. 1A F1, CXCR4 mRNA was found to be up-regulated in most of
the tumor samples (11 of 15). When we performed statistical
analysis, the differences in the expression levels of CXCR4 between
tumors and normal thyroid tissues were statistically significant
(P = 0.0084; Fig. 1A).
To verify whether CXCR4 mRNA overexpression resulted in an
increase in the protein levels, we used protein extracts from a
different set of ATC samples and three normal thyroid tissues in an
immunoblot experiment with CXCR4-specific antibodies. As shown
in Fig. 1B , CXCR4 protein levels were higher in ATC samples than
in normal thyroid. As a positive control for CXCR4 expression, the
ATC cell line ARO was used.
Finally, CXCR4 antibodies were used in immunohistochemical
experiments. We evaluated CXCR4 expression in normal thyroid
tissues and a set of ATC samples (n = 33). Whereas no CXCR4
expression was detected in normal thyroid tissues, 13 (39%) of the
ATC samples scored positive for CXCR4. A representative CXCR4
immunostaining is shown in Fig. 1C . These data indicate that a
significant fraction of human ATCs, similarly to other epithelial
Figure 1. A, expression levels of CXCR4 in human ATC samples versus six normal thyroid tissues by real-time RT-PCR. CXCR4 expression levels of tumors (Y axis )
are calculated relative to the mean CXCR4 level of normal human thyroid tissues (NT). All experiments have been performed in triplicate, and the average value of the
results was plotted on the diagram. P value was calculated with the two-tailed, nonparametric Mann-Whitney test. B, protein lysates (100 Ag) extracted from the
indicated samples underwent Western blotting with anti-CXCR4-specific antibodies. Immunocomplexes were revealed by enhanced chemiluminescence. Equal protein
loading was ascertained by anti-tubulin immunoblot. C, immunohistochemical staining for CXCR4 of formalin-fixed, paraffin-embedded ATCs. Tissue samples from
normal thyroid or ATC were incubated with a mouse monoclonal anti-CXCR4 antibody. ATCs show a strong immunoreactivity for CXCR4, whereas normal thyroid
tissue is negative. Representative pictures of normal and pathologic positive samples are shown. Isotype control was also performed (data not shown). D, the
expression levels of CXCR4 protein were analyzed in thyroid tumor samples from transgenic mice models. Tumor tissues were snap frozen and immediately
homogenized by using the Mixer Mill apparatus in lysis buffer. Equal amounts of proteins were immunoblotted and stained with anti-CXCR4 polyclonal antibodies
(Abcam). ATC-like samples displayed a more intense immunoreactivity for CXCR4. As a control for equal loading, the anti-a-tubulin monoclonal antibody was used.
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cancers, feature high expression levels of the CXCR4 receptor.
Furthermore, they suggest that the increase in CXCR4 levels occurs
at the transcriptional level.
CXCR4 is highly expressed in animal models of ATC. Several
transgenic mice model of thyroid cancer have been developed by
using various oncogenes under the transcriptional control of the
thyroid-specific thyroglobulin bovine promoter. Depending on the
specific transgene, these mice develop carcinomas that resemble,
for cytologic and histologic features, human PTC, FTC, or ATC.
In particular, mice expressing either RET/PTC3 (TGPTC3) or
TRK/T1 (TGTRK) oncogene develop PTC-like tumors (28, 29).
NRAS transgene expression results in follicular tumors that
progress to poorly differentiated carcinomas (TGNRAS; ref. 27).
Finally, animals expressing the SV40 large T antigen (TGSV) present
aggressive thyroid cancer with features similar to human ATC (30).
To evaluate the expression of CXCR4 in these animal models, we
extracted proteins from different tumor samples of the different
transgenic lines and performed Western blot analysis with CXCR4
antibodies. Histologic diagnosis of the thyroid lesion was verified
before processing of the samples. As shown in Fig. 1D , CXCR4
levels were higher in ATC models than in normal mouse thyroid
tissue. PTC samples displayed intermediate levels of CXCR4. These
data, together with previously published data (21, 22), suggest that
CXCR4 up-regulation is a frequent event in thyroid tumorigenesis
and that it correlates with the malignancy of the disease.
CXCR4 is a functional receptor in human ATC cells. To study
the role of CXCR4 in human ATC, we first needed to identify a
suitable cell model. To this aim, various normal thyroid and ATC-
derived primary cultures and continuous cell lines were tested for
CXCR4 expression by Western blot analysis. As shown in Fig. 2A
and B F2, whereas normal thyroid cultures displayed low or unde-
tectable CXCR4 expression levels, several ATC cell lines featured
high levels of the CXCR4 receptor. In particular, of 10 ATC cell
lines, 7 displayed high expression levels of CXCR4. In the case of
ATC cells, the increased levels of CXCR4 proteins were associated
to an increase in CXCR4 mRNA levels as assessed by quantitative
PCR analysis (Fig. 2C). We then asked whether this receptor was
expressed on the cell surface. To this aim, we performed flow
cytometry experiments using a PE-conjugated mouse monoclonal
anti-CXCR4 antibody. The percentage of CXCR4-positive cells was
Figure 2. A, CXCR4 up-regulation in cell lines derived from human thyroid carcinomas was evaluated by immunoblot with a polyclonal anti-CXCR4 antibody.
The expression levels of CXCR4 protein were analyzed in the P5 human primary thyroid cells, and in the indicated cell lines, derived from human PTCs (NIM, TPC1,
FB2, and NPA) or from human ATCs (8505C, ARO, CAL62, BHT101, FRO, and FB1). B, ATC-derived (S11T, S77T, S14T, and HTU8) and normal thyroid
primary culture (P5) were screened for CXCR4 expression by Western blot analysis with the polyclonal anti-CXCR4 antibody. As a control for equal loading, the
anti-a-tubulin monoclonal antibody was used. C, expression levels of CXCR4 in human ATC cells versus the P5 normal thyroid culture were evaluated by real-time
RT-PCR analysis. CXCR4 expression levels of ATC cell lines (Y axis ) are calculated relative to the expression level in the normal human cell culture P5. All
experiments were performed in triplicate, and the average value of the results was plotted on the diagram. SDs were smaller than 25% in all the cases (data not shown).
D, flow cytometric analysis (fluorescence-activated cell sorting) of surface-expressed CXCR4 in ATC cells. Subconfluent cells were detached from culture dishes
and incubated with PE-labeled antibodies specific for human CXCR4.
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determined. As shown in Fig. 2D , CXCR4 was expressed in almost
all the ATC cell lines tested, with the exception of the FB1 cells. The
ARO cells, which in a previous report were shown to feature high
CXCR4 levels (21), were included as a positive control. In contrast,
normal thyroid cells did not express CXCR4 (data not shown).
SDF-1, the CXCR4 ligand, was not expressed by ATC cells as
assessed by quantitative PCR or ELISA assay (data not shown).
We selected two cell lines, S11T and BHT101, for further
experiments. First, we tested the ability of recombinant SDF-1a to
stimulate signal transduction in ATC cells. It has been previously
reported that stimulation of CXCR4 induces the activation of
several kinase cascades mainly through the activation of the Ghg
subunit of the Gi protein (31, 32). We therefore tested the
phosphorylation of two downstream effectors, extracellular sig-
nal-regulated kinase (ERK) 1/2 and AKT, using phosphorylated-
specific antibodies. To this aim, cells were serum starved for 12
h and then stimulated with SDF-1a for different time points. As
shown in Fig. 3A and BF3 , SDF-1a induced rapid and sustained
activation of ERK1/2 in both cell lines. AKT activation was also
achieved in BHT101 cells on SDF-1a treatment, whereas it was less
evident in S11T cells. Together, these data indicate that CXCR4 is
functional in ATC cells. Activation of ERK1/2 and AKT was
observed in virtually all the ATC cell lines expressing CXCR4,
whereas normal thyroid cells, which do not express CXCR4, did not
display these effects (data not shown).
Biological activity of CXCR4 in ATC cells. To further test the
functional responsiveness of CXCR4 in ATC, we stimulated these
cells with SDF-1a and evaluated its ability to induce cell
proliferation. To this aim, BHT101 and S11T cells were maintained
in low-serum (2.5%) growth conditions for 24 h and then either left
untreated or stimulated with SDF-1a for 12 h. As a measure of DNA
synthesis, we counted BrdUrd-positive cells on a 1-h BrdUrd pulse.
As shown in Fig. 4F4 , SDF-1a consistently enhanced DNA synthesis in
both BHT101 and S11T cells. We then used a specific CXCR4
inhibitor, AMD3100, to block this effect. AMD3100 is a competitive
antagonist of SDF-1a, but it also displays partial agonist activity
(33). Normal thyroid cells were insensitive to SDF-1a stimulation
and to the effect of AMD3100 (data not shown). As shown in
Fig. 4A , AMD3100 inhibited SDF-1a–mediated BrdUrd incorpora-
tion in ATC cells. The positive effect of SDF-1 on cell proliferation,
measured as S-phase entry, was also observed in other ATC cell
lines (Fig. 5CF5 ). To evaluate whether SDF-1a could stimulate ATC
cell growth, we also performed growth curves in low-serum (2.5%)
conditions. As shown in Fig. 4B , the stimulation of BHT101 with
SDF-1a increased their proliferation rate, and AMD3100 reverted
this effect. SDF-1a was also able to increase the proliferation rate
of three different ATC cell lines, KAT4, CAL62, and ARO, which
express CXCR4, but was unable to do so on FB1 cells, which we
previously reported to be devoid of CXCR4 (Fig. 4B). AMD3100
alone did not have any effect on ATC cells (data not shown).
To exclude off-target effects of AMD3100 and to directly
determine the role of CXCR4 on ATC cell proliferation, we used
small duplex RNA oligos to knock down CXCR4. CXCR4 RNA
interference was verified by Western blot analysis in BHT101 cells
(Fig. 5A). We then transfected CXCR4 siRNAs into BHT101, KAT4,
CAL62, and 8505C cells. CXCR4 silencing substantially impaired
SDF-1a–induced S-phase entry in all the ATC cells but had no
effect on BrdUrd incorporation in the absence of the chemokine, as
shown in Fig. 5. When we used the control scrambled siRNA, this
inhibitory effect was not observed. Furthermore, scrambled oligos
had no effect on CXCR4 protein levels (Fig. 5A).
AMD3100 inhibits ATC tumor formation in nude mice. It has
been previously shown that the CXCR4/SDF-1 axis plays an
important role in the growth and in the metastatic ability of
several epithelial cancers (20). Because we had shown that CXCR4
inhibition blocked SDF-1a–mediated ATC cell growth in culture,
and because it has been shown that this chemokine is secreted by
stromal tumoral cells (34), we reasoned that SDF-1a-CXCR4 axis
blockade by AMD3100 might inhibit ATC tumor growth. To this
aim, we selected BHT101, ARO, and KAT4 cells for their ability to
respond to SDF-1a and their ability to form tumors in vivo with
high efficiency. Nude mice were injected s.c. with 5  106 cells.
When tumors measuredf40 mm3, mice (n = 20 for each cell line)
were randomized to receive AMD3100 (1.25 mg/kg/twice daily
i.p.) or vehicle 5 days per week for 3 to 4 weeks. Tumor diameters
were measured at regular intervals with caliper. After 21 days, the
mean volume of BHT101 tumors in mice treated with AMD3100
was 48 mm3, whereas that of mice treated with vehicle was
620 mm3. Representative experiments are shown in Fig. 6A and B F6.
Tumors induced by ARO and KAT4 reached the volume of 40 mm3
in only 1 week. In addition, in this case, AMD3100 was able to
inhibit tumor growth, although to a lesser extent. In fact, ARO-
induced tumor mean volume at the end of treatment with
AMD3100 was 220 mm3, whereas that of mice treated with vehicle
was 625 mm3. Similar results were also obtained when KAT4 cells
were used. In this case, the difference between the mean volume
of AMD3100-treated versus vehicle-treated tumors was not
statistically significant after 3 weeks. However, when treatment
Figure 3. A and B, protein extracts from the
indicated cell lines were subjected to
immunoblotting with anti-phosphorylated
p44/42 MAPK (apMAPK) and with
anti-phosphorylated AKT (apAKT)
antibodies. The blots were reprobed with
anti-p44/42 and anti-AKT antibodies for
normalization.
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was extended for 1 additional week, AMD3100-treated tumor mean
volume was 180 mm3, whereas that of mice treated with vehicle
was 690 mm3, and the P value was 0.039 (Fig. 6A). These data,
taken together, show that treatment with AMD3100 strongly inhi-
bits ATC tumor growth.
Discussion
Despite ATC is a rare disease, it is one of the most aggressive
human cancers (9). Although various therapeutic strategies have
been exploited to slow down the growth of this tumor, none of
these treatments improved survival (10). The molecular pathways
implicated in this disease are poorly understood, and this hampers
the application of novel rational therapeutic strategies. Genetic
alterations found in ATC are inactivating mutations of the p53
tumor suppressor and activating mutations of h-catenin, RAS,
BRAF, and PIK3CA (11). Recently, molecular genetic alterations of
FHIT have been also detected in ATC (35). Among the genes
involved in ATC, BRAF serine-threonine kinase has been exploited
as a potential therapeutic target (23).
Most epithelial cancers feature high levels of expression of the
chemokine receptor CXCR4 (20). This receptor has been widely
Figure 4. A, BrdUrd incorporation was measured to evaluate S-phase entry on treatment of BHT101 and S11T cells with SDF-1a in the presence or absence of
the CXCR4 inhibitor AMD3100. Columns, average results of three independent experiments; bars, SD. P < 0.05. B, the indicated cell lines were plated at the same
density (5  104) in 2.5% serum, harvested, and counted at the indicated time points. Columns, average results of at least three independent determinations; bars, SD.
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studied because its expression contributes to several phenotypes of
cancer cells, such as the ability to grow, survive, and spread
throughout the body. On the contrary, most epithelial cancers do
not express SDF-1, the unique CXCR4 ligand, whereas SDF-1 is
produced in high amounts in specific body districts. It has been
suggested that the role of this chemokine in cancer is mainly to
attract cancer cells to these districts (18). In support of this
hypothesis, it has been shown that SDF-1 is produced in several
metastatic sites. Recently, it has also been suggested that tumoral
stroma secretes high amounts of SDF-1, supporting the concept
that this chemokine is pivotal in sustaining local protumorigenic
events, such as growth and survival of cancer cells (34). Further-
more, the expression of SDF-1 by stromal cancer cells directly
recruits endothelial progenitors that are required for tumor
angiogenesis (19). As most epithelial and hematopoietic malignan-
cies, also thyroid cancer expresses high levels of CXCR4.
We previously reported functional expression of CXCR4 in
human papillary thyroid cancer (22). Furthermore, Hwang et al.
(21) showed that an anaplastic cell line, ARO, expressed high levels
of functional CXCR4. In this report, we analyzed human ATC
samples for CXCR4 expression. We also screened a large panel of
human ATC established and primary cell cultures for CXCR4
expression. We show that, both at the mRNA and at the protein
level, this receptor is overexpressed in ATC with respect to normal
thyroid samples. In contrast, SDF-1 was not detected. The
molecular mechanisms underlying CXCR4 up-regulation in ATC
are currently unknown. Because we had previously shown that
CXCR4 expression was under the control of the RET/PTC-RAS-
BRAF-ERK pathway in PTCs (22), and because this pathway is also
activated in ATC, we asked whether CXCR4 expression correlated
with the BRAF status in ATC. The ATC cell lines that we used in
this study had been previously characterized for BRAF mutations.
Figure 5. A, CXCR4 RNA interference was used to transiently suppress CXCR4 expression in BHT101 cells. BHT101 cells were transfected with siRNAs against
CXCR4 (siRNA CXCR4) or control nonspecific small duplex RNA containing the same nucleotides, but in scrambled fashion (siRNA SCR ), and harvested
48 and 72 h later. Protein lysates were subjected to immunoblotting with anti-CXCR4 and anti-tubulin antibodies. Control siRNA did not affect CXCR4 protein levels.
B, CXCR4 RNA interference (siRNA CXCR4 ) in BHT101 cells inhibited SDF-1a–stimulated S-phase entry as evaluated by BrdUrd incorporation assay. Control
siRNA (siRNA SCR ) did not inhibit DNA synthesis. Unstimulated BHT101 cells were not affected by siRNA transfection. C, CXCR4 RNA interference (siRNA CXCR4 )
inhibited S-phase entry in SDF-1a–stimulated KAT4, CAL62, and 8505C. ATC cells were transfected with siRNAs against CXCR4 (siRNA CXCR4 ) or control
siRNA (siRNA SCR ) and harvested 48 h later. Control siRNA did not inhibit DNA synthesis. Unstimulated cells were not affected by siRNA transfection.
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Furthermore, human ATC samples were screened for the presence
of BRAF mutations.6 FN3We found that most of the samples expressed
CXCR4, and this expression was present in both the BRAF-positive
and in the BRAF-negative tumors and cell lines. These data suggest
that CXCR4 up-regulation in ATC is not necessarily linked to the
BRAF pathway and that it can be possibly achieved through
different mechanisms. The mechanisms of CXCR4 up-regulation in
cancer thus far described are various and complex. It has been
shown that nuclear factor-nB (NF-nB) positively regulates the
expression of CXCR4 (36) in breast cancer cells. Interestingly,
NF-nB is activated in human thyroid cancer cells (37, 38). Interest-
ingly, transduction of human thyroid cancer cells with the mutant
BRAF(V600E) allele induced an increase in NF-nB DNA-binding
activity (39). Thus, it is possible that CXCR4 expression in ATC is
sustained by high NF-nB activity, which can be the result either of
BRAF activation or of the activation of other still undiscovered
pathways.
We also show that the CXCR4 expressed on the ATC cell surface
is able to transduce biochemical signals into the cell. Indeed,
stimulation of ATC cells with recombinant human SDF-1a
activated ERK1/2 and, less consistently, AKT pathways in ATC
cells. Moreover, we found that SDF-1a stimulated cell growth of
different ATC cell cultures, which was inhibited by the small
CXCR4 inhibitor AMD3100. Given the high rate of mortality of this
cancer and the lack of effective therapies, we focused our efforts in
the identification of novel potential therapeutic targets in ATC. We
found that the treatment with AMD3100 significantly suppressed
the development of tumors in different xenograft models of ATC
cells in nude mice.
The more dramatic biological effects of CXCR4 inhibition
observed in the animals with respect with those observed in cell
culture could be explained by the fact that SDF-1 can act, in
tumor microenvironment, at multiple levels. Indeed, tumoral
stromal cells, such as fibroblasts and bone marrow–derived cells,
express high levels of SDF-1 (34), which can directly enhance the
growth of epithelial tumoral cells and can recruit endothelial
progenitors, thus favoring angiogenesis. However, when we
analyzed xenograft tumors for CD31-positive tumor capillaries,
we found that there were no differences in vessel density of
AMD3100-treated versus untreated tumors. Preliminary data
suggest that AMD3100 activity in xenografts correlates better
with a proapoptotic than with an antiproliferative activity.7 FN4Our
findings are in accord with previous reports about the use of
CXCR4 inhibitors in brain tumor models (40, 41). Although
treatment of ATC xenografts with AMD3100 did not induce a
complete regression of tumors, we observed a strong reduction in
growth rate, which was more dramatic in the case of BHT101
xenografts. It is conceivable that the combination of conventional
anticancer therapies with CXCR4 targeting would display a
stronger antineoplastic effect. Given the strong antitumor activity
of AMD3100, newer-generation compounds have been developed,
such as AMD3465. This compound differs from the bicyclam
AMD3100 in that it is a monocyclam endowed with greater
solubility in water, higher affinity for CXCR4, and a potent
antitumor activity (41). Although these compounds are effective in
inhibiting various cancers, long-term sustained dosing of
Figure 6. A, antitumorigenic effects of AMD3100 in ATC cell xenografts.
BHT101, ARO, and KAT4 cells (5  106 per mouse) were injected s.c. into the
right dorsal portion of BALB/c athymic mice. When tumors measured 40 mm3,
mice were randomized to two groups (10 mice per group) to receive AMD3100 or
vehicle (PBS) by i.p. injection. Treatment was given for 5 consecutive days per
week for 3 to 4 wks (day 1 is the treatment starting day). Tumor diameters
were measured with calipers and tumor volumes were calculated. Unpaired
Student’s t test (normal distributions and equal variances) was applied. All
P values were two sided, and differences were statistically significant at
P < 0.05. B, tumors were excised and photographed. Two representative
examples of BHT101 xenografts are shown.
6 F. Basolo and P. Faviana, unpublished observations.
7 V. Guarino et al., unpublished observation.
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AMD3100 displayed a certain toxicity (42). For this reason, further
studies, aimed at understanding the effects of long-term
administration of CXCR4 inhibitors, must be pursued. Despite
these considerations, our data, together with several other reports,
strongly indicate that the inhibition of this pathway should be
actively evaluated as a novel anticancer therapy.
In conclusion, in this report, we identify CXCR4 as another
potential target of ATC anticancer therapy and suggest that
AMD3100, or other specific CXCR4 inhibitors, should be developed
and tested for the therapy of human ATC.
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OPN/CD44v6 overexpression in laryngeal dysplasia and
correlation with clinical outcome
S Staibano1, F Merolla2, D Testa3, R Iovine4, M Mascolo1, V Guarino2, MD Castellone2, M Di Benedetto1,
V Galli4, S Motta3, RM Melillo2, G De Rosa1, M Santoro2 and A Celetti*,2
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Laryngeal dysplasia is a common clinical concern. Despite major advancements, a significant number of patients with this condition
progress to invasive squamous cell carcinoma. Osteopontin (OPN) is a secreted glycoprotein, whose expression is markedly elevated
in several types of cancers. We explored OPN as a candidate biomarker for laryngeal dysplasia. To this aim, we examined OPN
expression in 82 cases of dysplasia and in hyperplastic and normal tissue samples. OPN expression was elevated in all severe dysplasia
samples, but not hyperplastic samples, with respect to matched normal mucosa. OPN expression levels correlated positively with
degree of dysplasia (P¼ 0.0094) and negatively with disease-free survival (Po0.0001). OPN expression was paralleled by cell surface
reactivity for CD44v6, an OPN functional receptor. CD44v6 expression correlated negatively with disease-free survival, as well
(P¼ 0.0007). Taken as a whole, our finding identify OPN and CD44v6 as predictive markers of recurrence or aggressiveness in
laryngeal intraepithelial neoplasia, and overall, point out an important signalling complex in the evolution of laryngeal dysplasia.
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Laryngeal squamous cell carcinoma (LSCC) is the most common
type of head and neck squamous cell carcinoma (HNSCC). LSCC
accounts for 1–2% of all malignancies diagnosed worldwide
(Vokes et al, 1993; Licitra et al, 2003; Mao et al, 2004).
Notwithstanding primary prevention, screening, surgical treat-
ment, and radiotherapy, the long-term survival rate of LSCC
patients has remained substantially unchanged in the last two
decades (Hoffman et al, 1998). Survival of the patients depends on
the stage of the disease; therefore, early detection and timely
therapy are essential (Vokes et al, 1993; Hoffman et al, 1998;
Licitra et al, 2003; Mao et al, 2004).
Laryngeal squamous cell carcinoma usually develops in a
multistep process: normal mucosa – dysplasia (laryngeal intra-
epithelial neoplasia, LIN) – LSCC in situ – invasive LSCC (Rosai
et al, 1992; Tabor et al, 2002; Zuckerberg, 2002; Johnson, 2003).
Dysplasia is characterised by increased cell growth, cellular atypia
(nuclear and nucleolar abnormalities, altered nuclear/cyto-
plasmatic ratio, and altered cytoplasmatic differentiation), and
architectural alteration of the epithelium. Conventionally, the
dysplastic changes are graded as mild (LIN I: dysplasia limited to
the basal third of the epithelium, few mitoses), moderate (LIN II:
dysplasia involving the lower two-thirds of the epithelium, marked
nuclear changes, prominent nucleoli, mitoses in the parabasal, and
intermediate layers), and severe (LIN III: dysplasia involving more
than two-thirds of the epithelial thickness, nuclear pleomorphism
and hyperchromasia, prominent nucleoli, cell crowding, and
atypical mitoses). Often, severe dysplasia and in situ carcinoma
are grouped in the same category (Rosai et al, 1992; Tabor et al,
2002; Zuckerberg, 2002; Johnson, 2003). Early forms of dysplasia
may be reversible if the initial stimuli (like smoke and volatile
irritating substances) are removed, while severe dysplasia, if left
untreated, is regarded as a precancerous lesion (Rosai et al, 1992;
Tabor et al, 2002; Zuckerberg, 2002; Johnson, 2003). For patients
with mild or moderate dysplasia, the reported rate of progression
to invasive cancer is up to 11.5 and 45%, respectively. In severe
dysplasia, higher rates of progression are commonly reported
(Rosai et al, 1992; Tabor et al, 2002; Zuckerberg, 2002; Johnson,
2003). The molecular events that induce the evolution of dysplasia
to carcinoma are still unknown (Cowan et al, 1992; Zuckerberg,
2002; Perez-Ordonez et al, 2006).
Osteopontin (OPN), also known as SPP1 (secreted phospho-
protein 1), is a highly acidic calcium-binding glycosylated
phosphoprotein (Weber, 2001; Rittling and Chambers, 2004;
Rangaswami et al, 2006). OPN can function both as cell adhesion
molecule and as cytokine. It binds to the cell surface receptors av-
or b1-containing integrins and CD44v6 (Weber, 2001; Rittling and
Chambers, 2004; Rangaswami et al, 2006), thereby supporting
proliferation, chemotaxis, attachment, and migration of many cell
types. CD44 is a cell surface glycoprotein that is involved in
regulating cell–cell and cell–matrix interactions, migration, and
tumour growth and progression (Ponta et al, 2003). CD44 is
Received 18 July 2007; revised 1 October 2007; accepted 9 October
2007; published online 6 November 2007
*Correspondence: Dr A Celetti; E-mail: celetti@unina.it
British Journal of Cancer (2007) 97, 1545 – 1551
& 2007 Cancer Research UK All rights reserved 0007 – 0920/07 $30.00
www.bjcancer.com
M
o
le
cu
la
r
D
ia
g
n
o
st
ic
s
expressed as a standard receptor (CD44s) and in multiple splice
isoforms (CD44v), whose expression is altered during tumour
growth and progression. Expression of the ‘v6’ variant exon of
CD44 is necessary for OPN binding (Ponta et al, 2003). OPN is
overexpressed in many human tumours, for example, colon,
breast, liver, prostate, gastric, ovarian, lung, thyroid, and kidney
carcinomas (Agrawal et al, 2002; Kang et al, 2003; Ye et al, 2003;
Schorge et al, 2004; Donati et al, 2005; Guarino et al, 2005;
Matusan et al, 2006).
We recently reported that OPN and CD44v6 are overexpressed
in full-blown LSCC (Celetti et al, 2005). Here, we have investigated
the role of the OPN/CD44v6 axis in laryngeal dysplasia.
MATERIALS AND METHODS
Study population
Patients (82 cases: 77 men and 5 women) underwent surgery at the
Otolaryngology Department of the University Federico II of Naples
between January 1993 and December 2001. The patients’ age
ranged from 23 to 83 years, with a mean of 62.46 years. Paraffin
blocks were retrieved from the files of the Department of
Biomorphological and Functional Sciences, Pathology Section,
University Federico II of Naples. Each patient agreed to and signed
a consent for the treatment of clinical data and tissues for
diagnostic and research purposes, according to the guidelines of
the Institutional Ethic Committee. For all the patients, clinico-
pathologic and follow-up data were recorded (Table 1). Before
surgery, patients underwent otolaryngological, fibreoptic, and
radiological evaluation. The mean follow-up time was 10.1 years
(range: 8–13 years). Follow-up consisted in clinical and radi-
ological evaluation at 3-month intervals for the first year and
6-months intervals thereafter. At completion of follow-up, patients
were subdivided into alive with absence of relapse (no); alive with
evidence of recurrent disease (LIN); and alive with progression of
disease to LSCC (SCC).
After surgical resection, tissues were fixed in 10% neutral
buffered formalin and embedded in paraffin blocks. Sections (4-mM
thick) were stained with haematoxylin–eosin for histological
examination. The pathologic analysis was performed in a blinded
fashion to the clinical informations. The cytological evaluation was
according to standard criteria (Evans et al, 1986; Gale et al, 2000;
Tabor et al, 2003).
Immunohistochemistry
Four-micromolar thick serial sections, mounted on poly-L-lysine-
coated glass slides, were dewaxed, rehydrated through multiple
graded ethanol solutions, treated with 3% hydrogen peroxide for
5min to inactivate endogenous peroxidases, and washed in
distilled water. After antigen retrieval (microwave oven 5min" 3
times, in 1% citrate buffer), nonspecific binding was blocked by
incubation (2 h at room temperature) with 1.5% blocking serum.
Slides were first incubated with anti-OPN (final concentration:
5 mgml#1) (10A16; Assay Designs, Ann Arbor, MI, USA) or anti-
CD44v6 (dilution of 1 : 100) (NCL-CD44v6, clone VFF-7; Novocas-
tra Laboratories Ltd, Newcastle upon Tyne, UK) monoclonal
antibodies and then with biotinylated anti-IgG and the premixed
avidin–biotin complex (overnight at 41C) (Vectastain ABC kits;
Vector Laboratories, Burlingame, CA, USA). The immune reaction
was revealed with 0.06mmol l#1 diaminobenzidine (DAB-DAKO,
Carpinteria, CA, USA) and 2mmol l#1 hydrogen peroxide. Finally,
slides were counterstained with haematoxylin and coverslipped
with a synthetic mounting media. Control slides in the presence of
preimmune serum were included for each staining as an additional
negative control. Anti-OPN antibody was preincubated with a
fivefold molar excess of OPN peptide to ascertain specificity of the
reaction.
The results of the immunohistochemical staining were evaluated
separately and in a blinded fashion by two pathologists. Five
representative microscopic areas at " 400 magnification were
randomly selected for examination. Expression of OPN was
semiquantitatively assessed as percentage of positive cells with
respect to the total number of epithelial cells. The samples were
assigned to one of the four following categories: 0 (absence of
positive cells); þ (o10% of positive cells); þ þ (10–50% of
positive cells); and þ þ þ (450% of positive cells). Staining
of CD44v6 was classified as ‘lower’ (lower third) (L), ‘lower and
middle’ (up to two-thirds of the thickness of the epithelium) (M),
and ‘full thickness’ (F).
Statistical analysis
The Pearson’s w2 test was used to assess the statistical significance
of the frequency distribution of all categories of OPN or CD44v6
expression by degree of dysplasia or by relapse. Differences were
significant with P-value o0.05.
Nonparametric Spearman’s correlation coefficient method was
used to assess the statistical significance of the correlation between
OPN expression vs CD44v6 positivity. A test was run for all the
patients’ cohort combined or grouped by degree of dysplasia or by
type of relapse. Correlations were significant when P-value was
o0.05. Disease-free survival curves of the patients were calculated
using the Kaplan–Meier method, and analysis was performed by
the log-rank test. Differences were significant when Po0.05. In this
analysis, a group of 31 patients has been censored for lack of data.
Statistical analysis was performed using the JMP software program
(version 5.1.1; SAS Institute Inc., Austin, TX, USA).
RESULTS
Immunohistochemical detection of OPN and CD44v6 in
laryngeal dysplasia
Eighty-two laryngeal samples with different degree of dysplasia
(Table 1) and the matched normal mucosa were tested for OPN
expression by immunohistochemistry with an anti-OPN-specific
monoclonal antibody. Representative stainings are shown in
Figure 1, and the entire data set is reported in Table 2. OPN was
virtually undetectable (o2.0% of the cells) in normal tissue
(n¼ 10). Dysplastic areas showed different degrees of OPN
positivity. In most (76%) of mild dysplasia cases, only few cells
Table 1 Clinicopathological features of studied laryngeal intraepithelial
neoplasia (LIN) patients
Characteristics Total (%)
No. of subjects
Male 77 (94)
Female 5 (6)
Disease site
Glottis –hypoglottis 43 (53)
Supraglottis 39 (47)
Degree of dysplasia
Mild 21 (47)
Moderate 8 (19)
Severe 53 (64)
Relapse
No 35 (43)
LIN 10 (12)
SCC 37 (45)
SCC¼ squamous cell carcinoma.
OPN in laryngeal displasia
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(þ ) were positive (Figure 1A), while 50% of moderate and severe
dysplasia samples had intense (þ þ þ ) OPN staining (Figures 1E
and G). Only 20% cases of mild dysplasia were highly positive for
OPN (þ þ þ ); interestingly, in these samples, OPN expression
coexisted with a diffuse CD44v6 staining (see below) (Figures 1C
and D).
The samples were also analysed for the expression of CD44v6,
the receptor that is involved in OPN binding (Table 2). Only basal
cells (L category) were CD44v6 positive in 76% of mild dysplasia
samples (Figure 1B). Instead, in moderate dysplasia, CD44v6
positivity was found in the basal two-thirds (M category)
(Figure 1F) or even full thickness (F category) of the epithelium.
Finally, 50% of severe dysplasia samples showed a full-thickness (F
category) CD44v6 staining (Figure 1H). The association between
OPN and CD44v6 immunoreactivity resulted significant when
analysed by the Spearman’s rank correlation test (Table 3A). The
frequency distribution of OPN positivity or CD44v6 immuno-
reactivity by degree of dysplasia resulted highly significant at
Pearson’s w2 test (Table 4A).
Foci of squamous metaplasia of laryngeal cylindric-cell-lined
areas were almost constantly present in our samples. Metaplastic
areas (n¼ 20) were almost constantly negative for OPN and
CD44v6 staining (Figures 2A and B). Only in few (5%) cases, we
observed an intense (þ þ þ ) OPN staining paralleled by full-
thickness CD44v6 positivity in the squamous metaplastic cells
(Figures 2C and D). Although the ultimate statistical relevance of
this finding is still to be verified on larger series of cases, it is
interesting to note that these OPN- and CD44v6-positive
metaplasia areas were found in patients with a history of
development of SCC at the follow-up.
OPN and CD44v6 expression levels in laryngeal dysplasia
negatively correlate with disease-free survival
The disease-free survival rate in patients affected by laryngeal
dysplasia negatively correlated with intense OPN staining and full-
thickness CD44v6 positivity. As shown by the Kaplan–Meier
Mild
Moderate Severe
OPN OPNCD44v6 CD44v6
OPN OPNCD44v6 CD44v6
A B C D
E F G H
Figure 1 (A and B) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the
lower third of the epithelium (B) (" 150). (C and D) Another mild dysplasia sample showing stronger immunostaining for both the markers (" 150).
(E and F) A representative case of moderate dysplasia showing a strong immunostaining for OPN (E) and a CD44v6 positivity involving the lower two-
thirds of the epithelium (F) (" 250). (G and H) A case of high-grade dysplasia showing strong immunostaining for OPN (G) and CD44v6 positivity up to
the upper third of the epithelium (H) (" 400).
Table 2 OPN and CD44v6 positivity in laryngeal intraepithelial neoplasia
at different degree
LIN OPN positivitya CD44v6 positivitya
Mild (21) 16/21 (+) 16/21 (L)
1/21 (++) 2/21 (M)
4/21 (+++) 3/21 (F)
Moderate (8) 3/8 (+) 2/8 (L)
1/8 (++) 3/8 (M)
4/8 (+++) 3/8 (F)
Severe (53) 16/53 (+) 15/53 (L)
11/53 (++) 12/53 (M)
26/53 (+++) 26/53 (F)
OPN¼ osteopontin. aOsteopontin and CD44v6 expression were assessed by
immunohistochemistry and scored respectively as follows: +¼o10% positive cells;
++¼ 10–50% positive cells; and +++¼ 50–100% positive cells; L¼ lower;
M¼ lower and middle; and F¼ full-thickness involvement of the epithelial layers.
OPN in laryngeal displasia
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survival curves reported in Figure 3A, the 8-years disease-free
survival was 94 and 91% for OPN (þ )- and OPN (þ þ )-positive
cases, respectively, and 33% for OPN (þ þ þ )-positive cases
(two-sided log-rank test, Po0.0001; Figure 4A). Relative to
CD44v6 expression, the probability of recurrence was 94 and
75% for cases that showed basal (L), or basal and middle (M)
staining, respectively, and 38% for patient that had full-thickness
(F) positivity (two-sided log-rank test, P¼ 0.007; Figure 4B).
At the Pearson’s test, the frequency distribution of OPN and
CD44v6 expression levels were significantly correlated with relapse
(Table 4B).
Moreover, the correlation between OPN and CD44v6 expression
in patients with absence of relapse, with recurrence of dysplasia, or
with progression to LSCC resulted very significant at the Spear-
man’s rank correlation test (Table 3B). Finally, the contingency
analysis showed that the frequency distribution of OPN by CD44v6
were highly significant in combined or grouped types of relapse
(Table 4C).
DISCUSSION
An in-depth understanding of the factors involved in the initial
steps of LSCC development will facilitate the prevention and
diagnosis of this condition. Currently, histological grading and the
A B
C D
Figure 2 (A and C) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the
lower third of the epithelium (C) (" 150). (B and D) The same samples as in (A) negative for OPN immunostaining after incubation with isotype control
antiserum (B) (" 150), and the same sample as in (C) negative for CD44v6 immunostaining after incubation with isotype control antiserum (D) (" 150).
Table 3A Correlation of osteopontin and CD44v6 expression in all
laryngeal intraepithelial neoplasia (LIN) patients combined or grouped by
degree of dysplasia
LIN rs Ps
Combined (82) 0.8231 o0.0001
Mild (21) 0.9941 o0.0001
Moderate (8) 0.2622 ¼ 0.5304
Severe (53) 0.7957 o0.0001
Note: Correlation between osteopontin and CD44v6 expression in LIN patients
analysed by Spearman’s rank correlation test. Correlation coefficient (rs) and Ps are
shown (Pso0.05 was considered significant).
Table 3B Correlation of osteopontin and CD44v6 expression in all
laryngeal intraepithelial neoplasia (LIN) patients combined or grouped by
relapse
Relapse rs Ps
Combined (82) 0.8231 o0.0001
no (35) 0.8133 o0.0001
LIN (10) 0.5976 ¼ 0.0734
SCC (37) #0.7892 o0.0001
SCC¼ squamous cell carcinoma. Note: Absence of relapse (no), recurrence of
dysplasia (LIN), progression to carcinoma (SCC). Correlation between osteopontin
and CD44v6 expression in LIN patients analysed by Spearman’s rank correlation test.
Correlation coefficient (rs) and Ps are shown (Pso0.05 was considered significant).
Table 4 Pearson’s test
v2 P
A. Contingency analysis of osteopontin (OPN) and CD44v6 positivity by degree of
dysplasia
OPN 13.425 0.0094
CD44v6 16.198 0.0028
B. Contingency analysis of OPN and CD44v6 positivity by relapse (no, LIN, SCC)
OPN 21.780 o0.0002
CD44v6 9.567 0.0484
C. Contingency analysis of OPN positivity by CD44v6 expression in all laryngeal
intraepithelial neoplasia combined or grouped by relapse
Combined (82) 73.026 o0.0001
No (35) 32.694 o0.0001
LIN (10) 10.000 0.0067
SCC (37) 34.857 o0.0001
LIN¼ laryngeal intraepithelial neoplasia; SCC¼ squamous cell carcinoma. Note:
Absence of relapse (no), recurrence of dysplasia (LIN), and progression to carcinoma
(SCC).
OPN in laryngeal displasia
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topographical extension of laryngeal dysplasia are used to predict
the risk for cancer and to determine the treatment strategy (Rosai
et al, 1992; Zuckerberg, 2002; Johnson, 2003). Although significant
efforts have been made to identify molecular markers of the
clinical outcome of premalignant laryngeal lesion, still neither
single nor combination of markers is accepted in clinical practice
(Tabor et al, 2002).
We have previously reported that both OPN and CD44v6 are
highly expressed in invasive LSCC (Celetti et al, 2005). Here, we
have explored whether the same ligand/receptor pair is involved in
the premalignant phases as well. To this aim, we have investigated
OPN and CD44v6 in a set of laryngeal dysplasia samples and
correlated their expression level to histological grading and clinical
outcome. Both OPN and CD44v6 were consistently overexpressed
in dysplastic but not hyperplastic or metaplastic mucosa.
Dysplasia, in particular high-grade dysplasia, is regarded as a
preneoplastic condition (Rosai et al, 1992). Importantly, OPN/
CD44v6 overexpression was significantly correlated with the
degree of dysplasia, type of recurrence, and reduced disease-free
survival. Taken together, these findings suggest that OPN
signalling through CD44v6 may play a role in the establishment
of dyplastic changes in the laryngeal epithelium. Interestingly, it
has been recently reported that genetic deletion of OPN in
transgenic mice did not change the rate of hyperplasia formation
but caused a reduction of benign papilloma formation after the
two-stage skin chemical carcinogenesis protocol; thus, also in this
experimental model system, OPN is involved in the early phases of
tumorigenesis (Hsieh et al, 2006).
Osteopontin is able to engage several cell surface receptors,
including integrins and CD44 variants. In particular, OPN binds
CD44 proteins that contain v6-encoded sequences, and OPN/
CD44v6 binding has been implicated in carcinogenesis (Ponta
et al, 2003). Here, we show that OPN expression levels were
paralleled by intense expression of CD44v6; at contingency
analysis, the frequency distribution of OPN expression by
CD44v6 positivity resulted highly significant at Pearson’s test;
moreover, the association between OPN and CD44v6 immunor-
eactivity was highly significant at the Spearman’s correlation
coefficient test, suggesting that CD44v6 is at least one of the
functional OPN receptors in laryngeal dysplasia.
To investigate whether the OPN/CD44v6 overexpression was
causally related with dysplasia, cytological changes induced by
OPN stimulation of primary human keratinocytes, obstructed by
CD44 blockade, have been observed (Celetti A et al, in prepara-
tion). Addressing CD44 as a functional receptor for OPN would be
important to explore the molecular mechanism underlying
dysplastic changes induced by the OPN/CD44 axis. It is known
that CD44 triggering stimulates diverse signalling pathways,
including activation of ERK (Bourguignon et al, 2005), RAC
(Teramoto et al, 2005), and RHO (Bourguignon et al, 2003), as well
as secretion of soluble factors, like cytokines and metalloprotei-
nases (Zhang et al, 2002; Bourguignon et al, 2003; Murphy et al,
2005). These pathways are potentially involved in dysplastic
changes induced by OPN/CD44v6.
A model for the initiation and progression of colorectal cancer
has become a paradigm for other human solid tumours (Fearon
and Vogelstein, 1990). Like colorectal cancer, HNSCC is thought to
OPN CD44v6
A B
C D
Figure 3 (A and B) An area of incomplete squamous metaplasia,
negative for OPN (A), and CD44v6 (B) immunostaining (" 250).
(C and D) Another case of incomplete squamous metaplasia (patient
with a history of laryngeal SCC), showing an intense OPN (C) and CD44v6
(D) immunostaining (" 106).
OPN+
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 1 2 3 4
Disease-free survival (interval in years)
Pr
ob
ab
ilit
y 
of
 re
cu
rre
nc
e
Pr
ob
ab
ilit
y 
of
 re
cu
rre
nc
e
5 6 7 8
0 1 2 3 4
Disease-free survival (interval in years)
5 6 7 8
OPN++
OPN+++
CD44v6 L
CD44v6 M
CD44v6 F
P<0.0001 (log rank test)
P=0.0007 (log rank test)
n=21
n=25
n=18
n=10
n=23
n=5
A
B
Figure 4 Osteopontin and CD44v6 staining in laryngeal dysplasia
negatively correlates with disease-free survival. Kaplan–Meier survival
plots for patients grouped on the basis of the OPN (A) or CD44v6
(B) expression level. (A) Patients were stratified into three categories
(þ (n¼ 21), þ þ (n¼ 5), and þ þ þ (n¼ 25)) based on OPN
immunostaining intensity. (B) Patients were stratified into three categories
(L (n¼ 18), M (n¼ 10), and F (n¼ 23) based on the thickness of CD44v6
staining). The P-value was determined by a two-sided log-rank test.
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progress through a series of well-defined clinical and histopatho-
logical stages. While not all of the specific mutations required for
progression have been delineated, a working molecular model has
been proposed (Silverman, 2003). The loss of chromosomal
regions 3p and 9p21 are among the first identified genetic changes
(Mao et al, 1996; Sanz-Ortega et al, 2003). In particular, loss-
of-heterozygosity (LOH) at 9p21 in conjunction with promoter
hypermethylation results is the inactivation of the CDKN2A gene,
coding for the cyclin-dependent kinase inhibitor 2A (p16INK4).
This alteration occurs prior to the development of histologic atypia
and is associated with the transition from normal to hyperplastic/
metaplastic mucosa (Papadimitrakopoulou et al, 2001; Sanz-
Ortega et al, 2003). Subsequent LOH at 17p with mutation of the
TP53 tumour suppressor gene is associated with progression to
dysplasia (Boyle et al, 1993). The overexpression of the EGF
receptor is also an early event in carcinogenesis (Rubin Grandis
et al, 1998). Amplification and overexpression of the CCND1 gene,
encoding cyclin D1 is a common late event in HNSCC formation
(Michalides et al, 1995; Izzo et al, 1998; Chatrath et al, 2006). Our
findings suggest that the upregulation of the OPN/CD44v6 axis is
an additional early event during the progression of laryngeal
dysplasia. Thus, early immunocytochemical detection of OPN and
CD44v6 can be exploited to set a screening test for laryngeal
dysplasia. Moreover, perturbation of OPN/CD44v6 signalling may
represent a promising novel strategy to prevent progression of
laryngeal preneoplastic lesions.
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Overexpression of the Cytokine Osteopontin Identifies Aggressive
Laryngeal Squamous Cell Carcinomas and Enhances
Carcinoma Cell Proliferation and Invasiveness
Angela Celetti,1Domenico Testa,2 Stefania Staibano,3 FrancescoMerolla,1Valentina Guarino,1
Maria Domenica Castellone,1Renata Iovine,2 GelsominaMansueto,3 Pasquale Somma,3
Gaetano De Rosa,3 Vieri Galli,2 RosaMarinaMelillo,1andMassimo Santoro1
Abstract Purpose: Osteopontin is a secreted cytokine that binds to the cell surface CD44v6 receptor.
We studied osteopontin and CD44v6 expression in laryngeal squamous cell carcinomas and
correlated osteopontin expression levels with clinicopathologic tumor features.
Experimental Design:Weused immunohistochemistry, immunoblotting, and reverse transcrip-
tion-PCR to study osteopontin expression in 58 laryngeal squamous cell carcinomas. Cultured
squamous carcinoma cells were treated with exogenous osteopontin or with RNA interference
to knockdownosteopontin expression.
Results: Osteopontin expression was higher in all the invasive carcinomas than in patient-
matched normal mucosa. Its expression levels were significantly correlated with tumor stage and
grade and with the presence of lymph node and distant metastases. Osteopontin positivity was
negatively correlated with overall survival (P = 0.03). Osteopontin expression was paralleled by
intense cell surface reactivity for CD44v6.Treatment of squamous carcinoma cells with recombi-
nant osteopontin sharply increased proliferation and Matrigel invasion in comparison with the
untreated cells parallel to activation of the mitogen-activated protein kinase/extracellular signal-
regulated kinase kinase/mitogen-activated protein kinase signaling cascade. Osteopontin
knockdown by RNA interference, anti-CD44 antibodies, and mitogen-activated protein kinase/
extracellular signal-regulated kinase kinase inhibition prevented these effects.
Conclusions:These results identify osteopontin as a marker and a potential therapeutic target in
cases of aggressive laryngeal squamous cell carcinomas.
Head and neck squamous cell carcinoma (HNSCC) is the sixth
most frequent cancer. Laryngeal squamous cell carcinoma
(LSCC) is the most common HNSCC (1–3). Notwithstanding
primary prevention, screening, surgical treatment, and radiother-
apy, the long-term survival rate of LSCC patients has remained
substantially unchanged in the last two decades (4, 5). Stage and
histologic grade are prognostic factors in LSCC but do not always
distinguish between high-risk and low-risk patients (1–5).
Various biological prognostic markers have been identified for
LSCC and other HNSCC types: mutation in the p53 tumor
suppressor gene (6), amplification of cyclin D1 (7, 8), over-
expression of the epidermal growth factor receptor (9) and vas-
cular endothelial growth factor (10), and reduced expression of
the CIP/KIP cell cycle inhibitory proteins (11). However, little is
known about the molecular mechanisms that govern the esta-
blishment and maintenance of the LSCC neoplastic phenotype.
Osteopontin, also known as secreted phosphoprotein 1, is a
highly acidic calcium-binding glycosylated phosphoprotein. It
is a cytokine (early T lymphocyte antigen-1 or interleukin-28)
that regulates T helper cell-1 function (12, 13). In addition,
osteopontin binds to the cell surface receptors av- or h1-
containing integrins and CD44 (14, 15), thereby supporting
chemotaxis, attachment, and migration of many epithelial cell
types (16, 17). CD44 is expressed as a standard receptor
(CD44s) and in multiple splice isoforms (CD44v), whose
expression is altered during tumor growth and progression.
Expression of the v6 variant exon of CD44 is necessary for
osteopontin binding (18). CD44 splice variants are thought to
be correlated with invasive growth and metastasis in many
tumor types (18). Osteopontin is overexpressed in many
human tumors (e.g., colon, breast, liver, prostate, gastric,
ovarian, and lung carcinomas; refs. 19–22).
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We have explored osteopontin expression in LSCC. Our
results indicate that osteopontin is a promising molecular
marker for LSCC risk assessment. At cellular level, osteopontin
binding to CD44v6 promoted SCC cell growth and invasion.
Materials andMethods
Tumors. Archival tumor samples from 58 patients (57 males and
1 female) with laryngeal cancer were retrieved from the files of the
Department of Biomorphological and Functional Sciences, Pathology
Section, University of Naples ‘‘Federico II,’’ after having obtained
informed consent. Clinicopathologic data were recorded (Table 1).
Patients underwent surgery at the Institute of Otolaryngology,
University of Naples ‘‘Federico II,’’ between 1997 and 2001. The study
was approved by the institutional review board committee. The
patients’ age ranged between 43 and 83 years, with a mean of 64.7
years. Patients underwent otolaryngologic examination, fiberoptic
study, and radiological evaluation and were treated by surgery alone,
except for patients with locally advanced tumors (T4), who received
postsurgical radiation therapy. The patients underwent a median of 60
months’ follow-up, which consisted of clinical and radiological
evaluation at 3-month intervals for the first year and at 6-month
intervals thereafter. After surgical resection, tissues were fixed in 10%
neutral buffered formalin and embedded in paraffin blocks. Sections
(4 Am thick) were stained with H&E. Histologic grading and tumor-
node-metastasis classification were done according to the recommen-
dations of the International Union Against Cancer (23, 24). The
pathologic analysis was done in a blinded manner with respect to the
patients’ clinical data. For five patients, a 10-Am-thick section was
processed for dissection. Paraffin was removed by treatment with xylene
for 3 hours at room temperature followed by tissue rehydration through
multiple graded ethanol solutions and distilled water. The cancerous
region was identified microscopically; normal and tumor tissues were
dissected with a sterile 30-gauge hypodermic needle. The collected
samples (f120,000 cells) were placed into 1.5-mL microcentrifuge
tubes and processed for RNA extraction.
Immunohistochemistry. Serial tumor sections (4 Am thick) were
mounted on poly-L-lysine-coated glass slides. After antigen retrieval,
the slides were incubated with anti-osteopontin (5 Ag/mL; 10A16,
Assay Designs, Ann Arbor, MI) or anti-CD44 (1:100; NCL-CD44v6,
clone VFF-7, Novocastra Laboratories Ltd., Newcastle upon Tyne,
United Kingdom) monoclonal antibodies (mAb). The sections were
incubated (overnight at 4jC) with the primary antibody, biotinylated
anti-IgG, and the premixed avidin-biotin complex (Vectastain ABC kits,
Vector Laboratories, Burlingame, CA). The immune reaction was
revealed with 0.06 mmol/L 3,3V-diaminobenzidine (DAKO, Carpinteria,
CA) and 2 mmol/L H2O2. The slides were counterstained with
hematoxylin. Anti-osteopontin antibody was preincubated with a
5-fold molar excess of osteopontin peptide to ascertain the specificity
of the reaction. Control slides, stained with preimmune serum, were
included as an additional negative control. The results of the
immunohistochemical staining were evaluated separately by two
investigators in a blinded manner. The percentage of positive tumor
cells was determined by examining at least five representative
microscope areas at a 400 magnification. For osteopontin, samples
were assigned to one of the four following categories: 0, absence of
positive cells; +, <10% of positive cells; ++, 10% to 50% of positive cells;
and +++, >50% of positive cells. Immunohistochemical staining for
CD44v6 was expressed as ‘‘basal’’ or ‘‘full thickness’’ based on the
epithelium layers stained.
Cell lines. Human normal epidermal keratinocytes (HNEK;
neonatal) were cultured in keratinocyte growth medium according to
the recommendation of the manufacturer (Cambrex, East Rutherford,
NJ). HN and BHY cell lines were derived from a human oral cavity SCC
(25), CAL27 and CAL33 cell lines were from human tongue SCC (26),
and Hep2 cells were from a LSCC (27); KB are epidermoid cancer cells
(28). Tumor cells were maintained in DMEM supplemented with
10% fetal bovine serum, 2 mmol/L L-glutamine, and 100 units/mL
penicillin-streptomycin (Life Technologies, Paisley, PA). For cell treat-
ments, recombinant mouse osteopontin protein was from R&D Systems
(Minneapolis, MN). U0126 was from Calbiochem (San Diego, CA).
Blocking CD44 mAbs were purified from the KM81 hybridoma cell line
(TIB-241, American Type Culture Collection, Manassas, VA; ref. 29). For
blocking experiments, cells were preincubated for 30 minutes with the
KM81 mAb (10 Ag/mL) at 37jC, 5% CO2.
RNA extraction and reverse transcription-PCR. Tissue samples were
snap frozen in liquid nitrogen and stored at 80jC before RNA
extraction. Tissues were homogenized using a Mixer Mill Homogenizer
(Qiagen, Crawley, West Sussex, United Kingdom). Total RNA from the
indicated cell cultures and from frozen tissue samples was prepared
using the RNeasy Mini kit (Qiagen) according to the manufacturer’s
instructions. Only tissue samples containing >70% neoplastic cells were
used. Total RNA (2.5 Ag) was retrotranscribed into cDNA by using the
GeneAmp RNA PCR Core kit (Applied Biosystems, Foster City, CA).
PCR amplification was done using 2.5 AL of the reverse transcription
product in a reaction volume of 25 AL. To exclude DNA contamination,
each PCR reaction was also done on untranscribed RNA. The levels of
the housekeeping h-actin transcript served as a control of equal RNA
loading. Primers were designed with the Primer 3 program (http://
www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi) and syn-
thesized by MWG Biotech (Ebersberg, Germany). Primer sequences
were osteopontin forward 5V-AGGAGGAGGCAGAGCACA-3V, osteopon-
tin reverse 5V-CTGGTATGGCACAGGTGATG-3V, CD44 (exon 2) forward
5V-GCTTTCAATAGCACCTTGCC-3V, CD44 (exon3) reverse 5V-GTTGT-
TTGCTGCACAGATGG-3V, CD44 (exon v6) reverse 5V-GTTGCCAAAC-
CACTGTTCCT-3V, h-actin forward 5V-TGCGTGACATTAAGGAGAAG-3V,
and h-actin reverse 5V-GCTCGTAGCTCTTCTCCA-3V. Reverse transcrip-
tion-PCR (RT-PCR) products were loaded on a 2% agarose gel and
stained with 0.5 Ag/mL ethidium bromide, and the corresponding
Table1. Clinicopathologic features of studied
laryngeal cancer patients
Characteristics Total (%)
No. subjects
Male 57 (98)
Female 1 (2)
Disease site
Glottis-hypoglottis 43 (74)
Supraglottis 15 (26)
Histologic differentiation
G1 19 (33)
G2 21 (36)
G3 18 (31)
Stage
T1 9 (16)
T2 19 (33)
T3/T4 30 (52)
Lymphnodes
N+ 15 (26)
No 25 (43)
Nx 18 (31)
Metastasis
Mo 27 (46)
Bone 4 (7)
Lung 8 (14)
Brain 1 (2)
Mx 18 (31)
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image was saved with the Typhoon 8600 laser scanning system
(Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom).
The density and width of each band were quantified using the
ImageQuant 5.0 (Amersham Pharmacia Biotech).
Protein studies. Immunoblotting experiments were done according
to standard procedures. For tissue protein extraction, samples were
snap frozen and homogenized in lysis buffer by using the Mixer
Mill apparatus (Qiagen). Protein concentration was estimated with
a modified Bradford assay (Bio-Rad, Hercules, CA). Antigens were
revealed by an enhanced chemiluminescence detection kit (Amersham
Pharmacia Biotech). Anti-osteopontin goat polyclonal antibody
(K20) and rabbit polyclonal anti-CD44 (H300) were from Santa Cruz
Biotechnology (Santa Cruz, CA). Monoclonal anti-a-tubulin was
from Sigma-Aldrich (St. Louis, MO). Anti-phosphorylated mitogen-
activated protein kinase/extracellular signal-regulated kinase (ERK)
kinase (MEK) 1/2 (Ser217/Ser221), anti-phosphorylated p44/42 mito-
gen-activated protein kinase (Thr202/Tyr204; ERK), and anti-p44/42
mitogen-activated protein kinase were from Cell Signaling Technology,
Inc. (Beverly, MA).
Flow cytometric analysis. Subconfluent cells (1  106) were detached
from culture dishes. After saturation with 1 Ag human IgG per 105 cells,
cells were incubated for 20 minutes on ice with antibodies specific for
human CD44v6 (R&D Systems) or isotype control antibody. After
incubation, unreacted antibody was removed. Cells were then
incubated (30 minutes, 4jC) with 100 AL fluorescein-conjugated goat
anti-mouse IgG/M (Jackson ImmunoResearch, West Grove, PA) and
analyzed on a FACSCalibur cytofluorimeter using the CellQuest
software (Becton Dickinson, San Jose, CA). Analyses were done in
triplicate. In each analysis, a total of 104 events were calculated.
Chemoinvasion. The cell suspension (1  105 cells per well) was
added to the upper chamber of Transwell cell culture chambers on a
prehydrated polycarbonate membrane filter of 8-Am pore size (Costar,
Cambridge, MA) coated with 35 Ag Matrigel (Collaborative Research,
Inc., Bedford, MA). The lower chamber was filled with complete
medium, and when required, purified recombinant osteopontin was
added at the concentration of 100 ng/mL. To inhibit Matrigel invasion,
cells were preincubated with 10 Ag/mL CD44-blocking antibodies
(KM81) or with 10 Amol/L U0126. After 24-hour incubation at 37jC,
nonmigrating cells on the upper side of the filter were wiped off and
migrating cells on the reverse side of the filter were stained with 0.1%
crystal violet in 20% methanol for 15 minutes and photographed. The
stained cells were lysed in 10% acetic acid. Triplicate samples were
analyzed at 570 nm with an ELISA reader (model 550 microplate
reader, Bio-Rad). The results were expressed as percentage of migrating
cells.
Bromodeoxyuridine incorporation. Cells were seeded on glass cover-
slips and bromodeoxyuridine (BrdUrd) was added to the cell culture
medium at a final concentration of 100 Ag/mL (BrdUrd Labeling and
Fig. 1. Immunohistochemical detection of
osteopontin in laryngeal carcinomas.A, an
infiltrating LSCC (G2, N+, M0) showing
intense (+++) osteopontin staining (106).
B, the same sample as in (A): no signal was
detected after preincubationwith a molar
excess of osteopontin-blocking peptide.
C, an infiltrating LSCC (G3, N0, M0)
showing (++) osteopontin
immunoreactivity (106;).D, the same
sample as in (C) after preincubationwith
a molar excess of osteopontin-blocking
peptide. E, hyperplastic epithelium (without
dysplasia) negative for osteopontin staining
(150). F, the same sample as in (E) after
preincubationwith osteopontin-blocking
peptide.
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Detection kit, Boehringer Mannheim, Mannheim, Germany). After
1-hour incubation, cells were fixed with 70% ethanol/50 mmol/L
glycine (pH 2.0). Coverslips were incubated with anti-BrdUrd mouse
mAb and with a FITC-conjugated anti-mouse antibody. All coverslips
were counterstained in PBS containing Hoechst 33258 (final concen-
tration, 1 Ag/mL; Sigma-Aldrich), rinsed in water and mounted in
Moviol on glass slides. The fluorescent signal was visualized with an
epifluorescent microscope (Axioskop 2, Zeiss) interfaced with the image
analyzer software Axiovision (Zeiss, Gottingen, Germany).
RNA silencing. Small inhibitor duplex RNAs targeting human
osteopontin were designed with a small interfering RNA (siRNA)
selection program available online at http://jura.wi.mit.edu/siRNAext/
and were chemically synthesized by PROLIGO (Boulder, CO). Sense
strand for siRNA targeting was (osteopontin siRNA) 5V-AAGCAG-
CUUUACAACAAAUACCC-3V. As a control, a nonspecific siRNA duplex
containing the same nucleotides but in irregular sequence (scrambled)
was used. The day before transfection, 1  105 cells were plated in
35-mm dishes in DMEM supplemented with 10% fetal bovine serum and
without antibiotics. Transfection was done using 360 pmol siRNA and 18
AL Oligofectamine reagent (Invitrogen, Groningen, the Netherlands)
Table 2. Osteopontin positivity in laryngeal
carcinomas
Characteristics (no. samples) Osteopontin positivity*
Disease site
Glottis-hypoglottis (43) 22/43 (+++)
16/43 (++)
3/43 (+)
2/43 (0)
Supraglottis (15) 7/15 (+++)
5/15 (++)
1/15 (+)
2/15 (0)
Stage
T1 (9) 3/9 (++)
2/9 (+)
4/9 (0)
T2 (19) 7/19 (+++)
10/19 (++)
2/19 (+)
T3/T4 (30)
22/30 (+++)
8/30 (++)
Grade
G1 (19) 4/19 (+++)
8/19 (++)
3/19 (+)
4/19 (0)
G2 (21) 11/21 (+++)
9/21 (++)
1/21 (+)
G3 (18) 14/18 (+++)
4/18 (++)
Lymphnodemetastases
N+ (15) 9/15 (+++)
6/15 (++)
No (25) 6/25 (+++)
9/25 (++)
8/25 (+)
2/25 (0)
Nx (18)
Distant metastases
M+ (13) 12/13 (+++)
1/13 (++)
Mo (27) 7/27 (+++)
12/27 (++)
4/27 (+)
4/27 (0)
Mx (18)
*Osteopontin expressionwas assessedby immunohistochemistry and scored
as follows: 0, absence of positive cells; +, <10% positive cells; ++, 10% to
50% positive cells; and +++, 50% to100% positive cells.
Table 3. Correlation of osteopontin expression
and clinicopathologic characteristics of laryngeal
carcinomas
Osteopontin positivity rs P
Tumor stage 0.6230 <0.0001
Grade 0.5169 <0.0001
Node 0.4391 <0.0046
Distant metastases 0.7821 <0.0001
NOTE: Correlation between osteopontin expression and tumor stage, grade,
node, and distant metastases analyzed by the Spearman rank correlation test:
correlation coefficient (r s) and Ps are shown (Ps < 0.05 were considered
significant).
Fig. 2. Osteopontin staining negatively correlates with LSCC patient survival.
Kaplan-Meier survival plots for LSCC patients grouped by the level of expression
of osteopontin (OPN). LSCC tumoral samples were stratified in three categories
[0/+ (n = 8), ++ (n = 21), and +++ (n = 29)] based on intensity of osteopontin
immunostaining. P was determined by a two-sided log-rank test. For patients
whose tumorshadosteopontin (++) immunostain, the 2- and 5-year overall survival
rates were 76.19% [95% confidence interval (95% CI), 56.53-95.87%] and
71.40% (95% CI, 48.53-94.27%), respectively. For patients whose tumors
had osteopontin (+++) immunostain, the 2- and 5-year overall survival rates
were 58.60% (95% CI, 35.85-81.35%) and 51.70% (95% CI, 26.41-76.99%),
respectively. All patients whose tumors had osteopontin (0/+) stain were still alive
at the end of the study.
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following the manufacturer’s instruction. Cells were kept in 2.5% serum
and BrdUrd incorporation was measured 48 hours after transfection.
Statistical analysis. Statistical evaluation of the data was done with
a two-tailed Student’s t test when simple comparison between two
groups was required; m2 test was used to establish the statistical
significance of distributions. Nonparametric Spearman’s correlation
coefficient method was used to assess the statistical significance of the
correlation between clinicopathologic characteristics of tumor and
osteopontin expression. Survival curves of the patients were calculated
using the Kaplan-Meier method and analysis was done by the log-rank
test. Differences were significant at P < 0.05. Statistical analysis was
done using the JMP software program version 5.1.1 (SAS Institute, Inc.,
Austin, TX).
Results
Immunohistochemical detection of osteopontin up-regulation in
laryngeal squamous cell carcinomas. Fifty-eight larynx carcino-
mas at different grades of malignancy and the corresponding
normal tissues (Table 1) were tested for osteopontin expression
by immunohistochemistry with an anti-osteopontin-specific
mAb. Representative immunohistochemical stainings are
shown in Fig. 1 and the entire data set is reported in Table 2.
Osteopontin was virtually undetectable (<2.0% of cells)
in normal tissues (n = 58; data not shown). Hyperplastic
epithelia (n = 20) were also constantly negative for
osteopontin staining (Fig. 1E; data not shown). In contrast,
93% (54 of 58) of the tumor samples were osteopontin
positive (Fig. 1A and C). The signal was confined to tumor
cells. The specificity of signal was shown by competition with
a molar excess of osteopontin-blocking peptide (Fig. 1B, D,
and F). Overall, 37% of T2 tumors and 73% of T3/T4 tumors
showed intense (+++) osteopontin immunostaining. More-
over, osteopontin immunostaining was intense (+++) in 21%,
52%, and 78% of G1, G2, and G3 tumors, respectively. Finally,
60% of tumors with lymph node metastases and 92% of
tumors with distant metastases had intense osteopontin
staining. Accordingly, metastatic tissues were intensely osteo-
pontin positive (data not shown). Thus, osteopontin reactivity
was correlated with tumor stage (P < 0.0001) and grade (P <
0.0001) and with the presence of lymph node (P < 0.0046)
and distant (P < 0.0001) metastases (Table 3). Importantly,
the 5-year survival rate for LSCC patients was negatively
correlated with intense osteopontin staining. Five-year survival
was 71.40% for osteopontin-positive cases (++) and 51.70%
for osteopontin-positive cases (+++) as shown by the Kaplan-
Meier survival curves reported in Fig. 2 (P = 0.03, two-sided
log-rank test).
The interaction of osteopontin with the CD44 cell surface
receptor has been implicated in many signal transduction
pathways. CD44 pre-mRNA is encoded by 20 exons. The
constant 5V-terminal five exons encode the NH2-terminal
extracellular portion of the CD44 protein, whereas the
constant 3V-terminal five exons encode the transmembrane
and the short cytosolic tail of the protein. An additional
10 exons (variants v1-v10) are alternatively spliced and encode
the extracellular membrane-proximal stem structure (18).
Cancer cells often overexpress CD44 variants that include a
variable number of ‘‘v’’ exons. The v6 exon has been reported
to be important for efficient osteopontin binding (18). Thus,
we sought to verify whether CD44v6 molecules were
expressed in LSCC. LSCC samples (n = 58) were constantly
CD44v6 positive at immunohistochemistry (representative
samples are shown in Fig. 3A-C). In tumors, CD44v6-positive
cells showed full thickness staining, whereas only basal cells
were CD44v6 positive in normal stratified epithelium (data
not shown).
Osteopontin and CD44 up-regulation in laryngeal squamous
cell carcinomas at protein and mRNA level. Protein lysates were
harvested from selected high-stage/grade snap-frozen LSCC
samples (T3, G3; n = 10) and from the corresponding adjacent
normal mucosa from the same patients, and osteopontin protein
levels were examined by immunoblotting. As shown in Fig. 4A,
the osteopontin protein (M r f60,000) was abundantly
expressed in all carcinomas but was barely detectable in matched
normal tissues (Fig. 4A). To determine whether up-regulation
occurred at transcriptional level, we subjected the same LSCC
Fig. 3. Expression of CD44v6 in LSCC. A, an infiltrating LSCC (G2, N0, M0)
strongly immunoreactive for CD44v6 (150). B, full thickness CD44v6 positivity in
a G2, N+, M0 LSCC sample (150). C, full thickness CD44v6 positivity in a G2, N0,
M0 LSCC sample (400).D, LSCC: absence of signal in the presence of preimmune
serum (400).
Fig. 4. Osteopontinup-regulation in LSCC samples at theprotein andmRNA levels.
A, levels of osteopontin protein were evaluated by immunoblot in LSCC and in
adjacent normal epithelium:T, tumoral sample; N, normal epithelium. Anti-a-tubulin
were used for normalization. Representative of three independent experiments.
B, semiquantitative RT-PCR (25 cycles) was done to detect osteopontinmRNA
levels in the indicated LSCC samples and in adjacent normal epithelium. h-Actin
mRNA detectionwas used for normalization. Band intensity was calculated by
phosphorimaging. Representative of three independent experiments. C, RT-PCR
(28 cycles) was done on purified cells from two representative samples of LSCC
(sample1: G3, N+, M0; sample 2: G2, N0, M0) and from the corresponding normal
cells after microscope-guided manual dissection.
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samples (n = 10) to RT-PCR. Osteopontin mRNA was
abundantly overexpressed at mRNA level in tumors with respect
to adjacent normal mucosa from the same patients
(Fig. 4B; data not shown). Phosphorimaging analysis of band
intensity indicated that osteopontin mRNA was 15 F 3–fold
higher in LSCC samples than in the normal tissue counterpart.
To validate the results, we analyzed osteopontin mRNA levels in
purified dissected tumor cells from five representative high-
stage/grade LSCC samples and corresponding normal cells by
RT-PCR; the representative samples shown in Fig. 4C showed
that osteopontin mRNA accumulation was restricted to tumor cells.
We next examined CD44 expression in LSCC (T3, G3) samples
(n = 10) using immunoblotting. An intense broad band of
a relative molecular mass of 90 kDa was detected in tumors
(Fig. 5A; data not shown). In contrast, CD44 was weakly
expressed (<10 F 3–fold compared with LSCC samples) in
normal tissue counterparts (Fig. 5A). Then, we used different
combinations of amplimers in RT-PCR experiments with RNA
extracted from LSCC (T3, G3) samples (n = 10). LSCC overex-
pressed CD44 mRNA species containing the v6 or both v3 and
v6 variant exons (Fig. 5B; data not shown).
Osteopontin and CD44v6 overexpression in squamous cell
carcinoma cell lines. We evaluated osteopontin expression in
six cultured human SCC lines. A primary culture of HNEK was
used as a control. Osteopontin protein and mRNA expression
was >7-fold higher in SCC than in normal cells (Fig. 6A and B).
Moreover, all the SCC cell lines featured high levels (>10-fold
with respect to HNEK) of standard and v6-containing CD44
species (Fig. 6C and D). All the cell lines featured abundant
cell surface CD44v6 expression by flow cytometry (Fig. 6E; data
not shown).
Fig. 6. Osteopontin and CD44
up-regulation in cultured SCC cells.
A, osteopontinprotein levels were evaluated
by immunoblot in the indicated cell lines.
Anti-a-tubulin was used for normalization.
B, semiquantitative RT-PCR (25 cycles) was
used to detect osteopontinmRNA levels in
the indicated cell lines. h-ActinmRNA
detectionwas used for normalization.
Band intensity was calculated by
phosphorimaging. C, CD44 protein levels
were determined by immunoblot.
D, semiquantitative RT-PCR (25 cycles)was
done (see Fig. 5 legend) to detect CD44
mRNA levels in the indicated cell lines.
E, flow cytometric analysis of cell surface
expression of CD44v6 in the indicated cell
lines. Black histogram, negative control
antibody.
Fig. 5. CD44up-regulationinLSCCsamples.A, equalamountsofproteins(100Ag)
fromLSCC tumor samples andadjacentnormalepitheliumunderwentWestern
blottingwithananti-CD44antibody.Anti-a-tubulinwasusedfornormalization.
Representativeof three independentexperiments.B, semiquantitativeRT-PCR
(25cycles)wasusedtodetectmRNAlevelsofCD44variants inLSCCsamples.Band
intensity was calculated by phosphorimaging. Amplimers mapping on exons 2 and
3 were used to detect all CD44 mRNA species, whereas the exon 2-v6 primer pair
was used to detect variant mRNA species containing exon v6. In LSCC, the latter
primer pair amplified twomajor products of 734 and 876 bp containing, alongwith
standard exons 2 to 5, exon v6 or both exon v3 and v6 as proven by subsequent
Southern hybridizationwith exon-specific probes (data not shown). h-Actin
mRNA detectionwas used for normalization. Representative of three independent
experiments.
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Osteopontin activates intracellular signaling, growth, and
invasiveness of squamous cell carcinoma cells. Various SCC cell
lines, washed in serum-free medium, were stimulated with
exogenous recombinant osteopontin and harvested at different
time points. Protein lysates were probed with phosphorylated
MEK and phosphorylated ERK (ERK1/2) antibodies. MEK and
ERK were readily activated in osteopontin-stimulated cells,
peaking at 5 to 15 minutes (Fig. 7A), but not in normal HNEK
cells (data not shown). We then examined the ability of SCC
cells to synthesize DNA in basal conditions and in the presence
of exogenous recombinant osteopontin. Osteopontin stimulat-
ed DNA synthesis in SCC cells, washed in serum-free medium,
but not in normal HNEK cells (P = 0.01, two tailed Student’s
t test). Thus, we asked whether osteopontin expression was
required for the growth of SCC cells. BrdUrd incorporation was
obtained in triplicate after BHY and CAL27 cell transfection
with osteopontin or scrambled siRNA. The transient silencing
of osteopontin (Fig. 7C, inset) significantly inhibited the
growth of BHY cells, whereas the negative control siRNA had
virtually no effect (Fig. 7C; data not shown). To determine
whether the CD44 receptor mediated these events, we treated
BHY, after washing in serum-free medium, with exogenous
osteopontin after CD44 blockade with specific antibodies or
chemical ERK blockade by the U0126 MEK inhibitor. Activa-
tion of MEK and ERK was virtually abrogated by pretreatment
with U0126 (Fig. 7A). Stimulation of cell proliferation by
osteopontin was obstructed by both anti-CD44 and U0126
(Fig. 7C). We next examined the ability of SCC cells to invade
Matrigel in basal conditions and in the presence of exogenous
osteopontin. Treatment with osteopontin induced a strong
migratory response of tumor cells but not of normal HNEK
cells (P = 0.04, m2 test; Fig. 7D). Treatment with CD44-blocking
antibodies or U0126 sharply inhibited these effects (P = 0.03,
two tailed Student’s t test; Fig. 7E).
Fig. 7. Osteopontin-mediated signaling,
growth, andMatrigel invasion in SCC cells.
A, total cell lysates were prepared at various
time points after stimulation of SCC cells,
washed in serum-free medium, with
recombinant osteopontin (100 ng/mL).
Immunoblots were probed with the
indicated phosphospecific antibodies.
Anti-ERK was used for normalization.
B, after starvation, the indicated cell lines
were treated (48 hours) or not with
exogenous recombinant osteopontin
(100 ng/mL). Cells were exposed to BrdUrd
for1hour, and cells were fixed and
processed for immunofluorescence.
Average results of three independent
experiments in which at least 400 cells were
counted; bars, 95% CI. C, BrdUrd
incorporationwas evaluated in BHYcells,
washed in serum-free medium, in response
to osteopontin (100 ng/mL) with and
without U0126 (10 Amol/L) or KM81
CD44-blocking mAb (10 Ag/mL). NT, not
treated cells. Moreover, osteopontin
knockdownwas obtained by transient
transfectionwith by siRNA (inset).
Mock-transfected cells and cells transfected
with scrambled siRNA served as a control.
BrdUrdwas evaluated in transfected cells.
All experiments were carried out in triplicate.
Bars, 95% CI.D, Matrigel invasion of the
various SCC cells in response to normal
culture medium or exogenous recombinant
osteopontin.The percentage of migrating
cells was quantified with an ELISA reader.
Top, average results of three independent
experiments; bars, 95% CI. Bottom,
representative micrographs. E, cells were
preincubated with U0126 (10 Amol/L)
or CD44-blocking antibody (10 Ag/mL)
andMatrigel invasionwas analyzed as
described in (D).
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Discussion
Here, we show that osteopontin expression was closely
correlated with advanced stage, high grade, metastatic disease,
and poor survival of LSCC. This is in accordance with our
observation that osteopontin affected the signaling and the
mitogenic and motile phenotypes of carcinoma cells. Thus,
although larger, prospective studies are needed to elucidate the
relevance of osteopontin status versus other prognostic factors,
our data suggest that osteopontin expression could be exploited
as a predictor of outcome in LSCC patients. Interestingly,
osteopontin plasma levels have been associated with treatment
outcome and survival of HNSCC patients (30).
After its identification as a protein secreted by neoplastic cells
(31), osteopontin has been detected in several human tumor
types (i.e., gliomas and lung, prostate, gastric, esophageal, and
ovarian carcinomas; refs. 16, 17, 19, 20). Osteopontin is also a
major determinant of breast (21) and liver (22) cancer
metastatization. Numerous growth factors (32), the RAS (33)
and SRC (34) oncogenes, and the tumor suppressor p53 (35)
regulate the expression of osteopontin. Many of these
oncogenic proteins are involved in the pathogenesis of HNSCC
(1) and thus might be responsible for osteopontin deregulation
in such a tumor type. Osteopontin is able to engage several
receptors, including integrins and CD44 variants, and thus may
stimulate diverse signaling pathways and influence cellular
events that, in turn, favor tumorigenesis and metastasis
(16, 17). In particular, osteopontin binds CD44 proteins that
contain v6-encoded sequences (14, 15), and osteopontin-
CD44v6 binding has been implicated in carcinogenesis
(16–18). In agreement with a report of CD44 (the standard
CD44 variant in that case) expression in HNSCC (36), we show
that osteopontin up-regulation is paralleled by intense expres-
sion of CD44 (in particular, CD44v6) in LSCC tissue samples
as well as in a panel of SCC cell lines. Thus, CD44v6 is a
candidate receptor for osteopontin in LSCC cells. Accordingly,
CD44 blockade obstructed osteopontin-mediated cellular
effects. CD44 activates a wealth of signaling proteins, among
which ERK (37), RAC (38), and RHO (39), as well as secretion
of cytokines (40), angiogenic factors, and metalloproteinases
(41). This could explain the effects exerted by the osteopontin-
CD44v6 axis. On the other hand, osteopontin induces CD44v6
overexpression (42). Of note, our experiments show that
osteopontin-CD44v6 binding mediates the effects occurring
in SCC cells, but they do not exclude that interactions between
osteopontin and integrins (16 –18) and between CD44,
hyaluronan (16–18), and other membrane receptors, such as
members of the MET and ERBB family (43–45), are involved in
the osteopontin-CD44 axis as well.
In conclusion, the results of this study suggest that patients
affected by LSCC that express high levels of osteopontin protein
may be more prone to a poor outcome than patients with low
osteopontin-expressing LSCC. Thus, therapies targeted at the
molecular mechanism (e.g., ligands that antagonize the inter-
action of osteopontin with CD44 or antibodies directed against
osteopontin and CD44) may prove useful in LSCC patients.
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Osteopontin Is Overexpressed in Human Papillary
Thyroid Carcinomas and Enhances Thyroid Carcinoma
Cell Invasiveness
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Context: The transmembrane glycoprotein CD44v6 is overexpressed
in most papillary thyroid carcinomas (PTC). We previously reported
that osteopontin (OPN), a secreted glycoprotein that functions as a
ligand for CD44v6, is overexpressed in thyrocytes transformed by the
RET/PTC oncogene.
Objective: In this study we asked whether OPN is overexpressed in
human PTC samples, and whether its expression correlates with
clinical and histological features of the tumors. Furthermore, we
wanted to establish the functional role of the CD44-OPN axis in
thyroid tumorigenesis.
Design: Thyroid samples from 117 patients who had undergone sur-
gical resection of the thyroid gland for benign or malignant lesions
were collected. OPN and CD44 expressions were evaluated by im-
munohistochemistry with specific monoclonal antibodies. OPN ex-
pression was correlated with different PTC histological variants,
lymph node metastasis, and PTC size.
Results: In this study we show that OPN is overexpressed in human
PTCs with respect to normal thyroid tissue, follicular adenomas, and
multinodular goiters (P 0.05). The prevalence and intensity of OPN
stainingwere significantly correlatedwith the presence of lymphnode
metastases (P  0.0091) and tumor size (P  0.0001). We also show
that treatment of human PTC cells with recombinant exogenous OPN
stimulated Matrigel invasion and activated the ERK and V-AKT
murine thymoma viral oncogene homolog 1/protein kinase B; signal-
ing pathways. Blockage of anti-CD44 antibodies prevented these
effects.
Conclusions: Given its prevalence and its correlation with aggres-
sive features of human PTCs, we suggest that OPN might be used as
a diagnostic and prognostic marker for these tumors. Furthermore,
given the role of the OPN-CD44v6 axis in PTC cells, we suggest that
CD44 and/or OPN may be molecular targets for therapeutic inter-
vention in aggressive PTCs. (J Clin Endocrinol Metab 90:
5270–5278, 2005)
THYROID TUMORS ARE the most common malignan-cies of the endocrine system; their annual incidence is
estimated to be 122,000 cases worldwide (1). Papillary thy-
roid carcinomas (PTC) far outnumber the other morpholog-
ical subtypes (2). The incidence of PTC has increased world-
wide. For instance, there were an estimated 22,000 new cases
in the United States in 2004 vs. 10,000 cases in 1980 (1). The
past decade has witnessed significant advances in our un-
derstanding of thyroid carcinogenesis at the molecular level.
Hallmarks of PTC are chromosomal translocations or inver-
sions that cause the recombination of the tyrosine kinase
domain of the RET receptor to heterologous genes, thereby
generating RET/PTC chimeric oncogenes (3). Similar rear-
rangements of the NTRKA receptor occur in a smaller frac-
tion of PTC (4). The activating V600E mutation in the BRAF
serine/threonine kinase, present in 36–69% of PTC cases, is
the most frequent genetic change in PTC (5–12). Very re-
cently, the oncogenic AKAP9-BRAF fusion has been found in
radiation-induced PTC (13). RAS point mutations are infre-
quent in PTC and are restricted to aggressive subtypes (14)
and to the follicular variant of PTC (15). Various lines of
evidence indicate that the formation of BRAF and RET/PTC
oncogenes is the first step of thyroid carcinogenesis: 1) these
oncoproteins recreate the disease in transgenic animals; 2)
they are activated in the early stages of tumor development;
and 3) radiation has been implicated in the oncogenic acti-
vation of both of them (16). Activation of the serine/threo-
nine V-AKT murine thymoma viral oncogene homolog
1/protein kinase B (AKT/PKB) kinase is another common
feature of human PTC (17).
Despite the link between these oncogenes and PTC, little
is known about the molecular mechanisms that control the
establishment and maintenance of the PTC neoplastic phe-
notype. Using oligonucleotide microarrays, we previously
found that osteopontin (OPN) is among the transcripts most
strongly induced by RET/PTC in thyroid follicular cells (18).
OPN, also known as SPP1 (secreted phosphoprotein 1), was
first identified as a noncollagenous bonematrix protein. Sub-
sequently, it was shown that OPN is indeed a cytokine, and
that it regulates cell trafficking within the immune system
(19, 20). OPN binds to the cell surface receptors v- or 1-
containing integrins and CD44 (21). CD44 is a cell surface
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Abbreviations: AKT/PKB, V-AKT murine thymoma viral oncogene
homolog 1/protein kinase B; FV, Follicular variant; OPN, osteopontin;
PI3-K, phosphatidylinositol 3-kinase; PTC, papillary thyroid carcinoma;
Q-RT-PCR, quantitative (real-time) RT-PCR.
JCEM is published monthly by The Endocrine Society (http://www.
endo-society.org), the foremost professional society serving the en-
docrine community.
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(9):5270–5278
Printed in U.S.A. Copyright © 2005 by The Endocrine Society
doi: 10.1210/jc.2005-0271
5270
 on October 21, 2005 jcem.endojournals.orgDownloaded from 
glycoprotein that can be expressed as a standard receptor
(CD44s) and as multiple splice isoforms (CD44v) whose ex-
pression is altered during tumor growth and progression.
Expression of the v6 variant exon is required for efficient
OPN binding (21, 22). Under normal conditions, only CD44s
is expressed on the cell surface of nonproliferating thyro-
cytes, whereas CD44v6 is invariably overexpressed in PTC
samples (23–26). OPN is expressed in numerous human tu-
mors, including colon, breast, prostate, gastric, ovarian, and
lung carcinomas. In addition, OPN expression often corre-
lates with a poor prognosis (27).
In our previous work we proposed that RET/PTC signal-
ing triggered the formation of an autocrine axis involving
OPN and its receptor, CD44. An intact kinase activity and the
integrity of tyrosine 1062 of RET were required for the up-
regulation of both OPN and CD44. Furthermore, we showed
that addition of exogenous OPN or transduction of OPN
through a lentiviral vector in RET/PTC1-expressing rat thy-
roid cells stimulated mitogenesis, survival, andmotility (18).
To validate these observations and to assess the role of OPN
expression in human thyroid tumors, we collected human
PTC tumor samples and studied OPN and CD44 expression.
Furthermore,weusedhumanPTC cell lines characterized for
the presence of the RET/PTC1 rearrangement or BRAF
(V600E) mutation. In this study we show that OPN is con-
sistently overexpressed in human PTC samples, and that
OPN-induced CD44 stimulation activates the ERK and
AKT/PKB signaling pathways, thereby sustaining Matrigel
invasion of human PTC cell lines.
Patients and Methods
Tumors
Archival thyroid samples from 117 patients were retrieved from the
files of the Department of Oncology of University of Pisa (Pisa, Italy).
Informed consent was obtained from the patients, and the study was
approved by the institutional review board committee. Tumor size,
extrathyroid invasion, node metastasis, associated thyroid lesions, and
metastatic deposits were recorded. After surgical resection, tissues were
fixed in 10% neutral buffered formalin and embedded in paraffin blocks.
Sections (4 m thick) were stained with hematoxylin and eosin for
histological examination. The nuclear and architectural features were
evaluated to ensure that the samples fulfilled the diagnostic criteria
required for the identification of PTC (enlarged nuclei with fine dusty
chromatin, nuclear grooves, single or multiple micro/macronucleoli,
and intranuclear inclusions) (28, 29). The final histological diagnoses of
the carcinomas were: classic papillary (n  40), follicular variant PTC
(PTC-FV; n 23), and tall cell variant PTC (n 8). In addition, 34 normal
thyroid samples, seven follicular adenomas, and five multinodular goi-
ters were examined.
Immunohistochemistry
Formalin-fixed and paraffin-embedded 4- to 5-m-thick tumor sec-
tions were deparaffinized, placed in a solution of absolute methanol and
0.3% hydrogen peroxide for 30min, and treatedwith blocking serum for
20min. The slideswere incubated overnightwith anti-OPNor anti-CD44
monoclonal antibodies, with biotinylated anti-IgG, and finally with pre-
mixed avidin-biotin complex (Vectostain ABC kits, Vector Laboratories,
Inc., Burlingame, CA). Anti-OPN IgG1 mouse monoclonal (10A16) was
obtained from Assay Designs (Ann Arbor, MI), and anti-CD44v6 IgG1
mouse monoclonal (NCL-CD44v6, clone VFF-7) was purchased from
Novocastra Laboratories Ltd. (Newcastle upon Tyne, UK). The immune
reaction was revealed with 0.06 mmol/liter diaminobenzidine (DAB-
Dako, DakoCytomation, Carpinteria, CA) and 2 mmol/liter hydrogen
peroxide. The slides were counterstained with hematoxylin. As a neg-
ative control, tissue slides were incubated with isotype-matched IgG1
control antibodies. The OPN immunostaining was mostly localized in
the cytoplasm. Staining intensity was scored semiquantitatively into
different grades on an arbitrary scale from 0–3: grade 0, no detectable
immunostaining; 1, weak staining; 2 moderate staining; and 3,
strong staining intensity. For each sample, the percentage of positive
cells for OPN staining was also evaluated.
Cell lines and plasmids
Human primary cultures of thyroid cells (P5) were obtained from F.
Curcio (Dipartimento di Patologia e Medicina Sperimentale e Clinica,
Universita` di Udine, Udine, Italy) and cultured as previously described
(30). Human RET/PTC1-positive (TPC1, FB2, BHP2-7, BHP7-13, and
BHP10-3) and BRAF V600E-positive (NPA and BCPAP) PTC cell lines
were described previously (5, 31). BHP5-16, BHP14-9, and BHP17-10
were shown by direct sequencing to harbor the BRAF V600E mutation
at the heterozygous level (Salvatore, G., V. Guarino, T. Nappi, F. Car-
lomagno, R.M.Melillo, andM. Santoro, unpublished observations). PTC
cells were maintained in DMEM supplemented with 10% fetal bovine
serum, 2 mm l-glutamine, and 100 U/ml penicillin-streptomycin (In-
vitrogen Life Technologies, Inc., Paisley, PA).
RNA extraction and RT PCR
Total RNA from the indicated cell cultures and from snap-frozen
tissue samples was prepared using the RNeasy Mini Kit (Qiagen, Craw-
ley, UK) and subjected to on-column deoxyribonuclease digestion with
the ribonuclease-free deoxyribonuclease set (Qiagen) following theman-
ufacturer’s instructions. Only tissue samples containing more than 70%
neoplastic cells were used. The quality of RNA from each sample was
verified by electrophoresis through 1% agarose gel. Total RNA (2.5 g)
was denatured, and cDNA was synthesized using the GeneAmp RNA
PCR Core Kit system (Applied Biosystems, Foster City, CA) following
the manufacturer’s instructions. PCR was amplified using 2.5 l reverse
transcriptase product in a reaction volume of 25 l with primer pairs
specific for the gene studied. To exclude DNA contamination, each PCR
was also performed with untranscribed RNA. The levels of the house-
keeping -actin transcript were used as a control for equal RNA loading.
Primers were designed with the Primer 3 program (www.genome.wi.
mit.edu/cgi-bin/primer/primer3_www.cgi) and synthesized by MWG
(Ebersberg, Germany). Primer sequenceswere as follows: OPN forward,
5-AGGAGGAGGCAGAGCACA-3; OPN reverse, 5-CTGGTATG-
GCACAGGTGATG-3; CD44 (exon 2) forward, 5-GCTTTCAATAG-
CACCTTGCC-3; CD44 (exon v6) reverse, 5-GTTGCCAAACCACTGT-
TCCT; -actin forward, 5-TGCGTGACATTAAGGAGAAG-3; and
-actin reverse, 5-GCTCGTAGCTCTTCTCCA-3.
Each RT-PCR product was loaded on 2% agarose gel, stained with
ethidium bromide (0.5 g/ml), and the corresponding image was saved
by the Typhoon 8600 laser scanning system (Amersham Biosciences,
Little Chalfont, UK). The density and width of each band were quan-
tified using ImageQuant 5.0 (Amersham Biosciences). OPN expression
in the different cell lines was expressed as the fold increase with respect
to normal P5 thyroid cells (1) after normalization for -actin
expression.
Quantitative (real-time) RT-PCR (Q-RT-PCR) was performed by us-
ing the SYBRGreen PCRMasterMix (Applied Biosystems) in the iCycler
apparatus (Bio-Rad Laboratories, Munich, Germany). Amplification re-
actions (25 l final reaction volume) contained 200 nm of each primer,
3 mmMgCl2, 300 m deoxy-NTPs, 1 SYBRGreen PCR buffer, 0.1 U/l
AmpliTaq Gold DNA polymerase, 0.01 U/l Amp Erase, ribonuclease-
free water, and 2 l cDNA samples. We performed 80 cycles of melting
to verify the absence of nonspecific products. In all cases, the melting
curve confirmed that a single product was generated. Amplificationwas
monitored by measuring the increase in fluorescence caused by SYBR
Green binding to double-stranded DNA. Fluorescent threshold values
were measured in triplicate, and fold changes were calculated by the
formula: 2(sample 1 Ct sample 2 Ct), whereCt is the difference between
the amplification fluorescent thresholds of themRNA of interest and the
-actin mRNA. Primer sequences were as follows: OPN forward, 5-
ATCCATGTGGTCATGGCTTT-3; OPN reverse, 5-GAAGGAGCT-
GAAGGAGCTGA-3; -actin forward, 5-TGCGTGACATTAAG-
GAGAAG-3; and -actin reverse, 5-GCTCGTAGCTCTTCTCCA-3.
Guarino et al. • Osteopontin in Papillary Thyroid Carcinoma J Clin Endocrinol Metab, September 2005, 90(9):5270–5278 5271
 on October 21, 2005 jcem.endojournals.orgDownloaded from 
Protein studies
Immunoblotting experiments were performed according to standard
procedures. Briefly, cells were harvested in lysis buffer [50 mm HEPES
(pH 7.5), 150 mm NaCl, 10% glycerol, 1% Triton X-100, 1 mm EGTA, 1.5
mm MgCl2, 10 mm sodium fluoride, 10 mm sodium pyrophosphate, 1
mmNa3VO4, 10 g aprotinin/ml, and 10 g leupeptin/ml) and clarified
by centrifugation at 10,000  g. For protein extraction from human
tissues, samples were snap-frozen and immediately homogenized in
lysis buffer in the Mixer Mill apparatus (Qiagen). Protein concentration
was estimated with a modified Bradford assay (Bio-Rad Laboratories).
Antigens were revealed by an enhanced chemiluminescence detection
kit (ECL, Amersham Biosciences). Anti-OPN goat polyclonal antibody
(K20) and rabbit polyclonal anti-CD44 (H300) were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Monoclonal anti--tubulin
was purchased from Sigma-Aldrich Corp. (St. Louis, MO). Anti-phos-
pho-p44/42 MAPK (ERK) and anti-p44/42 MAPK, anti-phospho-AKT,
and anti-AKT antibodies were obtained from New England Biolabs
(Beverly, MA). Secondary antimouse and antirabbit antibodies coupled
to horseradish peroxidase were purchased from Bio-Rad Laboratories.
Where indicated, densitometric analysis of the immunoreactive bands
was performed by phosphorimager scanning (Typhoon, AmershamBio-
sciences) and analyzed using ImageQuant 5.0 software. Protein levels
were expressed as fold increases with respect to normal thyroid samples
(1) after normalization for tubulin expression.
ELISA
Thyroid cells (3 105) were plated in six-well dishes, allowed to grow
to 70% confluence, and then serum-deprived for 24 h. Culture media
were centrifuged at 2000 rpm at 4 C to remove detached cells and debris.
Attached cells were lysed, and total protein concentrationwas evaluated
by a modified Bradford assay (Bio-Rad Laboratories), as described
above. OPN levels in culture supernatants weremeasured using a quan-
titative immunoassay ELISA kit (QuantiKine assay, R&D Systems, Inc.,
Minneapolis, MN) following the manufacturer’s instructions. Triplicate
samples were analyzed at 490 nm with an ELISA reader (model 550
microplate reader, Bio-Rad Laboratories). OPN levels, expressed in
nanograms per milliliter, were adjusted considering total protein levels
of the grown cells.
Flow cytometric analysis
Subconfluent cells were detached from culture dishes with a solution
of 0.5mm EDTA, thenwashed three times in PBS buffer. After saturation
with 1 g human IgG/105 cells, cells were incubated for 20 min on ice
with antibodies specific for human CD44v6 (R&D Systems, Inc.) or
isotype control antibody. After incubation, unreacted antibody was re-
moved by washing cells twice in PBS buffer. Cells were then incubated
(30 min, 4 C) with 100 l fluorescein-conjugated goat antimouse IgG/M
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Cells
resuspended in PBS were analyzed on a FACSCalibur cytofluorometer
using CellQuest software (BD Biosciences, San Jose, CA). Analyses were
performed in triplicate. In each analysis, a total of 104 events were
calculated.
Chemoinvasion
In vitro invasiveness through Matrigel was assayed using Transwell
cell culture chambers as described previously (18). Briefly, confluent cell
monolayers were harvested with trypsin/EDTA and centrifuged at
800  g for 10 min. The cell suspension (1  105 cells/well) was added
to the upper chamber of a prehydrated polycarbonate membrane filter
with a pore size of 8 m (Costar, Cambridge, MA) coated with 35 g
Matrigel (Collaborative Research, Inc., Bedford, MA). The lower cham-
ber was filled with complete medium, and when required, purified
recombinant OPN (R&D Systems, Inc.) was added at a concentration of
100 ng/ml. To inhibit Matrigel invasion, cells were preincubated with
5 g/ml CD44-blocking antibodies (KM81 hybridoma, TIB-241, Amer-
ican Type Culture Collection, Manassas, VA) (32). Alternatively, cells
were treated for 12 h with U0126 (10 m) or wortmannin (100 nm;
Upstate Biotechnology, Inc., Charlottesville, VA). Cells were then incu-
bated at 37 C in a humidified incubator in 5% CO2 and 95% air for 24 h.
Nonmigrating cells on the upper side of the filter and Matrigel were
wiped off, and migrating cells on the reverse side of the filter were
stained with 0.1% crystal violet in 20% methanol for 15 min and pho-
tographed. The stained cells were lysed in 10% acetic acid. Triplicate
samples were analyzed at 570 nm with an ELISA reader (model 550
microplate reader, Bio-Rad Laboratories). The results were expressed as
the percentage of migrating cells.
Statistical analysis
Statistical analysis (Statistica, StatSoft, Tulsa, OK) was performed
using 2  2 tables (2); differences were significant at P  0.05.
Results
Immunohistochemical determination of OPN expression
in PTC
We measured OPN expression by immunohistochemistry
with an anti-OPN-specific monoclonal antibody in 117 thy-
roid samples from patients who had undergone surgical
resection of the thyroid gland for benign or malignant le-
sions. Representative immunohistochemical stainings are
shown in Fig. 1, and the entire dataset is reported in Table
1. OPN was virtually undetectable (10% of cells) in normal
thyroid glands (n  34), follicular adenomas (n  7), and
multinodular goiters (n  5). In contrast, most of the PTC
samples examined (60 of 71), were positive for OPN expres-
sion, and positivity was confined to tumor cells (Table 1). As
shown in Table 2, the prevalence and intensity of OPN stain-
ing were significantly correlated with the presence of lymph
node metastases (P  0.0091) and tumor size (P  0.0001).
Furthermore, 85% (34 of 40) of the classic PTC tumors and
100% (eight of eight) of the tall cell variant PTC tumors
displayed intense (2/3) OPN immunoreactivity in more
than 70% of the cells, whereas PTC-FV tumors were char-
acterized by less intense or negative staining. Finally, in
accordance with previous data (23–26), classic PTC (n  40)
were invariably positive also to CD44v6-specific monoclonal
antibodies (Fig. 1H and data not shown).
Immunoblot and PCR analysis of OPN expression in PTC
Protein lysates were harvested from a pool of normal hu-
man thyroid tissues and from six classic PTC samples and
analyzed by immunoblotting. Densitometric analysis of the
blots was performed, and OPN levels were normalized to
tubulin. As shown in Fig. 2A, the OPN protein (molecular
mass,65,000) was abundantly expressed in all carcinomas,
but was barely detectable in normal tissue. To obtain an
additional assessment of OPN up-regulation and to deter-
mine whether up-regulation occurred at the transcriptional
level, we examined a small sample set using Q-RT-PCR. As
shown in Fig. 2B, the levels of OPN transcripts were signif-
icantly higher (8- to 22-fold) in tumor samples than in normal
thyroid tissue.
To verify these findings and to establish a model system
with which to study the role of OPN up-regulation, we an-
alyzed OPN mRNA expression in cultured human thyroid
cells. In these experiments we used a primary culture of
normal thyroid follicular cells (P5) (30) and a panel of PTC
cell lines characterized for the presence of RET/PTC rear-
rangements (TPC1, FB2, BHP2-7, BHP7-13, and BHP10-3) or
the V600E mutation in BRAF (BHP5-16, BHP14-9, BHP17-10,
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NPA, and BCPAP) (5, 31) (Salvatore, G., unpublished ob-
servations). As shown by the RT-PCR experiment, all the
PTC cell lines analyzed overexpressed OPN by more than
10-fold with respect to normal thyrocytes; BCPAP cells were
the least positive (Fig. 3A). Thus, OPN up-regulation corre-
lated with the presence of the two most common genetic
alterations in PTC, i.e. the RET/PTC and BRAF mutations
(16). To verify that the up-regulated OPN was indeed se-
creted by PTC cells, we used an ELISA to examine condi-
tioned medium harvested from the various cell lines. PTC
cells, but not normal P5 cells, secreted abundant OPN in the
culture medium (Fig. 3B). Again, BCPAP cells were the least
positive.
CD44 is an OPN cell surface receptor, and it is frequently
overexpressed in neoplastic cells. CD44 pre-mRNA is en-
coded by 20 exons, which are subject to alternative splicing.
The constant 5-terminal five exons encode the N-terminal
extracellular domain of the protein, whereas the constant
3-terminal five exons encode the transmembrane and the
short cytosolic tail. An additional 10 exons (variant v1–v10
exons) are alternatively spliced and encode the extracellular
membrane-proximal stem structure (21, 22). Cancer cells of-
ten overexpress CD44 variants that differ in the number of
v exons. The presence of the v6 exon is required for efficient
OPN binding (21, 22). Consequently, we screened PTC cell
lines for CD44 expression by RT-PCR using primers de-
signed on exons 2 and v6. As shown in Fig. 4A, all cancer cells
tested, but not normal cells, contained high levels of CD44v6
mRNA. To enable cells to bind OPN, CD44v6 must be ex-
pressed on the cell surface.We therefore used flow cytometry
to determine whether CD44v6 was expressed on the surface
of PTC cells. As shown in Fig. 4B, the TPC1 and BCPAP PTC
cell lines featured homogeneous cell membrane CD44v6 ex-
pression, whereas the others displayed varying expression
levels of CD44v6.
OPN activates intracellular signaling and invasiveness of
PTC cells
OPNprotein secretion and cell surface CD44v6 expression
reflected the existence of an autocrine/paracrine OPN-CD44
axis that affected PTC cells. To verify that this axis was
functional in human PTC cell lines, we examined cell inva-
sion of Matrigel under basal conditions and in the presence
of exogenous recombinant OPN. To this aim, we treated
normal P5 and PTC-derived cell lines with exogenous OPN
and evaluated the number of migrating cells. As shown in
Fig. 5A,OPN induced a strongmigratory response in all PTC,
but not in normal cells. Interestingly, the TPC1 and BCPAP
cells, which expressed the highest levels of CD44v6, dis-
played the best migratory response to OPN. To verify
whether OPN was able to induce a biochemical response in
PTC cells,we selectedBCPAP cells,which express high levels
of CD44v6 and relatively low levels of OPN. Cells were
stimulatedwith exogenous recombinant OPN and harvested
at different time points. Protein lysates were probed with
antiphospho-MAPK (ERK) and antiphospho-AKT/PKB an-
tibodies. As shown in Fig. 5B, both p44/42 MAPK and AKT
were readily activated in OPN-stimulated cells; they peaked
at 5–15 min. It has been previously reported that in immor-
talized liver carcinoma cells (HepG2), OPN up-regulated
TABLE 1. OPN positivity in thyroid lesions
Histology No. ofcases
OPN positivity no. of cases (%)a
	10% (1/3) 10% (0/1)
PTC 71 60 (84.5)b 11 (15.5)
Microfollicular adenoma 4 4 (100)
Macrofollicular adenoma 3 3 (100)
Multinodular goiter 5 5 (100)
Normal 34 34 (100)
a The OPN immunostaining wasmostly localized in the cytoplasm.
Cytoplasmic staining intensity was scored semiquantitatively as de-
scribed inPatients andMethods.The percentage of OPN-positive cells
was estimated. The samples were divided in two groups (	10% and
10% of positive cells). The intensity of OPN stainingwas graded into
the following categories: 0, no signal; 1, weak; 2, moderate; 3,
strong. The number of positive cells invariably correlated with stain
intensity.
b OPN positivity (	10% cells) in PTC vs. the other lesions: P 0.05
[2  2 tables (2)].
FIG. 1. Immunohistochemical detection of OPN and CD44 in thyroid
samples. Tissue samples fromnormal thyroid (A andB), primary PTC
(C and D), and a PTC node metastasis (F) were incubated with a
mouse monoclonal anti-OPN antibody. PTC samples showed intense
immunoreactivity for OPN. In PTC samples, intense immunoreac-
tivity was also seen with CD44v6 antibodies (H). Negative controls
were performed in all PTC cases using isotype control antibodies (E
and G). Magnification: A, C, E, and H, 100; B, D, F, and G, 200.
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plasma membrane CD44v6 protein expression in a concen-
tration- and time-dependent fashion (33). To determine
whether this was also the case for thyroid cancer cells, we
stimulated BCPAP with OPN and evaluated CD44 expres-
sion by Western blot analysis. As shown in Fig. 5C, OPN
treatment significantly increased CD44 protein levels. Such
an up-regulation reasonably occurred at a posttranscrip-
tional level, because it was not detected at the mRNA level
(not shown).
To evaluate whether the CD44 receptor mediated inva-
siveness of thyroid cancer cells, we treated CD44-blocked
BCPAP cells with exogenous OPN (for 5 or 30 min). As
FIG. 2. OPN up-regulation in PTC samples. A, OPN protein levels were evaluated by immunoblot in PTC samples and in a pool of five normal
thyroid samples (NT). Equal amounts of proteins (100 g) were immunoblotted with anti-OPN polyclonal antibodies. Antitubulin monoclonal
antibody was used as a control for equal loading. Densitometric analysis was performed with the Typhoon 8600 laser scanning system and the
ImageQuant 5.0 software (Amersham Biosciences), and data are shown in the bar graph. Each column represents the relative fold change with
respect to the normal thyroid (NT) sample expression (1). B, Q-RT-PCR was used to calculate OPN mRNA fold induction in six independent
PTC tumor samples with respect to a pool of four normal thyroids. The results are the average of three independent experiments 
 SD.
TABLE 2. Correlation between OPN positivity and clinicopathological features in PTC
T (no.)a,b
Node
metastases
(no.)c
Subtype (no.)d
OPN-positivity no. of casese
	70% (2/3) 30–70% (1/2) 10–29% (1) 10% (0–1)
T1–T2 (32) Yes (7) Classic (3) 3
Tall-cell (0)
Follicular (4) 1 2 1
No (25) Classic (6) 6
Tall-cell (0)
Follicular (19) 9 10
T3–T4 (39) Yes (25) Classic (17) 15 2
Tall-cell (8) 8
Follicular (0)
No (14) Classic (14) 10 4
Tall-cell (0)
Follicular (0)
a T was defined as follows: TX, primary tumor cannot be assessed; T0, no evidence of primary tumor; T1, the tumor is 2 cm (slightly less
than an inch) or smaller; T2, tumor is between 2 and 4 cm (slightly less than 2 inches); T3, tumor is larger than 4 cm or has slightly grown
outside the thyroid; T4a, tumor of any size and has grown beyond the thyroid gland to invade nearby tissues of the neck; T4b, tumor has grown
either back to the spine or into nearby large blood vessels.
b OPN positivity (	10% cells) in T1–T2 vs. T3–T4 PTC samples: P  0.0001 [2  2 tables (2)].
c OPN positivity (	10% cells) in N() vs. N() PTC samples: P  0.0091 [2  2 tables (2)].
d Weak or no OPN positivity (10% cells) in FV vs. other PTC variants: P  0.0001 [2  2 tables (2)].
e The OPN immunostaining was mostly localized in the cytoplasm. Cytoplasmic staining intensity was scored semiquantitatively. The
percentage of OPN-positive cells was estimated and the samples were divided in four groups. The intensity of OPN staining was graded into
the following categories: 0, no signal; 1, weak; 2, moderate; 3, strong. The number of positive cells invariably correlatedwith stain intensity;
for instance, a high fraction of positive cells (	70%) was paralleled by moderate-strong (2/3) stain intensity, whereas a reduced fraction of
positive cells (10%) was paralleled by weak staining.
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shown in Fig. 6A, p44/42 MAPK and AKT activation was
attenuated by pretreatment with CD44-blocking antibodies.
CD44 blockade also prevented migration through Matrigel
(Fig. 6B). These observations show that CD44 functions as an
OPN-signaling receptor in PTC cells. To investigate whether
intracellular signaling was involved in Matrigel invasion
FIG. 4. CD44v6 up-regulation in cultured PTC cells. A, Semiquantitative RT-PCR (25 cycles) was performed to evaluate mRNA levels of the
exon v6-containing CD44 variant in the indicated cell lines. Amplimers mapping on exons 2 and v6 were used. The exon 2-v6 primer pair
amplified one product of 780 bp, containing exons 2–5 and exon v6, as demonstrated by subsequent Southern hybridization with exon-specific
probes (not shown). -Actin mRNA detection was used for normalization. This figure is representative of three independent experiments. B,
Flow cytometric analysis of cell surface expression of CD44v6 receptor in the indicated PTC cell lines. The shadowed curve is the negative control
antibody.
FIG. 3. OPN up-regulation in cultured PTC cells. A, Semiquantitative RT-PCR (25 cycles) was performed to evaluate OPNmRNA levels in the
indicated cell lines; -actin mRNA detection was used for normalization. Band intensity was calculated by phosphorimaging and expressed as
the fold change with respect to P5 normal thyroid cells (1) in the lower panel. This figure is representative of three independent experiments.
B, OPN protein secretion by PTC cells was evaluated by ELISA. Normal thyroid cells (P5) were used as the negative control. The results of
three independent determinations performed in triplicate 
 SD are reported.
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mediated by the OPN-CD44 axis, we used U0126, an inhib-
itor of the MAPK pathway (MEK1/2), and wortmannin, an
inhibitor of the phosphatidylinositol 3-kinase (PI3-K)/AKT
pathway. As shown in Fig. 6B, both compounds sharply
inhibited (15 
 5-fold) Matrigel invasion in parallel with
MAPK and AKT blockade (Fig. 6A).
Discussion
OPN is overexpressed in many tumor types (21, 27). The
expression of OPN is induced by various signaling proteins
that are constitutively active in tumors: growth factors such
as the hepatocyte growth factor (34, 35), oncogenes such as
RAS (36) and SRC (37), and tumor promoters such as 12-O-
tetradecanoyl phorbol 13-acetate (38).
In this study we show that OPN up-regulation is involved
in the invasive phenotype of PTC. Overall, as many as 70%
of human PTC are estimated to carry mutations at the level
of the RET-RAS-BRAF-MAPK signaling cascade (16). We
previously reported high levels of OPN and CD44v6 in fol-
licular cells derived from rat thyroid glands and transformed
by the RET/PTC oncogene (18). We now show that OPN and
CD44v6 up-regulation is a common feature of PTC cells that
express the RET/PTC or BRAF V600E oncogenes. This find-
ing suggests that activation of the OPN-CD44v6 axis is one
of the end points of the RET-RAS-BRAF-MAPK oncogenic
cascade. This model is consistent with the idea that in other
cell types, OPN expression is induced by the RAS oncogene
(36, 39) and is dependent on theMAPK cascade (40), and that
CD44v6 splicing is under control of the RAS-MAPKpathway
(41).
Our findings could also clarify the role played by over-
expression of CD44v6 in PTC (22–26). CD44 is able to activate
a wealth of signaling proteins, such as ERK (42), RAC (43),
and RHO (44), leading to cell adhesion and migration, an-
giogenesis (45), and the secretion of cytokines (44) and met-
alloproteinases (46). Given the finding that OPN is able to
induce CD44v6 overexpression (33), it is conceivable that in
PTC cells, the RET-RAS-BRAF-MAPK oncogenic cascade
triggers OPN and CD44v6 up-regulation; this leads to OPN-
CD44v6 binding, thereby further increasing CD44v6 up-reg-
ulation and enhancing MAPK and AKT signaling. It is note-
worthy that AKT activation is a common feature of
aggressive thyroid cancers (17). The foregoing functional
autocrine loop may sustain the invasive capability of PTC
cells. Although our experiments demonstrate that OPN-
CD44v6 binding mediates cellular effects in thyroid carci-
noma cells, they do not exclude that other interactions be-
tween OPN and integrins (21, 27) and between CD44,
hyaluronan (22), and othermembrane receptors such asMET
and ERBB2 (47, 48) may be involved in the effects exerted by
the OPN-CD44 axis in PTC. Intriguingly, both MET (49) and
ERBB2 (50) are overexpressed in PTC. Normal and cancer
thyroid cells have been reported to express several integrin
receptors, among which the fibronectin receptors 3/1, v/
3, and v/5 (51, 52). Furthermore, immunohistochemistry
demonstrated altered expression of v3 in human PTC (52).
Using real-time RT-PCR, we found expression of the v, 3,
and 5, but not of 1, integrin in our PTC cell lines, including
BCPAP (Guarino, V., A. Celetti, R. M. Melillo, and M. San-
toro, unpublished observations).
In this study we show that OPN up-regulation correlates
with aggressive clinicopathological features of PTC. Indeed,
the presence of lymph node metastases and tumor size both
positively correlated with OPN positivity. Thus, OPNmight
be a diagnostic and prognostic marker for these tumors.
Indeed, OPN,which also occurs in blood, has already proven
useful as a tumor marker for ovarian (53) and lung (54)
carcinomas. Given the low prevalence of OPN overexpres-
sion in PTC-FV, our findings anticipate that OPN detection
will have a rather low sensitivity in this particular PTC vari-
ant. However, our series of PTC-FV is too small to draw firm
conclusions. Furthermore, it should be noted that the
FIG. 5. OPN-mediated signaling and Matrigel invasion. A, Matrigel
invasion of TPC cells in response to normal culture medium or ex-
ogenous recombinant OPN. Cells were incubated for 24 h. Thereafter,
filterswere fixed and stained. The upper surfacewaswiped clean, and
cells on the lower surface were stained with 0.1% crystal violet. The
stained cells were lysed in 10% acetic acid. Invasive ability is ex-
pressed as the percentage of migrating cells with respect to the total
cell number. Quantification was performed in triplicate samples with
an ELISA reader. This figure is representative of three independent
experiments. B, Total cell lysates were prepared at various time
points after stimulation of BCPAP cellswith recombinantOPN.West-
ern blots were probed with the indicated phospho-specific antibodies.
Anti-MAPK and anti-AKT were used for normalization. C, BCPAP
cells were stimulated with recombinant OPN for 12 h. Total cell
lysates were then prepared and subjected to immunoblot with anti-
CD44 antibodies. OPN stimulated CD44 up-regulation and sustained
MAPK activation, as shown by staining of the same filter with anti-
pMAPK antibodies. The filter was stripped and reprobed with anti-
MAPK antibodies to show equal protein loading.
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PTC-FV were all included in the T1-T2 stages, where the
positivity for OPN is less prevalent. The MAPK kinase and
PI3-K pathways could be targets for thyroid cancer therapy
(16, 55). Our experiments with CD44-blocking antibodies
and MAPK kinase and PI3-K inhibitors provide proof of
principle that the OPN-CD44v6 pathwaymay be amolecular
target for therapeutic intervention in cases of aggressive PTC.
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RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins
potentiates PI3-K signalling in thyroid tumors
Valentina De Falco1,3, Valentina Guarino1,3, Luca Malorni1, Anna Maria Ciraﬁci1,
Flavia Troglio2, Marco Erreni2, Giuliana Pelicci2, Massimo Santoro1 and Rosa Marina Melillo*,1
1Istituto di Endocrinologia ed Oncologia Sperimentale del CNR ‘G. Salvatore’, c/o Dipartimento di Biologia e Patologia Cellulare e
Molecolare, Via S. Pansini 5, 80131 Naples, Italy; 2Department of Experimental Oncology, European Institute of Oncology, Milan,
Italy
RAI, also named ShcC/N-Shc, one of the members of the
Shc proteins family, is a substrate of the RET receptor
tyrosine kinase. Here, we show that RAI forms a protein
complex with both RET/MEN2A and RET/PTC onco-
proteins. By coimmunoprecipitation, we found that RAI
associates with the Grb2-associated binder1 (GAB1)
adapter. This association is constitutive, but, in the
presence of RET oncoproteins, both RAI and GAB1 are
tyrosine-phosphorylated, and the stoichiometry of this
interaction remarkably increases. Consequently, the p85
regulatory subunit of phosphatidylinositol-3 kinase (PI-
3K) is recruited to the complex, and its downstream
effector Akt is activated. We show that human thyroid
cancer cell lines derived from papillary or medullary
thyroid carcinoma (PTC or MTC) carrying, respectively,
RET/PTC and RET/MEN2A oncoproteins express RAI
proteins. We also show that human PTC samples express
higher levels of RAI, when compared to normal thyroid
tissue. In thyroid cells expressing RET/PTC1, ectopic
expression of RAI protects cells from apoptosis; on the
other hand, the silencing of endogenous RAI by small
inhibitory duplex RNAs in a PTC cell line that expresses
endogenous RET/PTC1, increases the rate of sponta-
neous apoptosis. These data suggest that RAI is a critical
substrate for RET oncoproteins in thyroid carcinomas.
Oncogene advance online publication, 6 June 2005;
doi:10.1038/sj.onc.1208776
Keywords: thyroid tumor; RET oncogenes; RAI and
GAB1 adaptors
Introduction
The family of Shc-like proteins includes three members:
Shc, SLI (ShcB/ScK) and RAI (ShcC/N-Shc) (Cattaneo
and Pelicci, 1998; Luzi et al., 2000). It has been shown
that while Shc is ubiquitously expressed, the other two
members, RAI and SLI, are predominantly expressed in
neural tissues (O’Bryan et al., 1996; Pelicci et al., 1996;
Nakamura et al., 1998). In support of their role in the
developing brain, it has been shown that null mutations
of both RAI and SLI in mice results in a loss of
sympathetic neurons. In particular, neurons of the
superior cervical ganglia (SCG) are signiﬁcantly reduced
in number in the double-knockout mice, a phenotype
that resembles that induced by the knockout of RET
tyrosine kinase receptor (Sakai et al., 2000). Accord-
ingly, we showed that RAI is a physiological substrate
of the RET receptor, and that it potentiates RET-
mediated activation of phosphatydilinositol 3-kinase
(PI3-K) and RET-dependent survival of neuronal cells.
We also deﬁned the molecular determinants of this
interaction, which is mediated by tyrosine 1062 of RET
and the phosphotyrosine binding (PTB) domain of RAI
(Pelicci et al., 2002).
The RAI gene codes for two proteins, p64 RAI and
p52 RAI, as a consequence of alternative initiation
codon usage. These proteins, like the other members of
the Shc-like family, share a similar PTB-CH1-SH2
domains modular structure (Luzi et al., 2000; Ravi-
chandran, 2001). The PTB and SH2 domains are
phospho-tyrosine-recognition modules common to sev-
eral different proteins with similar functions. The CH1
region contains tyrosine-phosphorylation residues and
several SH3 binding sites. For these features, RAI
proteins have been implicated in signal transduction
mediated by tyrosine kinase receptors (Nakamura et al.,
1996; O’Bryan et al., 1998; Pelicci et al., 2002; Liu and
Meakin, 2002; Nakazawa et al., 2002). While RAI and
Shc share many common properties, speciﬁc features of
RAI-mediated signalling have been identiﬁed. First,
RAI transduces Grb2-SOS-RAS-dependent ERK acti-
vation less efﬁciently than Shc, because it binds less
efﬁciently Grb2. Furthermore, RAI has three novel
tyrosine phosphorylation sites that are not present in
Shc. These sites represent potential docking sites for
signalling adapters, one of which has been identiﬁed as
the CRK protein. These data implicate that recruitment
of RAI may result in speciﬁc signalling output and
consequent biological activities (Nakamura et al., 2002).
The receptor tyrosine kinase RET is speciﬁcally
activated by members of the GDNF family of ligands,
which are involved in the control of neuronal survival
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and differentiation, kidney development, and spermato-
gonial cell fate. These ligands bind RET through GPI-
anchored coreceptors (Santoro et al., 2004). RET
genetic alterations are responsible for the occurrence
of two thyroid malignancies, the medullary (MTC) and
the papillary thyroid carcinomas (PTC). These tumors
arise, respectively, from the parafollicular C-cells and
from the epithelial follicular cells of the thyroid gland.
Germline point mutations in RET cause MTC in the
context of three related dominantly inherited tumor
syndromes, multiple endocrine neoplasia type 2A
(MEN2A), multiple endocrine neoplasia type 2B
(MEN2B) and familial medullary thyroid carcinoma
(FMTC). RET point mutations are also found in a
fraction of sporadic MTCs (Santoro et al., 2004). PTC is
the most common endocrine malignancy. In a remark-
able fraction of these tumors, chromosomal aberrations
involving chromosome 10 are present. Following these
aberrations, the intracellular kinase domain of RET is
rearranged with heterologous genes, generating the so-
called RET/PTC oncogenes (Pierotti, 2001; Nikiforov,
2002). RET/PTC1 and RET/PTC3 are the most
frequent isolates. Both MTC- and PTC-associated
RET genetic alterations have a gain-of-function effect,
resulting in constitutive kinase activation and oncogenic
conversion. Activation of RET either by ligand trigger-
ing or by oncogenic conversion initiates most of the
signalling pathways activated by tyrosine kinases, such
as the RAS/RAF/ERK and the PI3-K/Akt pathways
(Santoro et al., 2004). Several groups have shown the
central role of tyrosine 1062 of RET in signal transduc-
tion. This residue is the binding site for several different
signalling adaptors, such as Shc, RAI, IRS1/2, FRS2,
Dok and Enigma (Hayashi et al., 2000). Activation of
PI3-K has been shown to depend on Y1062 of RET
through the formation of a Shc/Grb2/GAB1 complex
and consequent recruitment and activation of the p85
subunit of the PI3-K (Besset et al., 2000; Segoufﬁn-
Cariou and Billaud, 2000). Furthermore, it has been
shown that GAB1 is necessary not only for Akt
activation but also Rac1 activation and lamellipodia
formation (Maeda et al., 2004). In this study, we
examined involvement of RAI in human PTC and
MTC cell lines derived from these tumor histotypes, by
evaluating expression and tyrosine-phosphorylation of
this protein. Furthermore, we have studied how RAI
couples the PI3-K/Akt pathway to oncogenic RET. We
characterized molecular complexes containing RET,
RAI and the GAB1 adapter and showed that these
complexes lead to the activation of the PI3-K/Akt
pathway and cell survival.
Results
An RAI/GAB1 complex links Ret to the p85 subunit
of PI3-K and Akt activation
We had previously shown that RAI is able to complex
with p85, the regulatory subunit of the PI3-kinase, in
vivo, both in the presence and in the absence of RET
(Pelicci et al., 2002). However, the molecular mechanism
for p85 recruitment by RAI remains unclear. We had
also observed that RAI coprecipitated other phospho-
proteins of unknown identity. Among the different
phosphoproteins, a band of 115 kDa, a molecular
weight compatible with the adapter protein GAB1,
was detected (not shown). GAB1 is a likely candidate
for p85 recruitment since it has several tyrosine residues
that function as docking sites for p85 (Gu and Neel,
2003). To study whether RAI-recruitment of p85 was
indeed mediated by GAB1, we ﬁrst investigated whether
RAI, GAB1 and p85 were able to form stable complexes
in vivo. To this aim, we used 293 cells transiently
transfected with different combinations of cDNAs
encoding RAI, GAB1 and oncogenic RET/MEN2A.
In a ﬁrst set of experiments, we showed a complex
between RAI and GAB1 by reciprocal coimmunopreci-
pitation and Western blotting (Figure 1a). This interac-
tion was constitutive, since it occurred also in the
absence of RET, but it is strongly potentiated in the
presence of RET/MEN2A. Furthermore, RAI and
GAB1 are tyrosine-phosphorylated only in the presence
of RET/MEN2A (Figure 1a). To show that also RET/
PTC was able to recruit RAI–GAB1 complex, 293 cells
were transiently transfected with RAI, GAB1 and RET/
PTC1. Also, in this case, reciprocal coimmunoprecipita-
tion of RAI and GAB1 showed the presence of a RAI–
GAB1 complex, which was enhanced by RET/PTC1
(Figure 1b). Phosphotyrosine staining of anti-GAB1
immunoprecipitates showed that GAB1 was tyrosine-
phosphorylated only when RET/PTC1 was coexpressed
(data not shown). Since it has been described that Shc
recruits GAB through Grb2 (Besset et al., 2000;
Segoufﬁn-Cariou and Billaud, 2000), we asked whether
this was also the case for RAI. To this aim, we evaluated
the GAB1 ability to bind a mutant of RAI, RAI 3F, in
which the consensus sequences for Grb2 (Y304) and Crk
binding (Y221, Y222) have been converted to phenyla-
lanine. As shown in Figure 1c, RAI 3F retains the ability
to bind GAB1 despite the lack of tyrosine phosphoryla-
tion in vivo (not shown). It has been shown that the CH1
domain of RAI has additional tyrosines (Y259, Y260
and Y286) that are sites of phosphorylation in vivo. In
particular, Y286 is a binding site for CRK (Nakamura
et al., 2002). To investigate whether these tyrosines were
involved in RAI/GAB1 interaction, we generated the
mutant RAI 6F, derived from RAI 3F, in which we
introduced the Y259F, Y260F and Y286F mutations.
Also, this mutant retains its ability to bind GAB1, as
shown by the coimmunoprecipitation experiment in
Figure 1c. Furthermore, these mutants retained their
ability to bind GAB1 also in the absence of RET (data
not shown). We were unable to detect any Grb2-RAI
association in vivo by reciprocal immunoprecipitation,
while we could detect both Grb2–Shc and Grb2–GAB1
interactions (not shown).
One of the consequences of p85 recruitment could be
the activation of the PI3-K, which leads to the activation
of the serine-threonine kinase Akt (Pelicci et al., 2002).
To evaluate whether Akt was activated, 293 cells were
cotransfected with RET/PTC1 or RET/MEN2A with
Interaction of RET oncoproteins with an RAI(ShcC/N-Shc)–GAB1 complex
V De Falco et al
2
Oncogene
RAI in the absence or in the presence of GAB1. The
amounts of p85 recruited in the complex were then
evaluated by immunoprecipitation with anti-RET, anti-
RAI and anti-GAB1 antibodies. Furthermore, the
levels of endogenous Akt activation were evaluated
by Western blotting with anti-phosphoAkt antibodies.
Figure 1 RET oncoproteins induce RAI/GAB1 interaction and tyrosine phosphorylation. (a) 293 cells were cotransfected with
cDNAs encoding different combinations of RAI, GAB1 and RET/MEN2A, as indicated. Cell lysates were immunoprecipitated with
anti-GAB1 antibodies, and immunoblotted with antiphosphotyrosine (PY) and anti-RAI antibodies. Total cell lysates of the
corresponding transfections were immunoblotted with anti-RAI, anti-GAB1 and anti-RET antibodies. (b) 293 cells were cotransfected
with cDNAs encoding different combinations of RAI, GAB1 and RET/PTC1, as indicated. Cell lysates were immunoprecipitated with
anti-RAI antibodies, and immunoblotted with anti-PY and anti-GAB1 antibodies. Total cell lysates of the corresponding transfections
were immunoblotted with anti-RAI, anti-GAB1 and anti-RET antibodies. (c) RAI/GAB1 interaction does not depend on RAI-CH1
tyrosine phosphorylation. RAI mutants in residues Y221, Y222, Y304 (RAI 3F), and in residues Y221, Y222, Y259, Y260, Y286, Y304
(RAI 6F) were coexpressexd with GAB1 and, where indicated, RET/MEN2A. Lysates were immunoprecipitated with anti-RAI
antibodies and immunoblotted with anti-GAB1 and anti-PY antibodies. (d) RET oncoproteins recruitment of p85 and Akt activation
are enhanced by RAI and GAB1. The cell lysates from the indicated transfections were immunoprecipitated with anti-RET, anti-RAI
and anti-GAB1 antibodies and probed with anti-p85 antibodies. Total protein lysates were probed with anti-phospho Akt antibodies.
Anti-Akt antibodies were used as a control for equal protein loading
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As shown in Figure 1d, the coexpression of RET
oncoproteins with RAI induced Akt activation,
which was further potentiated when GAB1 was present.
GAB1 overexpression also potentiated p85 recruitment
(Figure 1d).
Molecular determinants of RAI–GAB1 interaction
To investigate the molecular mechanisms underlying the
interaction of RAI with GAB1, we performed in vitro
binding assays. To this aim, the PTB, CH1 and SH2
domains of RAI were expressed as recombinant GST-
fusion proteins in bacteria. Puriﬁed proteins were used
for pull-down assays in which each GST-protein was
incubated with lysates from 293 cells transiently
transfected with GAB1 both in the absence and in the
presence of activated RET (RET/MEN2A). As shown
in Figure 2a, two regions of RAI are involved in GAB1
binding: the CH1 region, which binds GAB1 irrespective
of the presence of RET/MEN2A, and the SH2 domain,
which binds GAB1 only when it is phosphorylated by
RET/MEN2A. These data suggest that the constitutive
interaction between RAI and GAB1 observed in the in
vivo coimmunoprecipitation experiments (Figure 1a) is
mediated by the CH1 domain of RAI, and that this
interaction can be further stabilized by tyrosine phos-
phorylation of GAB1 through the engagement of
another domain of RAI, the SH2. GAB1 lacks a
classical PTB domain, but it contains a noncanonical
PTB domain, the so-called MBD or c-Met binding
domain, which mediates the interaction with the c-Met
receptor. To investigate whether this region of GAB1 is
involved in the interaction with RAI, we performed pull-
down assays using GST-recombinant proteins fused to
either wild-type GAB1 or its MBD domain (GST-GAB1
and GST-MBD). Puriﬁed proteins were incubated with
cell lysates from 293 cells transfected with RAI both in
the absence and in the presence of activated RET (RET/
MEN2A). As shown in Figure 2b, GST-GAB1 was able
to recruit RAI, both in the presence and in the absence
of RET. This interaction was potentiated when RAI was
tyrosine phosphorylated by RET/MEN2A. GST-MBD,
on the other hand, was able to bind RAI only when
RET/MEN2A was coexpressed. By using anti-RET or
antiphosphotyrosine antibodies, RET/MEN2A was al-
ways detected in complex with RAI (data not shown).
To verify equal loading, the coomassie staining of GST-
fusion proteins used for pull-down experiments is shown
(Figure 2a and b).
To assess whether the constitutive interaction between
RAI and Gab1 is direct or mediated by other protein
adapters, we performed a Far Western overlay assay
using recombinant GST-GAB1 fusion protein. 293 cells
were transfected with RAI, and RAI immunoprecipi-
tates and total lysates were probed with unphosphory-
lated GST-GAB1. Consistent with previous data, GST-
GAB1 recognized RAI in RAI immunoprecipitates and
in total lysates (Figure 2c). These data show that RAI
and GAB1 are constitutively complexed in the cell and
that the constitutive RAI/GAB1 interaction is mediated
by the CH1 domain of RAI.
Figure 2 Molecular determinants of RAI/GAB1 interaction.
(a) RAI/GAB1 interaction is mediated by the CH1 and SH2
domains of RAI. In vitro binding experiments with immobilized
GST, GST-PTB-RAI, GST-RAI-CH1 and GST-RAI-SH2 (respec-
tively, GST, PTB-RAI, CH1-RAI and SH2-RAI) and protein
lysates from 293 cells transfected with GAB1 in the presence or
absence of RET/MEN2A. Bound proteins were revealed by
probing the ﬁlter with anti-GAB1 antibodies. GST-fusion protein
were visualized by Coomassie staining of the ﬁlters. (b) The MBD
domain of GAB1 is sufﬁcient to bind RAI in the presence of RET/
MEN2A. 293 cells transfected with RAI or RAI and RET/MEN2A
plasmids were lysed and incubated with GST, GST-GAB1 or GST-
MBD-GAB1 (respectively, GST, GAB1 and MBD-GAB1). Bound
proteins were revealed by probing the ﬁlter with anti-RAI
antibodies. Equal loading of GST-fusion protein was assessed by
Coomassie staining of the ﬁlters. (c) RAI and GAB1 binding is
direct. 293 cells were transfected with the indicated cDNAs. Anti-
RAI immunoprecipitated lysates or total protein lysates were
analysed by Far Western blotting with the GST-GAB1 fusion
protein. Filters were re-probed with anti-RAI and anti-PY
antibodies
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Ectopic RAI expression induces survival of RET/PTC1
expressing thyroid cells
To study the role of RAI in thyroid cells, we selected the
PC RET/PTC1 rat thyroid cells. This cell line derives
from PC Cl 3 rat thyroid epithelial cells, which are a
very well established model system to study oncogenic
transformation in a thyroid cell setting. Furthermore,
these cells express very low levels of endogenous RAI
proteins. PC RET/PTC1 cells were transduced with a
RAI retroviral vector to obtain the RET/PTC1-RAI
cells. RAI and RET/PTC1 expression were veriﬁed by
immunoblot. We show that also in this system RAI
coprecipitated with RET and was constitutively tyro-
sine-phosphorylated (Figure 3a). As a consequence of
RAI expression, Akt phosphorylation increased (not
shown). We then sought to examine whether RAI
induced survival of thyroid cells. Thyroid transformed
cells were treated with a strong apoptotic stimulus,
diethyl maleate (DEM) (Celetti et al., 2004). In these
conditions, we compared RET/PTC1 to RET/PTC1-
RAI cells and the apoptotic rate was evaluated by the
terminal desoxynucleotidyl transferase-mediated deso-
xyuridine triphosphate nick end-labelling (TUNEL)
assay, as described (Castellone et al., 2003). As shown
in Figure 3c, RAI overexpression signiﬁcantly reduced
DEM-mediated apoptosis.
We have shown that RAI can recruit the p85 subunit
of the PI3-K through GAB1. To investigate whether
RAI–GAB1 interaction is required to activate the PI3-
K/Akt pathway, and consequently, to induce survival in
thyroid cells, we used expression vectors encoding the
isolated CH1 and SH2 domains of RAI, RAI CH1 and
RAI SH2. We reasoned that the overexpression of these
vectors should be able to displace the interaction
between RAI and GAB1 by competition with RAI for
GAB1 binding. To address this issue, PC RET/PTC1-
RAI cells were transiently transfected with RAI CH1 or
RAI SH2. As shown in Figure 3b, RAI CH1 and RAI
SH2 were able to disrupt the interaction between wild-
type RAI and GAB1. As a consequence of this, p85
recruitment by RET/PTC1, and the levels of Akt
Figure 3 RAI exogenous expression promotes cell survival in PC RET/PTC1 cells. (a) PC RET/PTC1 cells were infected with a
retroviral vector expressing RAI to generate the PC RET/PTC1 RAI cells. Cell lysates were immunoprecipitated with anti-RAI or anti-
RET antibodies, and immunoblotted with anti-PY, anti-RAI, and anti-RET antibodies. Total cell lysates of the corresponding
transfections were immunoblotted with anti-RAI and anti-RET antibodies. (b) PC RET/PTC1 RAI cells were transfected with cDNAs
encoding either the isolated RAI-CH1 or RAI-SH2 domains. Cell lysates were immunoprecipitated with anti-RAI or with anti-GAB1
antibodies, and immunoblotted with the reciprocal antibodies: the interaction RAI–GAB1 strongly decreased. Furthermore, GAB1
recruitment of p85 and Akt phosphorylation decreases. Total cell lysates of the corresponding transfections were immunoblotted with
anti-Akt antibodies. (c) The TUNEL reaction was performed on PC RET/PTC1 and PC RET/PTC1-RAI cells in complete serum in
the presence of 0.9mM DEM. When indicated, cells were transfected with either GFP alone or GFP and RAI-CH1 or GFP and RAI-
SH2. GFP-positive cells were observed under an epiﬂuorescent microscope to detect TUNEL-positive cells (TMR-dUTP, red) and
total cells on the glass slide (Hoechst, blue stain). Bars are the mean7s.d. of three assays. Apoptotic cells were calculated by counting
at least 400 GFP-positive cells in ﬁve randomly selected microscopic ﬁelds
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activation decreased (Figure 3b). To verify whether the
disruption of RAI–GAB1 interaction resulted in a
decreased pro-survival effect in RET/PTC1-RAI expres-
sing cells, we transiently transfected these cells with RAI
CH1 or RAI SH2 together with a GFP expressing
vector. Transfected cells were treated with DEM,
and the rate of apoptotic death was evaluated in
GFP-positive cells by TUNEL assay. As shown in
Figure 3c, the expression of either RAI CH1 or RAI
SH2 inhibited the survival effect exerted by RAI in PC
RET/PTC1 cells.
RAI is expressed in human thyroid carcinoma cell lines
and in primary PTC
To investigate whether RAI is involved in RET-
mediated signalling in thyroid tumors in which RET is
involved, we screened a series of human cell lines derived
from either PTCs or MTCs for RET and RAI
expression by Western blot. As a positive control, the
MN1, a mouse motoneuron cell line expressing both
RET and RAI, was used. As shown in Figure 4a, several
PTC and one MTC cell line, coexpressed RAI and the
RET oncogenic proteins. In these cells, both the p64 and
the p52 isoforms of RAI were detected. A summary of
RET and RAI expression status in these cell lines is
showed in the table in Figure 4a. Furthermore, by
comparing RAI expression in the normal human
primary culture (P5) with its expression in TPC cell
lines, we veriﬁed that RAI is overexpressed in PTC cells.
To extend this observation to human tumors we also
tested, by Western blot and quantitative PCR, RAI
expression in a set of primary tumors from PTC patients
and a pool of normal thyroid samples. As shown in
Figure 4b, some PTCs samples scored positive for RAI
expression. Normal thyroid tissue displayed a lower, but
detectable reactivity. To further conﬁrm that RAI is
indeed expressed in human thyroid tumors, we extracted
total RNAs from a different set of human PTCs and
from a pool of 4 normal thyroid tissues, and analysed
them by Q-PCR. As shown in Figure 4c, RAI mRNA
expression was strongly increased in tumors versus
normal thyroids.
To determine whether RAI is involved in RET
signalling in human tumors, we analysed, in FB2 and
TT cells (derived, respectively, from a papillary and a
MTC), anti-RET immunoprecipitates with anti-RAI
antibodies, and showed binding of RAI to endogenous
Figure 4 RAI expression in human thyroid cancer cell lines and human PTCs. (a) The expression levels of RAI proteins were analysed
in human PTC and MTC cell lines and summarized in the table. Equal amounts of proteins were immunoblotted and stained with anti-
RAI mouse monoclonal antibody. As a control for equal loading, ﬁlters were stained with the anti-alpha tubulin monoclonal antibody.
(b) Human PTCs express high levels of RAI proteins. Tissues from human PTC samples were snap-frozen and immediately
homogenized by using the Mixer Mill apparatus (Qiagen) in lysis buffer. Equal amounts of proteins were immunoblotted and stained
with anti RAI polyclonal antibodies. As a control for equal loading, the anti-alpha tubulin monoclonal antibody was used. (c) Human
PTCs express high levels of RAI mRNA. After RNA extraction, quantitative PCR was used to calculate RAI mRNA fold induction in
the indicated tumor samples and in a pool of normal thyroid tissues; results are the average of three independent ampliﬁcations7s.d.
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RET/PTC1 and RET/MEN2A (Figure 5a). Further-
more, by probing anti-RAI immunoprecipitates with
anti-phosphotyrosine antibodies, we observed tyrosine
phosphorylation of RAI. By using the anti-GAB1
antibodies we detected a 115 kDa protein in RAI
immunoprecipitates (Figure 5b). Furthermore, when
GAB1 was immunoprecipitated from FB2 and TT cells,
anti-phosphotyrosine antibodies recognized a 52 kDa
protein, which was identiﬁed by the anti-RAI antibody
(Figure 5c). These data conﬁrm that RAI and RET/PTC
interact also when expressed at physiological levels and
support the concept that RAI is indeed involved in
RET/PTC signalling in human PTCs. To further
support the critical role of Gab1 in p85 recruitment
and Akt activation by RAI, we depleted FB2 cells of
endogenous Gab1 through small interference RNA. As
shown in Figure 5d, transient transfection of FB2
cell with human Gab1 small silencing RNA (siRNA)
signiﬁcantly reduced Gab1 levels at 48 h, without
affecting RAI and p85 levels. Gab1 knockdown
resulted in a reduction of the p85 quantity coprecipi-
tated with RAI, as shown by coimmunoprecipitation
experiments. Furthermore, Gab1 knockdown caused
the consequent inactivation of Akt, as shown by the
staining of the same ﬁlters with Akt phospho-speciﬁc
antibodies (Figure 5d).
Inactivation of endogenous RAI expression reduces
survival of human papillary thyroid cells expressing
RET/PTC1
To evaluate the effect of RAI inhibition in human
thyroid papillary cancer, we used RNA interference on
FB2 cells to deplete endogenous RAI. As shown in
Figure 6a, an siRNA duplex oligonucleotide was able to
sharply reduce RAI expression, whereas a scrambled
oligo did not. On the other hand, RAI siRNA did not
inhibit a-tubulin levels. RAI depletion suppressed
constitutive Akt activation in FB2 cells (Figure 6a)
while it did not affect endogenous Akt levels (not
shown). We performed a TUNEL assay on parental and
RAI-depleted FB2 cells. As shown in Figure 6b, RAI
depletion induced a signiﬁcant increase in the number of
apoptotic cells after 48 and 72 h. These data suggest that
RAI provides a survival signal to this cell line.
Discussion
In this study, we have investigated the role played by
RAI in oncogenic RET signalling. We focused on
identifying the protein complexes involved in RET-
mediated PI3-K/Akt activation through RAI. It has
Figure 5 Molecular complexes containing RET, RAI and GAB1 in human thyroid cancer cell lines. (a) FB2 and TT cells, expressing
endogenous RET and RAI, and P5 primary thyroid cells were serum-deprived for 12 h. Protein lysates were immunoprecipitated with
anti-RET antibodies, followed by SDS–PAGE and immunoblotting with the anti-RAI and anti-RET antibodies. Arrows indicate the
position of RAI and GAB1 proteins. (b) Anti-RAI immunoprecipitates from serum-deprived FB2 and TT cells were probed with anti-
PY, anti-RAI and anti-GAB1 antibodies. (c) Anti-GAB1 immunoprecipitates from FB2 and TT cells were probed with anti-PY, anti-
RAI and anti-GAB1 antibodies. (d) FB2 cells were transiently transfected with siRNA targeting Gab1. A scrambled oligo was used as
control. Cells were harvested at 48 h, and endogenous Gab1 protein levels were evaluated by Western blot analysis. Anti-RAI
immunoprecipitates from FB2 cells were probed with anti-p85 antibodies. Total protein lysates were probed with anti-phospho Akt
antibodies. Anti-Akt and anti-p85 antibodies were used as a control for equal protein loading and to shown the speciﬁc effect of the
siRNA
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been previously shown that RET can indirectly recruit
p85 through an Shc–Grb2–GAB1/2 complex. When
RET is activated, Shc binds to phosphorylated tyrosine
1062. Grb2 is then recruited by binding a phosphotyr-
osine in the CH1 of Shc with its SH2 domain. Grb2, in
turn, constitutively interacts with GAB1/2 through its
SH3 domain, which binds a non canonical polyproline
motif in GAB1/2. GAB1/2, in turn, binds the SH2
domain of p85 through several phosphotyrosine residues
(Besset et al., 2000; Lock et al., 2000; Schaeper et al.,
2000; Lewitzky et al., 2001). We previously showed that
RAI is able to complex with p85 in vivo, both in the
presence and in the absence of RET (Pelicci et al., 2002).
Here, we identify GAB1 as a key mediator of RET/RAI
signalling. This protein belongs to a group of docking
proteins which includes GAB1/2, IRS1/2, FRS2, and
p62 Dok, that function as substrates of tyrosine kinases
(Gu and Neel, 2003). GAB1, in particular, has been
identiﬁed as a speciﬁc substrate of the c-Met receptor.
This protein contains a NH2-terminal PH domain, a
central non canonical phosphotyrosine-binding domain,
the MBD, and a carboxyl-terminal domain which
contains several tyrosines that serve as docking sites
for downstream signalling components, such as p85,
PLC-g, Shc, Shp2 and Crk (Gu and Neel, 2003). Here
we show that RAI and GAB1 associate constitutively.
This association seems to be mediated by the CH1
domain of RAI, as shown by pull-down assays
performed with the GST-CH1 RAI recombinant pro-
tein. Given the high degree of conservation between
RAI and Shc, we hypothesized that RAI could recruit
GAB1 through the adapter Grb2. By coimmunopreci-
pitation assays and use of RAI mutants we showed that
Grb2 was not involved in RAI–GAB1 interaction.
Indeed we could demonstrate, by Far Western overlay
experiments, that RAI is involved in a direct interaction
with GAB1. It is conceivable that overexpression of
RAI leads to a stoichiometric recruitment of GAB1, and
to the consequent activation of GAB1-mediated signal-
ling pathways, such as PI3-K/Akt. How the recruitment
of GAB1 by RAI can trigger GAB1 and activate
downstream pathways remains to be solved. One
possibility is that RAI binding could localize GAB1 in
the proximity of a putative activator. Alternatively, this
interaction could exert a conformational change in
GAB1, with its consequent activation.
The interaction between RAI and GAB1 is poten-
tiated by the presence of activated RET. Indeed,
activated RET recruits RAI/GAB1 through its tyrosine
1062 and the PTB domain of RAI (Pelicci et al., 2002).
RAI/GAB1 interaction is further stabilized by tyrosine
phosphorylation of both RAI and GAB1, which creates
other interaction sites. The RAI SH2 domain possibly
recognizes a phosphotyrosine residue in GAB1, and the
GAB1 MBD region could bind one of the phosphotyr-
osines in RAI. Alternatively, GAB1 MBD could bind a
novel phosphotyrosine residue in RET. Whatever the
case, once GAB1 is phosphorylated, an increased
recruitment of p85 on activated RET is observed
parallel to an enhanced activation of Akt, and
potentiation of cell survival. The relevance of RAI
interaction with GAB1 is supported by the experiments
with the isolated RAI-CH1 and SH2 domains and by
the knockdown of endogenous Gab1, which inhibit
downstream signalling events and biological activity.
Ectopic expression of RAI in RET/PTC1 expressing rat
thyroid cells potentiates the ability of these cells to
survive in stress conditions, while depletion of endogen-
ous RAI in FB2 PTC cells increases the rate of
spontaneous apoptosis. These data, taken together,
suggest a role for this protein in human thyroid
tumorigenesis. This is further supported by the obser-
vation that RAI and oncogenic isoforms of RET (RET/
PTC1 or RET/MEN2A) are coexpressed in a series of
cell lines derived from thyroid malignancies in which
Figure 6 Effect of RNAi for RAI in FB2 Cells. (a) FB2 cells were
transiently transfected with siRNA targeting RAI. A scrambled
oligo was used as control. Decrease of endogenous RAI protein in
FB2 cells at the indicated time points was detected by Western blot
analysis. The knockdown of endogenous RAI resulted in the
inhibition of Akt activation, as measured by Western blotting with
anti-pAKT antibodies. Alpha-tubulin staining was used to show
the speciﬁc effect of the siRNA. (b) Inhibition of endogenous RAI
increases the percentage of apoptotic cells in FB2 cells. FB2 cells
were transienly transfected with RAI siRNA or with a scrambled
oligo, and ﬁxed after 48 or 72 h. TUNEL positive cells were
counted under an epiﬂuorescent microscope. Bars are the
mean7s.d. of three assays. Apoptotic cells were calculated by
counting at least 400 cells in ﬁve randomly selected microscopic
ﬁelds
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RET is involved, PTCs and MTCs. It is interesting to
note that RAI expression has been reported to be
restricted to the nervous system in post-mitotic neurons
(Ganju et al., 1998; Nakamura et al., 1998; Tanabe
et al., 1998; Conti et al., 2001). Despite this, we found
expression of RAI in human cell lines derived from
human thyroid tumors. While expression of RAI in
MTCs is not surprising, since these tumors derive from
cells of neural origin, its expression in PTCs, derived
from thyroid epithelial cells, is unexpected. It is possible
that in these tumors RAI expression is reactivated and
that this event is positively selected since it increases the
survival of cancer cells. In support of this hypothesis,
preliminary data obtained in our laboratory show that
RAI expression is also detected in surgical samples of
human PTCs by real-time PCR and Western blot. RET/
PTC rearrangements are considered tumor initiating
events (Viglietto et al., 1995). The early events that
follow RET/PTC activation do not lead to cell growth,
possibly due to concomitant stimulation of DNA
synthesis and apoptosis (Castellone et al., 2003; Wang
et al., 2003). RAI overexpression could be an event that
PTC cells select to overcome RET/PTC induced
apoptosis, thus promoting cancer progression. This is
not the only example of RAI involvement in human
tumors. Expression and tyrosine phosphorylation of
RAI has been found in a large set of neuroblastoma cell
lines. In these cells the ALK kinase is overexpressed due
to gene ampliﬁcation, and as a consequence of this,
constitutively activated. Activation of ALK was respon-
sible for RAI hyperphosphorylation in these cells
(Miyake et al., 2002). Thus, the role of RAI in human
tumors is just starting to be elucidated.
Materials and methods
Cell lines and plasmids
293 cells were maintained in Dulbecco’s Modiﬁed Eagle’s
medium (DMEM, Invitrogen Groningen, The Netherlands)
supplemented with 10% foetal calf serum. Transient transfec-
tions were effectuated with FUGENE reagent, as suggested by
the manufacturer (Roche Molecular Diagnostics, Basel,
Switzerland). P5 thyroid normal primary culture has been
previously described (Curcio et al., 1994).
Human papillary thyroid cancer cell lines TPC-1, FB2,
NIM, BHP10-3, BHP17-10, BHP14-9, BC-PAP, BHP2-7,
BHP5-16, have been described previously (Cerutti et al.,
1996; Ohta et al., 2001; Basolo et al., 2002), and were
maintained in DMEM supplemented with 10% foetal bovine
serum, 1% penicillin–streptomicin, and 1% glutamine. Me-
dullary thyroid cancer cell lines TT, MZ-CRC-1 (human), 6-23
(rat), MTC-M (mouse) have also been previously described
(Cooley et al., 1995).
PC Cl 3 is a differentiated thyroid epithelial cell line derived
from 18-month-old Fischer rats. They were maintained in
Coon’s modiﬁed F12 medium supplemented with 5% calf
serum and six hormones (6H) (thyrotropin, i.e., TSH, insulin,
transferrin, somatostatin, hydrocortisone and glycyl-histidyl-
lysine) (Invitrogen, Groningen, The Netherlands) as described
(Castellone et al., 2003). PC RET/PTC1 cells have been
previously described (Santoro et al., 1993). To obtain the PC
RET/PTC1-RAI cells, the PC RET/PTC1 cells were infected
with a PINCO-RAI virus, as described (Pelicci et al., 2002).
The efﬁciency of infection, measured as GFP positivity, was
evaluated by FACS scanning.
For transient transfections of PC Cl 3 cells, calcium
phosphate precipitates were added to the cells and removed
after 1 h. Cells were then subjected to glycerol shock and kept
in medium containing 5% calf serum and 6H.
Human RET/MEN2A and RET/PTC1 (subcloned into
pCDNA 3, Invitrogen) have been previously described
(Carlomagno et al., 2001). RAI and RAI 3F, in which
tyrosines 221, 222, 304 were replaced by phenylalanine,
expression vectors have been previously described (Pelicci
et al., 2002). To generate RAI 6F, point mutations in Y259,
260 and 286 were introduced into RAI 3F plasmid by using the
Quick-change site-directed mutagenesis kit (Stratagene), and
veriﬁed by sequencing. Plasmids encoding the isolated PTB,
CH1 and SH2 domains were obtained by PCR and subcloning
into pCDNA 3 vector (Invitrogen). The plasmid encoding
GAB1 was a kind gift of S Giordano and P Gual (Institute for
Cancer Research and Treatment, University of Torino School
of Medicine, Candiolo, Italy).
RNA extraction and real-time PCR
Retrospectively collected archival frozen thyroid tissue sam-
ples from patients affected by PTC and normal thyroid tissue
samples were retrieved from the ﬁles of the Pathology
Department of the University of Pisa upon informed consent.
Total RNA from the indicated samples was prepared using the
RNeasy Midi Kit (Qiagen, Crawley, West Sussex, UK) and
subjected to on-column Dnase digestion with the Rnase-free
Dnase set (Qiagen, Crawley, West Sussex, UK) following the
manufacturer’s instructions. The quality of RNA from each
sample was veriﬁed by electrophoresis through 1% agarose gel
and visualization with ethidium bromide.
Random-primed ﬁrst-strand cDNA was synthesized in a
50 ml reaction volume starting from 2.5 mg RNA by using the
GeneAmp RNA PCR Core Kit (Applied Biosystems, War-
rington, UK). PCR ampliﬁcation was performed using the
GeneAmp RNA PCR Core Kit system starting from 2 ml of
RT product in a reaction volume of 25 ml, according to the
manufacturer’s instructions. Primers were designed by using a
software available at http://www-genome.wi.mit.edu/cgi-bin/
primer/primer3_www.cgi, and synthesized by the MWG
Biotech (Ebersberg, Germany). Primer sequences were as
follows:
RAI F: 50-AGTTCTGCGCTCAATGAGGT-30
RAI R: 50-TTGCTCTTTCCCAAGATGCT-30
b-actin F: 50-TGCGTGACATTAAGAAG-30
b-actin R: 50-GCTCGTAGCTCTTCTCCA-30
To exclude DNA contamination, each PCR reaction was
also performed on untranscribed RNA. Levels of b-actin
transcripts served as a control for equal RNA loading.
Quantitative (real-time) reverse transcription polymerase chain
reactions (qRT–PCR) were performed by using the SYBR
Green PCR Master mix (Applied Biosystems) in the iCycler
apparatus (Bio-Rad, Munich, Germany). Ampliﬁcation reac-
tions (25ml ﬁnal reaction volume) contained 200 nM of each
primer, 3mM MgCl2, 300mM dNTPs, 1 SYBR Green PCR
buffer, 0.1U/ml AmpliTaq Gold DNA polymerase, 0.01U/ml
Amp Erase, RNase-free water, and 2ml cDNA samples.
Thermal cycling conditions were optimized for each primer
pair and are available upon request. To verify the absence of
nonspeciﬁc products, melting curves were performed (80 cycles
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starting from 551C for 10 s with increments of 0.51C). In all
cases, the melting curve conﬁrmed that a single product was
generated. Ampliﬁcation was monitored by measuring the
increase in ﬂuorescence caused by the SYBR-Green binding to
double-stranded DNA. Fluorescent threshold values were
measured in triplicate and fold changes were calculated by
the formula: 2(sample 1 DCtsample 2 DCt), where DCt is the difference
between the ampliﬁcation ﬂuorescent thresholds of the mRNA
of interest and the b-actin mRNA.
Protein studies
Immunoblotting experiments were performed according to the
standard procedures. Brieﬂy, cells were harvested in lysis
buffer (50mM HEPES, pH 7.5, 150mM NaCl, 10% glycerol,
1% Triton X-100, 1mM EGTA, 1.5mM MgCl2, 10mM NaF,
10mM sodium pyrophosphate, 1mM Na3VO4, 10mg of
aprotinin/ml, 10 mg of leupeptin/ml) and clariﬁed by centrifu-
gation at 10 000 g. Protein concentration was estimated with a
modiﬁed Bradford assay (Bio-Rad, Munich, Germany). RET/
PTC3 immunoprecipitation was performed with an anti-RET
antibody, as previously described (Santoro et al., 1994). RAI
immunoprecipitation was performed with an anti-RAI rabbit
polyclonal antibodies (Pelicci et al., 2002). Total lysates and
immunoprecipitates were separed by SDS–PAGE and then
transferred onto nitrocellulose ﬁlters (Schleicher & Schuell).
Filters were then probed with the indicated antibodies.
Antiphosphotyrosine (4G10), anti-p85 and anti-GAB1 anti-
bodies were from Upstate Biotechnology Inc., Lake Placid,
NY, USA. Anti-phospho Akt and anti-Akt antibodies were
from New England Biolabs, Beverly, MA, USA. Secondary
anti-mouse and anti-rabbit antibodies coupled to horseradish
peroxidase were from Bio-Rad Inc. Proteins were revealed by
an enhanced chemiluminescence detection kit (ECL, Amer-
sham, Bucks, England).
Binding assays and Far Western blotting
Expression vectors for GST-CH1 RAI, GST-SH2 RAI and
GST-PTB RAI were generated by cloning the respective
domains of RAI, obtained by PCR ampliﬁcation of the
fragments, in the vector pGEX (Pelicci et al., 2002). GST-
GAB1 and GST-MBD were obtained from S Giordano
(Institute for Cancer Research and Treatment, University of
Torino School of Medicine, Candiolo, Italy). Recombinant
proteins were produced in Escherichia coli and puriﬁed on
glutathione-conjugated sepharose (Amersham). For pull-down
assays, 5mg of the indicated recombinant protein bound to
sepharose were incubated with cell lysates 2 h at 41C. After
washing the beads, proteins were separed by SDS–PAGE and
probed with the indicated antibodies.
For Far Western blotting, total lysates or immunoprecipi-
tates, after SDS–PAGE and blotting on nitrocellulose ﬁlters,
were ﬁrst blocked for 2 h in the presence of 10mM glutathione,
and then incubated overnight with puriﬁed GST recombinant
proteins (1 mg/ml), extensively washed and then developed with
anti-GAB1 antibodies.
TUNEL assay
For the TUNEL, an equal number (5 103) of cells from the
different lines was seeded onto single well Costar L-polylisine-
treated glass slides. After 24 h treatment with 0.9mM DEM,
cells were ﬁxed in 4% (w/v) paraformaldehyde and, then, they
were permeabilized by the addition of 0.1% Triton X-100/
0.1% sodium citrate. Slides were rinsed twice with PBS, air-
dried and subjected to the TUNEL reaction (Boehringer,
Mannheim). All coverslips were counterstained in PBS
containing Hoechst 33258 (ﬁnal concentration, 1 mg/ml; Sigma
Chemical Co.), rinsed in water and mounted in Moviol on
glass slides. The ﬂuorescent signal was visualized with an
epiﬂuorescent microscope (Axiovert 2, Zeiss) (equipped with a
 100 objective) interfaced with the image analyser software
KS300 (Zeiss). For the experiments of survival inhibition by
the isolated RAI domains, PC RET/PTC1 RAI cells were
transiently transfected with vectors encoding RAI-CH1 or
RAI-SH2 together with a GFP expressing vector, or with GFP
alone. After 24 h treatment with 0.9mM DEM, cells were then
subjected to TUNEL reaction, as described. At least 100 GFP-
positive cells were counted in ﬁve different microscopic ﬁelds.
For the experiments of survival inhibition in RAI-depleted
FB2 cells, FB2 cells were transfected with the siRNA targeting
RAI or with the scrambled oligo. At 48 and 72 h post-
transfection, cells were ﬁxed for TUNEL reaction.
RNA silencing
Duplex oligonucleotides (Tuschl et al., 1999; Elbashir et al.,
2001), designed with an siRNA selection program available
online at http://jura.wi.mit.edu/siRNAext/, were chemically
sinthesized by PROLIGO, Boulder, CO, USA. Sense strand
for siRNA targeting RAI was the following:
RAIs: 50-GUA CUU GGG GUG CAU UGA AG TT-30
The scrambled oligo was
50-AGG AUA GCG UGG AUU UCG GU TT-30
The sequences of speciﬁc siRNA against human Gab1 were as
described (Jin et al., 2005). For siRNA transfection, FB2 cells
were grown under standard conditions. The day before
transfection, cells were plated in six-well dishes at 30–40%
conﬂuency. Transfection was performed using 5mg of duplex
RNA and 6 ml of Oligofectamine reagent (Invitrogen), as
previously described (Hingorani et al., 2003). Cells were
harvested at 48 and 72 h post-transfection.
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The RET/PTC-RAS-BRAF linear signaling 
cascade mediates the motile and mitogenic 
phenotype of thyroid cancer cells
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In papillary thyroid carcinomas (PTCs), rearrangements of the RET receptor (RET/PTC) and activating muta-
tions in the BRAF or RAS oncogenes are mutually exclusive. Here we show that the 3 proteins function along a 
linear oncogenic signaling cascade in which RET/PTC induces RAS-dependent BRAF activation and RAS- and 
BRAF-dependent ERK activation. Adoptive activation of the RET/PTC-RAS-BRAF axis induced cell prolifera-
tion and Matrigel invasion of thyroid follicular cells. Gene expression profiling revealed that the 3 oncogenes 
activate a common transcriptional program in thyroid cells that includes upregulation of the CXCL1 and 
CXCL10 chemokines, which in turn stimulate proliferation and invasion. Thus, motile and mitogenic proper-
ties are intrinsic to transformed thyroid cells and are governed by an epistatic oncogenic signaling cascade.
Introduction
Papillary thyroid carcinoma (PTC) is the most prevalent endocrine 
malignancy in humans (1). Four genetic lesions, at the somatic level, 
are associated with PTC: chromosomal alterations that affect the 
RET or TRKA tyrosine kinase receptors and oncogenic activation 
of the RAS or BRAF genes. RET encodes the tyrosine kinase recep-
tor of growth factors belonging to the glial-derived neurotrophic 
factor (GDNF) family (2). RET gene rearrangements occur in up to 
30% of PTCs (3). They cause the recombination of the intracellular 
kinase–encoding domain of RET with heterologous genes, thereby 
generating RET/PTC chimeric oncogenes. RET/PTC1 (the H4-RET 
fusion) and RET/PTC3 (the RET-fused gene–RET [RFG-RET] fusion) 
are the most prevalent variants. RET/PTC3 is frequently found in 
radiation-associated PTC (4). The finding that RET/PTC-trans-
genic mice develop PTC demonstrates that RET/PTC oncogenes 
can initiate thyroid carcinogenesis (5, 6). RET/PTC oncogenes are 
frequent in clinically silent small PTCs and are thus an early event 
of thyroid tumorigenesis (7). Similar rearrangements of TRKA, 
e.g., the high-affinity receptor for the nerve growth factor (NGF), 
can also be found, at a low frequency, in human PTC (8). Activat-
ing point mutations in RAS small GTPases occur in about 10% of 
PTCs, mainly in the follicular variant (9). Finally, point mutations 
in BRAF are the most common genetic lesions found in PTCs (up 
to 50% of cases) (10). BRAF belongs to the RAF family of serine/
threonine kinases that includes c-RAF and ARAF. RAF proteins 
are components of the RAF–MAPK kinase–ERK (RAF-MEK-ERK) 
pathway, which is a highly conserved signaling module in eukary-
otes. They are activated through binding to RAS in its GTP-bound 
state. Once activated, RAF kinases can phosphorylate MEK, which 
in turn phosphorylates and activates ERKs (11). As occurs in mela-
nomas (12), a V600E substitution (formerly designated V599E), in 
the activation segment accounts for more than 90% of BRAF muta-
tions in PTC (10, 13–15). This mutation enhances BRAF activity by 
disrupting the autoinhibited state of the kinase (15).
Thanks to their intrinsic kinase activity, receptor tyrosine 
kinases (RTKs) activate many intracellular signaling pathways. 
Upon binding to ligand, RTKs dimerize and autophosphory-
late various cytoplasmic tyrosines. The phosphorylated tyrosines 
thus become binding sites for intracellular molecules containing 
phosphotyrosine-binding motifs, thereby initiating a diverse array 
of signaling pathways (16). In RET/PTC rearrangements, fusion 
with protein partners possessing protein-protein interaction motifs 
provides RET/PTC kinases with dimerizing interfaces, which results 
in ligand-independent autophosphorylation. The RET intracellular 
domain contains at least 12 autophosphorylation sites, 11 of which 
are maintained in RET/PTC proteins (17). Tyrosine 905 (Y905) is 
a binding site for Grb7/10 adaptors (18), Y1015 for phospholipase 
Cγ (19), and Y981 for c-Src (20). Tyrosine 1062 is the binding site 
for several proteins, including the Shc proteins, insulin receptor 
substrate–1/2 (IRS-1/2), FGFR substrate 2 (FRS2), downstream of 
kinase 1/4/5 (DOK1/4/5), and Enigma, which, in turn, lead to the 
activation of many signaling pathways (2, 21). Binding to Shc and 
FRS2 mediates recruitment of Grb2-SOS complexes, which thus 
leads to GTP exchange on RAS and RAS/ERK stimulation (22).
In human PTC, RET/PTC, RAS, and BRAF genetic alterations 
are mutually exclusive, which suggests that mutations at more 
than 1 of these sites are unlikely to provide an additional biologi-
cal advantage (10, 13, 14). This is what would be expected if the 3 
proteins function in tandem along a common signaling cascade. 
To verify whether this is indeed the case, we examined the link 
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among the 3 oncogenic proteins in a thyroid cell culture model. 
RET/PTC triggered the RAS-BRAF-ERK signaling cascade in a 
Y1062-dependent fashion. Analysis of the transcriptional profile 
by oligonucleotide microarrays revealed that the RET/PTC3, HRAS, 
and BRAF oncogenes induced changes in the expression of widely 
overlapping sets of genes. 
The RET/PTC3-RAS-BRAF 
axis triggered upregulation 
of CXC chemokines and 
their receptors, which in turn 
stimulated the mitogenic and 
invasive capacity of thyroid 
cancer cells.
Results
A biochemical cascade linking 
RET/PTC to the activation of 
RAS, BRAF, and ERK. We pre-
viously showed that onco-
genic RET/PTC proteins 
activate GTP loading on RAS 
(23). Here, we transiently 
transfected HEK293 cells with 
myc-tagged BRAF and with 
the constructs shown in Fig-
ure 1A. We examined BRAF 
activity in an immunocomplex 
kinase assay, with the onco-
genic BRAF(V600E) and 
the kinase-dead BRAF(K–) 
mutants as positive and nega-
tive controls, respectively. As 
shown in Figure 1B, BRAF 
activation was induced by the 
expression of the RET/PTC3 
and HRAS(V12) oncogenes. 
Activation of BRAF depended 
on RET/PTC3 kinase activity 
and on the integrity of tyro-
sine 1062. Indeed, neither the 
kinase-dead RET/PTC3(K–) 
mutant nor a RET/PTC3 
mutant carrying a tyrosine 
to phenylalanine (Y → F) 
mutation at Y1062 activated 
BRAF. In contrast, the Y → F 
mutation at tyrosine 1015 
had virtually no effect on 
BRAF activation. By Western 
blot analysis with phospho-
specific anti-RET antibodies, 
we demonstrated that the 
tyrosine 1062 substitution 
does not affect RET/PTC3 
autophosphorylation levels 
overall or Y1015 and Y905 
phosphorylation (Supple-
mental Figure 1; supplemen-
tal material available online 
with this article; doi:10.1172/
JCI200522758DS1). Expression of the dominant-interfering 
HRAS(N17) mutant blocked RET/PTC3-mediated BRAF activa-
tion, which indicates that in this context, BRAF activation requires 
RAS (Figure 1B). We explored whether the RET/PTC3(Y1062)-
RAS-BRAF cascade resulted in ERK1/2 stimulation. RET/PTC3 
Figure 1
RET/PTC-mediated ERK activation is dependent on RAS and BRAF. (A) Schematic representation of the 
RET, HRAS, and BRAF constructs. The RET/PTC breakpoint and RET tyrosines 1015 and 1062 are indi-
cated. Residues V600 and K483 are mutated to E and M, respectively, in the BRAF(V600E) and BRAF(K–) 
plasmids. Residues G12 and S17 are mutated to V and N in the HRAS(V12) and HRAS(N17) plasmids. C, 
CAAX tail; CR1–3, conserved BRAF regions 1–3; Cys, cysteine-rich; EC, extracellular domain; ED, HRAS 
effector domain; H, heterogeneous region; JX, juxtamembrane; SP, RET signal peptide; TK, tyrosine kinase; 
TM, transmembrane. (B) Protein lysates (500 μg) extracted from HEK293 cells transfected with the indicated 
plasmids underwent immunoprecipitation with anti-tag (myc) antibody. Kinase assay was performed with 
GST-MEK as a substrate. BRAF and RET/PTC3 were detected by Western blotting (W.B.) with anti-myc 
and anti-RET antibodies, respectively. RAS expression was detected with an anti-RAS monoclonal antibody 
that also recognizes the endogenous protein. (C) HEK293 cells transfected with the indicated plasmids were 
harvested, and protein extracts were subjected to immunoblotting with anti–phospho-p44/p42 ERK (pERK) 
antibodies. The blot was reprobed with anti-p44/p42 antibodies for normalization. RET/PTC3 and RAS were 
detected by Western blotting with specific antibodies. These experiments are representative of at least 3 
independent assays. (D) Transient BRAF suppression was achieved by RNA interference. Whole cell lysates 
were prepared 48 hours after transfection and analyzed for protein expression by Western blotting with the 
indicated antibodies. siRNA(SCR), scrambled siRNA.
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stimulated ERK activation, as revealed by immunoblot with a 
phospho-specific antibody (Figure 1C). This activation did not 
depend on Y1015 (data not shown); instead, it was dependent 
on the integrity of Y1062 and on the activity of RAS and BRAF, 
being obstructed by the expression of HRAS(N17) and BRAF(K–) 
dominant negative mutants (Figure 1C). The BRAF(K–) domi-
nant negative mutant probably acts as a pan-RAF inhibitor in 
that it blocks the activity of the various RAF proteins. To specifi-
cally block BRAF, we used small interfering duplex RNA (siRNA) 
oligonucleotides that target endogenous BRAF. This duplex 
affected only BRAF and no other member of the RAF family (Fig-
ure 1D and data not shown). Silencing of BRAF in RET/PTC3-
transfected HEK293 cells inhibited ERK activation. This effect 
was specific, since a control scrambled siRNA did not alter ERK 
activity (Figure 1D). Taken together, these findings demonstrate 
that phosphorylation of RET/PTC tyrosine 1062 triggers RAS-
dependent stimulation of BRAF signaling.
Generation of the cellular model system. PC Cl 3 (referred to hereafter 
as PC) is a continuous line of follicular thyroid cells, derived from 
Fischer rats, that constitutes a model system with which to study 
differentiation and growth regulation in an epithelial thyroid cell 
setting. PC cells express the thyroid-specific gene thyroglobulin 
(TG) and the thyroid-specific transcription factors TTF-1 and 
PAX-8. They require a mixture of 6 hormones (6H), including 
thyrotropic hormone (TSH) for proliferation (24). RET/PTC1 
expression causes hormone-independent proliferation of PC cells 
(25–27); hence, the system lends itself to the study of RET/PTC-
mediated effects. We generated marker-selected mass popula-
tions of several PC cell clones stably transfected with RET/PTC3, 
HRAS(V12), or BRAF(V600E). The corresponding proteins were 
correctly synthesized (Figure 2A); ERK activity was stimulated by 
each of the 3 oncoproteins (Figure 2C). The oncogene-transfected 
cell populations showed a similar, albeit not identical, morpho-
logically transformed phenotype, i.e., spindle-shaped and refrac-
tile cells scattered on the surface of the culture dish (Figure 2B). 
RET/PTC3, HRAS(V12), and BRAF(V600E) oncogenes abolished 
the dependency of PC cell proliferation on the 6H (Figure 3A). 
Efficiency of colony formation was 35% ± 5% in the case of 
HRAS(V12), perhaps due to the reported proapoptotic role of 
acute overexpression of the oncoproteins (23, 27). Oncogene-
transfected cells maintained increased levels of G1 cyclin D1 under 
conditions of 6H deprivation (Figure 3A, inset). Moreover, onco-
gene-transfected PC cells exerted an invasive phenotype through 
Matrigel (Figure 3B) and lost the differentiated phenotype (data 
not shown). In the case of RET/PTC3, all these features, as well as 
BRAF-ERK activation, depended on tyrosine 1062 but not on tyro-
sine 1015 (Figures 2 and 3). Since tyrosine 1062 is a multi-docking 
site in RET and is required to activate several signaling pathways, 
we used RNA interference to specifically downregulate BRAF in PC 
cells transfected with RET/PTC3 (PC RET/PTC3 cells). As shown 
in Figure 2D, transfection with BRAF siRNA, but not with the 
control scrambled siRNA, diminished BRAF protein levels. ERK 
Figure 2
Generation of thyroid cell cultures. (A) Protein lysates (50 μg) extracted from the indicated cell lines underwent Western blotting with anti-RET, 
-tag (myc), or -RAS antibodies. Equal protein loading was ascertained by anti-tubulin immunoblot. (B) Mass populations of PC cells transfected 
with the indicated plasmids were photographed using a phase-contrast light microscope (magnification, ×150). RET/PTC3-, RET/PTC3(Y1015F)-, 
BRAF(V600E)-, and HRAS(V12)-expressing cells displayed a transformed morphology, whereas RET/PTC3(Y1062F)-expressing cells were virtu-
ally indistinguishable from parental cells. (C) Protein extracts from the indicated cell lines were subjected to immunoblotting with anti–phospho-
p44/42 ERK antibodies. The blot was reprobed with anti-p44/42 antibodies for normalization. (D) BRAF targeting by siRNA but not by scrambled 
siRNA induced BRAF downregulation and ERK inhibition, as shown by Western blotting with specific antibodies.
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activity was downregulated by BRAF knockdown (Figure 2D). 
Importantly, the transient silencing of BRAF inhibited the 
invasive activity and growth of PC RET/PTC3 cells, whereas 
the negative control siRNA was ineffective (Figure 3, B and C). 
Downregulation of ERK activity achieved with U0126, a specific 
MEK inhibitor, also inhibited PC RET/PTC3 proliferation (data 
not shown) and Matrigel invasion (Figure 3B).
A gene expression signature of the RET/PTC3-RAS-BRAF axis in thyroid 
cells. We explored gene expression changes after PC cell transfection 
with RET/PTC3, HRAS(V12), or BRAF(V600E). We also used cells 
expressing RET/PTC3(Y1062F) and RET/PTC3(Y1015F) mutants. 
To study the expression profiles, we used oligonucleotide-based 
DNA microarrays (GeneChip; Affymetrix) containing oligonucle-
otide probe pairs corresponding to more than 16,000 known genes 
and expressed sequence tag (EST) clusters. RNA was extracted 
from mass populations of cells (pool no. 3 for each oncogene), 
converted into fluorescently labeled complementary RNA (cRNA), 
and hybridized to arrays. Each chip was analyzed with Affymetrix 
Microarray Suite 5.0 Software to generate raw expression data. 
Fold change (signal log ratio [SLR]) was calculated by pairwise 
comparison of probe pairs from the experiment (cells expressing 
the different oncogenes) with baseline (untransfected parental 
cells). In order to sort the genes with changes in mRNA abun-
dance in response to the different oncogenes, we defined a filter 
query that “passed” only data sets that were denoted “increased” or 
“decreased” by the software and that showed a fold change of 4 or 
more (SLR ≥ 2 for upregulated genes; SLR ≤ –2 for downregulated 
genes). The entire data set is available as Supplemental Table 1.
We first examined genes whose expression was expected to be 
modified by thyroid cell transformation. Consistent with the 
Figure 3
The transformed phenotype of RET/PTC3 thyroid cells requires the integrity of the Y1062-RAS-BRAF-ERK pathway. (A) PC cells were transfected 
with the indicated plasmids or the empty vector and either selected in neomycin-containing medium or left in the absence of 6H. Three weeks 
later, colonies were stained with crystal violet and counted. The ratio of neomycin-resistant clones to 6H-independent colonies was calculated. 
The results of 3 independent experiments performed in duplicate ± SD are reported [the number of 6H-independent colonies induced by 
HRAS(V12) was set at 100]. Inset: Protein lysates (50 μg) underwent Western blotting with the indicated antibodies. cyc D1, cyclin D1. (B) Matrigel 
invasion of parental and transformed PC cells. Where indicated, in PC RET/PTC3 cells, suppression of endogenous BRAF was obtained by 
transfection of RNA interference against BRAF, and ERK inhibition was achieved by U0126 treatment. Cells were seeded in the upper chamber 
of 8-μM-pore transwells and incubated for 24 hours. Thereafter, filters were fixed and stained. The upper surface was wiped clean and cells on 
the lower surface photographed (top) and then solubilized. Absorbance at 570 nm was measured with a microplate reader. Cell migration is 
expressed as percentage with respect to RET/PTC3 cells, whose migration was arbitrarily set at 100. Each column represents the average ± SD 
of 3 independent experiments (bottom). (C) Suppression of endogenous BRAF in PC RET/PTC3 cells was obtained by transfection of RNA 
interference against BRAF. Cells were counted at different time points, and the average results of 3 independent experiments are reported.
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above-described cell phenotype, microarray screening demonstrated 
upregulation of G1 cyclins (D and E cyclins) and downregulation of 
thyroid differentiation markers (including TG, TTF-1, and PAX-8) 
(Supplemental Table 1). Then we examined the global expression 
profile. Some genes were regulated by only 1 or 2 oncoproteins. How-
ever, cross-comparison of the results revealed a group of sequences 
that were regulated in a similar fashion in RET/PTC3, HRAS(V12), 
and BRAF(V600E) cells (Figure 4 and Supplemental Figures 2 and 3). 
Whereas the former probably reflect the specific biological activity 
of each oncoprotein, the common targets represent a transcription-
al signature of the expression of the 3 oncogenes in thyrocytes. Of 
the 786 oligonucleotide probe pairs whose expression was increased 
in RET/PTC3 cells (Supplemental Figure 2A), 146 showed an SLR 
of 2 or more (average SLR, 3.2; Figure 4A). Tyrosine 1062 played 
a pivotal role in these expression changes. In fact, upregulation of 
most sequences (131 of 146, 90%) required the integrity of Y1062; 
the remaining 15 sequences were still induced after the Y1062F 
mutation, albeit to a lesser extent (average SLR, 1.8) (Figure 4A). In 
contrast, upregulation of a few of them (less than 15%) depended 
on tyrosine 1015; most of them depended also on Y1062 (data not 
shown). Many of the sequences induced by RET/PTC3 were also 
induced by HRAS(V12) (80 of 146, 54%) and BRAF(V600E) (70 of 
146, 48%) cells with a similar average SLR (Figure 4A). Overall, 60 
(41%) of the oligonucleotide probe pairs induced in RET/PTC3 cells 
were induced in both HRAS(V12) and BRAF(V600E) cells, and as 
many as 87% (52 of 60) were Y1062 dependent (Figure 4A). These 
upregulated oligonucleotide probe pairs corresponded to the 32 
genes and 19 ESTs listed in Table 1. Similarly, sorting of HRAS(V12)- 
and BRAF(V600E)-induced sequences showed that RET/PTC3 
cells upregulated a large set of them in a Y1062-dependent fashion 
(Supplemental Figure 3). Of the 2,517 oligonucleotide probe 
pairs whose expression was decreased in RET/PTC3 cells (Supple-
mental Figure 2B), 338 were downregulated 4-fold or more (aver-
age SLR, –2.96). Again, a large fraction of these sequences was 
also downregulated in HRAS(V12) (148 of 338, 44%; average SLR, 
3.2) and in BRAF(V600E) (121 of 338, 36%; average SLR, 2.5) cells 
(Figure 4B). Overall, 104 (31%) sequences were downregulated by all 
3 oncogenes, with 66 of them (64%) being dependent on the integrity 
of Y1062 (Figure 4B). These downregulated oligonucleotide probe 
pairs corresponded to the 50 genes and 41 ESTs listed in Table 2.
Validation of the expression data in cultured cells and in human PTCs. We 
used quantitative RT-PCR (Q-RT-PCR) to evaluate the expression of 
50 genes (31 of the 32 upregulated and 19 of the 50 downregulated 
genes listed in Tables 1 and 2). To verify that gene expression chang-
es were not due to a clonal effect during selection, we analyzed 
gene expression levels in the mass population (pool no. 3) and in 2 
individual clones (Cl1 and Cl2) for each cell line. We then statisti-
cally analyzed the expression changes induced by each oncogene. 
In most cases (37 of the 50 genes), RET/PTC3, HRAS(V12), and 
BRAF(V600E) activity altered the expression of a particular gene 
identified by the microarray method. The results of these experi-
ments and the relative statistical analysis are reported in Table 3. In 
5 cases (marked in bold in the table), Q-RT-PCR data were not sta-
tistically significant (P > 0.05); however, in these cases, expression 
changes showed a trend consistent with that in microarray data.
All the genes examined were affected by the Y1062F mutation, 
their expression changes being negligible in PC RET/PTC(Y1062F) 
cells (Tables 1 and 2 and data not shown). Moreover, using PC cells 
transfected by RET/PTC1, another RET/PTC variant, we also demon-
strated that gene changes were not restricted to the isoform (RET/PTC3) 
used in the array screen (data not shown). To determine whether 
activation of the RAS-BRAF-ERK pathway was required for gene 
expression regulation induced by RET/PTC3, we used Q-RT-PCR 
to measure the expression levels of the 37 genes listed in Table 3 in 
RET/PTC3 cells in which the pathway was transiently obstructed, 
either by BRAF siRNA or by the MEK inhibitor U0126. As shown in 
Table 4, expression of 22 of the 37 genes was affected by both BRAF 
silencing and U0126 treatment. With the sole exception of the Ca2 
gene, which was obstructed by U0126 but not by BRAF silencing, 
there was complete concordance between the results obtained with 
siRNA and U0126 treatment (Table 4). Scrambled siRNA, used as 
a negative control, did not affect expression levels (Table 4). These 
findings support the notion that the BRAF-MEK cascade is essential 
for the gene expression signature of RET/PTC-transformed cells, but 
they do not necessarily prove that it is also sufficient. It might well 
be that additional pathways (perhaps triggered by the same Y1062) 
contribute to the establishment of the phenotype.
We selected 4 genes upregulated more than 4-fold and 3 genes 
(Arpc1b, CD44, RUNX1) upregulated less than 4-fold in the microarray 
screen. Using Q-RT-PCR, we compared the expression levels of these 
Figure 4
Graphic representation of the gene expression changes 
(fold change of at least 4) in RET/PTC3, BRAF(V600E), 
and HRAS(V12) cells versus baseline (PC): upregulated 
genes (A) and downregulated genes (B). The numbers 
of upregulated and downregulated genes are repre-
sented on the y axis. Thick arrows indicate the Y1062-
dependent genes; thin arrows indicate the targets com-
mon to RET/PTC3, BRAF(V599E), and HRAS(V12). The 
different groups of genes are highlighted. Average SLRs 
(ASLR) are indicated.
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genes in a set of primary human PTC tissue specimens (n = 13) char-
acterized for oncogene activation (BRAF or RET/PTC) (28) to those in 
5 samples of normal thyroid tissue obtained from different donors. 
Successfully amplified samples are reported in Figure 5A. All 7 ana-
lyzed genes were found to be upregulated in most of the tumor sam-
ples, and for 5 of them, P was 0.05 or less. We then examined genes 
coding for the chemokines CXCL1/growth-related oncogene–α 
(CXCL1/GRO-α) and CXCL10/interferon-γ–inducible protein 10 
(CXCL10/IP-10), using a larger set of tumor samples (n = 18) in this 
case. Both chemokine-encoding genes were significantly upregulated 
in PTC samples with respect to normal thyroid tissue (Figure 5B).
Autocrine loops that sustain mitogenesis and motility of thyroid cancer 
cells. Chemokines are small chemotactic cytokines that are sub-
divided into 2 main families (α or CXC and β or CC chemokines) 
on the basis of the relative position of cysteine residues (29). 
Chemokines bind to 7-transmembrane receptors present in 
the cell surface that are coupled to Gαi class G proteins and are 
therefore inhibited by Bordetella pertussis toxin (PTX). Chemokine 
receptor activation leads to a cascade of cellular events: gen-
eration of diacylglycerol and inositol triphosphate, release of 
intracellular calcium, inhibition of adenylyl cyclase, and activa-
tion of several signaling proteins, including JAK/STATs, PKC, 
phospholipase C, PI3K, and small GTPases of the Ras and Rho 
families. This cascade results in activation of AKT and ERK and 
in cell polarization, adhesion, and migration (30, 31).
According to the microarray screen, CXCL1/GRO-α and CCL2/
monocyte chemotactic protein–1 (CCL2/MCP-1) were upregulated 
more than 4-fold in transformed thyrocytes (Table 1). CXCL10/IP-10 
was also upregulated, albeit to a lesser extent (Supplemental Table 1). 
CCL2 is known to be abundantly produced in human PTC 
(32). However, its receptor, CCR7, was not detectable in thyroid 
follicular cells (R.M. Melillo et al., unpublished observations). On 
the other hand, our Q-RT-PCR data demonstrated that CXCL1 
and CXCL10 were upregulated in human PTCs (Figure 5B). 
According to the microarray data, CXCR2 (the CXCL1 receptor) 
and CXCR3 (the CXCL10 receptor) were expressed in parental and 
transformed PC cells (Supplemental Table 1).
First, an ELISA assay demonstrated that CXCL1 and CXCL10 
were more abundantly secreted by human PTC cell lines spon-
taneously carrying the RET/PTC1 rearrangement (TPC1, FB2, 
BHP2-7) or the BRAF(V600E) mutation (BCPAP, BHP5-16) than 
by P5, a primary culture of normal human thyroid follicular 
cells (Figure 6A). Moreover, the mRNA for CXCR2 and CXCR3 
was upregulated in all the PTC cell lines compared with normal 
P5 cells (Figure 6B). Accordingly, both receptors were found to 
be expressed on the cell surface of the 5 PTC cell lines by flow 
cytometric analysis (Figure 6C and data not shown).
Treatment of TPC1 cells with BRAF siRNA caused a decrease 
in endogenous BRAF levels and a parallel reduction of ERK 
activity (Figure 6D). In parallel, BRAF siRNA, but not scrambled 
siRNA, remarkably attenuated CXCL1 and CXCL10 chemokine 
secretion (Figure 6E).
TPC1 cells were stimulated with recombinant CXCL1 or CXCL10; 
cells were harvested at different time points, and activation of ERK 
and AKT was analyzed with phospho-specific antibodies. Both 
chemokines stimulated potent ERK and AKT phosphorylation 
starting as early as 1 minute after treatment; ERK activation 
occurred earlier than AKT activation (Figure 7A). To measure DNA 
synthesis, we counted BrdU-positive cells upon a 1-hour BrdU pulse. 
The average results of 3 independent experiments are reported in 
Table 1
Genes upregulated 4-fold or more in RET/PTC3 cellsA
Gene UniGene no. RET/PTC3 Y1062F HRAS BRAF
Signaling/growth
AdmB Rn. 10232 3.6 NC 4.1 3.6
Dusp6B Rn. 4313 3.3 D 2.5 3
Itga1B Rn. 91044 2.9 NC 3.7 3.2
MarksC Rn. 9560 2.4 NC 2.1 2.4
Igf2r C Rn. 270 3 D 3.6 3.7
Sgk B Rn. 4636 2 D 1.4 3.1
PI4K2BB Rn. 21189 2.6 NC 2 0.8
Transcription     
Fhl2 B Rn. 3849 2.7 NC 3.5 2.8
CITED2 B Rn.31765 2.65 NC 2.45 2.65
IRF7-likeC Rn. 6246 2.1 D 2.3 2.7
Inflammation/immunity 
Spp1B Rn. 8871 6.1 NC 7.3 2.3
CCL2 B Rn. 4772 7 NC 6.15 6.5
CXCL1B Rn. 10907 5.3 NC 7.3 6.1
Proteolysis
Mmp13B Rn 10997 9.4 NC 8.9 9.6
Mmp10B Rn. 9946 10 NC 8.6 10
Mmp12B Rn. 33193 7.8 NC 5.1 6.7
Mmp3B Rn. 32086 7.5 NC 5.2 6.9
USP18-likeB Rn. 4165 2.7 NC 4 2.7
Metabolism
GSTm2 C Rn. 625 2.3 NC 0.7 3
ThB Rn. 11082 2 NC 4.8 1.6
FdpsC Rn. 2622 2.2 NC 1.9 0.4
Ca2B Rn. 26083 4.9 NC 6.6 5.7
DdbiC Rn. 3285 2.3 1.5 1.3 1.3
Ldlr C Rn. 10483 3 1 2.7 0.9
Structure/adhesion
Lgals3B Rn. 764 2.7 D 2.1 1.7
Col1a1 Rn. 2953 6.5 NC 1.4 4.9
Tmsb4x B Rn. 2605 3.5 D 2.4 2.3
VimC Rn. 2710 2 D 0.5 0.6
Lgals1B Rn. 57 2.5 NC 1.9 1.2
Dysf2-likeB Rn. 22869 2.9 2.9 3.5 2.3
Calcium binding
S100A4B Rn. 504 5 NC 3 3.6
S100A6B Rn. 3233 2.9 D 3 3
EST
AA849365 Rn. 22831 2.9 2.9 3.5 2.3
AA851210 Rn. 1392 2.4 NC 2.3 1.5
AA866419 Rn. 3099 2 NC 1.8 1.2
AA875032 Rn. 3212 2.1 D 1.2 0.7
AA900974  2 D 1.9 1.5
AA926129 Rn. 34404 2.6 D 1.1 1
AA944463 Rn. 7736 2.2 NC 3.9 3.9
AA945591 Rn. 1414 2.2 0.6 2.5 1.2
AA957167  3.2 NC 1.4 2.3
AA998535  2.6 1.8 2.6 1.4
AI010910 Rn. 17645 39 NC 2.5 2.2
AI013157 Rn. 98226 2.1 2.6 1.9 2.2
AI013888 Rn. 6715 2.6 0.9 2.5 2.2
AI029439 Rn. 18227 2.4 NC 2.3 2.3
AI029829 Rn. 18332 2.1 NC 2.3 1.6
AI044253 Rn. 15847 3.2 NC 3.3 3.6
AI059223 Rn. 19102 6.4 NC 2.7 7.2
AI059519 Rn. 19198 2.4 NC 2 0.8
AI059622 Rn. 105857 3.1 3.3 1.8 3.1
AThe genes induced in RET/PTC3 cells 4-fold or more and also 
upregulated in HRAS and BRAF cells are listed. BTargets whose 
upregulation was confirmed by RT-PCR. CTargets whose upregulation 
was not confirmed. Targets not further studied by PCR are unmarked. 
NC, not changed; D, decreased; Rn., rattus norvegicus unigene cluster.
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Gene UniGene no. RET/PTC3 Y1062F HRAS BRAF
Cell cycle
Gas 6B Rn. 52228 3 3.3 3 3.3
Transcription
Nr4a1C Rn. 10000 2.2 I 2.4 2.4
CremB Rn. 10251 3.6 NC 1.6 1.2
HhexB Rn.12188 3.2 NC 5.3 2.7
Nr4a3C Rn. 62694 2 NC 3.2 2.3
IRF8B Rn. 3765 2.9 NC 5.1 3.4
Thyroid differentiation
Titf1 Rn. 34265 3.4 NC 3.3 1.1
Tpo Rn. 91199 3.8 NC 3.8 4.5
Tshr Rn. 87913 2 NC 4 2.2
Tg Rn. 10429 4.95 I 6.8 4.82
Dio1 Rn. 87549 3.6 NC 2.5 3.15
Trg Rn. 10431 2.9 NC 2.6 1.2
Slc5a5 Rn. 10505 2.5 I 3.4 2.5
Metabolism 
Kcnk3 Rn. 80679 2.9 2.5 3.8 3.3
Decr1 Rn. 2854 2 0.6 1.9 1
Ephx1 Rn. 3603 2.5 1.3 6,3 2.6
Pygb Rn. 1518 2.5 NC 1.9 0.5
Ass Rn. 5078 2.8 0.8 2.5 1.6
Knkj16 Rn. 1989 3.7 NC 3.9 3.3
Rdh10 Rn. 19600 4.1 NC 0.9 0.8
Knk1 Rn. 15693 2.2 NC 6.4 1.9
Vdup1B Rn. 2758 4.1 0.75 5.55 1.8
GCGB Rn. 54383 5.8 2.2 6 5.6
ACY1C Rn. 3679 3 NC 2.2 2.1
Adhesion/structure
Spna2 Rn. 5812 2.1 NC 1.7 0.8
Ibsp Rn. 9721 3.6 NC 1.6 3.7
Sdc2 Rn. 11127 2.2 NC 2.4 1.3
Acta1 Rn. 39438 3.8 NC 1.9 2.2
WASL Rn. 104056 2.7 NC 1 2
Signaling
Gira1B Rn. 10109 3.4 NC 1.4 2.4
Pde4b Rn. 2485 3 NC 3.25 1.6
Pde4d Rn. 1004 2.4 NC 2.85 2.4
Pgf B Rn. 6960 2.85 NC 4.25 2.95
Adra1bB Rn. 10032 3.1 0.7 3.6 3.4
Pla2g4aB Rn. 10162 2.5 NC 1.4 1.9
Itpr2 Rn. 89152 2.3 I 4 1
Lrp2 Rn. 26430 3.1 NC  3.4 0.6
Ppp1r1b Rn. 36206 3 I 2.9 2.9
Pak3B Rn. 10128 4 NC 1.2 2.9
Rdc1B Rn. 12959 4.4 0.3 6.4 2.8
IRS-2 C Rn. 92308 3 0.5 3.5 1.3
Mig6B Rn. 100336 3.5 1.2 1.7 4.1
PELI1B Rn. 22814 2 I 1.5 2.6
PI4P5K-IB Rn. 22148 2 NC 1.9 1.9
 SLR
Gene UniGene RET/PTC3 Y1062F HRAS BRAF
Inflammation/immunity
F10 Rn. 21393 3 NC 3,8 3.1
TCRVaQ4a23  2.4 1.3 2,9 2.7
Proteolysis
Kng Rn. 54394 3.3 3.85 5,55 4.6
Other
Dig-1 Rn. 10656 2.3 0.9 1.5 2
LOC 207125C Rn. 10718 2.4 NC 2.5 1.5
Tcp1 Rn. 7102 3.2 2 2.6 2.2
EST
AA875654  2.4 0.5 1.1 1.1
AA892287 Rn. 3658 2.4 NC 3.7 1.2
AA892779 Rn. 7319 2.5 1.1 2.3 0.7
AA893192 Rn. 3568 6.2 0.2 3.9 4.3
AA899685 Rn. 3765 4.4 NC 3.3 3
AA925302 Rn. 8149 2.4 0.6 3.7 2.6
AA945679 Rn. 22639 2.7 0.5 5.9 0.7
AA946224 Rn. 8470 2 NC 2.2 0.9
AA955287 Rn. 3271 2.2 NC 2.4 1.3
AA956626 Rn. 8943 2.7 NC 2 1.5
AA956720 Rn. 9069 5.4 I 6.3 1.3
AA957707 Rn. 9366 3.2 0.7 1.7 2.1
AA957835 Rn. 104138 2.5 I 3.6 2.4
AA963282 Rn. 11431 2.6 1.2 3.3 1.5
AA964069 Rn. 26652 2 NC 3.4 3.9
AA964863 Rn. 23239 5.6 I 7.4 6.5
AA965122 Rn. 12011 2.5 0.8 4.8 1.8
AA998543  2.8 1.9 4.3 1.7
AA998660 Rn. 105756 3 0.6 4.4 1
AI008390 Rn. 13814 2.2 I 4.3 3
AI009321 Rn. 22641 2.2 NC 1 2.2
AI009822 Rn. 25030 2.6 0.3 7 2.4
AI010157 Rn. 17350 4.1 I 6 1.8
AI013875 Rn. 12763 2.3 NC 2.9 1.1
AI029070 Rn. 18139 3.5 NC 4.1 0.9
AI029492 Rn. 18238 3.7 0.6 3.8 3.6
AI029741 Rn. 18312 4.4 2.3 3.2 2.2
AI030145 Rn. 21563 2.3 2.3 1.9 3.2
AI030350 Rn. 21579 5.3 3.4 5.2 3.4
AI030351 Rn. 25503 5.1 2 3.5 4.1
AI030569  3.1 1.2 2.5 1.7
AI043701  2.1 2.4 4.5 4.8
AI043942 Rn. 17424 2.8 I 4.3 2.3
AI045936 Rn. 20936 3.7 NC 2.2 4.7
AI058357 Rn. 18850 2.5 NC 9.5 2.1
AI058863 Rn. 21000 2.4 NC 2.6 3.9
AI059078 Rn.19060 3.6 I 4.8 4.3
AI070112 Rn. 19658 2.4 NC 3.3 1.1
AI070185 Rn. 19684 3.2 NC 1.8 1.5
AI639238 Rn. 8434 3.5 NC 0.6 0.8
AI639473  4 I 4.9 3.1
AThe genes downregulated in RET/PTC3 cells 4-fold or more and also downregulated in HRAS and BRAF cells are listed. BTargets whose downregulation 
was confirmed by RT-PCR. CTargets whose downregulation was not confirmed. Targets not further studied by PCR are unmarked. I, increased.
Table 2
Genes downregulated 4-fold or more in PC RET/PTC3 cellsA
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Figure 7B. Treatment with recombinant CXCL1 and CXCL10 stim-
ulated (about 2- to 3-fold) DNA synthesis of TPC1 cells. In contrast, 
treatment with selective receptor antagonists or blocking antibod-
ies, but not with nonspecific IgG, impaired basal DNA synthesis 
(about 2-fold). Finally, we asked whether chemokines stimulated 
cell invasiveness through Matrigel. Representative micrographs are 
shown in Figure 7C (left) together with the average results of 3 inde-
pendent assays (right). TPC1 cells had basal levels of invasiveness; 
exogenous CXCL1 or CXCL10 further induced a strong migratory 
response. Basal TPC1 migration through Matrigel was inhibited by 
treatment with PTX, with CXCR2- or CXCR3-blocking antibodies, 
and with CXCL1- or CXCL10-blocking antibodies but not with 
nonspecific IgG. Cell motility was also blocked by selective CXCR2 
(SB225002) and CXCR3 (TAK-779) antagonists (33, 34). Finally, 
treatment of TPC1 cells with BRAF siRNA and U0126 inhibited 
basal migration in Matrigel. This effect was not observed when a 
scrambled control was used (Figure 7D).
Discussion
A RET/PTC-RAS-BRAF pathway drives thyroid cancer initiation. Here we 
show that the oncogenic proteins involved in the initiation of PTC 
work along the same signaling cascade. This pathway starts at the 
Table 3
Gene expression levels in transformed PC cells by Q-RT-PCR
      Cell typeB
GenesA   PTC3   BRAF    HRAS
 Cl1 Cl2 Pool no. 3 P C Cl1 Cl2 Pool no. 3 P C Cl1 Cl2 Pool no. 3 P C
Upregulated
Adm 10.6 10.6 13.3 <0.05 9 7.8 9.1 <0.05 1.6 2.2 2.8 <0.05
Dups6 78.6 51 39.9 <0.05 25 32.5 89.1 <0.05 >100 >100 >100 <0.05
Itga1 9.2 12.3 5.8 <0.05 16.4 13.7 24.3 <0.05 1.7 1.5 1.7 <0.05
Sgk 8 5 7.5 <0.05 9.4 9.2 9.2 <0.05 6.2 7.1 9.3 <0.05
PI4K2B 6.2 6.5 2.6 <0.05 11.2 12.1 23.7 <0.05 1.75 1.92 2.92 <0.05
Fhl2 10.3 9.6 6.2 <0.05 9.5 10.5 10.6 <0.05 7.6 7.9 13.3 <0.05
CITED2 2.5 9.2 1.4 <0.05 26.7 13.3 10.8 <0.05 2.6 2.9 1.7 <0.05
Spp1 20 15.5 37 <0.05 3.5 11.9 5 <0.05 30 >100 45 <0.05
CCL2 97 57 50 <0.05 37.8 >100 >100 <0.05 27.3 12.1 6.9 <0.05
CXCL1 42 35.9 14.5 <0.05 >100 67 80.6 <0.05 19.7 17.1 14.6 <0.05
Mmp13 >100 >100 32.7 <0.05 8.5 6.2 10 <0.05 27.9 48.5 35.9 <0.05
Mmp10 >100 >100 >100 <0.05 >100 >100 >100 <0.05 48.5 59.7 44.2 <0.05
Mmp12 >100 >100 48.5 <0.05 15.1 8.6 10 <0.05 1.8 1.9 2.1 <0.05
Mmp3 >100 >100 46.3 <0.05 1.6 1 10 >0.05 12.4 18.8 9.8 <0.05
USP18-like 31.4 28 18.2 <0.05 7.6 18 12.7 <0.05 3.6 4.2 4.8 <0.05
Th 20.6 45.3 21.6 <0.05 11.1 18.4 8.7 <0.05 19 21.6 18.6 <0.05
Ca2 17.6 9.9 23.3 <0.05 4 1.9 3 >0.05 1.3 1.5 1.9 <0.05
Lgals3 19.2 19.7 9.8 <0.05 12.1 3.7 9.8 <0.05 5.3 4.2 3 <0.05
Lgals1 4.4 4.9 6.5 <0.05 2.7 1.5 1.9 <0.05 1.6 4 1.5 <0.05
Tmsb4x 7.5 7.6 13.4 <0.05 1.7 2 2.6 <0.05 4.9 10.8 6.4 <0.05
Dysf2-like 13.3 8.6 19.7 <0.05 4.2 3 2 <0.05 56.8 69.7 54.4 <0.05
S100A4 12.5 9 33.5 <0.05 2.5 1.2 3.8 >0.05 3.1 6.2 10.4 <0.05
S100A6 13.5 3.5 18.9 <0.05 12 3.8 3 <0.05 6,2 8 10.3 <0.05
Downregulated
Gas6 0.04 0.02 0.01 <0.05 0.005 0.08 0.02 <0.05 0.01 0.01 0.02 <0.05
Crem 0.1 0.14 0.06 <0.05 0.2 0.2 0.2 <0.05 0.04 0.08 0.05 <0.05
Hhex 0.1 0.07 0.12 <0.05 0.1 0.04 0.07 <0.05 0.02 0.03 0.1 <0.05
IRF8 0.003 0.004 0.003 <0.05 0.008 0.01 0.008 <0.05 0.004 0.004 0.009 <0.05
Vdup1 0.35 0.07 0.1 <0.05 0.06 0.03 0.02 <0.05 0.02 0.02 0.01 <0.05
GCG <0.001 <0.001 0.001 <0.05 <0.001 <0.001 <0.001 <0.05 <0.001 <0.001 <0.001 <0.05
Gira1 0.2 0.4 0.3 <0.05 0.5 0.5 0.5 <0.05 0,3 0.4 0.2 <0.05
Pgf 0.06 0.1 0.04 <0.05 0.1 0.02 0.08 <0.05 0.006 0.005 0.006 <0.05
Adra1b 0.028 0.013 0.01 <0.05 0.03 0.02 0.01 <0.05 0.05 0.05 0.01 <0.05
Pla2g4A 0.05 0.11 0.02 <0.05 0.2 0.1 0.1 <0.05 0.007 0.01 0.007 <0.05
Pak3 0.17 0.7 0.07 >0.05 0.4 0.5 0.6 <0.05 0.008 0.01 0.008 <0.05
Rdc1 0.02 0.01 0.02 <0.05 0.16 0.07 0.01 <0.05 0.023 0.04 0.03 <0.05
Mig-6 0.2 0.3 0.3 <0.05 0.7 0.7 1.4 >0.05 0.1 0.2 0.2 <0.05
PELI1 0.18 0.44 0.13 <0.05 0.16 0.1 0.3 <0.05 <0.001 <0.001 0.3 <0.05
AGenes are classified as up- or downregulated based on their behavior in RET/PTC3-transformed with respect to parental PC cells. BGene expression levels 
are expressed as fold change with respect to parental PC cells. PCRs were performed in triplicate; SD was always <15%. CSignificance was determined by 
the Mann-Whitney U test. P < 0.05 was considered statistically significant. Samples in which P values were not statistically significant are indicated in bold.
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level of RET tyrosine 1062 and sequentially triggers RAS, BRAF, 
and ERK stimulation. These conclusions are supported by a body 
of experimental evidence. First, the transient block of RAS or BRAF 
activity in HEK293 cells, either by dominant negative mutants or 
by RNA interference, inhibited RET/PTC-mediated ERK activation. 
Second, in a thyroid cell setting, RET/PTC3-induced ERK activity 
depended on BRAF. Finally, the biological effects mediated by RET/
PTC3, i.e., cell proliferation and Matrigel invasion, depended on the 
integrity of the RET/PTC3-RAS-BRAF pathway.
According to such a model, in PC thyroid cells, the 3 activat-
ed oncoproteins stimulated largely overlapping gene expression 
signatures. Most of the common targets were under the control 
of RET/PTC(Y1062), and the use of BRAF siRNA and chemical 
blockade of MEK demonstrated that 22 of the 37 genes tested were 
under the control of the RET/PTC3-RAS-BRAF-ERK cascade. Con-
sistently, some genes had been previously shown to be regulated 
via the MAPK cascade. One example is DUSP6, a dual-specificity 
protein phosphatase, which binds to and inactivates ERK1/2 (35). 
It is likely that the gene expression signature shared by cells trans-
formed by RET/PTC, RAS, or BRAF characterizes a vast number 
of PTCs. Accordingly, our analysis of a small sample set of pri-
mary tumors showed that this gene expression signature may be 
exploited as a clinical diagnostic test. A larger number of samples 
will be required to refine the test and to determine whether it is 
sufficiently robust for clinical implementation.
One corollary of these observations is that therapeutic approach-
es can be tailored to target the proteins that act downstream from 
this cascade. Although selective RET kinase inhibitors (36) are 
effective only in tumors featuring RET rearrangements, and not in 
those carrying activating mutations in genes functioning down-
stream from the cascade, chemical blockade of BRAF (37) might be 
beneficial in carcinomas characterized by oncogenic activation of 1 
of the 3 proteins. Moreover, our findings imply that other proteins 
coupled, at different levels, to the RET/PTC-RAS-BRAF cascade 
could be involved in PTC samples negative for mutations in the 
3 oncoproteins. For instance, it is likely that oncogenic versions 
of the TRKA receptor, which occur in a small fraction of PTCs (8), 
substitute RET/PTC upstream from the cascade. It is also conceiv-
able that proteins that modulate the transmission of signals among 
RET, RAS, BRAF, and ERK can modify the phenotype of thyroid 
tumors carrying mutations at different levels of the cascade.
Differences in RET/PTC-, RAS-, and BRAF-driven transcriptional pro-
files. The analysis of transcriptional profiles indicated that the 3 
oncoproteins are not completely equivalent. Indeed, in addition 
to targets common to RET/PTC3, HRAS, and BRAF, there were 
relatively large sets of genes specifically modulated by only 1 or 2 
of the 3 oncogenes. Overall, the similarity between transcriptional 
Table 4
BRAF/MEK dependence of gene expression levels in PC RET/
PTC3 cells
GeneA UO126 TreatmentB siRNA (SCR) siRNA (BRAF)
Upregulated   
Dusp6 0.065 NC 0.43
Sgk 0.5 NC 0.8
Spp1 0.14 NC 0.3
CCL2 0.3 NC 0.4
CXCL1 0.16 NC 0.4
Mmp12 0.5 NC 0.5
Mmp3 0.19 NC 0.28
Mmp13 0.03 NC 0.3
Ca2 0.25 NC NC
Dysf2-like 0.2 NC 0.7
S100A6 0.4 NC 0.25
Downregulated   
Gas6 20 NC 3
Crem 200 NC 5
Vdup1 2 NC 2
GCG 4 NC 15
Glra1 2 NC 7
Pgf 2.3 NC 2.5
Adra1b 2 NC 4.6
Pla2g4a 4 NC 2.5
Pak3 2.4 NC 7.1
Rdc1 2.5 NC 2
PELI1 2 NC 2
AGenes are classified as up- or downregulated based on their behav-
ior in RET/PTC3-transformed with respect to parental PC cells. 
BGene expression levels are expressed as fold change with respect 
to RET/PTC3 cells. NC, expression level not changed with respect to 
untreated RET/PTC3 cells.
Figure 5
Expression levels of selected genes (A) and chemokines (B) 
in human PTC samples versus 5 normal thyroid tissues as 
determined by Q-RT-PCR. The PTC samples were character-
ized for the presence of either a RET/PTC rearrangement or a 
BRAF(V600E) mutation. For each target (indicated on the x axis), 
the expression levels values of tumors (y axis) were calculated 
relative to the average expression level in normal tissues (TN). All 
the experiments were performed in triplicate; SDs were smaller 
than 25% in all cases (data not shown). P values were calculated 
by the Mann-Whitney U test.
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profiles of HRAS(V12) and BRAF(V600E) thyroid cells was greater 
than that between RET/PTC3 and HRAS or RET/PTC3 and BRAF 
cells. For instance, HRAS and BRAF cells (but not RET/PTC cells) 
were characterized by overexpression of genes such as IL-6, CXCR1, 
PDGF-α, SPARC, MCM6, RAF1, and Akt and by downregulation of 
PLC-β1. This was not unexpected; although the 3 oncoproteins work 
together along a single cascade, they are biochemically different and 
therefore able to trigger specific signals in addition to the common 
ones. Molecular genetics evidence nicely supports this concept. For 
instance, BRAF mutations are frequently associated with aggressive 
thyroid carcinomas, such as poorly differentiated and anaplastic car-
cinomas, that rarely, if ever, harbor RET/PTC rearrangements (28). 
On the other hand, RAS point mutations are rare in classic PTCs 
and, instead, characterize PTCs of the follicular variant that are rarely 
affected by mutations in BRAF or RET (9). Detailed analysis of the 
gene expression signatures in a large set of samples may help to iden-
tify molecular profiles that characterize each oncoprotein.
Function of the genes modulated by RET/PTC3, HRAS(V12) and 
BRAF(V600E). Many of the commonly modulated genes were 
involved in hallmarks of neoplastic transformation, e.g., altered 
cell morphology, uncontrolled growth, loss of differentiation, and 
apoptosis. Induced genes included MMPs (MMP3, -10, -12, -13) 
(38). Another category of genes that was greatly overexpressed 
in transformed PC cells were those encoding adhesion/struc-
ture-associated proteins, such as collagen 1 (Col1α1), thymosin 
β4, and galectin-3, previously reported to be overexpressed in 
thyroid carcinomas (39–42). The dual-specificity phosphatase 
(DUSP6) was also previously identified as a gene upregulated in 
human PTC samples (41). Finally, upregulated genes included 
those coding for S100A4 (p9KA) and S100A6 (calcyclin); their 
elevated levels have been associated with cancer and metastasis 
(43). Consistent with the loss of the differentiated phenotype of 
transformed cells, genes coding for differentiation markers were 
downregulated. Interestingly, the gene Hhex, which encodes for 
a proline-rich homeodomain transcription factor and is regulat-
ed by thyroid-specific transcription factors, such as TTF-1 and 
PAX8 (44), was also downregulated. Another downregulated gene 
was mitogen-inducible gene–6 (Mig6). This protein is a negative-
feedback regulator of the epidermal growth factor receptor and a 
potential tumor suppressor (45).
Chemokine autocrine loops in transformed thyroid cells. PTC is associ-
ated with a striking chronic inflammatory reaction in about 30% 
of cases (1, 32). Our data provide a molecular explanation for this 
phenomenon by showing that the RET/PTC-RAS-BRAF signaling 
cascade that drives PTC initiation stimulates the overexpression of 
several chemokines. In turn, chemokines secreted by tumor cells 
Figure 6
Chemokines and chemokine receptors are expressed in human PTC-derived cell lines. (A) CXCL1 and CXCL10 secretion in human PTC cells was 
evaluated by ELISA. Experiments were performed in triplicate, and the average value of the results ± SD was plotted. Normal thyroid cells (P5) were 
used as a negative control. (B) Expression levels of CXCR2 and CXCR3 in PTC cell lines were evaluated by Q-RT-PCR. Expression values were 
calculated relative to the expression level in normal P5 cells. Experiments were performed in triplicate, and the average value of the results ± SD 
was plotted. (C) Flow cytometric analysis of surface expression of CXCR2 and CXCR3 in TPC1 cells. (D) TPC1 cells were transfected by BRAF or 
scrambled siRNA and harvested 72 or 96 hours later. Protein lysates were subjected to immunoblotting with anti-BRAF and anti–phospho-p44/p42 
ERK antibodies. (E) BRAF siRNA interference in TPC1 cells affected chemokine production as determined by ELISA.
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can recruit leukocytes (macrophages, dendritic cells, T cells, and 
natural killer cells) to tumor sites (30, 31). An interesting aspect 
of the relationship between inflammation and cancer is that sev-
eral tumors use molecules of the innate immune system not only 
to recruit leukocytes, but also for growth, survival, and metastasis. 
It can be envisaged that a mixture of chemokines is produced in 
the tumor microenvironment and act in an autocrine/paracrine 
fashion between neighboring homotypic cells (46, 47). Expression 
of CXCR2 and CXCR3, the receptors for CXCL1 and CXCL10, 
respectively, was detected in transformed thyroid cells. Therefore, 2 
autocrine/paracrine loops may mediate biological activities in PTCs 
that are relevant for the establishment of the neoplastic phenotype, 
e.g., autonomous proliferation and motility.
In conclusion, we propose that PTCs are initiated by a set of 
transforming events that target proteins that act along a linear 
signaling cascade. Activation of this signaling cascade results in 
upregulation of chemokines and their receptors that are relevant 
for sustained proliferation and cell motility of tumor cells. We sug-
gest that these genes may act cooperatively to commit transformed 
thyroid cells to a malignant invasive phenotype.
Methods
Plasmids. All the molecular constructs used in this study were cloned in 
pCDNA3(Myc-His) (Invitrogen Corp.). The RET/PTC constructs encode 
the short spliced form of RET (RET9) and are described elsewhere (22). 
For simplicity, we numbered the residues of RET/PTC proteins accord-
ing to the corresponding residues in unrearranged RET. RET/PTC1 and 
RET/PTC3 constructs encode the H4-RET and RFG-RET chimeric onco-
genes, respectively. RET/PTC3(K–) is a kinase-dead mutant, carrying the 
substitution of the catalytic lysine (residue 758 in full-length RET) with a 
methionine. RET/PTC3(Y1062F) and RET/PTC3(Y1015F) carry substitu-
tions of the indicated tyrosines with phenylalanine residues. BRAF and 
the kinase-dead BRAF(K–) were kindly donated by C.J. Marshall (Institute 
of Cancer Research, London, United Kingdom) (12). BRAF(V600E) was 
obtained by site-directed mutagenesis using the QuickChange mutagenesis 
kit (Stratagene). The mutation was confirmed by DNA sequencing. 
HRAS(V12) and HRAS(N17) plasmids are described elsewhere (23).
Cell cultures and transfections. PC Cl 3 (PC) is a differentiated thyroid 
follicular cell line derived from 18-month-old Fischer rats. PC cells were 
cultured in Coon’s modified Ham F12 medium supplemented with 5% 
calf serum and a mixture of 6H, including thyrotropin (10 mU/ml), hydro-
Figure 7
Functional activities of CXCL1 and CXCL10 in human PTC cell lines. (A) Stimulation with CXCL1 and CXCL10 (100 ng/ml) induced time-depen-
dent ERK and AKT activation in TPC1 cells. Cell lysates were harvested at the indicated time points; Western blots were probed with the indicated 
antibodies. (B) BrdU incorporation was measured to evaluate S-phase entry upon treatment with CXCL1 or CXCL10 or the indicated inhibitors. 
The average of the results of 3 independent experiments ± SD is indicated. (C) TPC1 cells were allowed to migrate for 24 hours toward serum-
free medium or, where indicated, a gradient of CXCL1 or CXCL10. Where indicated, cells were preincubated with blocking antibodies, control 
antibodies, chemical inhibitors, or PTX. Cells were treated with either BRAF siRNA or U0126. Representative micrographs (left) and absorbance 
at 570 nm (average ± SD of 3 experiments; right) are shown.
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 115   Number 4   April 2005 1079
cortisone (10 nM), insulin (10 μg/ml), apo-transferrin (5 μg/ml), soma-
tostatin (10 ng/ml), and glycyl-histidyl-lysine (10 ng/ml) (Sigma-Aldrich) 
(24). For stable transfections, 5 × 105 PC cells were plated 48 hours before 
transfection in 60-mm tissue culture dishes. The medium was changed to 
DMEM (Invitrogen Corp.) containing 5% calf serum and 6H. Three hours 
later, calcium phosphate DNA precipitates were incubated with the cells for 
1 hour. DNA precipitates were removed, and cells were washed with serum-
free DMEM and incubated with 15% glycerol in HEPES-buffered saline for 
2 minutes. Finally, cells were washed with DMEM and incubated in Coon’s 
modified F12 medium supplemented with 5% calf serum and 6H. Two days 
later, G418 (neomycin) was added at a concentration of 400 μg/ml. Mass 
populations (pool no. 3) of several PC cell clones were pooled and expand-
ed; 2 independent cell clones (Cl1 and Cl2) for each transfection were also 
isolated. For the colony formation assay, 2 dishes of PC were transfected 
with each plasmid. Two days later, G418 was added to 1 dish, whereas the 
other dish was kept in medium containing 5% calf serum without 6H. After 
15 days, cells colonies were fixed in 11% glutaraldehyde in PBS, rinsed in 
distilled water, stained with 0.1% crystal violet in 20% methanol for 15 
minutes, and counted. The percentage of hormone-independent colonies 
with respect to the total number of G418-resistant colonies was calculated 
as the average of 3 independent determinations ± SD. HEK293 cells were 
from American Type Culture Collection and were grown in DMEM supple-
mented with 10% fetal calf serum. Transient transfections were carried out 
with 5 μg of total DNA in the Lipofectamine reagent according to the man-
ufacturer’s instructions (Invitrogen Corp.). TPC1, FB2, BCPAP, BHP2-7, 
and BHP5-16 human PTC cell lines were grown in DMEM supplemented 
with 10% fetal calf serum. The P5 primary culture of normal human thy-
roid follicular cells was kindly donated by F. Curcio (University of Udine, 
Udine, Italy) and was grown as previously described (48).
RNA silencing. siRNAs targeting human BRAF are described else-
where (49). Duplex oligonucleotides targeting rat BRAF were designed 
with a siRNA selection program (50) and were chemically synthesized 
by PROLIGO. Sense strands for siRNA targeting were: rat BRAF, 5′-
AAAGCCACAGCUGGCUAUUGUUA-3′; human BRAF, 5′-AGAAUUG-
GAUCUGGAUCAUdTdT-3′; and scrambled, 5′-rArCrCrgUrCrgrAUUUr-
CrArCrCrCrgrgTT-3′. For siRNA transfection, PC RET/PTC3 and TPC1 
cells were grown under standard conditions. The day before transfection, 
cells were plated in 6-well dishes at 50–60% confluency. Transfection was 
performed using 5–15 μg of duplex RNA and 6 μl of Oligofectamine 
reagent (Invitrogen Corp.), as previously described (49). Cells were har-
vested at different time points after transfection and analyzed.
Tissue samples. Archival frozen thyroid tissue samples from 18 patients 
affected by PTCs were retrieved from the files of the Pathology Department 
of the University of Pisa upon informed consent. Special care was taken 
to select cases whose corresponding histological samples were available for 
matched analysis. Sections (4 μm thick) of paraffin-embedded samples were 
stained with H&E for histological examination to ensure that the samples 
fulfilled the diagnostic criteria required for the identification of PTCs 
(enlarged nuclei with fine, dusty chromatin, nuclear grooves, single or mul-
tiple micro-/macronucleoli, and intranuclear inclusions). Normal thyroid 
tissue samples were also retrieved from the files of the Pathology Depart-
ment of the University of Pisa upon informed consent. All experiments were 
approved by the “Comitato etico per la sperimentazione clinica del farma-
co” of the Azienda Ospedaliera — Universitaria Pisana (Pisa, Italy).
RNA extraction and RT-PCR. Total RNA was isolated using the RNeasy Kit 
(QIAGEN) and subjected to on-column DNase digestion with the RNase-
free DNase set (QIAGEN) according to the manufacturer’s instructions. 
Where indicated, cells were transfected with BRAF siRNA or treated with 
U0126 (20 μM) and harvested 72 hours after treatment. The quality of RNA 
was verified by electrophoresis through 1% agarose gel and visualized with 
ethidium bromide. We synthesized random-primed first-strand cDNA in 
a 50-μl reaction volume starting from 2 μg RNA using the GeneAmp RNA 
PCR Core Kit (Applied Biosystems). Primers were designed using Primer3 
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and 
synthesized by MWG Biotech. Primer sequences are available in Supplemen-
tal Tables 2 and 3. To exclude DNA contamination, each PCR reaction was 
also performed on untranscribed RNA. We performed Q-RT-PCRs using 
the SYBR Green PCR Master Mix (Applied Biosystems) in the iCycler appa-
ratus (Bio-Rad). Amplification reactions (25 μl final reaction volume) con-
tained 200 nM of each primer, 3 mM MgCl2, 300 μM deoxyribonucleoside 
triphosphates (dNTPs), 1× SYBR Green PCR buffer (Applied Biosystems), 
0.1 U/μl AmpliTaq Gold DNA Polymerase (Applied Biosystems), 0.01 U/μl 
Amp Erase (Applied Biosystems), RNase-free water, and 2 μl cDNA samples. 
Thermal cycling conditions were optimized for each primer pair using stan-
dard conditions and varying annealing temperatures as suggested by Prim-
er3. To verify the absence of nonspecific products, we performed 80 cycles of 
melting (55°C for 10 seconds). In all cases, the melting curve confirmed that 
a single product was generated. Amplification was monitored by measuring 
the increase in fluorescence caused by the binding of SYBR Green to double-
stranded DNA. Fluorescent threshold values were measured in triplicate, and 
fold changes were calculated by the formula 2–(sample 1 ΔCt – sample 2 ΔCt), where 
ΔCt is the difference between the amplification fluorescence thresholds of 
the mRNA of interest and the β-actin mRNA. We performed Q-RT-PCR 
for CXCL1 and CXCL10 using the predeveloped TaqMan assay reagent kit 
(Assay on Demand; Applied Biosystems).
Oligonucleotide DNA microarray. The detailed protocol for the microarray 
hybridizations, sample preparation, and the Rat Genome U34 Set are avail-
able from Affymetrix. Briefly, 10 μg purified total RNA was transcribed 
into a first cDNA using Superscript RT (Invitrogen Corp.), in the pres-
ence of T7-oligo(dT)24 primer, dNTPs, and T7 RNA polymerase promoter 
(Invitrogen Corp.). The double-stranded cDNA was cleaned, and an in 
vitro transcription reaction was then performed to generate biotinylated 
cRNA, which, after fragmentation, was used in a hybridization assay on 
RG-U34A and RG-U34B GeneChip microarrays. The A array contains 
probes representing full-length or annotated genes as well as EST clusters. 
The B array contains only EST clusters. Before hybridization, we estimated 
the efficiency of cDNA synthesis by calculating, in a test chip, the ratios 
for 5′ and middle intensities relative to 3′ for the control genes actin and 
GAPDH. Biotinylated RNA used as a target in the microarray hybridization 
was stained with a streptavidin-phycoerythrin conjugation including an 
amplification step with a secondary antibody and scanned in a confocal 
laser-scanning microscope (GeneArray Scanner G2500A; Hewlett Packard). 
Normalization was performed by global scaling, with the arrays scaled to 
an average intensity of 150. We performed analysis of differential expres-
sion using Microarray Suite software 5.0 (Affymetrix). The final results 
were imported into Microsoft Excel (version 11.1; Microsoft).
Protein studies. Protein extractions and immunoblotting experiments 
were performed according to standard procedures. Briefly, cells were har-
vested in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 
1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl2, 10 mM NaF, 10 mM sodium 
pyrophosphate, 1 mM Na3VO4, 10 μg aprotinin/ml, 10 μg leupeptin/ml) 
and clarified by centrifugation at 10,000 g. Protein concentration was esti-
mated with a modified Bradford assay (Bio-Rad Laboratories). Immune 
complexes were detected with the enhanced chemiluminescence kit (ECL; 
Amersham Biosciences). Signal intensity was analyzed with Phosphorim-
ager (Typhoon 8600; Amersham Biosciences) interfaced with ImageQuant 
software (version 5.0; Amersham Biosciences). Anti-RET is an affinity-puri-
fied polyclonal antibody raised against the tyrosine kinase protein fragment 
of human RET. Anti-ERK (no. 9101) and anti–phospho-ERK (no. 9102) 
were from Cell Signaling Technology. Anti-myc antibody and antibodies 
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against cyclin D1, BRAF, and c-RAF were from Santa Cruz Biotechnology 
Inc. Anti-RAS and anti-phosphotyrosine antibodies were from Upstate 
Biotechnology Inc. Anti-AKT and anti–phospho-AKT, specific for the active 
AKT phosphorylated at serine 473, were from Cell Signaling Technology. 
Monoclonal anti–α-tubulin was from Sigma-Aldrich. Secondary antibod-
ies coupled to HRP were from Amersham Biosciences. For the BRAF kinase 
assay, cells were cultured for 12 hours in serum-deprived medium and har-
vested. BRAF kinase was immunoprecipitated with the anti-myc epitope 
antibody and resuspended in a kinase buffer containing 25 mM sodium 
pyrophosphate, 10 μCi [32P]ATP, and 1 μg recombinant glutathione-S-
transferase–MEK (GST-MEK; Upstate Biotechnology Inc.). After 30 min-
utes incubation at 4°C, reactions were stopped by adding 2× Laemmli 
buffer. Proteins were then subjected to 12% SDS gel electrophoresis. The 
radioactive signal was analyzed with the Phosphorimager.
ELISA assay. Thyroid cells plated in 6-well dishes were allowed to grow to 
70% confluency and then serum deprived for 24 hours. The culture medi-
um was cleared by centrifugation at 800 g at 4°C to remove detached cells 
and debris. We measured CXCL1 and CXCL10 levels in culture superna-
tants using a quantitative immunoassay ELISA kit (QuantiKine ELISA kit; 
R&D Systems), following the manufacturer’s instructions. For chemokine 
detection in TPC1 BRAF-depleted cells, supernatants were harvested 96 
hours after siRNA transfection. Cells were serum starved for 4 hours before 
harvesting. Samples prepared in triplicate were analyzed at 490 nM with an 
ELISA reader (model 550 microplate reader; Bio-Rad Laboratories).
Flow cytometric analysis. Subconfluent TPC1 cells were detached from cul-
ture dishes with a solution of 0.5 mM EDTA and then washed 3 times in 
PBS buffer. After saturation with 1 μg of human IgG/105 cells, cells were 
incubated for 20 minutes on ice with fluorescein- or phycoerythrin-labeled 
antibodies specific for human CXCR2 or CXCR3 (R&D Systems) or isotype 
control antibody. After incubation, we removed unreacted antibody by 
washing cells twice in PBS buffer. Cells resuspended in PBS were analyzed 
on a FACSCalibur automated cell analysis system using CellQuest version 
3.3 software (BD). Analyses were performed in triplicate. In each analysis, 
a total of 104 events was calculated.
Matrigel invasion. In vitro invasiveness through Matrigel was assayed using 
transwell cell culture chambers according to previously described proce-
dures (51). Briefly, confluent cell monolayers were harvested with trypsin/
EDTA and centrifuged at 800 g for 10 minutes. The cell suspension (1 × 105 
cells/well) was added to the upper chamber of a prehydrated polycarbon-
ate membrane filter of 8-μM pore size (Costar; Corning) coated with 35 μg 
Matrigel (Collaborative Research Inc.). The lower chamber was filled with 
complete medium and, when required, purified CXCL1 or 10 (PeproTech), 
at a concentration of 100 ng/ml, was added to the lower chamber. When 
required, the cells were pretreated for 12 hours with U0126 (20 μM) or for 
20 minutes with CXCL1, CXCL10, CXCR2, and CXCR3 blocking antibodies 
(1 μg/ml; R&D Systems), PTX (0.1 μg/ml; Calbiochem), or the block-
ing compounds SB225002 (10 nM; Calbiochem) and TAK-779 (100 nM). 
The latter reagent was obtained from the NIH AIDS Research and Refer-
ence Reagent Program, Division of AIDS, National Institute of Allergy and 
Infectious Diseases. Where indicated, PC RET/PTC3 and TPC1 cells were 
transfected with BRAF siRNA, harvested at 48 and 72 hours, respectively, 
and plated on Matrigel. Cells were then incubated at 37°C in a humidified 
incubator in 5% CO2 and 95% air for 24 hours. Nonmigrating cells on the 
upper side of the filter and Matrigel were wiped off, and migrating cells on 
the reverse side of the filter were stained with 0.1% crystal violet in 20% meth-
anol for 15 minutes and photographed. The stained cells were lysed in 10% 
acetic acid. Triplicate samples were analyzed at 570 nM with an ELISA reader 
(model 550 microplate reader). The results were expressed as percentage of 
migrating cells to PC RET/PTC3- or chemokine-stimulated TPC1 cells.
S-phase entry. S-phase entry was evaluated by BrdU incorporation and indi-
rect immunofluorescence. Cells were grown on coverslips and serum deprived 
for 30 hours. When indicated, cells were treated with CXCL1 or CXCL10 
(PeproTech), at a concentration of 500 ng/ml, for 30 hours. When required, 
the cells were treated for 24 hours with CXCL1, CXCL10, CXCR2, and CXCR3 
blocking antibodies (1 μg/ml; R&D Systems), PTX (0.1 μg/ml; Calbiochem), 
or the blocking compounds SB225002 (10 nM; Calbiochem) and TAK-779 
(100 nM). BrdU was added at a concentration of 10 μM for the last 2 hours. 
Subsequently, cells were fixed in 3% paraformaldehyde and permeabilized 
with 0.2% Triton X-100. BrdU-positive cells were revealed with Texas red–con-
jugated secondary antibodies (Jackson ImmunoResearch Laboratories Inc.). 
Cell nuclei were identified by Hoechst staining. Fluorescence was visualized 
with a Zeiss 140 epifluorescence microscope (Carl Zeiss International).
Statistical analysis. Significance was determined by the Mann-Whitney 
U test using STATSOFT version 6.0 software. P values less than 0.05 were 
considered statistically significant.
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Functional expression of the CXCR4 chemokine receptor is induced by
RET/PTC oncogenes and is a common event in human papillary thyroid
carcinomas
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To identify genes involved in the transformation of thyroid
follicular cells, we explored, using DNA oligonucleotide
microarrays, the transcriptional response of PC Cl3 rat
thyroid epithelial cells to the ectopic expression of the
RET/PTC oncogenes. We found that RET/PTC was able
to induce the expression of CXCR4, the receptor for the
chemokine CXCL12/SDF-1a/b. We observed that
CXCR4 expression correlated with the transforming
ability of the oncoprotein and depended on the integrity
of the RET/PTC–RAS/ERK signaling pathway. We
found that CXCR4 was expressed in RET/PTC-positive
human thyroid cancer cell lines, but not in normal thyroid
cells. Furthermore, we found CXCR4 expression in human
thyroid carcinomas, but not in normal thyroid samples by
immunohistochemistry. Since CXCR4 has been recently
implicated in tumor proliferation, motility and invasive-
ness, we asked whether treatment with SDF-1a was able
to induce a biological response in thyroid cells. We
observed that SDF-1a induced S-phase entry and survival
of thyroid cells. Invasion through a reconstituted extra-
cellular matrix was also supported by SDF-1a and
inhibited by a blocking antibody to CXCR4. Taken
together, these results suggest that human thyroid cancers
bearing RET/PTC rearrangements may use the CXCR4/
SDF-1a receptor–ligand pathway to proliferate, survive
and migrate.
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Introduction
Thyroid tumors include a broad variety of lesions with
different biological and clinical behavior: benign ade-
nomas and well-differentiated (papillary and follicular),
poorly differentiated and undifferentiated (anaplastic)
carcinomas (Kroll et al., 2002). Papillary thyroid
carcinomas (PTCs) are the most frequent thyroid
tumors. Somatic rearrangements of the RET proto-
oncogene are frequent genetic events in PTCs, ranging
from 25 to 40%. Their prevalence is much higher in the
PTCs that occurred in children after the nuclear fallout
in the Chernobyl area (Nikiforov, 2002). RET/PTC
genes derive from chromosomal rearrangements that
juxtapose the TK domain of RET to heterologous
genes. RET/PTC1 (H4-RET) and RET/PTC3 (RFG-
RET) are the most prevalent variants (Nikiforov, 2002).
When RET/PTC1 or RET/PTC3 are targeted to the
thyroid in transgenic mice, animals develop thyroid
tumors resembling human thyroid papillary carcinoma
(Jhiang et al., 1996; Santoro et al., 1996; Powell et al.,
1998; Buckwalter et al., 2002). Consistent with their role
in thyroid carcinogenesis, RET/PTC oncogenes, when
ectopically expressed in PC Cl3 rat thyroid epithelial
cells, induce morphological transformation, TSH-inde-
pendent growth and the loss of the differentiated
phenotype (Santoro et al., 1993). Other frequent genetic
events in PTCs are activating point mutations of the
BRAF serine-threonine kinase (Kimura et al., 2003).
Activating point mutations of RAS are also seen in a
small percentage of human PTCs (Namba et al., 1990).
Interestingly, RET, RAS and BRAF signal on the same
pathway in thyroid cells and their mutations are
mutually exclusive in human PTC samples (Kimura
et al., 2003).
To identify genes involved in RET/PTC-mediated
transforming activity, we explored, using DNA oligo-
nucleotide microarray, the transcriptional response of
PC Cl3 cells to RET/PTC oncogenes. We identiﬁed
CXCR4, the receptor for the chemokine SDF-1a, as one
of the genes whose expression was upregulated in RET/
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PTC-expressing cells and correlated with the transform-
ing ability of RET/PTC. We show that CXCR4
expression depended on tyrosine 1062 of RET, which
mediates the activation of the RAS/ERK pathway
(Melillo et al., 2001). Consistent with this, we observed
upregulation of CXCR4 also in rat thyroid cell lines
transformed by the RAS and the BRAF oncogenes.
Human thyroid cancer cell lines derived from either
RET/PTC- or BRAF-positive tumors also feature high
levels of CXCR4, if compared with primary thyroid
cells. Here, we provide evidences that proliferation,
survival and migration of thyroid cancer cell lines can be
sustained by the CXCR4–SDF-1a receptor–ligand pair.
In conclusion, we suggest that overexpression of
CXCR4 is a common event in thyroid tumorigenesis
and that this receptor can mediate, upon ligand
addition, paracrine signals that promote malignant
progression.
Results
RET/PTC oncogenes upregulate the expression of the
CXCR4 chemokine receptor
To better understand the molecular mechanisms used by
RET/PTC oncogenes to transform thyroid cells, we
exploited the rat thyroid epithelial cell line PC Cl3,
widely used as a model system for thyroid transforma-
tion. In our previous work, we generated and character-
ized PC Cl3 cell lines expressing the RET/PTC1
oncogene, PC-PTC1 (Santoro et al., 1993). These cells
display a transformed phenotype with altered morphol-
ogy, loss of differentiation and hormone-independent
growth. We performed gene expression proﬁling of
parental and PC-PTC1 cell lines using the rat Affyme-
trix GeneChip U34 set. Among several genes that were
induced upon RET/PTC expression (RM Melillo et al.,
unpublished data), CXCR4, the receptor for the
chemokine CXCL12/SDF-1a/b, showed approximately
a threefold increase. RT–PCR experiment on PC-PTC1
and PC-PTC3 cells validated these results; densitometric
scanning revealed an induction of approximately four-
fold in transformed versus parental cells (Figure 1a).
Western blotting with anti-CXCR4 polyclonal antibo-
dies conﬁrmed the overexpression of CXCR4 in rat
transformed thyroid cells (Figure 1b). To further
characterize CXCR4 gene regulation by RET/PTC, we
performed RT–PCR experiments on RET/PTC3 mu-
tants, carrying mutations in residues corresponding to
Y1015 and Y1062 of wild-type RET. RET/PTC3
Y1015F and RET/PTC3 Y1062F display, respectively,
moderately and severely reduced biological activity
(Melillo et al., 2001; Knauf et al., 2003). Here we show
that CXCR4 mRNA expression depends on the integrity
of Y1062, but not Y1015. Y1062 drives the activation of
the RAS/ERKs and it is essential for the transforming
ability of RET/PTC oncogenes in thyroid cells (Melillo
et al., 2001, Melillo et al., in preparation). To verify
whether CXCR4 expression depends on RAS–BRAF
activation, we examined CXCR4 RNA levels in the PC-
Ha RAS (Fusco et al., 1987) and PC-BRAF cell lines,
which express, respectively, the oncogenes Ha-RAS V12
and BRAF V599E. Furthermore, we treated RET-PTC3
cells for 12 h with the ERK inhibitor PD98059. We
found CXCR4 upregulation in PC-Ha RAS and PC-
BRAF cells. CXCR4 was instead downregulated in PC-
PTC3 cells treated with PD98059 (Figure 1c). These
results suggest that CXCR4 can be upregulated by RET/
PTC, RAS and BRAF. They also suggest that PTC-
dependent CXCR4 upregulation requires the activation
of ERKs.
To show that CXCR4 expression depended on RET/
PTC kinase activity, cells were treated with two
pharmacological inhibitors of RET: a pyrazolo-pyrimi-
Figure 1 CXCR4 upregulation in PC-PTC rat thyroid cells. (a)
The indicated cell lines were harvested and RNAs were isolated and
analysed for CXCR4 expression by RT–PCR. PC-PTC cells
display an increased CXCR4 mRNA expression in comparison to
parental cells. The expression levels of CXCR4 mRNA were
normalized to b-actin mRNA levels for each experimental point.
(b) The overexpression of CXCR4 in transformed cells was also
conﬁrmed by Western blot analysis. Cell lines were harvested and
proteins were extracted as indicated in Materials and methods, and
analysed by Western blot with the anti-CXCR4 antibody (Santa
Cruz). (c) CXCR4 expression depends on the RAS-MAPKs
signaling, as shown by the RT–PCR analysis on PC Cl3 cell lines
expressing RET/PTC3 mutants. A mutation in residue Y1062 or
treatment with the compound PD98059 abolished CXCR4 expres-
sion. Consistent with this, PC-Ha RAS and PC-BRAF, carrying
the corresponding activated oncogenes, overexpress CXCR4. (d)
PC-PTC1 cells were treated with two RET TK inhibitors, PP1
(5mM) and ZD6474 (5 mM), for 72 h. Protein lysates were analysed
by immunoblot with anti-CXCR4 antibodies. To conﬁrm the
inhibition of RET/PTC1 kinase activity, an immunoblot with anti-
phospho-Ret Y905-speciﬁc antibodies was also performed. (e) PC
cells expressing an inducible RET/PTC1 protein were treated with
doxycycline. Cells were then harvested at the indicated time points
and after doxycycline washout. Protein lysates were analysed by
immunoblot with anti-CXCR4 antibodies. To conﬁrm the induc-
tion of PTC1, an immunoblot with anti-ret-speciﬁc antibodies was
also performed
CXCR4 is overexpressed in human PTCs
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dine, PP1, and an anilino-quinazoline, ZD6474. We
reported that these compounds are able to inhibit RET/
PTC enzymatic activity (Carlomagno et al., 2002a, b).
As shown in Figure 1d, CXCR4 protein levels decreased
following treatment with the two inhibitors. The
inhibition of RET/PTC kinase activity was monitored
with a RET antibody that recognizes the tyrosine
residue 905 when phosphorylated.
To further support the hypothesis that CXCR4
expression is directly dependent on RET/PTC, and not
a late event that cells select during neoplastic transfor-
mation, we used a PC Cl3 cell line in which the
expression of RET/PTC1 is under the control of a Tet-
on promoter (Wang et al., 2003), and can be induced by
treatment of cell with doxycycline, a tetracycline analog.
As shown in Figure 1e, CXCR4 protein upregulation
followed RET/PTC1 expression, and peaked between 24
and 48 h, when RET/PTC1 levels reached a plateau.
CXCR4 upregulation was abrogated upon doxycycline
washout.
CXCR4 is expressed in human thyroid carcinoma cells
and in primary papillary thyroid carcinomas
We then asked whether CXCR4 upregulation was also a
feature of human thyroid cancer cells. To this aim, we
determined the expression of CXCR4 in a series of cell
lines, derived from human PTCs (Cerutti et al., 1996;
Ohta et al., 2001; Basolo et al, 2002) compared to a
primary thyroid cell culture P5 (Curcio et al., 1994).
These cell lines are characterized by either a RET/PTC1
rearrangement (TPC-1, FB2, BHP2-7, BHP7-13,
BHP10-13) or a BRAF V599E mutation (NPA87,
BHP5-16, BHP14-9, BHP17-10) (Kimura et al., 2003;
Nikiforova et al., 2003; Xu et al., 2003). According to
the concept of a common signaling pathway that
involves RET/PTC and BRAF, all the cancer cell lines
tested, but not the normal thyrocytes, express CXCR4
(Figure 2a). CXCL12/SDF-1a and b are the only
physiological ligand so far known for the CXCR4
receptor. They are encoded by a single gene, and derive
from an alternative splicing. The two encoded proteins
are identical, except for the last four amino acids of
SDF-1b, which are absent in SDF-1a. We failed to
detect the chemokines in cell culture medium by using
an ELISA assay, and we found a very weak expression
of the chemokines in both normal and cancer-derived
thyroid cells by RT–PCR (not shown). We also tested,
by Western blot, CXCR4 expression in a set of primary
tumors from PTC patients and a normal thyroid sample.
As shown in Figure 2b, PTC samples scored positive for
CXCR4 expression. Normal thyroid tissue displayed a
lower, but detectable reactivity. This reactivity could be
due to follicular thyroid cells, stromal cells or inﬁltrating
lymphocytes. To answer this question and to conﬁrm
CXCR4 expression, we tested receptor expression in a
set of primary tumors (N¼ 19) from PTC patients by
immunohistochemistry. In most of the samples, we
detected immunoreactivity against CXCR4 in epithelial
cancer cells (17/19). This reactivity was speciﬁc, since it
could be displaced with the corresponding immunizing
peptide (not shown), and it could not be detected with
an isotype control antibody. Tissue samples from
normal thyroid scored negative for CXCR4 expression.
A representative example of these experiments is shown
in Figure 2c.
CXCR4 activates downstream signaling pathways in
thyroid cancer cells
To evaluate whether CXCR4 receptor expressed on
thyroid cells is functional, we stimulated rat and human
Figure 2 CXCR4 upregulation in human thyroid papillary cancer. (a) CXCR4 upregulation in cell lines derived from RET/PTC-
positive human PTCs was evaluated by immunoblot with a polyclonal anti-CXCR4 antibody (Abcam). The expression levels of
CXCR4 protein were analysed in the P5 human primary thyroid cells, and in the indicated cell lines, derived from human PTCs. TPC1,
FB2 BHP2-7, BHP7-13 and BHP10-13 bear an endogenous RET/PTC1 rearrangement; BHP5-16, BHP14-9, BHP17-10 and NPA87
carry the typical V599E mutation in the BRAF gene. (b) The expression levels of CXCR4 protein were analysed in human PTC
samples. Tissues were snap-frozen and immediately homogenized by using the Mixer Mill apparatus (Qiagen) in lysis buffer. Equal
amounts of proteins were immunoblotted and stained with anti-CXCR4 polyclonal antibodies (Abcam). As a control for equal
loading, the anti-alpha tubulin monoclonal antibody was used. (c) Immunohistochemical staining for CXCR4 of formalin-ﬁxed,
parafﬁn-embedded thyroid carcinoma; Harris hematoxylin counterstaining. Tissue samples from normal thyroid (NT) or PTCs either
classic or follicular variant (PTC and FV) were incubated with a mouse monoclonal anti-CXCR4 antibody (R&D). PTC shows a
strong immunoreactivity for CXCR4. Strong immunoreactivity is also present in the case of follicular variant of PTC (FV). Normal
thyroid tissue is negative (NT). Representative pictures of normal and pathological positive samples are shown. Isotype control is
represented in the lower panel
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cancer cells with recombinant SDF-1a. In Figure 3a and
b, the results obtained from PC-PTC1 (Santoro et al.
1993) and FB2 (Basolo et al., 2002) cell lines are shown;
similar results were also obtained when PC-PTC3 and
TPC1 were used (not shown). Cells were harvested at
different time points. Since it has been described that
SDF-1a activates the ERK and PI3K/Akt pathways
(Zhou et al., 2002), cell lysates were subjected to
Western blot analysis and probed, respectively, with
anti-phospho-MAPK and anti-phospho-Akt antibodies.
As shown in Figure 3a and b, activation of both p44/42
MAPK and Akt readily occurred in stimulated cells.
MAPK activation occurred at 1min of stimulation and
was biphasic in PC-PTC1 and in human FB2 cells
(Figure 3a and b). In contrast, the highest activation of
Akt was observed at 30min in both the cell lines (Figure
3a and b). These observations demonstrate that CXCR4
can function in both rat and human thyroid cells as a
signaling receptor.
SDF-1a induces S-phase entry and survival of
transformed thyroid cells
Since CXCR4 is expressed and functional in thyroid
cells, its triggering could contribute to the phenotype of
cancer cells. We ﬁrst asked whether SDF-1a treatment
increased the proliferation rate of parental PC and PC-
PTC1 cells. To address this point, we measured BrdU
incorporation as a readout of DNA synthesis after 24 h
treatment with 100 ng/ml of SDF-1a. Figure 4a shows
that treatment with SDF-1a caused an increase in BrdU
incorporation rate in PC -PTC1 but not in parental cells.
The average results of three independent experiments
are reported. To evaluate whether the addition of SDF-
1a was able to inhibit apoptosis, we measured inter-
nucleosomal DNA fragmentation by the TUNEL assay.
Cells were subjected to serum starvation or treated with
2 ng/ml vincristine, two potent apoptotic stimuli
(Figure 4b): both treatments induced apoptosis. The
effect of both serum deprivation and vincristine treat-
Figure 3 Effects of SDF-1a in cells overexpressing CXCR4. PC
RET/PTC1 (a) and FB2 (b) cells were cultured in complete
medium, as indicated in Materials and methods, starved for 12 h
with the respective serum-free media and then stimulated with
100 ng/ml SDF-1a. Cell lysates were prepared and analysed by
Western blot with the anti-phospho-MAPK and the anti-phospho-
Akt antibodies. To conﬁrm equal loading of the lysates, blots were
also probed with total MAPK and total Akt antibodies
Figure 4 Effects of SDF-1a on thyroid cell proliferation and survival. (a) S-phase entry was evaluated by BrdU incorporation and
indirect immunoﬂuorescence. PC and PC-PTC1 cells were grown on coverslips, serum deprived and treated with SDF-1a (100 ng/ml)
for 48 h. Cells were observed under an epiﬂuorescent microscope to detect BrdU-positive cells. S-phase cells were calculated by
counting at least 400 cells in ﬁve randomly selected microscopic ﬁelds. Results are from three independent experiments. (b) The
TUNEL reaction was performed on PC and PC-PTC1 upon 24 h serum deprivation or in complete serum with vincristine, as indicated,
in the presence or in the absence of 100 ng/ml SDF-1a. Cells were observed under an epiﬂuorescent microscope to detect TUNEL-
positive cells (TMR-dUTP, red) and total cells on the glass slide (Hoechst, blue stain). Bars are the mean7s.d. of three assays.
Apoptotic cells were calculated by counting at least 400 cells in ﬁve randomly selected microscopic ﬁelds. (c, d) S-phase entry and
survival were analysed in human FB2 cells. SDF-1a increased proliferation and survival also in these cells
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ment is stronger in PC-PTC1 than in parental cells, due
to the ability of RET/PTC oncogenes to induce
apoptosis, as previously shown (Castellone et al.,
2003). SDF-1a displayed a strong protective effect in
PC-PTC1, but not in parental cells. Apoptosis was
measured in ﬁve randomly selected microscopic ﬁelds;
the average results of three experiments are reported in
the ﬁgure.
To show that SDF-1a induced the same effects also in
human cells, we treated FB2 cells with the chemokine
and evaluated both proliferative and antiapoptotic
effects. As shown in Figure 4c and d, SDF-1a was able
to increase BrdU incorporation and inhibit apoptosis
also in these cells.
SDF-1a triggers chemotaxis and enhances the invasive
behavior of cancer thyroid cell lines
CXCR4 has been recently shown to be involved in
migration and extracellular matrix invasion of different
cancer cells (Muller et al., 2001; Murphy et al., 2001). To
verify whether thyroid cancer cells also use CXCR4 to
migrate in response to SDF-1a, PC, PC-PTC1 and FB2
cells were seeded into the top chamber of transwells, and
their ability to invade a reconstituted extracellular
matrix (matrigel) was evaluated. Parental PC cells were
not responsive to SDF-1a even when exposed to a high
concentration of the chemokine (Figure 5a). A concen-
tration of 100 ng/ml was able to support the invasive
ability of PC-PTC1 cells. Even a very low concentration
of the factor (2.5 ng/ml) was sufﬁcient to induce matrix
invasion of the human FB2 cells (Figure 5c). The
activity of CXCR4 can be inhibited by pertussis toxin,
which inactivates the regulatory proteins Gi and Go, by
CXCR4-blocking antibodies, or by blocking peptides.
One of these peptides, T22, has been shown to inhibit
chemotaxis induced by SDF-1a in human cells (Mur-
akami et al., 2002). We found that the ability to invade
matrigel of both rat and human cells was inhibited by
each one of these compounds (Figure 5).
The induction of branching morphogenesis in type I
collagen gels efﬁciently reﬂects invasive and motile
properties of malignant cells, also deﬁned as ‘invasive
growth’ (Comoglio and Trusolino, 2002). Untrans-
formed cells form small and regular nests in collagen
gel and they do not proliferate, whereas malignant cells
proliferate and form branched colonies with protruding
cells, which invade the surrounding matrix (Medico
et al., 1996). We tested the ability of PC, PC-PTC1 cells
and human FB2 cell lines to grow in type I collagen gels
and the effects of SDF-1a. In cancer, but not in parental
cells, SDF-1a supported the formation of irregularly
shaped colonies with protruding cells. This phenomenon
was inhibited by the addition of a blocking antibody to
CXCR4. In the absence of SDF-1a, most cells remained
single, with very few cells showing proliferation and
scattering (Figure 6).
Discussion
In this report, we show that CXCR4 expression is
induced in rat thyroid cell lines that ectopically express
the RET/PTC oncoproteins. This result was veriﬁed by
RT–PCR and Western blot experiments. Using a
tetracycline-inducible RET/PTC1, we could conﬁrm
that the expression of CXCR4 in thyroid cells depends
on the expression of the oncoprotein. We also show that
CXCR4 induction depends on a speciﬁc tyrosine
residue, tyrosine 1062, that is critical in mediating
downstream signaling (Asai et al., 1996; De Vita et al.,
2000; Grimm et al., 2001; Melillo et al., 2001; Murakami
et al., 2002; Pelicci et al., 2002). In particular, we
Figure 5 Effects of SDF-1a on thyroid cell matrigel invasion. (a) PC cells were grown in complete medium to 70% conﬂuence, and
then 1 105 cells were incubated in the upper chamber. Extracellular matrix was placed into the top chamber of Transwells. The lower
chamber was treated with the indicated concentration of SDF-1a. Cells were incubated for 24 h. Migration was evaluated by the
intensity of the spot. A representative experiment is shown. (b, c). PC-PTC1 and FB2 cells were seeded in the upper chamber and
allowed to migrate toward the indicated concentrations of SDF-1a in the absence or in the presence of CXCR4-blocking antibodies,
T22-blocking peptide or PTX. Migration was evaluated by the intensity of the spot. A representative experiment is shown
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demonstrate that the RAS/ERK pathway, which
depends on the integrity of tyrosine 1062, is required
for CXCR4 mRNA induction in thyroid cells. RET/
PTC oncogenes are able to activate the BRAF isoform
of the RAF family of serine-threonine kinases and this
activity also requires the integrity of Y1062 (RMMelillo
et al., unpublished). It is interesting to note that PC Cl3
thyroid cells preferentially express the BRAF isozyme
(RM Melillo et al., unpublished), and BRAF-activating
mutations are found in a high percentage of human
PTCs (Kimura et al., 2003). Given the foregoing, it is
tempting to speculate that CXCR4 expression could
depend on the integrity of a RET-PTC/RAS/BRAF/
ERK pathway, and that oncogenic activation of each of
these proteins can drive CXCR4 overexpression. Tyr-
osine 1062 is also implicated in the activation of other
pathways. Indeed, oncogenic RET is able to induce NF-
kappaB activity, and this activity depends on tyrosine
1062 and PI3-K signaling (Hayashi et al., 2000; Ludwig
et al., 2001; Russell et al., 2003). It has been previously
shown that CXCR4 expression is regulated by NF-
kappaB in mammary cell carcinomas (Helbig et al.,
2003). It is possible that RET/PTC oncoproteins can
also induce CXCR4 by activating the NF-kappaB
pathway. More recently, it has been shown that the
hypoxia-inducible factor (HIF) is capable of positively
regulating the expression of CXCR4 (Bernards, 2003;
Schioppa et al., 2003; Staller et al., 2003). Upregulation
of HIF protein levels in human tumors is a common
event, which can be induced by hypoxia and leads to the
block of degradation of the HIF1 subunit via the
proteasome pathway. Alternatively, growth factor
receptor activation, either by ligand triggering or by
oncogenic mutations, can upregulate the levels of HIF1
by increasing its synthesis (Bernards, 2003). It will be
interesting to test whether HIF is involved in RET/PTC-
mediated CXCR4 induction.
SDF-1a/b are ubiquitous chemokines and are the only
known ligands for CXCR4. Chemokines are chemoat-
tractant cytokines that play a major role in the
recruitment of leukocytes to sites of inﬂammation.
Chemokines are also secreted in the tumor microenvir-
onment by inﬁltrating inﬂammatory cells and by tumor
cells (Balkwill and Mantovani, 2001; Coussens and
Werb, 2002). These small molecules have been classiﬁed
into four groups, based on the position of their
conserved cysteine residues: CXC, CC, C and CX3C.
Most tumors produce CXC and CC chemokines, which
interact with seven-transmembrane G-protein-linked
receptors, CXCR and CCR, respectively. These recep-
tors mediate several biological activities, such as
chemotaxis, cytoskeletal rearrangements and adhesion
to speciﬁc cells. Binding of chemokines to their receptors
triggers a cascade of events including receptor dimeriza-
tion and tyrosine phosphorylation, recruitment of the
heterotrimeric G proteins of the Gai family, activation
of the JAK/STAT, PI3-kinase and MAP kinase path-
ways, and the activation of the Rho family of small G
proteins (Rossi and Zlotnik, 2000). Here we show that in
PC-PTC1 cells, SDF-1a stimulation induced MAPK
and AKT activation. Consistently, SDF-1a treatment
increased the percentage of cells in the S phase, exerted a
signiﬁcant antiapoptotic effect and induced cell motility
and invasive capacity. These results imply that SDF-1a
in these cells contributes not only to cell growth but also
to survival and migration. Stimulation of CXCR4 in PC
parental cells is able to stimulate ERK and Akt
activation (data not shown), but could not elicit
Figure 6 Effects of SDF-1a in thyroid cell spreading in collagen gel. The indicated cell lines were suspended at a concentration of 105
cells in collagen gels and allowed to gel for about 15min at 371C before adding 200ml of complete medium. Recombinant SDF-1a
(Peprotech) was added to the medium to a concentration of 100 ng/ml. Micrographs of representative ﬁelds were taken. A
representative experiment is shown
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biological events such as cell growth, survival and
motility. This is likely due to the lower levels of CXCR4
in PC cells. However, preliminary observations suggest
that stimulation of the receptor, even when ectopically
overexpressed in PC cells, induces increased adhesion,
but does not confer to these cells the ability to migrate
and proliferate (MD Castellone and V Guarino,
unpublished data), suggesting that other signals are
required. We suggest that in PC-PTC cells, RET/PTC
and CXCR4 cooperate to trigger biological effects. A
similar cooperation has also been observed in small cell
lung cancer (SCLC) cells, in which the c-kit tyrosine
kinase receptor and CXCR4 are commonly coexpressed
(Kijima et al., 2002). An alternative explanation to the
different activity of the receptor in PC and PC-PTC cells
might be a difference in CXCR4 desensitization,
possibly due to inhibition of G-protein-coupled receptor
kinases (GRKs) (Lorenz et al., 2003) or interference
with the b-arrestins activity (Kohout et al., 2001) in
RET/PTC-transformed cells.
We found that CXCR4 is expressed and functional in
human cell lines derived from papillary thyroid cancers,
but not in normal cells. The presence of this receptor has
also been conﬁrmed in a set of human PTCs by
immunohistochemistry. The expression of CXCR4 in
human PTCs is of peculiar interest for several reasons.
First, its activity on thyroid tumor cells could contribute
to the biological features of the tumor, that is, the ability
to grow autonomously, to survive and to invade and
metastasize. In a recent report, SDF-1a expression was
detected in stromal thyroid ﬁbroblasts, while very low
levels were found in thyrocytes and leukocytes (Aust
et al., 2001), suggesting that ﬁbroblasts might be the
main source of chemokines. Second, these tumors
preferentially metastasize via the lymphatic stream to
latero-cervical lymphonodes. It is possible that the
preferential localization of PTC metastases depends on
the repertoire of chemokine receptors that they express
on the cell surface. Indeed, lymphonodes have been
described as sites of high production of SDF-1a (Muller
et al., 2001). The expression of RET/PTC itself could
induce proinﬂammatory pathways in thyroid epithelial
cells (Russell et al., 2003). For instance, it has been
shown that stimulation of CXCR4 in ovarian cancer
leads to the production of other proinﬂammatory
factors, such as TNF-alpha, which, in turn, can act as
a growth factor for cancer cells or mediate other
phenomena such as recruiting leukocytes to tumor site
(Scotton et al., 2002). In this view, CXCR4 expression
can be considered as a factor that enhances the tumor
inﬂammatory inﬁltrate.
Expression of chemokines and their receptors is not
exclusive to thyroid cancer. Other tumors, such as
breast, brain, ovarian, prostate, lung cancers, melano-
mas and lymphomas, express chemokine and chemokine
receptors, implicating a general role for this class of
molecules in tumor progression and metastasis (Oh et al.,
2001; ; Murakami et al., 2002; Scotton et al., 2002;
Taichman et al., 2002; Zhou et al., 2002; Barbero et al.,
2003; Burger et al., 2003; Kijima et al., 2002; Zeelenberg
et al., 2003). Muller et al. (2001) showed that breast
cancer cells expressed CXCR4 and CCR7, and that the
migration of these cells toward the sites of metastasis
depended on local production of SDF-1a . Indeed, small
interfering RNAs and peptide antagonists have been
used as breast cancer antimetastatic agents (Chen et al.,
2003; Tamamura et al., 2003). The presence of CXCR4
on thyroid cancer deserves further investigation. Experi-
ments to deﬁne the expression and the role of this
receptor in other human thyroid malignancies, such as
follicular, poorly differentiated and anaplastic tumors,
and its potential use as a prognostic factor are under
investigation. Finally, CXCR4 or its ligand can be
potential targets for therapeutic intervention. Inhibitors
of CXCR4 are already available. In particular, the
bicyclam AMD3100, a speciﬁc antagonist for CXCR4,
(Murakami et al., 2002; De Clercq, 2003), is currently
being tested in preclinical studies in human cancers (De
Clercq, 2003). It would be interesting to test whether it is
active in human thyroid cancers expressing CXCR4.
Materials and methods
Cell lines and plasmids
PC Cl3 is a differentiated thyroid epithelial cell line derived
from 18-month-old Fischer rats. PC Cl3 were maintained in
Coon’s modiﬁed F12 medium supplemented with 5% calf
serum and six hormones (6H) (thyrotropin, i.e. TSH, insulin,
transferrin, somatostatin, hydrocortisone and glycyl-histidyl-
lysine) (GIBCO-BRL, Paisley, PA, USA) as described
(Castellone et al., 2003). PC-PTC1, PC-PTC3, PC-PTC3
Y1015F and PC-PTC3 Y1062F cells have been described
elsewhere (Castellone et al., 2003). The residues Y1062 and
Y1015 correspond to Y588 and Y541 in PTC3. PC Cl3 cells
expressing a conditional PTC1 oncogene have been previously
described (Wang et al., 2003). To induce RET/PTC1 expres-
sion, cells were cultured in the presence of doxycycline (1 mg/
ml; Sigma Chemical Co.) for the indicated time points. PC-Ha
RAS cells, carrying the mutant HaRAS V12 oncogene, have
been previously described (Fusco et al., 1987). PC-BRAF cells
were obtained by transfection of the PC cells with the BRAF
V599E mutant. The plasmid BRAF, which expresses a myc-
tagged version of the protein, was a kind gift of C Marshall.
To obtain the BRAF V599E mutant, site-directed mutagenesis
was performed using the QuickChange mutagenesis kit
(Stratagene, La Jolla, CA, USA). The mutation was conﬁrmed
by DNA sequencing. For transfections of PC Cl3 cells, calcium
phosphate precipitates were added to the cells and removed
after 1 h. Cells were then subjected to glycerol shock and kept
in medium containing 5% calf serum and 6H, as described.
After 2 days, G418 was added to a concentration of 400 mg/ml.
Cell clones and pools were further expanded, and proteins
expression was detected by Western blot analysis with speciﬁc
antibodies. They were maintained in Coon’s modiﬁed F12
medium supplemented with 5% calf serum. Human primary
cultures of thyroid cells (P5) were obtained from F Curcio and
cultured as previously described (Curcio et al., 1994) Human
thyroid cancer cell lines TPC-1, FB2, NPA87, BHP2-7, BHP7-
13, BHP10-13, BHP5-16, BHP14-9 and BHP17-10 have also
been described previously (Cerutti et al., 1996; Ohta et al.,
2001; Basolo et al., 2002), and were maintained in DMEM
supplemented with 10% fetal bovine serum, 1% penicillin–
streptomycin and 1% glutamine. Treatment of cell cultures
with RET TK inhibitors was performed as described by
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Carlomagno et al. (2002a, b). PC-PTC3 cells were treated with
35mM of the ERK inhibitor PD98059 for 12 h (Calbiochem).
RNA extraction
Total RNA from the indicated cell cultures was prepared using
the RNeasy Mini Kit (Qiagen, Crawley, West Sussex, UK) and
subjected to on-column DNase digestion with the RNase-free
DNase set (Qiagen, Crawley, West Sussex, UK) following the
manufacturer’s instructions. The quality of RNA from each
sample was veriﬁed by electrophoresis through 1% agarose gel
and visualization with ethidium bromide.
Semiquantitative RT–PCR
Transcript levels of the indicated genes were assayed by RT–
PCR. A total of 2.5mg of total RNA was denatured, and
cDNA was synthesized using the GeneAmp RNA PCR Core
Kit system from Applied Biosystems following the manufac-
turer’s instructions. Subsequent PCR ampliﬁcation was
performed using 2.5 ml of RT product in a reaction volume
of 25ml with primer pairs speciﬁc for the gene studied. To
exclude DNA contamination, each PCR reaction was also
performed on untranscribed RNAs. The levels of the house-
keeping b-actin transcript were used as a control for equal
RNA loading. Primers were designed according to the
program Primer 3 (www-genome.wi.mit.edu/cgi-bin/primer/
primer3_www.cgi), and synthesized by the MWG biotech.
For rat CXCR4 and b-actin, the primers were as follows:
CXCR4 F: 50-AAGCTGTCACACTCCAAGGG-30
CXCR4 R: 50-TCCCCACGTAATACGGTAGC-30
b-Actin F: 50-GTCAGGCAGCTCATAGCTCT-30
b-Actin R: 50-TCGTGCGTGACATTAAAGAG-30
Each RT–PCR product was loaded on 2% agarose gel,
stained with ethidium bromide (0.5 mg/ml), and the corre-
sponding image was saved by Typhoon 8600 laser scanning
system (Amersham Pharmacia Biotech). The density and width
of each band were quantiﬁed using IMAGEQUANT 5.0
(Molecular Dynamics).
TUNEL assay
For the terminal desoxynucleotidyl transferase-mediated
desoxyuridine triphosphate nick end-labeling (TUNEL), an
equal number (5 103) of cells from the different lines was
seeded onto single-well Costar glass slides. After 48 h serum
deprivation in the presence or in the absence of SDF-1a
(100 ng/ml, Peprotech) and vincristine (2 ng/ml, Sigma), cells
were ﬁxed in 4% (w/v) paraformaldehyde and then they were
permeabilized by the addition of 0.1% Triton X-100/0.1%
sodium citrate. Slides were rinsed twice with PBS, air-dried
and subjected to the TUNEL reaction (Boehringer, Man-
nheim). All coverslips were counterstained in PBS containing
Hoechst 33258 (ﬁnal concentration, 1 mg/ml; Sigma Chemical
Co.), rinsed in water and mounted in Moviol on glass slides.
The ﬂuorescent signal was visualized with an epiﬂuorescent
microscope (Axiovert 2, Zeiss) (equipped with a  100
objective) interfaced with the image analyser software KS300
(Zeiss).
S-phase entry
S-phase entry was evaluated by BrdU incorporation and
indirect immunoﬂuorescence. Cells were grown on coverslips,
serum deprived and treated with SDF-1a (100 ng/ml) for 48 h.
BrdU was added at a concentration of 10 mM for the last 2 h.
Subsequently, cells were ﬁxed in 3% paraformaldehyde and
permeabilized with 0.2% Triton X-100. BrdU-positive cells
were revealed with Texas-red-conjugated secondary antibodies
(Jackson Immuno Research Laboratories Inc., Philadelphia,
PA, PA). Cell nuclei were identiﬁed by Hoechst staining.
Fluorescence was visualized with a Zeiss 140 epiﬂuorescent
microscope.
Protein studies
Immunoblotting experiments were performed according to
standard procedures. Brieﬂy, cells were harvested in lysis
buffer (50mM Hepes, pH 7.5, 150mM NaCl, 10% glycerol, 1%
Triton X-100, 1mM EGTA, 1.5mM MgCl2, 10mM NaF,
10mM sodium pyrophosphate, 1mM Na3VO4, 10mg of
aprotinin/ml, 10mg of leupeptin/ml) and clariﬁed by centrifu-
gation at 10 000 g. For protein extraction from human tissues,
samples were snap-frozen and immediately homogenized in
lysis buffer using the Mixer Mill apparatus (Qiagen). Protein
concentration was estimated using a modiﬁed Bradford assay
(Bio-Rad, Munich, Germany). Antigens were revealed by an
enhanced chemiluminescence detection kit (ECL, Amersham,
Bucks., England). Anti-CXCR4 antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA) and from Abcam
Ltd (Cambridge, UK). Blocking anti-CXCR4 antibodies were
from R&D and from Santa Cruz Biotechnology. Anti-
phospho-p44/42 MAPK and anti-p44/42 MAPK, anti-phos-
pho-Akt and anti-Akt antibodies were from New England
Biolabs (Beverly, MA, USA). Anti-tubulin were from Sigma,
and secondary anti-mouse and anti-rabbit antibodies coupled
to horseradish peroxidase were from Bio-Rad Inc.
Chemoinvasion and morphogenic assays
Cell invasion was examined using a reconstituted extracellular
matrix (Matrigel, Beckman Coulter Labware). Brieﬂy, 40 ml of
the extracellular matrix was placed into the top chamber of
Transwells. After 2 h incubation at 371C, cells (1 105 cells/
well) were seeded in the upper chamber in serum-free medium.
Recombinant SDF-1a (Peprotech), at the indicated concentra-
tions, was added to lower chamber. For CXCR4 inhibition,
cells were preincubated with the blocking antibody (1 mg/ml,
R&D for human cells and Santa Cruz Biotechnology for rat
cells), pertussis toxin (0.1 mg/ml, Calbiochem) or the blocking
peptide T22 (1 mM, Synpep corporation). The chamber was
incubated for 24–30 h at 371C in 5% CO2 and ﬁlters were
processed and analysed as described (Medico et al., 1996).
Invasion was quantiﬁed by the intensity of the spot. These
experiments were performed in triplicate.
Morphogenic response of thyroid cells to SDF-1a was
evaluated by collagen gel cultures as described previously by
Medico et al. (2001). Brieﬂy, cells were harvested from cultures
using trypsin–EDTA and suspended at a concentration of
105 cells/ml in collagen solution containing type I collagen
(3mg/ml; Collaborative Biomedical Products; Becton Dick-
inson Labware), 10DMEM and 0.5M Hepes pH 7.4.
Aliquots (100 ml) of the cell suspension were dispensed in
microtiter 96-well plates and allowed to gel for about 15min at
371C before adding 200ml of complete medium. Recombinant
SDF-1a (Peprotech) was added to the medium to a concentra-
tion of 100 ng/ml. The medium was changed every 2 days. The
morphogenic response was evaluated after 7 days in the
presence of SDF-1a or vehicle alone. These experiments were
performed in triplicate.
Immunohistochemistry
Tissue samples were formalin ﬁxed, parafﬁn embedded and
stained with hematoxylin and eosin. For immunohistochem-
CXCR4 is overexpressed in human PTCs
MD Castellone et al
5965
Oncogene
istry, parafﬁn sections (3–5mm) were dewaxed in xylene,
dehydrated through graded alcohols and blocked with
5% nonimmune mouse serum in PBS with 0.05% sodium
azide for 5min. Mouse monoclonal antibody against
CXCR4 (clone 12G5; R&D) was added at 1 : 1000 dilution
for 15min. After incubation with biotinylated anti-mouse
secondary antibody for 15min followed by streptavidin–biotin
complex for 15min (Catalyzed Signal Ampliﬁcation System;
DAKO, Copenhagen, Denmark), sections were developed
for 5min with 0.05% 3,30-diaminobenzidine tetrahydrochlor-
ide, 0.01% hydrogen peroxide in 0.05M Tris-HCl buffer
pH 7.6, counterstained with hematoxylin, dehydrated and
mounted.
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Autocrine stimulation by osteopontin plays a pivotal role in the expression
of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid
cells
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Fulvio Basolo2, Riccardo Giannini2, Enzo Medico3, Mogens Kruhoffer4, Torben F Orntoft4,
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Papillary thyroid carcinomas are characterized by re-
arrangements of the RET receptor tyrosine kinase
generating RET/PTC oncogenes. Here we show that
osteopontin (OPN), a secreted glycoprotein, is a major
RET/PTC-induced transcriptional target in PC Cl 3
thyroid follicular cells. OPN upregulation depended on
the integrity of the RET/PTC kinase and tyrosines Y1015
and Y1062, two major RET/PTC autophosphorylation
sites. RET/PTC also induced a strong overexpression of
CD44, a cell surface signalling receptor for OPN.
Upregulation of CD44 was dependent on RET/PTC
Y1062, as well. Constitutive OPN overexpression or
treatment with exogenous recombinant OPN sharply
increased proliferation, Matrigel invasion and spreading
in collagen gels of RET/PTC-transformed PC Cl 3 cells.
These effects were impaired by the treatment of PC Cl
3-RET/PTC cells with OPN- and CD44-blocking anti-
bodies. Thus, RET/PTC signalling triggers an autocrine
loop involving OPN and CD44 that sustains proliferation
and invasion of transfomed PC Cl 3 thyrocytes.
Oncogene (2004) 23, 2188–2196. doi:10.1038/sj.onc.1207322
Published online 23 February 2004
Keywords: kinase; carcinoma; motility; Ras; tyrosine;
thyroid
Introduction
Papillary thyroid carcinoma (PTC) is the most prevalent
malignancy of the thyroid gland. PTC hallmarks are
chromosomal inversions or translocations that cause the
recombination of the intracellular kinase-encoding
domain of the RET receptor with heterologous genes,
generating the RET/PTC chimeric oncogenes. RET/
PTC1, the H4-RET fusion, and RET/PTC3, the RFG-
RET fusion, are the most prevalent variants (Fagin,
2002). RET/PTC-transgenic mice develop PTC, proving
that RET/PTC oncogenes are able to initiate thyroid
carcinogenesis (Santoro et al., 1996; Buckwalter et al.,
2002).
Fusion with protein partners possessing protein–
protein interaction motifs provides RET/PTC kinases
with dimerizing interfaces. This results in constitutive
dimerization and phosphorylation of the chimeric
oncoproteins and constant upregulation of signal
transduction. RET signalling mainly depends on three
key tyrosine residues: tyrosine 905, in the activation
loop, whose phosphorylation stabilizes the active con-
formation of the catalytic domain (Iwashita et al., 1996),
tyrosine 1015, a docking site for phospholipase Cg
(Borrello et al., 1996) and tyrosine 1062. This last
residue is embedded in an NKLpY (single-letter amino-
acid code) motif and mediates recruitment of various
proteins to RET and RET/PTC (Hayashi et al., 2000;
Manie’ et al., 2001). Shc and FRS2 are recruited to
pY1062 via their phosphotyrosine binding (PTB)
domains (Melillo et al., 2001; Mercalli et al., 2001)
and, by bridging RET/PTC to Grb2-Sos complexes,
they play a key role in the activation of Ras small
GTPases (Castellone et al., 2003).
By using oligonucleotide microarrays, we have found
that osteopontin (OPN) is one of the most heavily RET/
PTC3-induced transcripts in PC Cl 3 thyroid follicular
cells (Melillo RM, Castellone MD, Kruhoffer M,
Orntoft TF Santoro M, unpublished). OPN, also known
as secreted phosphoprotein 1(spp1), is a highly acidic
calcium-binding glycosylated phosphoprotein. OPN is
also regarded as a cytokine (ETA-1, Early T-lymphocyte
antigen or IL-28) regulating T helper cell-1 function
(Ashkar et al., 2000; Chabas et al., 2001). CD44 is one of
the cell surface receptors for OPN (Weber et al., 1996).
Furthermore, OPN contains an RGD (single-letter
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amino-acid code) peptide that binds av-containing
integrins (Miyauchi et al., 1991). By binding to these
receptors, OPN supports various functions including
chemotaxis, cell attachment and cell migration. Re-
cently, much interest has focused on the association of
OPN with tumorigenesis and metastasis formation.
OPN is expressed in many neoplastic tissues, such as
colon, breast, prostate and lung carcinomas, being a
circulating plasma marker for several neoplasms (for a
review, see Weber, 2001).
Here, we show that signals elicited at the level
of speciﬁc RET/PTC tyrosine residues stimulate an
OPN-CD44 autocrine loop sustaining proliferation and
invasiveness of transformed thyrocytes.
Results
RET/PTC induces OPN upregulation in PC Cl 3 cells
We used the oligonucleotide GeneChips Rat Genome
U34 Set (Affymetrix, SantaClara, CA, USA) to detect
genes that are induced in thyroid cells upon RET/PTC-
mediated transformation. Comparative analysis was
performed by the GeneChips software: 87 genes were
upregulated oﬁvefold in RET/PTC3-transformed cells
with respect to parental cells. One of the most strongly
upregulated genes was OPN (9.4-folds) (Melillo RM,
Castellone MD, Kruhoffer M, Orntoft TF Santoro M,
unpublished).
We sought to conﬁrm microarray data by quantitative
RT–PCR (Q-PCR); we also asked whether OPN over-
expression was speciﬁcally linked to the RET/PTC3
variant or it was a feature of different RET/PTC
oncogenes (Figure 1a). Quantitation of the OPN mRNA
by Q-PCR showed o10-fold OPN induction in RET/
PTC1- and RET/PTC3-expressing thyrocytes
(Figure 1b). Thus, microarray screen underestimated
OPN upregulation. To ascertain whether OPN upregu-
lation was linked to RET/PTC expression and was
not a late secondary effect of cell transformation, we
analysed OPN mRNA expression by semiquantitative
RT–PCR in PC Cl 3 cells expressing a doxycycline-
inducible RET/PTC3. Actin mRNA detection was used
for normalization. RET/PTC3 mRNA started to be
detected at 12 h of doxycycline treatment and accumu-
lated thereafter (Figure 1c). OPN transcripts were barely
detectable in unstimulated cells. In stimulated cells,
OPN upregulation followed that of RET/PTC3, starting
after 24 h and peaking after 48 h of doxycycline
treatment. Upon doxycycline washout, expression of
both RET/PTC3 and OPN was no longer detectable
(Figure 1c).
To conﬁrm these ﬁndings, cells stably expressing
RET/PTC1 or RET/PTC3 oncogenes were harvested,
protein lysates were obtained and OPN protein levels
were examined by Western blotting; housekeeping
tubulin detection was applied to conﬁrm equal gel
loading. Accumulation of OPN protein was detected in
RET/PTC1- and RET/PTC3-transformed cells
(Figure 1d).
OPN upregulation depends on tyrosines 1015 and 1062 of
RET/PTC
OPN mRNA levels were measured by semiquantitative
RT–PCR in mass populations of PC Cl 3 cells stably
Figure 1 OPN overexpression in RET/PTC-transformed PC Cl 3
cells. (a) Schematic drawing of RET and RET/PTC proteins:
SP: signal peptide, EC: extracellular domain, Cys: cysteine-rich
domain, TM: transmembrane domain, TK: tyrosine kinase
domain. (b) Q-PCR was used to calculate OPN mRNA fold
induction in the indicated cell lines; results are the average of three
independent ampliﬁcations7s.d.. (c) RT–PCR (25 cycles) was used
to detect RET/PTC3 and OPN mRNA levels in PC Cl 3 cells
expressing a tet-inducible RET/PTC3 construct upon treatment
with doxycycline (1mg/ml) at the indicated time points or after 24 h
of doxycycline washout. (d) Protein lysates (100mg) underwent
Western blotting with anti-OPN antibody. Immunocomplexes were
revealed by enhanced chemiluminescence. As a control of the
speciﬁcity of the antibody, anti-OPN was preincubated with a
ﬁvefold molar excess of recombinant OPN. Anti-p-tubulin
antibodies were used for normalization
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expressing RET/PTC3, a kinase-dead mutant (K758M)
or mutants harbouring substitutions of tyrosines 1015 or
1062 to phenylalanine (Figure 2a). Figure 2b shows that
OPN stimulation was strongly dependent on the
catalytic activity of RET/PTC3 and the integrity of
tyrosine 1062. It was also dependent on tyrosine 1015,
although the mutation of this last residue impaired OPN
stimulation at a lower extent than mutation of Y1062
(Figure 2b). Accordingly, when RET/PTC3 kinase was
turned-off by a 48 h treatment with an RET/PTC3
kinase inhibitor (ZD6474, 1 mM) (Carlomagno et al.,
2002), OPN mRNA was strongly downregulated
(Figure 2b). One possible mediator of OPN upregula-
tion was the Ras small GTPase. Indeed, oncogenic Ras
stimulates OPN expression in various cell types (Guo
et al., 1995), and Y1062 is a crucial residue mediating
Ras stimulation in PC Cl 3-RET/PTC cells (Castellone
et al., 2003). RNA was extracted from PC Cl 3 cells
transformed by constitutively active v-Ha-Ras and
used to assess OPN mRNA levels in comparison to
parental cells. Similar to RET/PTC-expressing cells,
PC-Ha-Ras cells featured high levels of OPN transcripts
(Figure 2c).
Quantitation of the OPN mRNA by Q-PCR showed
othreefold inhibition of OPN induction upon mutation
of Y1015; mutation of Y1062 virtually abrogated OPN
upregulation (Figure 2d). Furthermore, a 24 h treatment
of RET/PTC3-expressing thyrocytes with 35 mM
PD98059 (a selective MEK1 inhibitor) sharply reduced
OPN upregulation (Figure 2d). Thus, OPN upregulation
by RET/PTC likely depends on the cooperation between
Ras/MAPK stimulation by Y1062 and signals derived
from Y1015.
PC-RET/PTC cells feature CD44 upregulation
OPN exerts biological effects by binding two types of
cell surface receptors: CD44 and av-containing integ-
rins. We analysed PC-RET/PTC cells for CD44 and av
integrins expression by semiquantitative RT–PCR. The
expression of av integrins was detected at similar levels
in normal and transformed cells (data not shown).
Notably, CD44 resulted among the RET/PTC upregu-
lated genes (ﬁvefolds) in our microarray screening
(Melillo RM, Castellone MD, Kruhoffer M, Orntoft
TF Santoro M, unpublished). By amplifying exons 1–2
of CD44 mRNA, we found that CD44 mRNA was
upregulated in PC Cl 3 cells transformed by RET/PTC1
or RET/PTC3 in comparison to parental cells, this
upregulation being impaired, similarly to OPN, by a
24 h treatment with 35 mM PD98059 (Figure 3a). Quan-
titation of RET/PTC-mediated CD44 mRNA stimula-
tion was obtained by real-time PCR (Figure 3b).
Finally, immunoblot experiments conﬁrmed CD44
upregulation, showing a strong upregulation of a broad
band of relative molecular mass of about 90 kDa likely
containing multiple CD44 protein species (Figure 3c).
Accumulation of CD44 protein in RET/PTC-expressing
cells was even stronger than accumulation of CD44
mRNA, suggesting the contribution of post-transcrip-
tional events.
Figure 2 OPN upregulation depends on active RET/PTC signal-
ling. (a) Schematic drawing of RET/PTC3 mutants used in this
study. (b, c) RT–PCR (25 cycles) was performed to detect OPN
mRNA levels in the indicated cell lines; b actin mRNA detection
was used for normalization. ZD6474 (1mM, 48 h) was used to
inhibit the RET/PTC3 kinase. This ﬁgure is representative of three
independent experiments. (d) Q-PCR was used to calculate OPN
mRNA fold induction in the indicated cell lines; results are the
average of three independent ampliﬁcations7s.d.
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CD44 transcripts are subject to alternative splicing.
CD44 pre-mRNA is encoded by 20 exons. The constant
50-terminal ﬁve exons encode the N-terminal extracel-
lular portion of the CD44 protein, while the constant 30-
terminal ﬁve exons encode the transmembrane and the
short cytosolic tail. Additional 10 exons (variant ‘v1–
v10’ exons) are alternatively spliced and code for the
extracellular membrane-proximal stem structure. Can-
cer cells often overexpress CD44 variants that include
variable numbers of small ‘v’ exons. The presence of the
v6 exon has been reported to be important for efﬁcient
OPN binding, while v3 is important for the binding of
heparin-associated growth factors (Ponta et al., 2003).
Thus, by using different combinations of amplimers, we
explored whether CD44 transcripts, accumulated in
RET/PTC-transformed thyroid cells, contained variant
exons. Figure 3d shows that CD44 mRNAs upregulated
in PC-RET/PTC cells contained v3, v6 or both v3 and
v6 exons. Overexpression of CD44 mRNAs was
strongly dependent on Y1062, but not on Y1015.
CD44 expression was induced by v-Ha-Ras, as well
(Figure 3d).
OPN cooperates with RET/PTC to increase DNA
synthesis of PC Cl 3 cells
We asked whether OPN upregulation played any role in
the establishment of the neoplastic phenotype of RET/
PTC-transformed PC Cl 3 cells. We either stimulated
cells with recombinant puriﬁed OPN or transduced cells
with a lentiviral vector for OPN fused to enhanced GFP
autoﬂuorescent protein (OPN-GFP: OG) (Medico et al.,
2001) (Figure 4a). For lentiviral transduction, normal
and RET/PTC3-transformed PC Cl 3 cells were
subjected to three subsequent rounds of infection with
high titre OG vector (multiplicity of infection o1). OG
transduction was conﬁrmed by ﬂow cytometry: 49.21%
of PC Cl 3 and 48.53% of PC-RET/PTC3 cells scored
GFP-positive (not shown). Western blot with an anti-
OPN antibody conﬁrmed OG transduction: of note, OG
migrated more slowly than endogenous OPN protein
due to the GFP protein moiety (Figure 4a).
We asked whether OPN stimulated proliferation of
RET/PTC-expressing cells. As a measure of DNA
synthesis, we counted BrdU-positive cells upon a 1 h
BrdU pulse. Average results of three independent
experiments are reported in Figure 4b. OG gene
transduction potently stimulated the rate of BrdU
incorporation in RET/PTC3-transfomed cells (about
10-fold increase). Treatment with recombinant OPN
also stimulated DNA synthesis of transformed thyroid
cells, albeit at a lower extent (about ﬁvefold increase).
Notably, in both cases, the response of parental cells to
OPN was signiﬁcantly smaller than that of RET/PTC3-
transfomed cells (Figure 4b). This could be due to the
Figure 4 OPN stimulates DNA synthesis of RET/PTC-trans-
formed PC Cl 3 cells. (a) Schematic drawing of the OG-expressing
lentivirus. Protein lysates (50mg) underwent Western blotting with
anti-OPN antibody to ascertain OG gene transduction. Anti-p-
tubulin antibodies were used for normalization. (b) BrdU was
added for 1 h and cells were ﬁxed and processed for immuno-
ﬂuorescence: anti-BrdU, monitored by a FITC-conjugated anti-
mouse antibody, was used to detect the fraction of cells in S-phase.
The average results7s.d. of three independent experiments in
which at least 60 cells were counted are reported. When indicated,
cells were pretreated (15min) with exogenous recombinant OPN
(100 ng/ml), anti-OPN-blocking antibodies (5 mg/ml) or unrelated
IgG (5mg/ml). Where indicated, cells infected with the OG
lentivirus were used
Figure 3 CD44 overexpression in RET/PTC-transformed PC Cl 3
cells. (a) RT–PCR (25 cycles) was performed to detect CD44
mRNA levels in the indicated cell lines; amplimers mapping on
exons 1 and 2 (all CD44 mRNAs) were used. (b) Quantitative PCR
was used to calculate CD44 mRNA fold induction in the indicated
cell lines; results are the average of three independent ampliﬁca-
tions7s.d. (c) Protein lysates (100mg) underwent Western blotting
with anti-CD44 antibody. Anti-p-tubulin antibodies were used for
normalization. (d) RT–PCR (25 cycles) was performed to detect
CD44 mRNA levels in the indicated cell lines. Amplimers mapping
on exons 1 and 2 (standard CD44 mRNA), exons v3 and 16, and v6
and 16 were used. The v3-16 primer pair ampliﬁed two products of
489- and 283 bp-containing exons v3-v6-16 and v3-16, respectively,
as proved by subsequent Southern hybridization with exon-speciﬁc
probes (not shown)
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parallel upregulation of the CD44 receptor in trans-
formed cells or to OPN cooperation with additional
pathways triggered by RET/PTC. Treatment with anti-
OPN-blocking antibodies (5 mg/ml), but not with non-
speciﬁc IgG, impaired DNA synthesis of both PC-RET/
PTC3 and OPN-stimulated PC-RET/PTC3 cells
(Figure 4b). Thus, although in many cell systems OPN
has been shown to produce effects other than cell
mitogenesis (Zhang et al., 2003), in RET/PTC-trans-
formed thyrocytes (see also below) OPN exerts detect-
able stimulation of DNA synthesis.
OPN cooperates with RET/PTC to increase invasiveness
of PC Cl 3 cells
We examined cell invasiveness through Matrigel in basal
conditions, upon OG transduction and towards exo-
genous recombinant OPN in the lower chamber of
transwells. Figure 5a shows that PC-RET/PTC3 cells
had basal levels of invasiveness higher than parental
cells. Treatment with exogenous OPN further induced
migratory response of PC-RET/PTC3 cells but not of
parental cells (Figure 5a). Importantly, PC-RET/PTC3
migration through Matrigel was inhibited by pretreat-
ment with anti-OPN-blocking antibodies, but not by
nonspeciﬁc IgG (Figure 5a). Also, anti-CD44-blocking
antibodies (IM7) blocked cell migration, consistent with
known effects exerted by CD44 either upon binding to
OPN (Lin et al., 2000; Weiss et al., 2001) or when
triggered otherwise. Finally, OG gene transduction
strongly stimulated Matrigel invasion of RET/PTC3-
transformed cells (Figure 5b), while it only slightly
stimulated that of parental cells (not shown). These
effects were inhibited by anti-CD44 antibodies, as well
(Figure 5b).
Finally, we asked whether OPN increased the capacity
of PC Cl 3 cells to spread in tridimensional type I
collagen gels. When seeded in collagen, wild-type PC Cl
3 cells showed a round phenotype and no spreading
ability (Figure 6). In contrast, a sizeable fraction of
PC-RET/PTC3 cells dispersed in the collagen matrix
during the ﬁrst few hours of incubation (Figure 6). OG
gene transduction signiﬁcantly increased spreading
ability of RET/PTC3 cells. According to known effects
of CD44 in mediating cell spreading, these effects were
reduced when cells were incubated with anti-CD44
antibodies (Figure 6). After 48 h, most RET/PTC cells
lost the spreading phenotype and started to die, while
OG-expressing cells continued to be alive and spreading
(not shown).
OPN and CD44 overexpression in human thyroid
papillary carcinoma cell lines
To conﬁrm our ﬁndings in a different cell system, we
used human thyroid carcinoma cells. TPC1 (Ishizaka
et al., 1990) and FB2 (Basolo et al., 2002) are human cell
lines established from thyroid papillary carcinomas
spontaneously harbouring the RET/PTC1 oncogene.
Both cancer cell lines expressed increased levels of OPN
(Figure 7a) and CD44 (Figure 7b) with respect to P5, a
primary culture of normal human thyrocytes. We
transduced TPC1 cells with the OG lentiviral vector:
70.62% of cells scored GFP-positive (not shown). OG
gene transduction signiﬁcantly stimulated the rate of
BrdU incorporation in TPC1 cells (about ﬁvefold
increase). Treatment with recombinant OPN also
stimulated DNA synthesis of TPC1 cells (about 2.5-
fold increase). Treatment with anti-OPN-blocking anti-
bodies (5 mg/ml), but not with nonspeciﬁc IgG (not
shown), impaired DNA synthesis of TPC1 and OPN-
treated TPC1 cells (Figure 7c).
We examined cell invasiveness through Matrigel in
basal conditions and towards exogenous recombinant
OPN. Figure 7d shows that treatment with exogenous
OPN induced a strong migratory response of TPC1
cells. Migration through Matrigel was inhibited by
Figure 5 OPN stimulates Matrigel invasion of RET/PTC-
transformed PC Cl 3 cells. Matrigel invasion of parental PC Cl 3
and RET/PTC3-transformed cells (a) or OG transduced cells (b) in
response to normal culture medium or exogenous recombinant
OPN in the lower chamber of 8mM pore transwells. Where
indicated, blocking anti-CD44 or -OPN antibodies were used. In
this case, cells were pretreated for 15min with the required
antibody (10mg/ml) and then seeded in transwells in which the
lower chamber contained the antibody (20 mg/ml). Cells were
seeded in the upper chamber and incubated for 24 h. Thereafter,
ﬁlters were ﬁxed and stained. The upper surface was wiped clean
and cells on the lower surface were photographed. This ﬁgure is
representative of three independent experiments
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pretreatment with anti-OPN-blocking antibodies, but
not by nonspeciﬁc IgG (Figure 7d).
When seeded in tridimensional type I collagen gel,
TPC1 cells showed a ﬂat elongated phenotype and
modest spreading ability (Figure 7e). OG gene transduc-
tion signiﬁcantly increased proliferative and spreading
ability of TPC1 cells, these effects being greatly reduced
when cells were incubated with anti-CD44 antibodies
(Figure 7e).
Materials and methods
Plasmids, recombinant proteins, antibodies and cell lines
All the constructs used in this study encode the short (RET-9)
RET spliced form and were cloned in pCDNA3(Myc-His)
(Invitrogen, Groningen, The Netherlands). For simplicity, we
number the residues of RET/PTC proteins according to the
corresponding residues in unrearranged RET. RET/PTC1 and
RET/PTC3 constructs are described elsewhere (Melillo et al.,
2001). RET/PTC3(K) is a kinase-dead mutant, carrying the
substitution of the catalytic lysine (residue 758 in full-length
RET) with a methionine. RET/PTC3(Y1062F) and RET/
PTC3(Y1015F) carry substitutions of the indicated tyrosines
with phenylalanine residues (Castellone et al., 2003).
Parental and transformed PC Cl 3 cells were cultured in
Coon’s modiﬁed Ham F12 medium supplemented with 5%
calf serum and a mixture of thyrotropin (10mU/ml), hydro-
cortisone (10 nM), insulin (10 mg/ml), apo-transferrin (5 mg/ml),
somatostatin (10 ng/ml) and glycyl–histidyl–lysine (10 ng/ml)
(Sigma Chemical Co., St Louis, MO, USA) according to Fusco
et al. (1987). PC Cl 3 transfected with RET/PTC1, RET/PTC3,
Y1015F, Y1062F and K758M mutants have been described
previously (Castellone et al., 2003). PC Cl 3 transformed by
v-Ha-Ras have been described (Fusco et al., 1987). A PC Cl 3
cell line expressing RET/PTC3 in a doxycyline-dependent
manner was obtained by sequential stable transfection with
expression vectors for the tetracycline(tet)-dependent trans-
activating rtTA protein and for tet-inducible RET/PTC3
(Saavedra et al., 2000). To induce RET/PTC3 expression,
cells were treated for different times with 1mg/ml doxycycline.
TPC1 (Ishizaka et al., 1990) and FB2 (Basolo et al., 2002) cell
lines derive from RET/PTC1-positive human PTC and were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% FCS (Sigma Chemical Co.). The P5
primary culture of normal human thyroid follicular cells
was a kind gift of F Curcio and was grown as described
(Curcio et al., 1994).
Figure 6 OPN stimulates spreading in collagen gels of RET/PTC-
transformed PC Cl 3 cells. The indicated cell types were kept in
collagen gels for 6 h, micrographs of representative ﬁelds were
taken. This ﬁgure is representative of three independent experi-
ments
Figure 7 OPN and CD44 overexpression in human thyroid
carcinoma cells. (a) RT–PCR (25 cycles) was performed to detect
OPN mRNA levels in the indicated cell lines; b actin mRNA
detection was used for normalization (top). Western blotting with
anti-OPN antibody. Anti-p-tubulin was used for normalization
(bottom). (b) RT–PCR (25 cycles) was performed to detect CD44
mRNA levels in the indicated cell lines; amplimers mapping on
exons 1 and 2 were used. (c) BrdU was added for 1 hand cells were
ﬁxed and processed for immunoﬂuorescence. When indicated, cells
were pretreated (15min) with anti-OPN-blocking antibodies (5mg/ml)
or unrelated IgG (5mg/ml). Where indicated, cells infected with the
OG lentivirus were used. The average results7s.d. of three
independent experiments are reported. (d) Matrigel invasion was
assessed as described in Figure 5. This ﬁgure is representative of
three independent experiments. (e) The indicated cell types were
kept in collagen gels for 6 h and micrographs of representative
ﬁelds were taken. Also, this ﬁgure is representative of three
independent experiments
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Recombinant mouse OPN protein and blocking goat anti-
mouse OPN antibody (AF808) were from R&D Systems
(Minneapolis, MN, USA). Blocking monoclonal antibody
against CD44 (IM7 clone) was from BD Biosciences (San Jose,
CA, USA). Anti-OPN goat polyclonal antibody (K-20) and
rabbit polyclonal anti-CD44 (H-300) were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Monoclonal anti p-
tubulin was from Sigma Chemical Co. Secondary antibodies
were from Santa Cruz Biotechnology.
RNA extraction, PCR, real-time PCR
Total RNA was isolated by the RNeasy Kit (Qiagen, Crawley,
West Sussex, UK) and subjected to on-column DNase
digestion with the RNase-free DNase set (Qiagen) following
the manufacturer’s instructions. The quality of RNA was
veriﬁed by electrophoresis through 1% agarose gel and
visualization with ethidium bromide. Random-primed ﬁrst-
strand cDNA was synthesized in a 50 ml reaction volume
starting from 2mg RNA by using the Gene Amp RNA
PCR Core Kit (Applied Biosystems, Warrington, UK). PCR
ampliﬁcation was performed using the GeneAmp RNA
PCR Core Kit system following the manufacturer’s instruc-
tions. To exclude DNA contamination, each PCR reaction was
also performed on untranscribed RNA. Levels of b-actin
transcripts were used as a control for equal RNA loading.
RT–PCR products were loaded on 2% agarose gel, stained
with ethidium bromide and the image saved by the Typhoon
8600 laser scanning system (Amersham Pharmacia Biotech,
Bucks, England). The density and width of each band was
quantiﬁed using the IMAGEQUANT 5.0 software.
Quantitative PCR reactions were performed by using the
SYBR Green PCR Master mix (Applied Biosystems) in the
iCycler apparatus (Bio-Rad, Munich, Germany). Ampliﬁca-
tion reactions (25 ml ﬁnal reaction volume) contained 200 nM of
each primer, 3mM MgCl2, 300 mM dNTPs, 1 SYBR-Green
PCR buffer, 0.1U/ml AmpliTaq Gold DNA Polymerase,
0.01U/ml Amp Erase, RNase-free water and 2 ml cDNA
samples. Thermal cycling conditions consisted of an initial
cycle of 2min at 501C, a cycle of 10min at 951C and 40 cycles
of 15 s of denaturation (951C) followed by 1min of annealing/
extension (601C). To verify the absence of nonspeciﬁc
products, 80 cycles of melting (551C for 10 s) were performed.
In all cases, the melting curve conﬁrmed that a single product
was generated. Real-time ampliﬁcation was monitored by
measuring the increase in ﬂuorescence caused by the SYBR-
Green binding to double-stranded DNA. Fluorescent thresh-
old values were measured in triplicate and fold changes were
calculated by the formula: 2(sample 1 DCtsample 2DCt), where DCt is
the difference between the ampliﬁcation ﬂuorescent thresholds
of the mRNA of interest and the b actin mRNA.
Primers were designed by using a software available at
http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.
cgi and synthesized by the MWG biotech (Ebersberg,
Germany). Primers sequences were as follows:
ratb actin forward: 50-GTCAGGCAGCTCATAGCTCT-30
ratb actin reverse: 50-TCGTGCGTGACATTAAAGAG-30
humanb actin forward: 50-TGCGTGACATTAAGGA-
GAAG-30
humanb actin reverse: 50-GCTCGTAGCTCTTCTCCA-30
ratOPN forward: 50-GAGGAGAAGGCGCATTACAG-30
ratOPN reverse: 50-ACAGAATCCTCGCTCTCTGC-30
humanOPN forward: 50-AGGAGGAGGCAGAGCACA-30
humanOPN reverse: 50-CTGGTATGGCACAGGTGA
TG-30
humanCD44 (exon1) forward: 50-GCTTTCAATAGCACC
TTGCC-30
humanCD44 (exon2) reverse: 50-GTTGTTTGCTGCACA-
GATGG-30
ratCD44 (exon1) forward: 50-CAGCTTGGGGACTAC
TTTGC-30
ratCD44 (exon 2) reverse: 50-CTGCATGTTTCAAACC
CCTT-30
ratCD44 (exon v3) forward: 50-CTGGAAGCCAAATGAG
GAAA-30
ratCD44 (exon v6) forward: 50-TGGTTTGAGAAT-
GAATGGCA-30
ratCD44 (exon 16) reverse: 50-TTCGGATCCATGAGT-
CACAG-30
RET/PTC3 forward: 50-AAGCAAACCTGCCAGTGG-30
RET/PTC3 reverse: 50-TGCTTCAGGACGTTGAAC-30.
Protein extraction and Western blotting
Protein extractions and immunoblotting experiments were
performed according to standard procedures. Brieﬂy,
cells were harvested in lysis buffer (50mM HEPES, pH7,5,
150mM NaCl, 10% glycerol, 1% Triton X-100, 1mM EGTA,
1.5mM MgCl2, 10mM NaF, 10mM sodium pyrophosphate,
1mM Na3VO4, 10 mg of aprotinin/ml, 10mg of leupeptin/ml)
and clariﬁed by centrifugation at 10 000 g. Protein concentra-
tion was estimated with a modiﬁed Bradford assay (Bio-Rad).
Immune complexes were detected with the enhanced chemilu-
minescence kit (ECL, Amersham). Signal intensity was
analysed at the Phosphorimager (Typhoon 8600, Amersham
Pharmacia Biotech) interfaced with the ImageQuant software.
Lentiviral infection with the OPN-GFP fusion gene
The lentiviral transfer vector pLC-OG, standing for Lentiviral
(vector)-CMV (promoter)-OPN-GFP (transgene), is described
elsewhere (Medico et al., 2001). The virus was produced by
transient transfection of 293T cells with pLC-OG together
with the VSV-G and pCMVR8.93 plasmids, as described. Viral
p24 concentration was determined by HIV-1 p24 Core proﬁle
ELISA (NEN Life Science Products). Transduction experi-
ments were performed by adding a 1 : 2 dilution of the virus-
containing 293T supernatant onto cells in six-well plates
(Costar) in the presence of polybrene (8 mg/ml). Transduced
cells were checked by ﬂow cytometry and Western blot for
expression of the recombinant protein.
BrdU incorporation
DNA synthesis was measured by the 50-bromo-30-deoxyuridine
Labeling and Detection Kit from Boehringer Mannheim
(Germany). Cells were seeded on glass coverslips, BrdU was
added to the cell culture media at a ﬁnal concentration of
100 mg/ml. Cells were incubated for 1 h, permeabilized with
Triton X-100 (0.2%) and ﬁxed with paraformaldehyde (4%)
prior to staining. Coverslips were incubated with anti-BrdU
mouse monoclonal antibody and with an FITC-conjugated
anti-mouse antibody. All coverslips were counterstained in
PBS containing Hoechst 33258 (ﬁnal concentration, 1 m/ml;
Sigma Chemical Co.), rinsed in water and mounted in Moviol
on glass slides. The ﬂuorescent signal was visualized with an
epiﬂuorescent microscope (Axiovert 2, Zeiss) (equipped with a
 100 lens) interfaced with the image analyzer software KS300
(Zeiss).
Matrigel invasion
In vitro invasiveness through Matrigel was assayed using
Transwell cell culture chambers according to described
procedures (Yue et al., 1994). Brieﬂy, conﬂuent cell mono-
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layers were harvested with trypsin/EDTA and centrifuged at
800 g for 10min. The cell suspension (1 105 cells/well) was
added to the upper chamber of a prehydrated polycarbonate
membrane ﬁlter of 8mM pore size (Costar, Cambridge, MA,
USA) coated with 35mg Matrigel (Collaborative Research
Inc., Bedford, MA, USA). The lower chamber was ﬁlled with
F12 complete medium and, when required, puriﬁed intact
OPN. When required, the cells were pretreated with blocking
antibodies for 20min. Plates were incubated at 371C in a
humidiﬁed incubator in 5% CO2 and 95% air for 24 h.
Nonmigrating cells on the upper side of the ﬁlter and Matrigel
were wipped off and migrating cells on the reverse side of the
ﬁlter were stained with 0.1% crystal violet in 20% methanol
for 15min, counted and photographed.
Cell spreading in collagen gel
Cells were harvested from cultures using trypsin-EDTA and
resuspended in gelling solution prepared as described (Medico
et al., 1996). Brieﬂy, eight parts of type I collagen solution
(2mg/ml) (ICN Biomedicals, Eschwege, Germany) was mixed
with one part of 10 DMEM and one part of HEPES 0.5M
(pH 7.4) and kept on ice to prevent premature gelation.
Resuspended cells were seeded into 24-well plates (4 104/
well). After gelation, F12 medium containing 5% FCS and six
hormones was added. Cell spreading was examined at regular
time intervals for 4 days.
Discussion
RET/PTC rearrangements are prevalent in thyroid papillary
carcinomas and experimental evidence indicate that they are
able to initiate thyroid carcinogenesis. This not withstanding,
very little is known about the mechanisms by which RET/PTC
oncogenes transform thyroid follicular cells. Model systems of
thyroid follicular cells have been widely used to study growth
regulation and neoplastic transformation (Kimura et al.,
2001). By using PC Cl 3 cells, here we identify OPN as a
major transcriptional target of RET/PTC in thyroid cells. By
using recombinant OPN protein, an OPN-expressing lentivirus
and OPN-blocking antibodies, we show that OPN upregula-
tion is implicated in mitogenic and motile phenotype of RET/
PTC-transformed PC Cl 3 cells. These results were conﬁrmed
in human cell lines spontaneously harbouring the RET/PTC1
oncogene.
OPN binds cell surface av-containing integrins and the
hyaluronate receptor CD44. CD44, in turn, has been
implicated in cell–cell and cell–matrix interactions and homing
of tumour cell metastasis (Ponta et al., 2003). CD44 is a
signalling receptor able to induce activation of the phospha-
tidylinositol 3-kinase/Akt pathway (Kamikura et al., 2000; Lin
and Yang-Yen, 2001) and to associate to ezrin to control cell
motility in a PKC-regulated manner (Legg et al., 2002). We
show that CD44 is upregulated in RET/PTC-transformed
cells. It is possible that, in thyroid cells, OPN effects are
mediated in part by av-containing integrins and that CD44
upregulation affects the transformed phenotype per se
independently of OPN (for instance by lateral recruitiment
of other membrane proteins). However, some evidences
suggest that CD44 is implicated in OPN signalling in RET/
PTC-transformed PC Cl 3 cells. Indeed, the increased response
to OPN of RET/PTC-transformed with respect to parental
cells parallels CD44 overexpression. Furthermore, anti-CD44
antibodies (Lin et al., 2000; Weiss et al., 2001) reduced OPN
effects in thyroid cells. Finally, PC-RET/PTC cells overexpress
CD44 mRNAs containing the v6 exon, important for efﬁcient
OPN binding. Intriguingly, CD44 and its splicing variants are
often found overexpressed in human thyroid tumors (Ermak
et al., 1995; Bartolazzi et al., 2001). Whether RET/PTC solely
induces CD44 overexpression or it also stimulates CD44
activity (for instance by the recently described PKC-mediated
phosphorylation mechanism, Legg et al., 2002) remains to be
determined.
An intact kinase activity and phosphorylation of Y1062 are
essential for efﬁcient stimulation of OPN and CD44 by RET/
PTC. OPN upregulation, in turn, depended also on Y1015. Of
note, both Y1062 and Y1015 are required for RET/PTC-
mediated cell transformation (Asai et al., 1996; Borrello et al.,
1996) and they are constitutively phosphorylated in RET/PTC
proteins in human thyroid cancer specimens (Salvatore et al.,
2000). Moreover, both tyrosines are required for thyroid
tumors formation in RET/PTC1-transgenic mice (Buckwalter
et al., 2002). Tyrosine 1015 is the docking site for PLCg,
implicated in RET-mediated activation of protein kinase Ca
(PKCa) (Andreozzi et al., 2003). Tyrosine 1062 is implicated in
the activation of multiple signalling pathways (Hayashi et al.,
2000), including the Ras one (Melillo et al., 2001). The OPN
promoter contains multiple AP-1 and ETS-family proteins
binding sites (Chang and Prince, 1993; Guo et al., 1995).
Indeed, it responds to PKCa triggering (Chang and Prince,
1993) and to oncogenic Ras, as well (Guo et al., 1995 and this
paper). We suggest that in PC Cl 3 cells, CD44 upregulation is
determined by signals starting from Y1062 and leading to Ras/
MAPK activation, while OPN upregulation is the result of the
cooperation of multiple signalling pathways downstream
RET/PTC, the Ras/MAPK pathway being one of them.
In conclusion, our data demonstrate that RET/PTC
signalling triggers the formation of an autocrine loop involving
OPN and CD44 that stimulates proliferation and motility of
PC Cl 3 cells. These ﬁndings prompt further studies to
ascertain whether OPN could be a useful PTC tumour marker
and a promising therapeutic target.
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